Molecular genetics and epidemiology of steroid 21-hydroxylase deficiency. Origin of disease-causing mutations. by Koppens, P.F.J.
   
Molecular genetics and epidemiology of steroid 21-hydroxylase deficiency 
Origin of disease-causing mutations 
 leeg 
   
Molecular genetics and epidemiology of steroid 21-hydroxylase deficiency 
Origin of disease-causing mutations 
 
 
Moleculaire genetica en epidemiologie van steroïd 21-hydroxylase deficiëntie 
Herkomst van klinisch relevante mutaties 
 
 
 
 
 
 
Proefschrift 
 
 
 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus 
Prof.dr.ir. J.H. van Bemmel 
en volgens besluit van het College voor Promoties 
 
 
 
De openbare verdediging zal plaatsvinden op 
woensdag 26 juni 2002 om 11.45 uur 
 
 
 
door 
 
 
 
Paul Franciscus Joannes Koppens 
geboren te Brecht, België 
 
 Promotiecommissie 
 
Promotoren: 
Prof.dr. H.J. Degenhart 
Prof.dr. H.A. Büller 
 
Overige leden: 
Dr. A.O. Brinkmann 
Prof.dr. B.A. van Oost 
Prof.dr. R. Pieters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© P.F.J. Koppens, 2002 
Chapter 2.1 © Springer-Verlag 
Chapter 2.3 © Blackwell Publishing 
Chapter 2.4 © Elsevier Science B.V. 
Chapter 3.1 © Nature Publishing Group 
Chapter 6 © Blackwell Publishing 
 
ISBN: 90 77017 85 2 
 
Printed by Optima Grafische Communicatie, Rotterdam, The Netherlands (www.ogc.nl) 
   
Contents 
 
 
 Scope of this thesis 9 
   
1. General Introduction 11 
1.1. Perspective 13 
1.2. Adrenocortical steroid biosynthesis 16 
1.3. Steroid 21-hydroxylase 20 
1.4. Congenital adrenal hyperplasia 23 
1.5. The CYP21 gene in the Major Histocompatibility Complex 29 
1.6. Variability of the RCCX region 38 
1.7. Genetic mechanisms creating CYP21 defects 44 
1.8. Methods used to study CYP21 and the RCCX module 61 
1.9. Reference section 65 
   
2. CYP21/C4 haplotyping 103 
2.1. Family studies of the steroid 21-hydroxylase and complement C4 
genes define 11 haplotypes in classical congenital adrenal 
hyperplasia in the Netherlands 
Eur J Pediatr 1992; 151: 885-892 
105 
2.2. CYP21 and C4 haplotypes in the Netherlands: an update 119 
2.3. The PvuII restriction site in the second intron of the human steroid 
21-hydroxylase gene CYP21 is polymorphic 
Clin Genet 1995; 48: 109-110 
133 
2.4. A rare TaqI polymorphism in a human complement C4 gene is 
caused by an additional restriction site in the first intron 
Immunol Lett 1992; 34: 93-97 
137 
   
3. CYP21 mutation analysis 145 
3.1. CYP21 and CYP21P variability in steroid 21-hydroxylase 
deficiency patients and the general population in the Netherlands 
Eur J Hum Genet 2000; 8: 827-836 
147 
3.2. Distribution of CYP21 mutations in a Dutch population 165 
   
  
4. A de novo unequal crossover generates a dual deficiency haplotype 
carrying no steroid 21-hydroxylase (CYP21) gene and a non-
functional hybrid tenascin-X (TNX) gene: mapping of the 
recombination site between chromosomes each carrying two RCCX 
modules 
173 
   
5. Carriership of a defective tenascin-X (TNXB) gene in steroid 21-
hydroxylase deficiency patients: consequences of breakpoint 
location in bimodular RCCX modules that lack the CYP21 gene 
191 
   
6. Aldosterone production despite absence or defectiveness of the 
CYP21 genes in two patients with salt-losing congenital adrenal 
hyperplasia caused by steroid 21-hydroxylase deficiency 
Clin Endocrinol 1998; 49: 815-822 
205 
   
7. Duplication of the CYP21 gene may complicate mutation analysis 
of steroid 21-hydroxylase deficiency: characteristics of three 
unusual haplotypes 
219 
   
8. General discussion 231 
8.1. Mutational mechanisms causing CYP21 defects 233 
8.2. Steroid 21-hydroxylase deficiency alleles in the population 239 
8.3. Implications and perspectives of CYP21 mutation analysis 242 
   
9. Summary / Samenvatting 251 
9.1. Summary 253 
9.2. Samenvatting 257 
   
 Abstracts related to the work in this thesis 261 
 Articles in Dutch 262 
 Curriculum vitae 263 
 Nawoord 265 
 
   
Abbreviations 
 
3βHSD 3β-hydroxysteroid dehydrogenase.  
ACTH adrenocorticotropin 
AGS adrenogenital syndrome 
bp basepair(s) 
C4 fourth component of complement (A or B) 
CAH congenital adrenal hyperplasia 
CYP cytochrome P450 
CYP any human cytochrome P450 gene 
Cyp any non-human cytochrome P450 gene 
CYP11A cytochrome P450 11A: cholesterol desmolase; side chain cleaving enzyme 
CYP11B1 cytochrome P450 11B1: steroid 11β-hydroxylase 
CYP11B2 cytochrome P450 11B2: aldosterone synthase 
CYP17 cytochrome P450 17: steroid 17α-hydroxylase / 17,20-lyase 
CYP21 cytochrome P450 21: steroid 21-hydroxylase 
CYP21 the human steroid 21-hydroxylase gene 
CYP21P the human steroid 21-hydroxylase pseudogene 
Cyp21 a non-human steroid 21-hydroxylase gene 
HERV human endogenous retrovirus 
HLA human leukocyte antigen 
kb kilobasepair(s) 
Mb megabasepair(s) 
MHC major histocompatibility complex 
NC nonclassical 
PCR polymerase chain reaction 
PRA plasma renin activity 
psi pounds per square inch 
RCCX RP1-C4-CYP21-XB 
RFLP restriction fragment length polymorphism 
RP1 serine/threonine protein kinase gene (named after Rodney Porter) 
RP2 the truncated pseudogene of RP1 
SEM standard error of the mean 
SL salt loss / salt-losing 
SLE systemic lupus erythematosus 
StAR steroidogenic acute regulatory protein 
SV simple virilising 
TNX tenascin X 
TNXA (also: XA) the truncated tenascin-X pseudogene 
TNXB (also: XB) the tenascin-X gene 
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Scope of this thesis 
 
Steroid 21-hydroxylase deficiency is an inherited defect of the synthesis of aldosterone and 
cortisol by the adrenal cortex.  It is the cause of more than 90 % of all cases of congenital 
adrenal hyperplasia and has a worldwide incidence of 1:10,000 to 1:15,000.  Lack of cortisol 
induces enhanced secretion of ACTH by the pituitary gland, causing hyperplasia of the 
adrenal cortex.  The hyperplastic adrenal produces excessive amounts of androgens which are 
converted peripherally to testosterone, causing pre- and postnatal virilisation.  Severe steroid 
21-hydroxylase deficiency is a potentially life-threatening condition because lack of 
aldosterone causes massive urinary salt loss with severe dehydration in untreated paediatric 
patients. 
Steroid 21-hydroxylase is encoded by the CYP21 gene in the central region of the human 
Major Histocompatibility Complex (MHC), a highly variable and gene-dense part of the 
human genome. 
This thesis is aimed at understanding the relationship between the genetic defects that cause 
steroid 21-hydroxylase deficiency and the clinical phenotype, and the molecular mechanisms 
that create these mutations in the CYP21 gene, in a patient population from the Netherlands. 
Soon after the discovery of the CYP21 gene and the nearby CYP21P pseudogene, a picture 
emerged of great variability in the arrangement of these genes on chromosome 6p21.31.  
Some of these variants constitute genetic defects that cause steroid 21-hydroxylase deficiency.  
The study's initial objective was therefore to obtain an image of that variability by charting the 
layout of the genetic environment of the CYP21 gene in steroid 21-hydroxylase deficiency 
patients and in the general population.  Two genetic mechanisms that are fundamental to the 
evolution of the genome, and especially the MHC, are also instrumental in generating the 
variability in this region: 
- simultaneous deletion and duplication of genes by unequal crossover, and: 
- non-reciprocal sequence transfer between genes by gene conversion. 
A major point of attention in this thesis is how these mechanisms create alleles that carry 
steroid 21-hydroxylase deficiency. 
The allele frequency of genes in the MHC varies among human populations, and the 
association between the different categories of steroid 21-hydroxylase deficiency and specific 
HLA serotypes has been noted even before the advent of molecular genetics.  The thesis 
therefore addresses the relationship between CYP21 defects and the clinical severity of steroid 
21-hydroxylase deficiency, and compares the mutational spectrum in the Dutch population to 
the variability found elsewhere.  Ancient mutations in conserved haplotypes are likely to have 
spread among human populations, whereas recent mutations may be concentrated in a single 
group due to a founder effect, contributing to differences between populations.  On the other 
hand, defects that already exist in the population may again arise independently as de novo 
mutations, as illustrated in this thesis. 
 
 
 
10 
CYP21 mutation analysis is a valuable diagnostic tool in individual steroid 21-hydroxylase 
patients and their family members.  Knowledge of CYP21 mutations and their phenotypical 
severity has already led to a genotype-based definition of patient categories.  Since the overall 
relationship with the phenotype is good in most patients, the danger of overtreatment can be 
reduced by determining the genetic defect to confirm the clinical diagnosis.  Still, there may 
be discrepancies between clinical manifestation, biochemical data and genetic defects - two 
such cases are described in detail in this thesis. 
Mutation detection in family members of a patient provides information for genetic 
counselling and is especially relevant if the patient has CYP21 defects of differing severity.  
Genetic analysis may also identify previously undiagnosed patients with mild symptoms.  
Finally, since over 90 % of all CYP21 defects are attributable to a limited set of about 10 
mutations, it is possible to identify most unrelated heterozygotes, which is of relevance to the 
spouses of known carriers. 
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1.1. Perspective 
The traditional route to understanding a genetically controlled disease leads from phenotype to 
genotype - schematically, from medicine to biochemistry to molecular genetics, with 
knowledge from each of these fields adding to progress in all of them. 
Congenital adrenal hyperplasia (CAH) is no exception.  Nowadays, the statement that this 
common inherited metabolic disease is mostly due to steroid 21-hydroxylase deficiency 
caused by a genetic defect in the CYP21 gene is routinely made in most reports on this subject, 
including the chapters of this thesis - but decades of research were needed to gain such 
knowledge. 
 
Early medical reports 
The most frequently quoted early report on CAH was written in 1865 by de Crecchio 
(summarised by Bongiovanni and Root [1963]).  However, for a scientist living in the 
Netherlands, it is difficult to forego an opportunity to claim the primacy of the famous Dutch 
physician Reinier de Graaf by quoting a 1672 case report, translated by Jocelyn and Setchell 
300 years later [Jocelyn and Setchell 1972; Wallace 1995]: 
 
'On 27th June 1670, there was born at Delft an infant, whom, because of 
malformation of its genital parts, its parents did not want distinguished with 
either male or female name until they consulted experts in the matter.  The 
experts judged it to be a male because of an apparently perfect male member 
and swellings hanging like testicles underneath.  The infant was, therefore, 
called Cornelius.  Struck by a serious illness, Cornelius departed this life on 
19th July.' 
 
Prenatal virilisation of female patients (at autopsy, Cornelius turned out to be a girl) remains a 
hallmark of CAH caused by steroid 21-hydroxylase deficiency.  In addition, severe urinary 
salt loss becomes manifest in many male and female patients within the first weeks of life.  
Untreated salt-losing CAH in paediatric patients is a very dangerous condition: before the 
advent of steroid replacement therapy [Wilkins et al. 1950; Crigler et al. 1952], the disease 
was fatal in most cases [Knudson 1951; Iversen 1955].  The term 'congenital adrenal 
hyperplasia' was not ubiquitously used during that period: 'adrenogenital syndrome' was more 
popular and used in early reports [Broster 1934], but the nomenclature often depended on the 
nationality of the author [Iversen 1955].  However, it later became evident that the 
'adrenogenital syndrome' also included unrelated adrenocortical abnormalities [Bongiovanni 
and Root 1963], and the term was eventually considered too generic [Stempfel and Tomkins 
1966]. 
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Steroids and enzymes 
By the mid-1960's, considerable knowledge had been acquired on the biosynthesis of steroid 
hormones in the adrenal cortex and steroid 21-hydroxylase deficiency had been recognised as 
the cause of more than 90 % of all cases of  CAH [Wilkins 1962; Stempfel and Tomkins 
1966].  The finding that adrenocortical steroid synthesis is controlled by ACTH led to the 
establishment of the ACTH stimulation test as a diagnostic tool in suspected 21-hydroxylase 
deficiency.  These developments were complemented by improvements in the measurement of 
(first) urinary steroid metabolites and (later) steroids in blood serum (notably, 17α-
hydroxyprogesterone).  Radioimmunoassay of  17α-hydroxyprogesterone in dried blood spots 
[Pang et al. 1977] is the basis for present-day neonatal screening programmes [Brosnan and 
Brosnan 2000; Therrell 2001].  A choice of steroid analysis techniques for basic research and 
clinical diagnosis is now available [Wallace 1995; Andrew 2001]. 
Parallel to recent advances in molecular genetics, progress in the field of enzymology has been 
ongoing.  Steroid 21-hydroxylase was the first cytochrome P450 for which an enzymatic 
function was demonstrated [Estabrook et al. 1963], but its isolation and its reconstitution in an 
active form proved difficult due to its hydrophobicity and strong association with the 
microsomal membrane [Kominami et al. 1980; Hiwatashi and Ichikawa 1981].  By 1980, the 
adrenocortical steroidogenic pathways and  the enzymatic activities involved were understood 
in considerable detail [Grant 1978; Degenhart 1979; Mitani 1979; Fevold 1983], but it was not 
until the 1990's that the mapping of those activities to individual cytochrome P450 proteins 
was completed [White 1994; Pascoe and Curnow 1995]. 
 
Classical genetics 
The hereditary nature of CAH was first perceived in the 1930's [Broster 1934; Jacobziner and 
Gorfinkel 1936] and discussed in detail by Knudson [1951].  Differences in aldosterone 
secretion between salt-losing and non-salt-losing patients were attributed to differences in 
enzymatic defect [Degenhart et al. 1965], a hypothesis later confirmed by mutation analysis 
[Amor et al. 1988].  A major breakthrough in the genetics of steroid 21-hydroxylase 
deficiency was achieved in 1977, when Dupont et al. found that the disease-carrying allele co-
segregated with the HLA type in family studies of CAH patients [Dupont et al. 1977].  No 
genetic linkage to HLA was found for 11β-hydroxylase deficiency, which is the next most 
common defect in CAH (although it accounts for only about 5 % of all cases in most 
populations) [New et al. 1981].  Association with a specific HLA allele (B47) was 
demonstrated for salt-losing steroid 21-hydroxylase deficiency [Klouda et al. 1980], but not 
for the non-salt-losing ('simple virilising') form.  A mild 'late onset' variant of 21-hydroxylase 
deficiency frequently found in combination with HLA-B14, was recognised as an allelic 
variant [Kohn et al. 1982].  Association of steroid 21-hydroxylase deficiency with different 
alleles of the genes encoding the fourth component of complement (C4A and C4B) was 
established at the same time [O'Neill et al. 1982].  By the early 1980's, differences in 
hormonal response to ACTH stimulation between severely and mildly affected patients, 
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heterozygotes, and controls, had been firmly established [New et al. 1983], although a 
substantial overlap between some of these categories was found. 
 
Molecular genetics 
The availability of a reliable procedure to purify steroid 21-hydroxylase from bovine adrenal 
cortex [Kominami et al. 1980; Hiwatashi and Ichikawa 1981] paved the road to cDNA cloning 
[White et al. 1984b] and soon afterwards, to the identification in man of the gene now known 
as CYP21 by White and co-workers in 1984 [White et al. 1984c].  CYP21 and its closely 
linked pseudogene CYP21P, each approximately 3.4 kb in size, were mapped to the class III 
region of the Major Histocompatibility Complex (MHC) on chromosome 6p21.3, adjacent to 
the complement C4 genes.  Absence or reduced gene dosage of CYP21 was detected in some, 
but not all, steroid 21-hydroxylase deficiency patients [White et al. 1985; Carroll et al. 1985a; 
Carroll et al. 1985b]. 
After CYP21 and CYP21P had been sequenced [Higashi et al. 1986], it soon became evident 
that a limited number of mutations typically found in CYP21P [Amor et al. 1988; Globerman 
et al. 1988; Higashi et al. 1988a; Higashi et al. 1988b; Speiser et al. 1988; Chiou et al. 1990; 
Tusié-Luna et al. 1991] accounted for the majority of the defects causing steroid 
21-hydroxylase [Higashi et al. 1991; Mornet et al. 1991; Speiser et al. 1992; Wedell et al. 
1994].  Today, molecular genetic analysis is a valuable resource in understanding the 
aetiology of steroid 21-hydroxylase deficiency [Nordenström et al. 1999; Ritzén et al. 2000] 
and it is indispensable in the management of prenatal treatment (see Chapter 8 for a more 
elaborate discussion and references). 
Twenty years of molecular genetic research of the CYP21/C4 region have provided us with a 
picture of great detail, but also of amazing complexity.  Haplotyping studies [Harada et al. 
1987; White et al. 1988; Collier et al. 1989; Morel et al. 1989a; Koppens et al. 1992a; Lobato 
et al. 1998; Blanchong et al. 2000] show great differences between individuals and between 
populations in the size and composition of this region, now known as the RCCX module 
[Blanchong et al. 2001].  This variability reflects ancient genetic rearrangements and 
contributes to new ones: recombinational events involving CYP21 and CYP21P followed by 
unequal crossover [Sinnott et al. 1990] or gene conversion [Collier et al. 1993] were among 
the first examples of de novo mutations causing a genetic defect in humans. 
Insight into the structure and function of the adjacent genes that are also duplicated or deleted 
by these unequal crossovers has progressed at a similar pace.  The difference between C4A 
and C4B and their variants was shown at a molecular level [Yu et al. 1988] and the first 
genomic sequence of a C4 gene was published [Yu 1991].  The size variation between C4 
genes (16 or 23 kb) was attributed to an endogenous retroviral sequence present in the long 
variant only [Dangel et al. 1994].  Another surprising feature was the presence of a gene 
transcribed from the opposite strand of CYP21, partly overlapping its 3' flank [Morel et al. 
1989b].  This gene was later shown to encode a tenascin-like protein [Bristow et al. 1993b] 
and turned out to be the opposite of CYP21 in more than one way: discovery of the gene came 
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first, and a molecular defect with an associated clinical phenotype came later [Burch et al. 
1997]. 
 
A crossroads of genetic research 
Though research on the CYP21 gene has been initiated, and intensively pursued, by research 
groups interested in the causes of steroid 21-hydroxylase deficiency, it is not surprising that 
many others were also involved: to name but a few fields, the study of complement genetics, 
HLA alleles, autoimmunity, evolution of the MHC, genetic recombination, and recently the 
availability of complete genomic sequences of the MHC class III region [MHC Sequencing 
Consortium 1999; International Human Genome Sequencing Consortium 2001], have each 
provided invaluable contributions to our current knowledge of CYP21 genetics and will 
continue to do so in the future.  In addition, questions regarding the discrepancies between 
phenotype and genotype observed in some patients [Wilson et al. 1995b; Krone et al. 2000] 
and the highly complex regulation of the CYP21 gene [Zanger et al. 1992; Wijesuriya et al. 
1999; Bobba et al. 2000] warrants an ongoing interest from the field of molecular 
endocrinology itself. 
 
1.2. Adrenocortical steroid biosynthesis 
The human adrenal 
The adult human adrenal is an inconspicuous organ situated on top of each kidney.  In adults, 
each adrenal weighs no more than 4 to 5 g and consists of the small adrenal medulla in the 
centre, covered by the adrenal cortex that makes up more than 80 % of the total mass of the 
adrenal.  The adrenal cortex consists of three histologically distinct and metabolically 
specialised zones: the outer zona glomerulosa, the intermediate zona fasciculata (about 80 % 
of the adrenal cortex) and the narrow zona reticularis on the inside (see fig. 1 for a schematic 
overview). 
Fig. 1.  Overview of human adrenocortical steroid biosynthesis.  Top: structure of cholesterol with the 
carbon atoms numbered in italics.  Middle: principal steroidogenic steps; dashed arrows indicate 
multiple steps, sometimes performed by the same enzyme.  StAR: steroidogenic acute regulatory 
protein; CYP11A: cholesterol desmolase / side chain cleaving enzyme; CYP11B1: steroid 11β-
hydroxylase; CYP11B2: aldosterone synthase; CYP17: steroid 17α-hydroxylase / 17,20-lyase; CYP21: 
steroid 21-hydroxylase; 3βHSD: 3β-hydroxysteroid dehydrogenase/∆5-∆4 isomerase.  Bottom: diagram 
of the adrenal.  Each cortical zone produces a different class of steroid hormones.  Minor pathways 
(such as 17α-hydroxyprogesterone -> androstenedione) and intermediate products of single-enzyme 
conversions (notably, deoxycorticosterone->corticosterone->18-OH-corticosterone->aldosterone) are 
not shown; for details and references, see the text. 
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Since ACTH exerts its influence on the adrenal cortex , it is this part of the adrenal that 
becomes hyperplastic in steroid 21-hydroxylase deficiency patients.  However, additional 
adverse effects on the adrenal medulla have recently been reported [Merke et al. 2000]. 
Surprisingly, the adrenal cortex is at least as large in newborns as in adults (and thus, much 
larger relative to the body mass).  The foetal adrenal consists of a large inner 'foetal' zone 
surrounded by a narrow outer 'definitive' zone and reaches its maximum size in the fourth 
month of gestation.  Gradual replacement by the definitive adrenal starts thereafter and speeds 
up considerably after birth.  The layered structure  mentioned above is complete by the third 
year of life [Mesiano and Jaffe 1997; Stratakis and Rennert 1999; White and Speiser 2000].  
Enhanced transcription of genes involved in growth and development [Rainey et al. 2001] 
probably accounts for the large size of the foetal adrenal. 
Enzymatic conversion of steroids 
In the adrenal cortex, three distinct biosynthetic pathways convert cholesterol into the main 
mineralocorticoid aldosterone, the main glucocorticoid cortisol and the (pre-)androgen 
androstenedione, respectively (see fig. 1). Androstenedione is converted to the primary 
androgen testosterone by the testis, or to the oestrogens oestrol and oestradiol by the ovary.  
These three steroids are the end products of the three pathways, but they are by no means the 
only products secreted by the adrenal cortex.  The intermediates shown in fig. 1 also circulate: 
some of them act as hormones in their own right (although their biological activity is usually 
limited), others reach characteristic high levels in deficiencies (see below) and can be 
monitored for diagnostic purposes.  After performing their function in metabolism, steroids 
are inactivated by the liver and excreted.  Since steroid biosynthesis and metabolism have 
been thoroughly reviewed elsewhere [Degenhart 1979; Mitani 1979; Fevold 1983; New et al. 
1989; Morel and Miller 1991; White 1994; Simpson and Waterman 1995; Andrew 2001], a 
concise description should suffice here. 
Most adrenocortical steroidogenic enzymes are cytochrome P450s.  Cytochrome P450s are 
haem-containing catalysts of oxidative reactions present in many tissues and in a wide range 
of organisms ranging from mammals to plants and bacteria.  They were named after the 
characteristic 450 nm spectrophotometric absorption maximum obtained by saturation of the 
reduced form with carbon monoxide [Estabrook et al. 1963; Omura and Sato 1964a; Omura 
and Sato 1964b; Tétreau et al. 1997].  Nowadays, hundreds of cytochrome P450s make up the 
CYP superfamily [Nebert and Gonzalez 1987; Graham-Lorence and Peterson 1996; Negishi et 
al. 1996; Honkakoski and Negishi 2000], and the number of available sequences and alleles is 
ever-expanding [Cytochrome P450 Nomenclature Committee 2002].  The basic scheme of a 
cytochrome P450 catalysed hydroxylation in mammals is: 
 
substrate-H + NADPH + H+ + O2   substrate-OH + NADP+ + H2O 
 
This reaction requires electron transfer mediated by either one or two 'redox partners', a 
distinction which has been used to categorise cytochrome P450s: somewhat inconsistently, 
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class I P450s have two redox partners (generically termed ferredoxin and ferredoxin reductase; 
the adrenocortical enzymes are adrenodoxin and adrenodoxin reductase), while class II P450s 
have one partner (cytochrome P450 reductase) [Lambeth et al. 1982; Takemori and Kominami 
1984; Guengerich 1988; Hall 1989; Graham-Lorence and Peterson 1996; Lewis and Lee-
Robichaud 1998]. 
With a few exceptions, cytochrome P450s are tightly bound to membranes: in mammalian 
cells, typically to mitochondria or to microsomes.  Three out of the five adrenocortical 
cytochrome P450s are mitochondrial: CYP11A (cholesterol desmolase, the side-chain-
cleaving enzyme, also known as P450scc), CYP11B1 (steroid 11β-hydroxylase, P450c11) and 
CYP11B2 (aldosterone synthase, P450aldo).  Two are microsomal: CYP17 (steroid 17α-
hydroxylase / 17,20-lyase, P450c17) and CYP21 (steroid 21-hydroxylase, P450c21).  The 
mitochondrial enzymes are class I P450s, the microsomal enzymes are class II P450s.  The 
adrenal has one steroidogenic enzyme that is not a P450: 3β-hydroxysteroid 
dehydrogenase/∆5-∆4 isomerase [Miller 1988; Morel and Miller 1991; White 1994; Lewis and 
Lee-Robichaud 1998]. 
Differences in the distribution of cytochrome P450s between the zones of the adrenal cortex 
(glomerulosa, fasciculata and reticularis) were demonstrated early [Ichikawa et al. 1970] and 
functional studies confirmed that each zone plays its own role in steroidogenesis [Kater and 
Biglieri 1983; Yagi et al. 1983; Stoner et al. 1986; Biglieri and Kater 1991].  The overview 
presented in fig. 1 is a simplification, outlining the major pathways of adrenocortical steroid 
biosynthesis.  Reactions that are of minor importance under normal conditions can become 
prominent when changed physiological conditions alter their stoichiometry: for example, 
concentrations of 17α-hydroxyprogesterone in steroid 21-hydroxylase deficiency patients can 
be so high that this steroid becomes an important substrate for the 17,20-lyase activity of 
CYP17 and for 11β-hydroxylation by CYP11B1.  Also, differences in steroid synthesis and 
function between humans and other mammals limit the usefulness of animal models. 
 
Steroid function and regulation 
Quantitatively, cortisol is by far the most prominent adrenocortical steroid hormone: 
throughout life, its secretion surpasses that of aldosterone and the adrenal androgens by 
several orders of magnitude [Sippell et al. 1980; Kuhnle et al. 1986; Eldar-Geva et al. 1990; 
Glass et al. 1994; Witchel and Lee 1998].  Cortisol is the primary glucocorticoid, and its 
action are manifold: to name but a few, increased cortisol levels mobilise bodily energy 
resources by glycogenolysis and gluconeogenesis, increases the heart rate, alters brain 
physiology and has an anti-inflammatory effect by mediating the immune response.  Thus, an 
adequate cortisol response is of particular importance in stressful conditions [Munck and 
Náray-Feyes-Tóth 1995; Miesfeld 1995; Sapolsky et al. 2000]. 
Adrenocortical steroid biosynthesis is primarily under the control of ACTH [Simpson and 
Waterman 1995; Waterman and Keeney 1996; Honkakoski and Negishi 2000].  ACTH is 
produced by the anterior lobe of the pituitary gland as a part of the precursor molecule pro-
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opiomelanocortin, and its effect on the adrenal is enhanced by other peptides that are also 
parts of this precursor [Szalay 1993; Tóth and Hinson 1995; Bicknell et al. 1996].  ACTH 
production is stimulated by hypothalamic neuropeptides such as corticotropin releasing factor, 
arginine vasopressin and oxytocin.  Cortisol decreases these activities by the hypothalamus 
and pituitary, thus regulating its own production [Engler et al. 1999].  This negative feedback 
mechanism is known as the hypothalamic-pituitary-adrenal (HPA) axis. 
The adrenal responds to ACTH stimulation in several ways: within minutes, the production of 
steroids increases; within hours to days, the synthesis of steroid-producing enzymes increases.  
Eventually, long-term ACTH stimulation leads to morphological changes and hyperplasia of 
the adrenal cortex [Knudson 1951; Bongiovanni and Root 1963; Mitani et al. 1996; Hernanz-
Schulman et al. 2002], from birth in untreated steroid 21-hydroxylase patients, or later in life 
when an ACTH-secreting tumour causes Cushing's disease.  Zonation becomes irregular and 
may be completely lost [Bongiovanni and Root 1963; Robbins 1974; Merke et al. 2000]. 
Aldosterone is the main mineralocorticoid in man, and its function is to promote sodium 
resorption and potassium excretion in the distal tubuli of the kidney [Crabbé 1978; Mortensen 
et al. 1995; Funder and Marver 1995; White 1996].  Synthesis of aldosterone is primarily 
under the control of the renin-angiotensin system: low serum sodium levels increase renin 
secretion by the kidney, resulting in an enhanced conversion of angiotensinogen by renin and 
angiotensin converting enzyme.  The resulting angiotensin II is a potent stimulator of 
aldosterone secretion, which is also enhanced by high levels of potassium [Aguilera 1993; 
Clark and Brown 1995; Ehrlich et al. 1995]. 
The adrenal androgens, dehydroepiandrosterone(-sulphate) and androstenedione, do not have a 
high biological activity, but they are converted peripherally to the potent androgen 
testosterone.  During foetal development, high levels of testosterone produced by Leydig cells, 
combined with anti-Müllerian hormone from Sertoli cells, result in the development of male 
internal urogenital structures - in the absence of these factors, female structures are formed.  
Dihydrotestosterone is formed from testosterone by steroid 5α-reductase and causes 
development of the prostate and virilisation of the external genitalia [New and Wilson 1999; 
White and Speiser 2000; American Academy of Pediatrics 2000].  The ovaries express CYP19 
(steroid aromatase), which converts androstenedione to oestrone and testosterone to oestradiol.  
Since fluctuations of the serum levels of adrenal androgens are not recognised by the organism 
as an abnormal condition, there is no regulatory feedback mechanism such as for cortisol or 
aldosterone. 
 
1.3. Steroid 21-hydroxylase 
The adrenocortical enzyme 
Steroid 21-hydroxylase (CYP21; P450c21; E.C. 1.14.99.10) is a microsomal cytochrome P450 
enzyme that converts progesterone to deoxycorticosterone and 17α-hydroxyprogesterone to 
11-deoxycortisol  (see fig. 2).    It  is  tightly  bound  to  the  microsomal  membrane:  after  re- 
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Fig. 2.a.  Conversion of 17α-hydroxyprogesterone to 11-deoxycortisol by steroid 21-hydroxylase.  The 
conversion of progesterone to deoxycorticosterone is exactly the same, but without the hydroxyl group 
in position 17.  The reaction mechanism and the electron transport as shown here is a simplification of 
a highly complex interaction; the electrons are actually transferred one at a time [Guengerich 1988; 
Sevrioukova et al. 1999; Kominami et al. 2001].  b. Progress of this reaction in a reconstituted enzyme 
system [Kominami et al. 1980]; separation by thin-layer chromatography; bottom: incubation time in 
minutes.  c. Bovine adrenocortical steroid 21-hydroxylase purified to homogeneity [Kominami et al. 
1986], as shown on a 15 % SDS-polyacrylamide gel  (leftmost lane; right: reference proteins with their 
molecular mass in kD) .  Figures 2b and 2c courtesy of Mrs. S. Zwakhals and Mr. J.W.M. van der 
Maarel. 
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incorporation into vesicle membranes, the purified enzyme retains its catalytic activity and 
other physicochemical properties even after tryptic digest [Kominami et al. 1993].  Contrary 
to mitochondrial adrenocortical P450s, which lose an N-terminal 5 kD 'signal sequence' before 
membrane integration, steroid 21-hydroxylase is synthesised as a full-size enzyme of 
approximately 54 kD [DuBois et al. 1981; Ogishima et al. 1983; Ogishima et al. 1985].  
Reliable protocols to isolate and assay bovine adrenocortical steroid 21-hydroxylase were 
established in the early 1980's [Kominami et al. 1980; Hiwatashi and Ichikawa 1981; Bumpus 
and Dus 1982].  NADPH-cytochrome P450 reductase (E.C. 1.6.2.4) receives two electrons 
from NADPH and transfers them, one at a time, to P450's such as steroid 21-hydroxylase.  
Cytochrome P-450 reductase contains one molecule of FAD and one molecule of FMN as 
cofactors in the electron transfer.  A reconstituted system containing the isolated enzymes, 
NADPH, a substrate, and an energy source, performs the steroidogenic reaction in vitro.  
Steroid 21-hydroxylase converts 17α-hydroxyprogesterone more efficiently than it does 
progesterone.  It was previously assumed that transfer of the second electron from the 
reductase to the cytochrome P450 was the rate-limiting step, but a recent study showed that 
the rate-limiting step is the actual hydroxylation in the case of 17α-hydroxyprogesterone and 
the dissociation of the substrate in the case of progesterone [Kominami et al. 2001].  
Expression studies have shown that common mutations in steroid 21-hydroxylase deficiency 
affect functions such as substrate binding, membrane integration and reductase interaction in 
different ways (see table 3 in paragraph 1.7).  Molecular modelling studies have already been 
performed for the normal enzyme and the reductase [Lewis and Lee-Robichaud 1998; 
Sevrioukova et al. 1999] and similar efforts may soon provide additional insight into the 
effects of disease-causing mutations at protein level. 
 
Peripheral 21-hydroxylase activity 
The zona fasciculata and the zona glomerulosa of the adrenal cortex are the primary sites of 
CYP21 gene expression.  However, numerous reports have shown that steroid 21-
hydroxylation also occurs elsewhere.  Deoxycorticosterone [Casey and MacDonald 1982; 
Winkel et al. 1983; Antonipillai et al. 1983; Agdere et al. 1989] and 21-hydroxypregnenolone 
[Shackleton et al. 1987] were found in steroid 21-hydroxylase deficiency patients, and urinary 
aldosterone metabolites [Speiser et al. 1991] and serum aldosterone [Koppens et al. 1998] 
even in patients where a complete genetic defect of the CYP21 gene could be demonstrated.  
Substantial peripheral conversion of progesterone to deoxycorticosterone has been 
demonstrated in microsomes from several human foetal tissues [Casey et al. 1983]. 
Early molecular studies based on Northern blotting did not find CYP21 mRNA outside the 
adrenal cortex [Voutilainen and Miller 1986; Mellon and Miller 1989], but recent use of the 
more sensitive technique of RT-PCR demonstrated  CYP21 expression in the human skin 
[Slominski et al. 1996], lymphocytes [Zhou et al. 1997], heart [Kayes-Wandover and White 
2000] and hippocampus [Beyenburg et al. 2001], and a putative unrelated 21-hydroxylase 
activity in skin keratinocytes [Rogoff et al. 2001].  Despite the low levels of expression, the 
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large size of these organs as compared to the adrenal cortex could make them important 
contributors to peripheral steroid 21-hydroxylation. 
Other candidate enzymes to perform extra-adrenal steroid 21-hydroxylation may be hepatic 
cytochrome P450s.  The liver contains many P450s with a wide spectrum of metabolic 
activities, and 21-hydroxylation of progesterone is one of them in the rabbit [Dieter et al. 
1982; Sethumadhavan and Senciall 1987], the cow [Ichikawa et al. 1984] and the rat [Endoh 
et al. 1995]. 
Obviously, the extra-adrenal 21-hydroxylation of steroids by CYP21 and by (possibly 
multiple) unidentified other enzymes, may complicate the diagnosis of defects in the 'regular' 
adrenocortical steroid biosynthesis and possibly alter the phenotype of patients affected by 
such diseases. 
 
1.4. Congenital adrenal hyperplasia 
Classical steroid 21-hydroxylase deficiency 
Steroid 21-hydroxylase deficiency (MIM: 201910) accounts for at least 90 % of all cases of 
classical congenital adrenal hyperplasia.  The next most frequent type of CAH, representing 5-
8 % of all cases, is steroid 11β-hydroxylase deficiency; other deficiencies of adrenocortical 
steroid biosynthesis are relatively rare [White 1994; Pascoe and Curnow 1995; Pang 1997; 
Stratakis and Rennert 1999; White 2001] 
As normal adrenocortical steroidogenesis (see fig. 1) is impaired, the concentrations of steroid 
hormones change, alternative biosynthetic pathways gain importance and attempts by the 
organism to counteract these effects further complicate matters.  Complete steroid 
21-hydroxylase deficiency results in the inability to synthesise aldosterone and cortisol.  Lack 
of aldosterone incapacitates renal resorption of Na+ and excretion of K+ and H+, with a 
characteristic massive urinary salt loss.  Salt-losing (also termed salt-wasting) steroid 
21-hydroxylase deficiency is often fatal in untreated paediatric patients [Knudson 1951; 
Iversen 1955].  Typical symptoms occur within a few weeks after birth and include weight 
loss and lack of appetite, dehydration, vomiting, diarrhea, acidosis and a general failure to 
thrive.  Lack of cortisol impairs cardiac output and the ability to cope with stress.  Patients 
may succumb to an 'adrenal crisis' involving shock and circulatory collapse  [New et al. 1989; 
Pang 1997; New 1998; Speiser 2001; White 2001].  Continual ACTH stimulation in response 
to absent or reduced cortisol causes hyperplasia of the adrenal cortex and accumulation of 
precursor steroids such as progesterone and 17α-hydroxyprogesterone which may serve as 
mineralocorticoid receptor antagonists [Jacobs et al. 1961; Holcombe et al. 1981; Kuhnle et 
al. 1986] in salt-losing steroid 21-hydroxylase deficiency even in patients where aldosterone is 
unexpectedly present [Koppens et al. 1998].  Curiously, there have been several reports of  
non-persistence of salt loss later in life [Horner et al. 1979; Stoner et al. 1986; Sinnott et al. 
1989; Speiser et al. 1991; Hoffman et al. 1996] and a patient with a homozygous deletion of 
the CYP21 gene who never experienced a salt-losing crisis has been mentioned [Bachega et al. 
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1999].  Also, steroid 21-hydroxylase deficient mice needed exogenous corticosteroids only 
during a few weeks after birth and survived without treatment after that period [Gotoh et al. 
1994].  Such seemingly contradictory phenomena may be due to improved renal function later 
in life [Rösler 1984], to extra-adrenal production of aldosterone, or to both. 
Physiological aldosterone levels are typically two or three orders of magnitude smaller than 
cortisol levels.  About 25 % of all patients with classical steroid 21-hydroxylase deficiency 
retain the capacity to synthesise sufficient amounts of aldosterone to avert the acute crises 
outlined above.  However, the adrenal cortex still turns hyperplastic and produces excess 
amounts of steroids that do not need 21-hydroxylation (see fig. 1).  Although the most 
abundant of these, 17α-hydroxyprogesterone, is a poor substrate for the 17,20-lyase activity of 
CYP17 [Auchus et al. 1998], peripheral conversion of excess adrenal androgens still leads to 
high testosterone levels.  Testosterone itself does not cause major abnormalities of the internal 
genitalia in female steroid 21-hydroxylase patients [New et al. 1989], but it is converted to 
dihydrotestosterone in the skin of the external genitalia, causing pre- and postnatal virilisation 
[Speiser 1999b; White and Speiser 2000; American Academy of Pediatrics 2000].  Virilisation 
is prominent in all patients with classical steroid 21-hydroxylase deficiency; as opposed to salt 
losers, patients without salt loss constitute a separate category termed 'simple virilisers'.  Since 
virilisation is obviously more perceptible in girls, steroid 21-hydroxylase deficiency was often 
not recognised in boys in previous decades and many of them died of an unsuspected adrenal 
crisis soon after birth. 
 
Nonclassical steroid 21-hydroxylase deficiency 
A further category of patients has 'nonclassical' (also termed 'late onset') steroid 
21-hydroxylase deficiency, with no salt-losing crises or prenatal virilisation.  Here, signs of 
androgen excess are typically noticed during childhood or later in life [Kohn et al. 1982; New 
et al. 1989; Dewailly et al. 1993; Morán et al. 1998; Morán et al. 2000; Speiser 2001].  It 
should be emphasised here that the distinction between the three categories described above is 
not very sharp: the severity of salt loss and the degree of virilisation may vary between 
patients with the same genetic defect, and designations such as 'mild salt loss' or 'some degree 
of virilisation' are common in the literature. 
Deviant growth patterns and precocious puberty are hallmarks of all forms of steroid 
21-hydroxylase deficiency, and a frequent reason for medical examination of patients not 
previously admitted with the more severe symptoms described above.  While early growth 
appears to be relatively normal [Thilén et al. 1995], bone age often advances beyond 
chronological age by several years during childhood (see New [1995] for a striking example), 
but adult height is below average due to early epiphyseal closure [Grumbach et al. 1978; Kohn 
et al. 1982; Kandemir and Yordam 1997; Hagenfeldt 2000; Eugster 2001; New 2001b; Speiser 
2001]. 
Several other signs of androgen excess, especially in women, in steroid 21-hydroxylase 
deficiency may become manifest later in life [Eldar-Geva et al. 1990; Holmes-Walker et al. 
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1995; Rumsby et al. 1998; Morán et al. 2000].  Reduced fertility has been reported in women 
and men [Morán et al. 1998; Meyer-Bahlburg 1999; Jääskelainen et al. 2000; Cabrera et al. 
2001; Krone et al. 2001]. 
Several types of tumour-like tissue have been found in the adrenals of CAH patients 
[Takayama et al. 1988; Ogo et al. 1991; Ravichandran et al. 1996].  Also, so-called 
'incidentalomas' [Ogo et al. 1992; Sasano 1994; Seppel and Schlaghecke 1994; Kloos et al. 
1995; Abo et al. 1999; Sadoul et al. 1999; Morioka et al. 2000; Grossrubatscher et al. 2001] 
are frequently discovered in the adrenal by computed tomography scans performed for 
unrelated purposes.  Some of these produce steroids and cause clinical phenomena that may 
resemble various hereditary or acquired defects of adrenocortical steroidogenesis [Rao and 
Melby 1997; Reincke et al. 1997; Forsbach et al. 2000; Phillips et al. 2000].  Adrenal rest 
tissue and  steroidogenic Leydig cell tumours have been found in the testis [Bongiovanni and 
Root 1963; Solish et al. 1989; Namiki et al. 1991; Avila et al. 1996; Rich et al. 1998]; a recent 
systematic study found these at high frequency even in well controlled steroid 21-hydroxylase 
patients [Stikkelbroeck et al. 2001].  Adrenal-like tissue has also been detected in the ovary 
[Russo et al. 1998; Al-Ahmadie et al. 2001]. 
 
Diagnosis 
Patients with classical congenital adrenal hyperplasia typically present with one or several of 
the symptoms summarised above.  Deviant serum electrolytes and the resulting increase in 
plasma renin activity (PRA) are clinical-chemical characteristics of salt loss.  Plasma sodium 
concentrations may drop to 100 mM (normal reference range: 135-145 mM [Mitruka and 
Rawnsley 1981]).  A defining marker of steroid 21-hydroxylase deficiency is a serum level of 
17α-hydroxyprogesterone [Lippe et al. 1974; Hughes and Winter 1978; Petersen and 
Christensen 1979] that is well above the upper limit of the normal reference range of 6 nmol/l.  
Basal levels of more than 1,000 nmol/l have been observed in some patients with classical 
steroid 21-hydroxylase deficiency [Koppens et al. 1998].  An ACTH stimulation test [New et 
al. 1983; Höller et al. 1985] allows a distinction between the different categories of the 
disease, although there is some overlap.  Androstenedione offers similar information, but the 
differences are less pronounced [New et al. 1983].  The alternative of 21-deoxycortisol, which 
is synthesised from 17α-hydroxyprogesterone by CYP11B1 in steroid 21-hydroxylase 
deficiency and thus provides a convenient distinction with 11β-hydroxylase deficiency, has 
been advocated more recently [Gueux et al. 1988; Fiet et al. 1989; Fiet et al. 1994]. 
Radioimmunoassay of steroids purified by conventional chromatography purification is a 
reliable method, but cross-reactivity of antibodies has been reported [Makela and Ellis 1988; 
Hashimoto et al. 1989; Koshida et al. 1989; Brotherton and Rothbart 1990; Al Saedi et al. 
1996; Andrew 2001].  HPLC separation prior to RIA avoids this problem [Imaizumi et al. 
1987; Koshida et al. 1989; Senciall et al. 1990; Volin 1995; Koppens et al. 1998].  Other 
steroid analysis methods have been described [Wallace 1995; Andrew 2001], the most 
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prominent of which is gas chromatography-mass spectrometry of urinary or serum steroids 
[Miyazaki et al. 1985; Blau et al. 1987; Wudy et al. 1995; Wudy et al. 2000]. 
Prenatal diagnosis of congenital adrenal hyperplasia in new pregnancies in families with a 
known index case was first based on steroid measurements in amniotic fluid.  The discovery 
of the genetic linkage of steroid 21-hydroxylase deficiency to the MHC [Dupont et al. 1977] 
soon led to the introduction of HLA serotyping and segregation analysis as a supplementary 
technique [Price et al. 1978; Levine et al. 1979; Pollack et al. 1979; New et al. 1981; Pang et 
al. 1985; Grosse-Wilde et al. 1988].  Later, DNA analysis of the CYP21 gene itself and 
closely linked MHC markers [Mornet et al. 1986; Strachan et al. 1987; Killeen et al. 1988; 
Olerup et al. 1989; New 1990] allowed earlier diagnosis by chorionic villi sampling.  
Nowadays, direct detection of CYP21 mutations [Wedell 1998b; New et al. 2001] or 
microsatellite analysis [Ezquieta et al. 1997; Lako et al. 1999] are the methods of choice. 
Newborn screening to detect unsuspected cases of steroid 21-hydroxylase deficiency is based 
on assay of steroids (notably, 17α-hydroxyprogesterone) in blood spots on filter paper [Pang 
et al. 1977; Broessler et al. 1986].  Screening programmes have been introduced in many 
countries [Wallace et al. 1986; Pang et al. 1988; Cicognani 1992; Cutfield and Webster 1995; 
Lange et al. 1995; Balsamo et al. 1996; Allen et al. 1997; Sack et al. 1997; Tajima et al. 1997; 
Witchel et al. 1997; Therrell et al. 1998; Brosnan et al. 1999; Cartigny-Maciejewski et al. 
1999; Brosnan and Brosnan 2000], including the Netherlands [van der Kamp et al. 2001]. 
 
Treatment 
Steroid replacement therapy has been the universally accepted treatment of CAH patients for 
more than half a century now.  Lacking aldosterone in salt-losing patients is replaced with 9α-
fluorocortisol (usually termed fludrocortisone in this context), a strong mineralocorticoid.  The 
glucocorticoid replacement in children is cortisol itself (termed hydrocortisone).  
Glucocorticoid replacement therapy is aimed at suppressing the hypothalamic-pituitary-
adrenal axis in order to avoid excessive ACTH-driven androgen production [Miller and 
Levine 1987; New 1995; Lopes et al. 1998; Charmandari et al. 2001; Speiser 2001; White 
2001].  Several alternative approaches to the treatment of steroid 21-hydroxylase deficiency 
have been discussed in recent years [Van Wyk et al. 1996; Speiser 1999a; Stratakis and 
Rennert 1999; White and Speiser 2000]. 
  
Incidence of different types of steroid 21-hydroxylase deficiency 
The incidence of classical steroid 21-hydroxylase deficiency is often reported as 1:10,000 to 
1:15,000.  Several factors may influence that figure.  Before the advent of neonatal screening, 
estimates were based on case survey: the number of reported CAH patients who were born 
within a certain period of time divided by the total number of newborns during that period.  A 
few decades ago, many cases escaped detection, and salt-losing patients often died before the 
diagnosis of CAH was made.  The survival of newborn boys with SL CAH, where virilisation 
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(which could serve as a warning sign in girls) was not apparent, was especially problematic.  
This is reflected in the ratio between male and female patients, and between salt losers and 
simple virilisers (table 1). 
 
 
Table 1.  Percentages of male patients and salt losers in historic and recent reports on classical congenital 
adrenal hyperplasia 
time perioda region patients % male % SL  reference 
1924-1955 worldwide 135 42.2 --  Iversen [1955]b 
before 1950 Switzerland 49 34.7 20.4  Prader et al. [1962]c 
1950-1962 Switzerland 42 47.6 64.3  Prader et al. [1962]c 
before 1963 worldwide -- -- 30  Bongiovanni and Root [1963]d 
before 1950 USA (Mass.) 57 -- 7.0  Fife and Rappaport[1983] 
1950-1959 USA (Mass.) 76 -- 47.4  Fife and Rappaport[1983] 
1960-1979 USA (Mass.) 57 -- 61.8  Fife and Rappaport[1983] 
1958-1985 Birmingham, UK 117 40.2 60.2  Virdi et al. [1987]e 
1959-1988 Netherlands 48 54.2 70.8  Koppens et al. [1992a]f 
1960-1969 USA (Texas) 40 35.0 65.0  Marks and Fink [1969] 
1963-1979 France 472 41.9 72.7  Bois et al. [1985]g 
1969-1986 Sweden 143 44.1 65.0  Thilén and Larsson [1990]h 
1969-1998 Central Europe 484 43.0 64.7  Kovács et al. [2001] 
1971-1995 Turkey 219 17.4 38.8  Kandemir and Yordam [1997]i 
1980-1988 worldwide 77 -- 75.3  Pang et al. [1988]j 
1980-1991 Northern Italy 29 58.6 69.0  Balsamo et al. [2000]j 
1986-1994 Sweden 66 45.5 83.6  Thilén et al. [1998]j,k 
1989-1995 USA (Texas) 121 54.5 72.7  Therrell et al. [1998]j 
--: not reported 
a: approximate period during which the patients were born (not always mentioned in the cited reports) 
b: report includes only salt losers 
c: calculated from table 4 
d: percentage salt losers as stated in this review 
e: percentage salt losers based on 113 patients 
f: supplemented with data from Chapter 2.2 
g: compiled from table II and the text 
h: calculated from table 2 
i: compiled from table 1 
j: neonatal screening programme; the other studies are case surveys 
k: compiled from table 3 and the text 
 
 
Earlier diagnosis during recent years [Fife and Rappaport 1983; Virdi et al. 1987; Thilén and 
Larsson 1990; Kovács et al. 2001] has probably contributed to the improvement in the 
detection of salt-losing patients, but screening programmes are necessary to avoid missing SL 
patients, since they find a higher incidence of steroid 21-hydroxylase deficiency than case 
survey in the same region [Pang et al. 1988; Hofman and Pang 1993; Therrell 2001].  Clearly, 
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reliable estimates of disease incidence and allele frequency in each population can only be 
made by systematic searches in large groups of individuals.  Table 2 summarises such data 
from several countries. 
 
 
Table 2.  Approximate incidence of classical congenital adrenal hyperplasia due to steroid 21-hydroxylase 
deficiency in several countries. 
country incidence reference 
Belgium 1 : 25000 F. Eyskensa 
Brazil 1 : 7500 b 
France 1 : 11337 Cartigny et al. [1999]c 
Germany 1 : 8000 A.A. Roscherd 
Israel (Arabs) 1 : 7979 Sack et al. [1997] 
Israel (Jews) 1 : 29589 Sack et al. [1997] 
Italy (Emilia) 1 : 25090 Balsamo et al. [2000] 
Italy (Romagna) 1 : 7437 Balsamo et al. [2000] 
Japan 1 : 18000 Tajima et al. [1997] 
Netherlands 1 : 11779 van der Kamp et al. [2001] 
New Zealand 1 : 23344 Cutfield and Webster [1995] 
Phillipines 1 : 7000 C.D. Padillab 
Portugal 1 : 14285 e 
Sweden 1 : 9800 Thilén et al. [1998] 
Switzerland 1 : 12730 Lange et al. [1995] 
Taiwan 1 : 28000 Lee et al. [2000b]f 
UK (Scotland) 1 : 18410 Wallace et al. [1986] 
USA (Texas) 1 : 16008 Therrell et al. [1998] 
USA (Wisconsin) 1 : 10692 Allen et al. [1997] 
USA (Alaska, Yupik) 1 : 282 Pang et al. [1982]g 
a: quoted by van der Kamp et al. [2001] 
b: quoted by Therrell [2001] 
c: including three suspected patients who died before recall 
d: quoted by Krone et al. [2000] 
e: quoted by Hofman and Pang [1993] 
f: no neonatal screening; calculated from a mutation analysis of 1000 controls 
g: salt-losers only 
 
 
Clearly, classical steroid 21-hydroxylase deficiency is a common inherited metabolic disorder, 
with an estimated worldwide allele frequency of 1:60 [Pang et al. 1988], but considerably 
higher in some populations.  Remarkable differences in incidence may exist over a relatively 
small distance between apparently related population groups, such as between two adjacent 
regions in Italy [Balsamo et al. 2000]. 
Similar data are not available for nonclassical 21-hydroxylase deficiency, because patients 
with this mild form of the disease often escape detection by neonatal screening.  Reported 
estimates based on ACTH testing in selected groups are much higher: 0.1 to 1 % of the 
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general Caucasian population (which implies a carrier frequency of 1:5 to 1:16) and 3 to 5 % 
in Ashkenazi Jews [Speiser et al. 1985; Sherman et al. 1988; Speiser et al. 1989; Dumic et al. 
1990; Zerah et al. 1990].  However, searches for the most common mutations in this disease in 
several countries [Dacou-Voutetakis and Dracopoulou 1999; Fitness et al. 1999; Dolzan et al. 
1999; Chapter 3.2] did not confirm this high carrier frequency in other Caucasian populations.  
Since androgen excess is a feature of congenital adrenal hyperplasia, several authors have 
searched for unrecognised cases of (nonclassical) steroid 21-hydroxylase deficiency in 
hyperandrogenic women.  Here too, recent molecular data [Blanché et al. 1997; Ostlere et al. 
1998; Dolzan et al. 1999; Escobar-Morreale et al. 1999] did not confirm earlier findings based 
on hormonal data [Morán et al. 1998]. 
 
1.5. The CYP21 gene in the Major Histocompatibility Complex 
The significance of the Major Histocompatibility Complex (MHC) to the study of steroid 
21-hydroxylase deficiency is one of genetic linkage.  The co-segregation of the deficient allele 
with the HLA type in families of 21-hydroxylase patients was first described by Dupont et al. 
in 1977 [Dupont et al. 1977], a discovery foreshadowed five years earlier by the finding that 
testosterone production in mice was linked to the H-2 system (the murine MHC) [Iványi et al. 
1972].  Additional linkage studies allowed the construction of an early version of an MHC 
map that included the steroid 21-hydroxylase locus [Levine et al. 1978]. 
The associations of salt-losing steroid 21-hydroxylase deficiency with the HLA-B47 serotype 
and of the nonclassical (then termed 'late-onset') form with HLA-B14 were described soon 
after [Klouda et al. 1978; Pucholt et al. 1978; Laron et al. 1980].  HLA serotyping was soon 
used for segregation studies and prenatal diagnosis of steroid 21-hydroxylase deficiency 
[Levine et al. 1979; New et al. 1981].  These insights led the way to the association of the 
21-hydroxylase gene with the gene encoding the fourth component of complement [O'Neill et 
al. 1982] and to the identification of the gene later known as CYP21 [White et al. 1984c].  
Closely linked markers remain an important tool to follow the segregation of steroid 
21-hydroxylase deficiency, although HLA serotyping has given way to microsatellite marker 
analysis [Ezquieta et al. 1997; Lako et al. 1999; White and Speiser 2000; Matsuzaka et al. 
2001]. 
 
The human MHC 
The human MHC is a segment of the short arm of chromosome 6, located at the chromosomal 
band 6p21.31 (see fig. 3).  The size of the conventional MHC is at least 3.3 Mb and inclusion 
of peripheral areas that have been characterised in recent years extends it to nearly 8 Mb [Beck 
and Trowsdale 2000].  Understandably, there has been some dispute as to where the MHC 
should end [Klein and Sato 1998]. 
The MHC derives its name from the term 'histocompatibility', referring to the early studies - 
on rejection or acceptance of transplanted tumours in mice - that defined this area of research 
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[Gorer et al. 1948].  The proteins involved in this host-versus-graft reaction were termed H-2 
in mice and HLA (Human Leukocyte Antigen) in humans.  Insight into the crucial role of the 
MHC in immunity came later, initiated by the Nobel-Prize-winning research of Zinkernagel 
and Doherty [1974]. 
Class I HLA molecules are on the outside of most cells, presenting cytosolic peptides to 
patrolling cytotoxic T lymphocytes.  Class II HLA molecules are expressed on B lymphocytes 
and macrophages (and on some other cells), presenting extracellular peptides (such as the 
remains of bacteria that have been eliminated by macrophages) to helper T cells [Abbas et al. 
1997]. 
The classical HLA class I genes, HLA-A, -B and -C, are highly polymorphic; several more 
recently discovered class I-like genes show a smaller degree of polymorphism [Marsh et al. 
2001].  The designation HLA-D was originally used to define a serologically identifiable B 
lymphocyte antigen that was soon found to be identical to another antigen first named 'DR' 
(D-related).  The name HLA-DR was assigned to the corresponding class II locus and by a 
peculiar twist of genetic etymology, other HLA class II loci were baptised HLA-DP, -DQ, 
-DM, etc. 
 
Fig. 3.  Overview of the human MHC.  Top: short arm of chromosome 6 with band 6p21.31 (not all 
chromosome bands are shown).  Centre: Major Histocompatibility Complex with the 'classical' and 
'extended' ('ext.') class II and class I regions and the central region known as 'class III'.  Only a few 
'well-known' genes are shown; many more genes and pseudogenes exist in each region [Beck and 
Trowsdale 2000; Milner and Campbell 2001].  Bottom: the RCCX region and its surroundings.  A 
bimodular arrangement is shown; the Human Genome Project sequence of the area [Rowen et al. 
1999a] features a monomodular sequence and uses the designation 'CYP21A2' for the CYP21 gene.  
The origin of the scale is the centromeric boundary of the RCCX region.  The dotted lines do not 
delineate either the MHC in the central part of the figure or the RCCX region in the bottom part, but 
merely serve as an indicator of the magnification.  The arrows indicate the direction in which each gene 
is transcribed.  Proteins encoded are: HLA-A, -B, -C and -DRA: HLA antigens; TNF: tumour necrosis 
factor; BF: complement factor B (properdin); C2: second component of complement; RP1, C4, CYP21, 
TNXB: see text; the exact function of the ubiquitously expressed genes DOM3Z, SKI2W and RD [Yang 
et al. 1998] remains to be elucidated. 
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The 0.7 Mb of DNA that separates the MHC class I and class II areas has been termed 'class 
III', although the genes it contains are structurally and functionally unrelated to the HLA 
antigens.  Quite a few class III genes are somehow related to immune function, but many 
others are not, and many non-HLA genes have been found in the class I and II regions as well.  
A recent gain in  subdividing the MHC has been the 'class IV region' [Gruen and Weissman 
2001], a proposed split of class III to distinguish genes involved in inflammation from the 
complement area.  However, others have questioned the wisdom of any concept of the entire 
MHC as a immunological 'superstructure' and indeed there seems no reason to assume that 
unrelated genes residing in the MHC owe their physical closeness to anything but chance - 
although a case can be made for co-ordination of expression [Kelly and Trowsdale 1994].  It 
has been rightfully pointed out that while 'class I' and 'class II' are acceptable designations for 
the respective HLA genes and proteins, the term 'class III' has no functional significance 
[Klein and Sato 1998; Dawkins et al. 1999].  Summarising, the question: 'What is the MHC?' 
[Powis and Geraghty 1995] is a matter of ongoing research and debate. 
 
Polymorphism and evolution of the MHC 
The classical class I HLA genes (HLA-A, -B and -C) and most of the class II genes (notably, 
HLA-DRB1 and -DPB1) are highly polymorphic [Marsh et al. 2001].  Several types of natural 
selection are believed to be responsible for maintaining this high degree of polymorphism in 
different populations [Forsdyke 1991; Kaufman et al. 1993; Parham and Ohta 1996; Meyer 
and Thomson 2001]: in the eloquent wording of Potts and Wakeland [1993], it is 'a tale of 
incest, pestilence and sexual preference'.  The complexity and the organisation of the 
mammalian MHC are not typical of other vertebrates: for example, the chicken MHC is only 
0.1 Mb in size and has the regions in a II-I-III order [Kaufman et al. 1999] and the class I and 
class II region are not linked in many teleostic fish [Klein and Sato 1998].  How the MHC 
evolved is a matter of controversy in evolution biology [Abi Rached et al. 1999; Kasahara 
1999; Yeager and Hughes 1999; Hughes and Pontarotti 2000].  However, consensus seems to 
exist about the following issues: 
- the genes now referred to as 'class III' existed before the class I and class II genes [Klein 
and Sato 1998]; 
- duplication and translocation of chromosomal segments have generated the tandem 
arrangement of structurally similar class I and II genes [Trowsdale et al. 1995; Dawkins et 
al. 1999]; 
- the layout of each region varies dramatically between species [Kaufman et al. 1993; 
Kronenberg et al. 1994; Trowsdale 1995; Klein and Sato 1998]; 
- the class I and class II regions contain many pseudogenes [Beck and Trowsdale 2000], but 
the class III region does not (the 21-hydroxylase pseudogene CYP21P is a rare exception) 
[Milner and Campbell 2001]; 
- recombination, gene conversion and point mutation have each contributed to the 
variability of the MHC genes and alleles in various ways [Kuhner et al. 1991; Ohta 1995; 
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Ohta 1997; Martinsohn et al. 1999; Högstrand and Böhme 1999; Carrington 1999], which 
may differ per species, per region and per locus [Cadavid et al. 1999; Matsui et al. 1999; 
Yeager and Hughes 1999]; 
- recombination occurs more often in specific small areas ('hotspots') than in the relatively 
stable large regions ('frozen blocks') that separate them [Carrington 1999; Dawkins et al. 
1999; Jeffreys et al. 2001]. 
The genetic mechanisms that drive the evolution of the MHC also play a key role in 
generating diversity at the CYP21 locus, thus creating the inherited defects that cause steroid 
21-hydroxylase deficiency (see below). 
 
Ancestral haplotypes and MHC disease association 
An ancestral haplotype is a conserved set of (MHC) loci that occurs in a specific population at 
a higher frequency than might be expected from the frequencies of each individual marker that 
is characteristic of the haplotype.  The concept of ancestral haplotypes (previously: extended 
haplotypes, or supratypes)  [Dawkins et al. 1983; Degli-Esposti et al. 1992] has proved its 
value to define the association between certain diseases and the MHC: although some diseases 
(such as steroid 21-hydroxylase deficiency) are clearly caused by a defect in a single gene, 
many others remain elusive and are more clearly associated with an extended haplotype than 
with an allelic variant at any individual MHC locus.  Ancestral haplotypes consist of 
'polymorphic frozen blocks' that vary in size and composition [Tokunaga et al. 1988; Zhang et 
al. 1990], and a growing number of characteristic alleles is assigned to each haplotype 
[Dawkins et al. 1999].  Although such areas show reduced combination [O'hUigin et al. 
2000], the 'freezing' should not be taken too literally, as the study of the CYP21/C4 loci has 
clearly shown: for example, differences in size [Donohoue et al. 1987] and composition [Chu 
et al. 1992; Levo and Partanen 1997a] have been found in the HLA-B47 haplotype that is 
strongly associated with steroid 21-hydroxylase deficiency, and unequal crossing-over has 
been observed in the well-characterised 8.1 ancestral haplotype [Sinnott et al. 1990; Yang et 
al. 1999], as well as other variants of the RCCX module [Fasano et al. 1992; Koppens et al. 
2002a]. 
Not surprisingly, many MHC-associated diseases have a (putative or confirmed) 
immunological component.  To name but a few: ankylosing spondylitis [Szöts et al. 1986; 
Dawkins et al. 1999], common variable immunodeficiency and IgA deficiency [Volanakis et 
al. 1992; Price et al. 1999], insulin-dependent diabetes mellitus [Cohen-Haguenauer et al. 
1985; Cheong et al. 2001], multiple sclerosis [Hillert and Olerup 1993; Ramachandran and 
Bell 1995; Haines et al. 1998], myasthenia gravis [Leelayuwat et al. 1994; Franciotta et al. 
2001], myocardial infarction [Kramer et al. 1994; Lefvert et al. 1995; Nityanand et al. 1999]; 
psoriasis vulgaris [Dawkins et al. 1999; Gruen and Weissman 2001], rheumatoid arthritis 
[Hillarby et al. 1990; Mimori et al. 1990; Park et al. 1996; Rupert et al. 1999; Ota et al. 2001], 
spontaneous abortions [Laitinen et al. 1992; Lokki and Laitinen 2001], sudden infant death 
[Schneider et al. 1989; Opdal et al. 1999], systemic sclerosis [Briggs et al. 1993; Takeuchi et 
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al. 1998; Venneker et al. 1998], systemic lupus erythematosus [Schur et al. 1990; Takeuchi et 
al. 1996; Würzner and Dierich 1997; Carroll 1998; Reveille et al. 1998; Veggeberg 1998; 
Takeda et al. 1999; Einav et al. 2002] and susceptibility to several infectious diseases [Hill et 
al. 1991; De Messias et al. 1993; Leelayuwat et al. 1993; Jaatinen et al. 1999; Price et al. 
1999; Meyer and Thomson 2001; Seppänen et al. 2001].  The HLA- and complement C4- 
association of the diseases on this far-from-complete list were often identified early, but recent 
research has expanded to defects in other genes as well [Gruen and Weissman 2001].  Steroid 
21-hydroxylase deficiency was the first HLA-linked disease that was obviously not related to 
the immune system [Dupont et al. 1977].  Although the completion of the MHC genomic 
sequence [MHC Sequencing Consortium 1999] has greatly facilitated the analysis of 
monogenic diseases, finding the genetic basis of many clinically diverse and probably 
polygenic disorders that are associated with specific ancestral haplotypes, remains a 
challenging task for years to come [Price et al. 1999; Alper and Awdeh 2000; Gruen and 
Weissman 2001]. 
 
Genes of the central MHC (the class III region) 
As explained above, the genes of the central MHC share no common characteristics and the 
term 'class III region' is merely a designation of a 730 kb stretch of DNA that lies between the 
class II and class I regions without harbouring any of the typical HLA genes (see fig. 3).  The 
class III area contains at least 62 genes, with NOTCH4 near the centromeric and BAT1 near 
the telomeric end [Beck and Trowsdale 2000; Milner and Campbell 2001].  Insight in to the 
structure and function of the individual genes is growing rapidly [Cheng et al. 1993; Iris et al. 
1993; Marshall et al. 1993; Dangel et al. 1995b; Albertella et al. 1996; Nalabolu et al. 1996; 
Yang et al. 1998; Yu 1998; Dawkins et al. 1999; Allcock et al. 2001; Gruen and Weissman 
2001; Milner and Campbell 2001]. 
The area surrounding the CYP21 gene lies some 200 kb from the centromeric end of the class 
III region.  This stretch of DNA has the most complicated structure of the MHC and probably 
of the entire human genome.  The four key constituent genes (starting from the telomeric side) 
are: 
- RP1 (also known as G11 or STK19), 11.4 kb in size and ubiquitously expressed [Sargent 
et al. 1994; Shen et al. 1994; Yang et al. 1998], encoding a nuclear serine/threonine 
protein kinase [Gomez-Escobar et al. 1998]; 
- C4,  either 20.5 or 14.2 kb in size and primarily expressed in the liver, encoding the fourth 
component of complement [Carroll and Porter 1983; Belt et al. 1984; Carroll et al. 1984; 
Yu et al. 1988; Yu 1991; Dangel et al. 1994]; 
- CYP21 (also known as CYP21B, 21OHB, or several variant designations), 3.4 kb in size 
and primarily expressed in the adrenal cortex, encoding steroid 21-hydroxylase [White et 
al. 1984c; White et al. 1985; Carroll et al. 1985b; Higashi et al. 1986; White et al. 1986; 
Rodrigues et al. 1987]; 
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- TNXB (also known as TNX or XB), 68.2 kb in size and expressed in several tissues 
including skin, tendons and blood vessels, encoding an extracellular matrix protein 
[Morel et al. 1989b; Gitelman et al. 1992; Matsumoto et al. 1992; Bristow et al. 1993b]. 
These four genes constitute the RCCX module, a stretch of DNA that is usually present in a 
tandemly duplicated arrangement (see below).  As a consequence of this duplication, most 
chromosomes carry two complement C4 genes (C4A and C4B) and one CYP21 gene plus one 
CYP21P pseudogene. 
The complement system is aimed at destroying the cell walls of invading bacteria, or 
generally, any cell to which an antibody has attached.  The fourth component (C4) is required 
for the classical pathway of complement activation [Abbas et al. 1997].  C4 has two isoforms, 
C4A ('acidic') and C4B ('basic') that differ from each other by a few amino acids in a protein 
region known as C4d.  Activated C4 binds covalently to the cell surface; C4A has a higher 
affinity towards amino groups, C4B towards hydroxyl groups [Campbell et al. 1986; 
Williamson and Turner 1987; Law and Dodds 1990; Dodds and Law 1990; Yu 1998; Martinez 
et al. 2001].  The C4 proteins are highly polymorphic: the C4d region also contains the Chido 
and Rodgers blood cell antigens, each of which have multiple subtypes [Carroll and Alper 
1987; Yu et al. 1988; Yu 1998; Blanchong et al. 2001; Martinez et al. 2001]. 
Non-expression of either C4A or C4B is relatively common in the general population, with 
reported frequencies of C4A*Q0 and C4B*Q0 of 5-20 % [Howard et al. 1986; Wang et al. 
1989; Hartung et al. 1992; Briggs et al. 1993; Franciotta et al. 1995; Nityanand et al. 1995; 
Lhotta et al. 1996].  Nevertheless, an increased frequency of C4 null alleles has been observed 
in many patients reporting with diverse immunological problems, including most of the HLA-
associated diseases listed in the previous paragraph.  Complete C4 deficiency is a rare disease, 
associated with severe forms of systemic lupus erythematosus in most cases [Reveille et al. 
1985; Fredrikson et al. 1991; Fasano et al. 1992; Lokki et al. 1999]. 
Tenascin-X is the name assigned to the product of the TNX gene [Bristow et al. 1993b].  
Tenascins are large extracellular matrix proteins, expressed in specific embryonal and adult 
tissues.  At present, five tenascins have been described [Jones and Jones 2000; Joester and 
Faissner 2001].  The TNXB gene was first discovered by cDNA cloning of a gene expressed 
on the opposite strand of CYP21 [Morel et al. 1989b; Gitelman et al. 1992].  The biological 
function of tenascin-X was explained by the finding that patients with TNX deficiency suffer 
from a variant of the Ehlers-Danlos syndrome [Burch et al. 1997; Mao and Bristow 2001; 
Schalkwijk et al. 2001], a term that covers a spectrum of skin and connective tissue disorders, 
some of which have been characterised at the molecular level [Burrows 1999].  Tenascin-X 
deficiency patients manifest characteristics such as hyperextensible skin, poor wound healing, 
joint laxity and vascular fragility. 
 
The RCCX module 
The RCCX module was named after the four genes listed in the previous paragraph (RP1-C4-
CYP21-XB) [Shen et al. 1994; Yu 1998].  Its modular character has significance at the DNA 
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level only, but exerts a powerful influence on the structure and expression of three of these 
genes.  The RCCX module has its centromeric boundary in intron 32 of TNXB and its 
telomeric boundary in exon 5 of RP1.  There are two size variants: a 'short' RCCX module is 
26,483 bp and a 'long' RCCX module is 32,856 bp [Rowen et al. 1999a].  The difference is 
determined by the presence or absence of a 6373 bp insert in the ninth intron of the C4 gene, 
which is an inserted human endogenous retrovirus [Patience et al. 1997] known as HERV-
K(C4) [Schneider et al. 1986; Palsdottir et al. 1987; Yu and Campbell 1987; Dangel et al. 
1994; Tassabehji et al. 1994; Chu et al. 1995; Dangel et al. 1995a].  HERV-K(C4) is oriented 
in an opposite direction to C4 and it may provide an antisense-based protection mechanism 
against exogenous retroviruses [Schneider et al. 2001]. 
Most human chromosomes have two RCCX modules (see figs. 3 and 4; the term 'RCCX 
region' will be used to designate all contiguous RCCX modules on the same chromosome).  
This is apparently due to a duplication of a primordial single RCCX module that happened 
more than 23 million years ago, well before the speciation of the great apes [Kawaguchi et al. 
1990; Bontrop et al. 1991; Kawaguchi et al. 1992; Horiuchi et al. 1993].  In an evolutionary 
step typical of the expansion of the MHC, this duplication created two separate C4 genes.  The 
CYP21 gene was copied at the same time.  A mechanism can be envisioned by which C4 and 
CYP21 developed in opposing directions from this situation of two identical tandem RCCX 
modules.  Variants of C4 with different affinities probably already existed, and a crossover or 
gene conversion involving such a variant could well have generated the first bimodular 
chromosome with two different C4 genes, conferring a selectional advantage due to a greater 
flexibility of attachment to different antigens.  This notion is supported by the observation that 
C4 duplicated independently in many other species [Horiuchi et al. 1993]; for example, a 
region of 55 kb (again including the Cyp21 gene) has been duplicated in the mouse [Chaplin et 
al. 1983; White et al. 1984a].  In contrast to C4, two active CYP21 genes offered no benefit 
and may have been a liability considering the sensitivity of regulatory mechanisms (despite 
the variability of the RCCX region found in modern humans, no chromosome with two active 
CYP21 genes has yet been found).  At the very least, the second CYP21 gene was not needed, 
and analysis of CYP21P variability [Horiuchi et al. 1993; Koppens et al. 2000] suggests that it 
gradually accrued several deleterious mutations in a specific order. 
The TNXB and RP1 genes were duplicated in part, giving rise to truncated remainders known 
as TNXA (XA) and RP2.  While the 1 kb duplicated part of RP2 is identical to the 
corresponding part of RP1, the 5.7 kb TNXA pseudogene has a 120 bp deletion on an intron-
exon boundary as compared to TNXB.  This is inconsequential in the normal situation, but can 
play a role in the generation of genetic defects (see below). 
As mentioned above, the TNX genes are transcribed in the opposite direction of the RP, C4 
and CYP21 genes.  The 3' ends of TNXB (which is also expressed in the adrenal cortex) and 
CYP21 overlap, and their mRNAs need protection by nuclear proteins to avoid hybridisation 
in vivo [Speek and Miller 1995].  The transcriptional complexity of the RCCX region is 
remarkable: in this extremely gene-dense area, no fewer than fifteen RNA transcripts have so 
far been found (see fig. 4).  By analogy to the designation 'gene X' which was initially used for
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TNX, some of these RNA's have been assigned to 'gene Y' and 'gene Z', each of which is also 
duplicated (hence YA, YB, ZA and ZB).  However, the mRNA's of 'only' five genes in the 
RCCX region (C4A, C4B, CYP21, TNXB and RP1/G11) are actually translated into protein. 
 
CYP21 and CYP21P gene structure 
The CYP21 gene, encoding steroid 21-hydroxylase and its pseudogene CYP21P, are highly 
similar, sharing about 98 % sequence homology [Higashi et al. 1986; White et al. 1986; 
Rodrigues et al. 1987].  The most significant differences are shown in fig. 8 in paragraph 1.7: 
several mutations cause CYP21P to be inactive, and the same mutations are the most frequent 
cause of CAH caused by 21-hydroxylase deficiency (see below).  There is nothing very 
remarkable about the CYP21 gene itself: it owes its complex genetics exclusively to the 
turbulent genetic environment of the RCCX region. 
Steroid 21-hydroxylase is either 494 or 495 amino acids in size (the difference is due to an 3 
bp insert in the first exon that has no influence on the enzyme's function [Higashi et al. 1991]).  
It has domains for integration into the membrane, interaction with cytochrome P450 reductase, 
haem binding, substrate binding and oxygen/water binding [Lewis and Lee-Robichaud 1998; 
White and Speiser 2000].  Studies of artificial and naturally occurring mutations have 
identified the amino acids that define the functioning of  these domains [Sakaki et al. 1990; 
Wu et al. 1991; Hsu et al. 1993; Hsu et al. 1996; Hu et al. 1996; Nikoshkov et al. 1998]. 
Several elements in the promoter region of CYP21 influence its expression in different ways 
[Rice et al. 1990; Schimmer and Parker 1992; Parissenti et al. 1993; Wilson et al. 1993; 
Morley et al. 1996; Chin and Chang 1998].  It has been found that the promoter region of 
CYP21P, although structurally similar to the CYP21 promoter, has at most 10-20 % of its 
activity [Bristow et al. 1993a; Chang and Chung 1995; Kyllo et al. 1995; Endoh et al. 1998].  
Some regulatory elements of CYP21 lie as far as 3 to 5 kb upstream, inside the C4 gene 
[Milstone et al. 1992; Watanabe et al. 1993; Tee et al. 1995b; Wijesuriya et al. 1999]. 
 
1.6. Variability of the RCCX region 
Approximately two-thirds to three-quarters of all copies of chromosome 6 have two RCCX 
modules, and a large majority of these have the (centromere-to-telomere) layout TNXB-
CYP21-C4B-RP2-TNXA-CYP21P-C4A-RP1, as described above and illustrated in figs. 3 and 
4.  However, there are many variants with regard to the number of modules and to the 
composition of each gene within those modules.  The overall layout of the RCCX region, 
which can vary from monomodular to quadrimodular, is described in detail in Chapter 2, and 
Chapters 4, 5 and 8 provide a discussion about the genetic mechanisms that account for this 
variability.  The most prominent disease-causing mutations of CYP21 and the consequences of 
the variability of CYP21P are discussed in Chapter 3.1.  A concise overview of RCCX 
variability should therefore suffice here. 
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Historically and technically, the dual complementary approach to analysing RCCX variability 
is: 
- 'haplotyping' by restriction analysis, Southern blotting and hybridisation; 
- a gamma of other methods, often based on PCR amplification of sequences of interest. 
Of course, this approach is based on the insights gained from earlier biochemical and genetic 
research, and a wealth of other techniques from molecular biology have been successfully 
applied to answer many questions regarding the structure, regulation and expression of the 
genes in the RCCX module - but the approach outlined above covers a vast area of research in 
this field and is as viable today [White and Speiser 2000; Baumgartner-Parzer et al. 2001; 
Blanchong et al. 2001] as it was more than a decade ago [White et al. 1988; Morel et al. 
1989a; Owerbach et al. 1990]. 
Conceptually, analysing RCCX variability revolves around two questions: 
- How many RCCX modules are aligned on each chromosome 6 and what is their 
composition? 
- What defines the structure and function of the genes in each module? 
The answers to these questions allow us to understand the origin of disease-causing mutations 
in this intriguing part of the human genome.  As explained below, the dual experimental 
approach mentioned above roughly parallel these questions. 
 
CYP21/C4 haplotyping 
A haplotype can simply be described as a chromosomal segment inherited from one parent 
[Dawkins et al. 1983].  In terms of the RCCX region, a haplotype is usually defined in terms 
of certain characteristics of the CYP21 (and CYP21P) and C4 genes.  There is no generally 
accepted standard that defines which characteristics make up an RCCX haplotype, so 
depending on the focus of their research, different authors have described haplotypes in terms 
of CYP21 genes [Werkmeister et al. 1986; Dawkins et al. 1987; White et al. 1988; Morel et al. 
1989a; Strumberg et al. 1992], C4 genes [Palsdottir et al. 1987; Partanen 1987; Teisberg et al. 
1988; Blanchong et al. 2000], or both [Carroll et al. 1985a; Rumsby et al. 1988; Collier et al. 
1989; Partanen et al. 1989; Hillarby et al. 1990; Schneider 1990; Haglund-Stengler et al. 
1991; Koppens et al. 1992a; Weg-Remers et al. 1997; Lobato et al. 1998].  In this thesis, each 
haplotype is assigned a capital letter to represent the configuration of CYP21/CYP21P, plus a 
number to distinguish between the different sizes of the C4 genes [Koppens et al. 1992a], but 
several other systems have been used by other groups [Hillarby et al. 1990; Schneider 1990; 
Haglund-Stengler et al. 1991; Weg-Remers et al. 1997; Blanchong et al. 2000].  A 
nomenclature of that is both concise and systematic has not been proposed so far. 
Technically, CYP21/C4 haplotyping has greatly benefited from the fortuitous circumstance 
that TaqI restriction patterns proved to be an extremely reliable indicator of the composition of 
the RCCX region.  The TaqI sites and cDNA probes used for haplotyping are shown in fig. 5 
(the method is discussed in detail in paragraph 1.8 and Chapter 2). 
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Fig. 5.  TaqI and BglII restriction sites in a bimodular RCCX module, and typical banding patterns.  This example 
shows two RCCX modules, a long one and a short one; the 5.4 and 7.0 kb C4 bands are characteristic of this 
haplotype.  The TaqI banding pattern shown indicates heterozygosity: the other haplotype of this individual has 
two long RCCX modules, as shown by the 6.0 kb TaqI band.  The small triangle underneath TNXA represents a 
120 bp deletion; the corresponding site in TNXB (which has no deletion) is indicated by a dashed line.  The BglII 
patterns are the same for all bimodular chromosomes: the 11 kb band represents the most centromeric module, 
while all other modules have a 12 kb band. 
 
 
The CYP21 probe allows a distinction between CYP21 and CYP21P and between TNXA and 
TNXB: 
- 3.7 kb: CYP21; 
- 3.2 kb: CYP21P; 
- 2.5 kb: TNXB; 
- 2.4 kb: TNXA. 
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The 3.7 kb versus 3.2 kb difference is due to an additional TaqI site in the 5' flank of CYP21P 
only (see figs. 5 and 6).  The nucleotide change involved lies close to, but not inside, a region 
of importance to the activity of the CYP21 promoter [Chang and Chung 1995].  A completely 
functional CYP21 gene that has this extra TaqI site has never been found, but partly active 
hybrid genes have been described [Killeen et al. 1991; l'Allemand et al. 2000].  Although rare, 
these exceptions may confound the interpretation of CYP21 haplotypes.  The 2.5 kb versus 2.4 
kb difference is due a 120 bp deletion in TNXA. 
The C4 probe allows a distinction between 'long' (20.5 kb) and 'short' (14.2 kb) C4 genes and 
it shows whether C4 is adjacent to an RP1 gene or to a truncated RP2 pseudogene.  The 
following fragments can be found: 
- 7.0 kb: long C4 gene adjacent to RP1; 
- 6.4 kb: short C4 gene adjacent to RP1; 
- 6.0 kb: long C4 gene adjacent to RP2; 
- 5.4 kb: short C4 gene adjacent to RP2. 
These differences are due to the position of the most telomeric TaqI site, which lies outside of 
the RCCX region, and to a TaqI site in the 6.3 kb HERV-K(C4) insert.  The sizes listed above 
are those traditionally mentioned in the literature [Schneider et al. 1986], but the fragments are 
actually about 0.2 kb larger [Koppens et al. 1992b; Rowen et al. 1999a]. 
Other TaqI bands than those listed above have been described in a few isolated cases [Higashi 
et al. 1988a; Goldstein et al. 1991; Koppens et al. 1992b; Lim and Chan 1996; Bachega et al. 
1999]. 
TaqI digestion of genomic DNA and hybridisation to CYP21 and C4 probes is usually 
sufficient by itself, especially when a segregation study can be done.  BglII restriction analysis 
is a useful complementary method, especially when no C4 probe is used, to distinguish 
between monomodular and bimodular in CAH patients with an apparent deletion of the 
CYP21 gene.  In complicated cases, long-range SacII restriction mapping can provide 
additional information.  Haplotyping is discussed in detail in Chapters 2 and 6 (see fig. 1 in 
Chapter 2.2 for an overview of monomodular, bimodular, trimodular and quadrimodular 
CYP21/C4 haplotypes).  A comparison of different populations shows considerable 
differences between the haplotype frequencies found in each group (see Chapter 2); such 
differences probably influence the frequency of de novo mutations that cause 21-hydroxylase 
deficiency [Sinnott et al. 1990; Yang et al. 1999] or C4 [Fasano et al. 1992] deficiency. 
CYP21/C4 haplotyping has a dual significance in understanding the genetic defects that cause 
steroid 21-hydroxylase deficiency.  First, the relative intensity of the 3.7 kb TaqI band on 
autoradiograms is a reliable indicator of the number of CYP21 genes a person has.  Absence of 
CYP21 is the molecular defect in approximately one-third of the 21-hydroxylase deficiency 
alleles in Western European populations.  Second, determining the overall arrangement of the 
RCCX region is the first step in understanding how unequal crossover and gene conversion 
create genetic defects in the RCCX region (see below). 
Haplotyping was the only available approach to study CYP21 defects until the advent of PCR-
based mutation analysis about ten years ago.  Recent results underline the continued 
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importance of determining the composition of the RCCX module by means of haplotyping, 
especially in 'non-standard' cases [Krone et al. 1998; Wedell 1998a; Baumgartner-Parzer et al. 
2001; Koppens et al. 2002c]. 
An elegant direct demonstration of the arrangement of the RCCX module by fluorescent in 
situ hybridisation has been published a few years ago [Suto et al. 1996], but this approach has 
not been widely adopted. 
 
Variation not detected by haplotyping 
The duplicated structure of the 'standard' RCCX region features genes that are, by their very 
nature, highly similar but slightly different.  Many methods to characterise the DNA sequence 
alterations that define the functionality of each gene have been applied.  Before the advent of 
the PCR, these methods were rather laborious, for example: 
- complement C4 serotyping [O'Neill et al. 1978; Marcus and Alper 1986; Mauff et al. 
1993]; 
- RFLP analysis of genomic DNA with restriction enzymes that have been selected to 
recognise functional sequence differences [Yu and Campbell 1987; Partanen and 
Campbell 1989; Urabe et al. 1990];  
- hybridisation of allele-specific oligonucleotides to digested genomic DNA in dried 
agarose gels [Amor et al. 1988; Globerman et al. 1988; Speiser et al. 1988] or on 
Southern blots [Higashi et al. 1988a]; 
- sequencing of patient genes to detect defects directly [Harada et al. 1987; Rodrigues et al. 
1987; Higashi et al. 1988b; Barba et al. 1993]. 
Nowadays, mutation detection is usually based on (diverse variants of) the PCR; a few popular 
methods are: 
- hybridisation of allele-specific oligonucleotides to membrane-fixed PCR products [Braun 
et al. 1990; Owerbach et al. 1992a; Rumsby et al. 1992; Speiser et al. 1992; Dondi et al. 
1994; Ezquieta et al. 1996; Koppens et al. 2000; Weintrob et al. 2000]; 
- allele-specific PCR with oligonucleotides that have a single-base mismatch at the 3' end 
[Wedell and Luthman 1993b; Wilson et al. 1995a; Carrera et al. 1997]; 
- electrophoresis of digested and undigested amplified DNA fragments [Barba et al. 1993; 
Shevtsov et al. 1994; Killeen et al. 1998; Grant et al. 2000; Lee et al. 2000a; Yokoyama 
et al. 2000; Koppens et al. 2002a; Koppens et al. 2002b]; 
- amplification-created restriction sites, based on the creation of a restriction site that 
matches part of an oligonucleotide an part of either the wild type or the mutated sequence 
[Lee et al. 1996; Oriola et al. 1997; Tajima et al. 1997; Ko et al. 1998]; 
- direct sequencing of PCR products by various methods [Berg et al. 1990; Rumsby et al. 
1992; Ohlsson and Schwartz 1997; Chin et al. 1998; Lokki et al. 1999]; 
- single strand conformational polymorphism analysis [Barba et al. 1993; Siegel et al. 
1994; Vaishnaw et al. 1995; Bobba et al. 1997; Hayashi et al. 1997]; 
- ligase detection of amplified fragments reaction [Day et al. 1995]; 
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- cleavase fragment length polymorphism analysis [Wei and Killeen 1998]; 
- reverse dot-blot hybridisation [Yang et al. 2001]. 
The merits of most of these methods have been compared in two recent reviews [White and 
Speiser 2000; Lee 2001].  In the author's opinion, allele-specific PCR is currently the method 
of choice for rapid detection of the most common mutations, especially when the number of 
samples is small.  Allele-specific oligonucleotide hybridisation is still a good alternative for 
large numbers of samples and offers the advantage that blots can be re-hybridised many times 
with different probes.  Microarray technology has so far not been used in the routine detection 
of CYP21 mutations, but is likely to be implemented in the near future [Lee 2001]. 
Defective CYP21 genes usually contain one or more of nine defects typically found in 
CYP21P.  Other mutations are relatively rare: in classical 21-hydroxylase deficiency they 
represent fewer that 5 % of all deficiency alleles in most populations (see tables 3 and 5), but 
they may be more common in NC 21-hydroxylase deficiency.  The CYP21P pseudogene 
shows a high variability in the general population, a factor which complicates the analysis of 
hybrid CYP21 genes [Helmberg et al. 1992a; Wedell and Luthman 1993a; Koppens et al. 
2000].  Gene conversion-like processes are believed to be responsible for sequence exchange 
between CYP21 and CYP21P.  With respect to the layout of the RCCX module, one element 
seems to be constant: all CYP21-like genes that are transcribed and translated into an enzyme 
are part of the most centromeric RCCX module.  No chromosomes have ever been found 
where an active CYP21 gene lies telomeric to an inactive CYP21P pseudogene, or even to 
another CYP21 gene. 
Sequence variability has a rather different impact at the complement C4 locus.  Defects may 
lead to non-expression of the C4 gene (C4A*Q0 or C4B*Q0), but a small number of 
differences, primarily in the C4d region, determines whether the gene is C4A or C4B gene and 
what its Chido or Rodgers antigen is.  In a bimodular RCCX region, the telomeric C4 gene 
usually expresses C4A and the centromeric usually expresses C4B, but all kinds of variants to 
this theme have been described in the literature [Yu et al. 1986; Carroll and Alper 1987; Yu 
and Campbell 1987; Braun et al. 1990; Barba et al. 1993; Barba et al. 1994; Paz-Artal et al. 
1994; Moulds et al. 1996; Schneider et al. 1996; Yu 1998; Lokki et al. 1999; Blanchong et al. 
2001; Martinez et al. 2001]. 
Considerable polymorphism exists at the TNX locus.  The most important difference between 
TNXB and the truncated TNXA pseudogene is the 120 bp deletion in TNXA.  This difference 
can be detected by haplotyping (see the previous paragraph), but PCR-based methods [Burch 
et al. 1997; Koppens et al. 2002a; Koppens et al. 2002b] are more convenient.  Presence of the 
deletion (which lies on an exon-intron boundary) in TNXB causes a frameshift and contributes 
to tenascin-X deficiency [Burch et al. 1997; Schalkwijk et al. 2001].  TNXA pseudogenes 
without the deletion have also been reported [Rupert et al. 2001; Koppens et al. 2002b], but 
this change is phenotypically inconsequential.  Apart from this 120 bp difference, several 
other (neutral) polymorphisms exist in this region [Weissensteiner and Lanchbury 1997; 
Koppens et al. 2002a; Koppens et al. 2002b]. 
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The 1 kb section of the RP gene that lies within the RCCX module is also polymorphic 
[Ulgiati and Abraham 1996]. 
 
1.7. Genetic mechanisms creating CYP21 defects 
Misalignment  and genetic defects 
Mutational mechanisms have been thoroughly studied in lower eukaryotes such as yeasts, 
where generation times are short, chemicals or radiation can be used to induce specific 
mutations, and the products of de novo events are readily available.  In studies of human 
patients suffering from an inherited disease however, genetic mechanisms can often only be 
inferred by comparing consensus 'wildtype' sequences with sequences that somehow deviate 
from that consensus - and assuming that a certain type of mutation has caused the difference.  
De novo mutations are relatively rare (see table 4 for examples involving CYP21 and 
CYP21P) and chance determines which of the recombined chromosomes will be available for 
analysis.  Nevertheless, recent studies on single mammalian cells [Högstrand and Böhme 
1997; Carrington 1999; Högstrand and Böhme 1999; Jeffreys et al. 1999; Martinsohn et al. 
1999; Johnson and Jasin 2000; Jeffreys et al. 2001] have greatly contributed to our knowledge 
of two mutational mechanisms: 
- recombination, a reciprocal exchange of a large part of homologous chromosomes 
aligning during meiosis; 
- gene conversion, a non-reciprocal copying of a small part of one sister chromatid to the 
other in somatic cells. 
Actually, an important lesson from these (and other) recent reports is that this grouping of 
mechanisms into two categories constitutes a simplification in several respects.  
Recombination also occurs during mitosis [Tischfield et al. 1997; Holt et al. 1999; Wijnhoven 
et al. 2001], gene conversion in the mouse MHC appears to be limited to germline cells 
[Högstrand and Böhme 1997; Högstrand and Böhme 1999], and several lines of evidence 
indicate that complex rearrangements including but not limited to combinations of gene 
conversion and recombination occur during mitosis, meiosis and DNA repair [Jeffreys et al. 
1999; Martinsohn et al. 1999; Johnson and Jasin 2000; Wijnhoven et al. 2001].  The 
preference for the sister chromatid in gene conversion is probably simply a matter of 
proximity [Johnson and Jasin 2000]. 
In the light of this recent evidence, it is clear that routine assignment of terms such as 'gene 
conversion' or 'gene deletion' to specific CYP21 defects should be seen as a categorisation of 
mutations rather than a concise description of the exact genetic mechanism that caused these 
mutations.  Still, careful analysis of de novo mutations (see table 4 and Chapter 4) and hybrid 
genes (see Chapters 3 and 5) does provide considerable insight into the 'origin of disease-
causing mutations'. 
The high degree of sequence similarity between tandemly repeated RCCX modules increases 
the propensity of chromatids to misalign in this region.  Difference in the number of RCCX 
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modules necessarily causes misalignment, but two bimodular chromatids may also misalign 
[Koppens et al. 2002a].  Within the limitations outlined above, a simple model of unequal 
crossover and gene conversion in the RCCX region can be envisioned (see fig. 6).  The only 
direct study of these mechanisms in the RCCX region in single cells [Tusié-Luna and White 
1995] showed that unequal crossovers were exclusively meiotic, and gene conversions 
primarily mitotic. 
 
Fig. 6.  Hypothetical unequal crossover and gene conversion between two bimodular chromosomes. 
The misalignment requires additional loops to correctly align neighbouring areas of the chromosomes 
that lie outside the RCCX module; for an example, see fig. 6 in Chapter 4.  6a: Unequal crossover after 
misalignment of homologous chromosomes during meiosis leads to the transfer of an RCCX module 
from one chromosome to the other, creating a defective CYP21P/CYP21 hybrid.  6b: Non-reciprocal 
gene conversion in somatic cells copies a part of one sister chromatid to the other, introducing a 
CYP21P-like defect into CYP21 if these genes misalign. 
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Large-scale gene deletions by unequal crossover 
As illustrated in fig. 6a, meiotic unequal crossover effectively results in the transfer of an 
RCCX module from one chromosome to the other.  The location of the actual crossover site 
determines the composition of the hybrid module that is formed by this process: fig. 7 shows 
how different breakpoint locations between a misaligned bimodular and monomodular 
chromosome result in various hybrids.  Depending on the analysis method, such hybrids may - 
by comparison to the standard bimodular layout - be classified as, for example,  'CYP21 and 
C4B deletion' (fig. 7a, 7b and 7c), 'CYP21P and C4B deletion' (fig. 7d), or 'CYP21P and C4A 
deletion' (fig. 7e). 
The existence of specific zones in the RCCX module where the crossover occurs preferentially 
or even exclusively, has been suggested [Donohoue et al. 1989].  However, CYP21P 
variability [Helmberg et al. 1992a; Wedell and Luthman 1993a; Koppens et al. 2000] has 
blurred the borders of such putative crossover zones, and the identification of several 
additional crossover sites in the CYP21 [Killeen et al. 1991; Tusié-Luna and White 1995; 
l'Allemand et al. 2000; Baumgartner-Parzer et al. 2001] and TNX genes [Burch et al. 1997; 
Rupert et al. 1999; Yang et al. 1999; Koppens et al. 2002a; Koppens et al. 2002b] suggests 
that crossovers may take place anywhere in the RCCX module.  However, the high degree of 
DNA sequence similarity limits the possibility to pinpoint the exact location. 
Again by comparison to the standard layout, bimodular RCCX regions with two CYP21P 
genes (as judged by TaqI restriction analysis - see fig. 1 in Chapter 2.2) are usually called 
'large-scale conversions of CYP21 to CYP21P'.  However, mutation analysis of the hybrid 
RCCX modules found in such haplotypes showed that they are highly similar to the above-
mentioned monomodular 'deletion' haplotypes [Koppens et al. 2000; Koppens et al. 2002a; 
Koppens et al. 2002b].  Since there seems to be no reason to postulate a different mechanism 
for the generation of monomodular and bimodular chromosomes with one hybrid RCCX 
module, the term 'large-scale gene conversion' should be avoided in this context: 'CYP21 gene 
deletion by unequal crossover' is more consistent [Koppens et al. 2002b]. 
 
Small-scale gene conversions and other mutations 
CYP21 defects that are characteristics of the consensus sequence of the CYP21P pseudogene 
[Higashi et al. 1986; White et al. 1986; Rodrigues et al. 1987] are attributed to gene 
conversion (see fig. 6b).  Although gene conversion can cover several kb [Johnson and Jasin 
2000], a gene conversion-like event that transfers a part of CYP21P to CYP21, or vice versa, 
typically involves a few hundred bp at most - a phenomenon that has also been observed 
elsewhere in the MHC [Martinsohn et al. 1999].  Theoretically, no distinction can be made 
between a double crossover (or two consecutive single crossovers) and a gene conversion, 
since the non-reciprocity of the conversion cannot be demonstrated - however, in a short 
stretch of DNA, gene conversion is far more likely. 
Nine or ten small-scale gene conversions (see below; Pro453→Ser may or may not be a 
conversion) and  combinations of  these, account for  the  majority  of  the genetic defects  that 
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cause steroid 21-hydroxylase deficiency in all populations studied to date (see table 5).  Many 
other mutations have been identified (see table 3), but they have usually been found in isolated 
cases and are not present in CYP21P. 
A small-scale gene conversion that transfers the TaqI restriction site in the 5' flanking 
sequence of CYP21P to CYP21 will be recognised as a larger defect in haplotyping studies.  
No conversion limited to this single marker has so far been reported; it could be distinguished 
from a 'genuine' hybrid RCCX module by examining sequences that lie telomeric to the TaqI 
site. 
 
 
 
 
 -1000 1000 2000 30000
Le
u3
0
Pr
o3
0
A 
or
 C
 a
t b
p 
65
5
G
 a
t b
p 
65
5
8 
bp
 d
el
et
io
n
n
o
 d
el
et
io
n
Ile
17
2
As
n1
72
Ile
Va
lG
lu
M
et
23
6
Va
l2
81
As
nG
lu
G
lu
Ly
s
Le
u2
81
Ph
e3
06
1 
bp
 in
se
rt
G
ln
31
8
st
op
31
8
Ar
g3
56
Tr
p3
56
Pr
o4
53
Pr
o 
or
 S
er
45
3
TaqI
TaqI TaqI TaqI
TaqI
AATAAApromoter
transcription of CYP21 transcription of TNXB
telomere centromere
3.2 kb0.5 kb
scale (bp)
CYP21P
CYP21
regulatory elements
at 3-5 kb upstream
Fig. 8. Principal differences between the CYP21 gene and the CYP21P pseudogene.  The orientation 
of the figure is opposite to fig. 3: the transcription of CYP21 is from left to right, so the centromere is on 
the right.  Open boxes represent CYP21 exons [Higashi et al. 1986]; the open boxes with the dashed 
outline represent the two final exons of the TNXB gene [Bristow et al. 1993b], which is transcribed in 
the opposite direction.  The CYP21 polyadenylation signal lies at the leftmost A of AATAAA.  The 
differences in the coding area also represent the most common CYP21 defects found in steroid 
21-hydroxylase deficiency (see the text).  The amino acids shown for CYP21P are an indication of 
substitution mutations; CYP21P is not translated.  G versus A or C at bp 655 is the intron 2 splice 
junction mutation. Ser453 has been reported in some CYP21P pseudogenes but not in the consensus 
sequence.  The characteristic TaqI sites are shown, with the 3.2 kb CYP21P fragment and the extra 
0.5 kb for CYP21.   
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Phenotype and genotype 
The relationship between genotype and clinical phenotype is rather straightforward in most 
steroid 21-hydroxylase deficiency patients: the more severe the genetic defects as predicted by 
the DNA sequence or demonstrated by expression studies, the more severe the manifestation 
of CAH.  However, there are quite a few deviations from this pattern.  As explained above, the 
clinical manifestations of steroid 21-hydroxylase deficiency are manifold and may change as 
patients age [Horner et al. 1979; Stoner et al. 1986; Sinnott et al. 1989; Speiser et al. 1991; 
Hoffman et al. 1996]; also, aldosterone production in patients with a homozygous CYP21 
deletion [Speiser et al. 1991; Koppens et al. 1998] constitutes a paradox.  Phenotypic variation 
between patients with the same genetic defect [Speiser et al. 1992; Wilson et al. 1995b; 
Witchel et al. 1996; Krone et al. 2000] is another peculiar phenomenon, especially when the 
patients are sibs [Sinnott et al. 1989; Bormann et al. 1992; Chin et al. 1998] (many of the 
mutation analysis studies listed in table 5 also report on clinical differences between patients 
where the same mutations were found). 
To address phenotype-genotype relationship in a systematic way, the concept of 'mutation 
groups' has been introduced [Speiser et al. 1992; Wilson et al. 1995b]: patients are categorised 
on the basis of the CYP21 defects found on both chromosomes and this genotype is matched 
to a set of clinical and biochemical parameters.  Thematically, this is a refinement of an earlier 
notion: patients should theoretically have the phenotype that matches their 'least defective' 
allele [New et al. 1989].  Phenotypic variation has recently been reported in 23 out of 85 
mutation groups [New 2001a]. 
Expression studies of mutated steroid 21-hydroxylase have provided a wealth of information 
on the enzyme's structure and function [Higashi et al. 1988b; Tusié-Luna et al. 1990; Higashi 
et al. 1991; Wu et al. 1991; Chung et al. 1995; Hu et al. 1996; Lajic et al. 1997; Nikoshkov et 
al. 1997; Nikoshkov et al. 1998; Lajic et al. 1999; Ohlsson et al. 1999].  However, these in 
vitro experiments do not necessarily predict the in vivo enzymatic activity or the clinical 
severity of CAH [White and Speiser 2000]. 
An overview of naturally occurring CYP21 mutations together with their reported clinical 
association is presented in table 3 (amino acid and nucleotide numbering is according to 
Higashi et al. [1986]).  A brief discussion of the most common defects (those attributed to 
recombination or gene conversion), in descending order of severity, is warranted: 
- deletion of CYP21 by unequal crossover: no enzyme is produced; 
- nonsense and frameshift mutations (8 bp deletion in exon 3; 1 bp insertion in exon 7; 
Gln318→stop): truncation of the protein before the haem binding site, due to premature 
termination of translation [Globerman et al. 1988; Higashi et al. 1988a]; 
- cluster of three mutations (Ile236→Asn, Val237→Glu, Met239→Lys) in exon 6: no 
enzymatic activity, possibly due to a defect in substrate binding [Higashi et al. 1988b]; 
- Arg356→Trp: usually reported as complete deficiency due to impaired reductase 
interaction [Chiou et al. 1990; Lajic et al. 1997]; unlike the defects listed above, this 
mutation is sometimes associated with SV 21-hydroxylase deficiency (see table 5); 
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- additional splice acceptor site in intron 2: the most frequent mutation in SL 
21-hydroxylase deficiency, but not consistently associated with that form because a small 
amount of RNA is still spliced correctly [Higashi et al. 1988b; Higashi et al. 1991; 
Witchel et al. 1996]; 
- Ile172→Asn: results in a conformationally changed enzyme with an altered cellular 
location, but retains about 1 % of  the wildtype enzymatic activity, sufficient to prevent 
salt loss; this is the most common defect in SV 21-hydroxylase deficiency [Amor et al. 
1988; Hsu et al. 1996]; 
- Pro30→Leu: reduces enzyme stability and activity, causing NC 21-hydroxylase 
deficiency but occasionally a more severe form [Tusié-Luna et al. 1990; Hu et al. 1996; 
Frisch et al. 2001]; 
- Val281→Leu: probably reduces haem group binding, causing NC 21-hydroxylase 
deficiency; this mutation is associated with HLA-B14 DR1 [Speiser et al. 1988; Wu et al. 
1991]; 
- Pro453→Ser: conformational effect unknown, but contributes to a subtle form of NC 
21-hydroxylase deficiency that may remain largely asymptomatic; reports differ as to 
whether this mutation represents a CYP21P to CYP21 gene conversion or an  independent 
mutation [Helmberg et al. 1992b; Owerbach et al. 1992b; Wedell et al. 1992; Nikoshkov 
et al. 1997; Chapter 3.2]. 
The location of each of these mutations is shown in fig. 8. 
 
De novo mutations 
In the study of steroid 21-hydroxylase deficiency, several reasons have been described why a 
patient can have a mutation that was not present in the previous generation: 
non-paternity (or even non-maternity); this can be checked with independent genetic markers 
(microsatellite analysis is the method of choice); 
a new meiotic mutation; in this case, one of the parents is not a carrier; 
a new somatic mutation in a parent's germline; in this case, the parent is a carrier, but the 
mutation is not found in leukocyte DNA (which is routinely used for genetic analysis); 
uniparental isodisomy, when the patient receives two identical copies of chromosome 6 from a 
parent who is a steroid 21-hydroxylase deficiency carrier. 
Reports on de novo mutations are summarised in table 4.  The mechanics of such mutations 
are not always easy to visualise: because most authors did not analyse putative template genes 
in gene conversions, the actual extent of the converted area often remains uncertain. 
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 9
 
Tr
p4
05
→
st
op
 
no
ns
en
se
 m
ut
at
io
n 
S
L 
W
ed
el
l a
nd
 L
ut
hm
an
 [1
99
3b
] 
24
91
 
ex
on
 1
0 
G
ly
42
4→
S
er
 
un
kn
ow
n 
S
V
 
B
ill
er
be
ck
 e
t a
l. 
[1
99
9]
 
24
98
 
ex
on
 1
0 
A
rg
42
6→
H
is
 
un
kn
ow
n 
S
V
 
B
au
m
ga
rtn
er
-P
ar
ze
r e
t a
l. 
[2
00
1]
 
24
98
 
ex
on
 1
0 
A
rg
42
6→
P
ro
 
ne
ut
ra
l p
ol
ym
or
ph
is
m
 
no
rm
al
 
H
ig
as
hi
 e
t a
l. 
[1
98
6]
; W
hi
te
 e
t a
l. 
[1
98
6]
 
24
98
 
ex
on
 1
0 
P
ro
42
6→
A
rg
 
ne
ut
ra
l p
ol
ym
or
ph
is
m
 
no
rm
al
 
H
ig
as
hi
 e
t a
l. 
[1
98
6]
; W
hi
te
 e
t a
l. 
[1
98
6]
 
24
98
 
ex
on
 1
0 
P
ro
42
6→
H
is
 
un
kn
ow
n 
S
V
 
B
au
m
ga
rtn
er
-P
ar
ze
r e
t a
l. 
[2
00
1]
 
25
16
 
ex
on
 1
0 
P
ro
43
2→
A
rg
 
un
kn
ow
n 
un
kn
ow
n 
Lo
ba
to
 e
t a
l. 
[1
99
9]
 
25
33
 
ex
on
 1
0 
G
lu
43
7→
A
sp
 
ne
ut
ra
l p
ol
ym
or
ph
is
m
 
no
rm
al
 
H
ig
as
hi
 e
t a
l. 
[1
98
6]
; K
o 
et
 a
l. 
[1
99
8]
 
25
89
 
ex
on
 1
0 
A
sp
45
6→
G
lu
 
un
kn
ow
n 
un
kn
ow
n 
Lo
ba
to
 e
t a
l. 
[1
99
9]
 
25
96
 
ex
on
 1
0 
P
ro
45
9→
S
er
 
un
kn
ow
n 
un
kn
ow
n 
Lo
ba
to
 e
t a
l. 
[1
99
9]
 
26
46
 
ex
on
 1
0 
1 
bp
 d
el
et
io
n:
 T
 (P
ro
47
5)
 
fra
m
es
hi
ft 
m
ut
at
io
n 
S
L 
O
rd
oñ
ez
-S
án
ch
ez
 e
t a
l. 
[1
99
8]
 
26
62
 
ex
on
 1
0 
G
ln
48
1→
Ly
s 
un
kn
ow
n 
un
kn
ow
n 
Lo
ba
to
 e
t a
l. 
[1
99
9]
 
26
65
 
ex
on
 1
0 
P
ro
48
2→
Th
r 
un
kn
ow
n 
un
kn
ow
n 
Lo
ba
to
 e
t a
l. 
[1
99
9]
 
26
65
 
ex
on
 1
0 
P
ro
48
2→
S
er
 
un
kn
ow
n 
un
kn
ow
n 
B
al
sa
m
o 
et
 a
l. 
[2
00
0]
 
26
69
 
ex
on
 1
0 
A
rg
48
3→
P
ro
 
se
ve
re
ly
 re
du
ce
d 
en
zy
m
e 
st
ab
ili
ty
 
S
V
 
W
ed
el
l a
nd
 L
ut
hm
an
 [
19
93
a]
; 
N
ik
os
hk
ov
 
et
 a
l. 
[1
99
8]
 
26
69
 - 
26
70
 
ex
on
 1
0 
1 
bp
 d
el
et
io
n:
 G
G
→
C
 (A
rg
48
3)
 
fra
m
es
hi
ft 
m
ut
at
io
n 
S
L 
W
ed
el
l e
t a
l. 
[1
99
2]
 
26
99
 
ex
on
 1
0 
A
sn
49
3→
S
er
 
ne
ut
ra
l p
ol
ym
or
ph
is
m
 
no
rm
al
 
R
od
rig
ue
s 
et
 
al
. 
[1
98
7]
; 
C
hi
ou
 
et
 
al
. 
[1
99
0]
 
Th
e 
re
po
rts
 c
ite
d 
ab
ov
e 
ar
e 
us
ua
lly
 th
e 
fir
st
 d
es
cr
ip
tio
n 
of
 th
e 
m
ut
at
io
n 
an
d 
an
 in
 v
itr
o 
ex
pr
es
si
on
 s
tu
dy
 o
f t
he
 a
lte
re
d 
en
zy
m
e.
  T
he
 (p
ut
at
iv
e)
 fu
nc
tio
na
l s
ig
ni
fic
an
ce
 
of
 th
e 
ch
an
ge
 is
 a
n 
as
su
m
pt
io
n 
or
 a
 s
pe
cu
la
tio
n 
(in
di
ca
te
d 
by
 '?
') 
of
 th
e 
au
th
or
s 
of
 (o
ne
 o
f) 
th
es
e 
re
po
rts
.  
B
as
e 
pa
irs
 a
re
 n
um
be
re
d 
ac
co
rd
in
g 
to
 H
ig
as
hi
 e
t a
l. 
[1
98
6]
.  
 
 
 
 
Ta
bl
e 
4.
  R
ep
or
te
d 
de
 n
ov
o 
m
ut
at
io
ns
 o
f t
he
 C
Y
P
21
 a
nd
 C
Y
P
21
P
 g
en
es
 
C
Y
P
21
(P
) m
ut
at
io
n 
fre
qu
en
cy
a  
m
od
ea
 
m
os
t l
ik
el
y 
m
ec
ha
ni
sm
 
re
fe
re
nc
e 
C
Y
P
21
 d
el
et
io
n 
1 
/ 3
0 
M
 
un
eq
ua
l c
ro
ss
ov
er
 w
ith
in
 th
e 
TN
X
 g
en
e,
 b
et
w
ee
n 
a 
m
on
om
od
ul
ar
 a
nd
 a
 b
im
od
ul
ar
 c
hr
om
os
om
e 
S
in
no
tt 
et
 a
l. 
[1
99
0]
; S
in
no
tt 
et
 a
l. 
[1
99
1]
 
C
Y
P
21
 d
el
et
io
n 
un
kn
ow
n 
M
 
un
us
ua
l d
el
et
io
n 
in
cl
ud
in
g 
th
e 
H
LA
 g
en
es
 
H
ej
tm
an
ci
k 
et
 a
l. 
[1
99
2]
 
C
Y
P
21
 d
el
et
io
n 
1 
/ 8
5 
M
 
un
eq
ua
l c
ro
ss
ov
er
  w
ith
in
 th
e 
TN
X
 g
en
e,
 b
et
w
ee
n 
tw
o 
bi
m
od
ul
ar
 c
hr
om
os
om
es
 
K
op
pe
ns
 e
t a
l. 
[2
00
2a
] 
C
Y
P
21
P
 d
el
et
io
n 
un
kn
ow
n 
M
 
un
eq
ua
l c
ro
ss
ov
er
 w
ith
in
 th
e 
C
4 
ge
ne
, b
et
w
ee
n 
a 
m
on
om
od
ul
ar
 
an
d 
a 
bi
m
od
ul
ar
 c
hr
om
os
om
e 
Fa
sa
no
 e
t a
l. 
[1
99
2]
 
P
ro
30
→
Le
u 
2 
/ 9
4 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
O
rd
oñ
ez
-S
án
ch
ez
 e
t a
l. 
[1
99
8]
 
P
ro
30
→
Le
u 
an
d 
in
tro
n 
2 
sp
lic
e 
1 
/ 9
4 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
O
rd
oñ
ez
-S
án
ch
ez
 e
t a
l. 
[1
99
8]
 
in
tro
n 
2 
sp
lic
e 
2 
/ 1
54
 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
Le
vo
 a
nd
 P
ar
ta
ne
n 
[2
00
1]
 
in
tro
n 
2 
sp
lic
e 
1 
/ 1
84
 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
W
ed
el
l e
t a
l. 
[1
99
4]
 
in
tro
n 
2 
sp
lic
e 
2 
/ 1
76
 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
S
pe
is
er
 e
t a
l. 
[1
99
2]
 
in
tro
n 
2 
sp
lic
e 
2 
/ 4
6 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
Ta
jim
a 
et
 a
l. 
[1
99
3]
 
in
tro
n 
2 
sp
lic
e 
4 
/ 9
4 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
O
rd
oñ
ez
-S
án
ch
ez
 e
t a
l. 
[1
99
8]
 
Ile
17
2→
A
sn
 
un
kn
ow
n 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
w
ith
in
 a
 3
90
 b
p 
re
gi
on
 
C
ol
lie
r e
t a
l. 
[1
99
3]
 
Ile
17
2→
A
sn
 
1 
/ 3
10
 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
K
ro
ne
 e
t a
l. 
[2
00
0]
 
Ile
17
2→
A
sn
 
2 
/ 1
34
 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
O
hl
ss
on
 e
t a
l. 
[1
99
9]
 
Ile
17
2→
A
sn
 
1 
/ 9
4 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
O
rd
oñ
ez
-S
án
ch
ez
 e
t a
l. 
[1
99
8]
 
A
rg
35
6→
Tr
p 
2 
/ 4
6 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
 
Ta
jim
a 
et
 a
l. 
[1
99
3]
 
no
t r
ep
or
te
d 
1 
/ 1
16
 
G
 
C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
of
 u
nk
no
w
n 
ex
te
nt
, e
ith
er
 th
e 
in
tro
n 
2 
sp
lic
e 
m
ut
at
io
n 
or
 A
rg
35
6→
Tr
p 
B
al
sa
m
o 
et
 a
l. 
[2
00
0]
 
Le
u3
00
→
P
he
 
1 
/ 3
10
 
G
 
no
ve
l m
ut
at
io
n,
 n
ot
 a
 C
Y
P
21
P
 to
 C
Y
P
21
 c
on
ve
rs
io
n 
K
ro
ne
 e
t a
l. 
[2
00
0]
 
A
sn
G
lu
G
lu
Ly
s2
36
 
→
Ile
V
al
G
lu
M
et
 
1 
/ 8
5 
G
 
C
Y
P
21
 to
 C
Y
P
21
P
 c
on
ve
rs
io
n 
w
ith
in
 a
 6
83
 b
p 
re
gi
on
 
K
op
pe
ns
 e
t a
l. 
[2
00
0]
 
in
tro
n 
2 
sp
lic
e 
an
d 
V
al
28
1→
Le
u 
1 
/ 9
4 
D
 
pa
te
rn
al
 u
ni
pa
re
nt
al
 d
is
om
y 
fo
r c
hr
om
os
om
e 
6 
O
rd
oñ
ez
-S
án
ch
ez
 e
t 
al
. 
[1
99
8]
; 
Ló
pe
z-
G
ut
ié
rr
ez
 e
t a
l. 
[1
99
8]
 
Ile
17
2→
A
sn
 
un
kn
ow
n 
D
 
m
at
er
na
l u
ni
pa
re
nt
al
 d
is
om
y 
fo
r c
hr
om
os
om
e 
6 
S
pi
ro
 e
t a
l. 
[1
99
9]
 
Th
e 
m
ut
at
io
n 
fre
qu
en
ci
es
 h
er
e 
ap
pl
y 
to
 e
ac
h 
in
di
vi
du
al
 m
ut
at
io
n 
lis
te
d 
in
 th
e 
le
ftm
os
t c
ol
um
n.
  T
o 
ca
lc
ul
at
e 
th
e 
co
m
po
un
d 
m
ut
at
io
n 
ra
te
 re
po
rte
d 
by
 a
 s
pe
ci
fic
 
re
se
ar
ch
 g
ro
up
, t
he
 n
um
be
r o
f m
ut
at
io
ns
 s
ho
ul
d 
be
 s
um
m
ed
, b
ut
 th
e 
nu
m
be
r o
f c
hr
om
os
om
es
 s
ho
ul
d 
no
t; 
fo
r e
xa
m
pl
e,
 th
e 
to
ta
l n
um
be
r o
f d
e 
no
vo
 m
ut
at
io
ns
 
re
po
rte
d 
by
 T
aj
im
a 
et
 a
l. 
[1
99
3]
 is
 4
, i
n 
46
 c
hr
om
os
om
es
. 
a:
 n
um
be
r o
f d
e 
no
vo
 e
ve
nt
s 
/ n
um
be
r o
f h
ap
lo
ty
pe
s 
in
 th
e 
st
ud
y 
(u
nk
no
w
n:
 re
po
rt 
on
 a
 s
in
gl
e 
ca
se
) 
b:
 p
re
su
m
ed
 m
od
e 
of
 in
he
rit
an
ce
: M
=m
ei
ot
ic
 d
e 
no
vo
 m
ut
at
io
n;
 G
=p
ar
en
ta
l g
er
m
lin
e 
m
os
ai
ci
sm
;  
D
=u
ni
pa
re
nt
al
 d
is
om
y
  Ta
bl
e 
5.
  F
re
qu
en
cy
 o
f C
Y
P
21
 d
ef
ec
ts
 in
 s
te
ro
id
 2
1-
hy
dr
ox
yl
as
e 
de
fic
ie
nc
y 
pa
tie
nt
s 
in
 d
iff
er
en
t p
op
ul
at
io
ns
 
po
pu
la
tio
n 
reference(s)a 
typeb 
number of alleles 
no CYP21 genec 
Pro30 → Leu 
intron 2 splice 
exon 3 del 8 bp 
Ile172 → Asn 
cluster exon 6 
Val281→ Leu 
exon 7 ins 1 bp 
Gln318 → stop 
Arg356 → Trp 
Pro453 → Ser 
combinationd 
other mutatione 
not foundf 
A
rg
en
tin
a 
1 
S
L 
48
 
10
.4
+1
4.
6 
nd
 
22
.9
 
2.
1 
0 
0 
nd
 
nd
 
18
.8
 
2.
1 
nd
 
2.
1 
nd
 
27
.1
 
 
 
S
V
 
24
 
0+
4.
2 
nd
 
4.
2 
0 
45
.8
 
0 
nd
 
nd
 
4.
2 
12
.5
 
nd
 
0 
nd
 
29
.2
 
A
us
tri
a 
2 
 
15
8 
31
.0
 
3.
2 
22
.8
 
0 
15
.8
 
1.
9 
12
.0
 
nd
 
2.
5 
3.
2 
1.
3 
4.
4 
1.
3 
0.
6 
B
ra
zi
l 
3 
S
L 
51
 
5.
9+
11
.8
 
nd
 
27
.5
 
2.
0 
9.
8 
0 
2.
0 
3.
9 
7.
8 
0 
nd
 
7.
8 
nd
 
19
.6
 
 
 
S
V
 
24
 
12
.5
+1
6.
7 
nd
 
12
.5
 
0 
37
.5
 
0 
0 
4.
2 
0 
8.
3 
nd
 
8.
3 
nd
 
4.
2 
B
ra
zi
l 
4 
 
22
8 
4.
4+
6.
6 
-- 
20
.6
 
-- 
14
.0
 
-- 
18
.0
 
-- 
-- 
-- 
-- 
6.
3 
-- 
20
.0
 
B
ra
zi
l 
5 
S
L 
10
2 
18
.6
 
0 
26
.5
 
6.
9 
2.
9 
nd
 
2.
0 
1.
0 
9.
8 
10
.8
 
nd
 
13
.7
 
nd
 
7.
8 
 
 
S
V
 
32
 
18
.8
 
0 
28
.1
 
0 
25
.0
 
nd
 
3.
1 
0 
9.
4 
0 
nd
 
15
.6
 
nd
 
0 
C
hi
le
 
6 
S
L 
96
 
28
.1
 
nd
 
18
.8
 
nd
 
9.
4 
2.
1 
nd
 
0 
9.
4 
14
.6
 
nd
 
2.
1 
nd
 
15
.6
 
C
hi
le
 
7 
S
V
 
30
 
10
.0
 
0 
6.
7 
nd
 
26
.7
 
0 
13
.3
 
3.
3 
6.
7 
0 
0 
0 
nd
 
33
.3
 
D
en
m
ar
k 
8 
 
13
4 
36
.6
 
2.
2 
32
.8
 
0 
9.
7 
0.
7 
2.
2 
0.
7 
7.
5 
0.
7 
nd
 
2.
2 
4.
5 
0 
Fi
nl
an
d 
9 
 
10
0 
35
.0
+6
.0
 
0 
12
.0
 
0 
30
.0
 
0 
3.
0 
0 
2.
0 
1.
0 
0 
8.
0 
1.
0 
2.
0 
Fr
an
ce
 
10
 
S
L 
84
 
33
.3
 
nd
 
22
.6
 
4.
8 
8.
3 
4.
8 
1.
2 
1.
2 
4.
8 
nd
 
0 
3.
6 
7.
1 
8.
3 
 
 
S
V
 
44
 
11
.4
 
nd
 
27
.3
 
4.
5 
27
.3
 
6.
8 
9.
1 
0 
2.
3 
nd
 
0 
6.
8 
2.
3 
2.
3 
 
 
C
L 
22
 
27
.3
 
nd
 
45
.5
 
0 
9.
1 
4.
5 
0 
4.
5 
0 
nd
 
0 
9.
1 
0 
0 
 
 
N
C
 
10
8 
9.
3 
nd
 
11
.1
 
0.
9 
1.
9 
4.
6 
35
.2
 
0.
9 
4.
6 
nd
 
0 
1.
9 
8.
3 
19
.4
 
G
er
m
an
y 
11
 
S
L 
18
4 
25
.5
+7
.6
 
0 
37
.0
 
2.
2 
7.
6 
1.
6 
0 
0.
5 
7.
6 
6.
0 
0 
2.
2 
1.
6 
0.
5 
 
 
S
V
 
10
4 
12
.5
+5
.8
 
4.
8 
21
.2
 
1.
0 
44
.2
 
0 
1.
0 
0 
1.
0 
2.
9 
0 
1.
0 
1.
9 
2.
9 
 
 
N
C
 
22
 
13
.6
+9
.1
 
13
.6
 
18
.2
 
0 
4.
5 
0 
36
.4
 
0 
0 
0 
4.
5 
0 
0 
0 
G
re
ec
e 
12
 
S
L 
98
 
24
.5
 
0 
42
.9
 
5.
1 
2.
0 
0 
0 
0 
14
.3
 
1.
0 
0 
1.
0 
0 
9.
2 
 
 
S
V
 
68
 
5.
9 
19
.1
 
29
.4
 
0 
35
.3
 
0 
1.
5 
0 
5.
9 
0 
0 
0 
0 
2.
9 
 
 
N
C
 
56
 
3.
6 
21
.4
 
5.
4 
0 
7.
1 
0 
41
.1
 
0 
1.
8 
0 
14
.3
 
0 
0 
5.
4 
 
 
 
 po
pu
la
tio
n 
reference(s)a 
typeb 
number of alleles 
no CYP21 genec 
Pro30 → Leu 
intron 2 splice 
exon 3 del 8 bp 
Ile172 → Asn 
cluster exon 6 
Val281→ Leu 
exon 7 ins 1 bp 
Gln318 → stop 
Arg356 → Trp 
Pro453 → Ser 
combinationd 
other mutatione 
not foundf 
In
di
a 
13
 
S
L 
33
 
12
.1
 
3.
0 
27
.3
 
nd
 
12
.1
 
nd
 
nd
 
nd
 
27
.3
 
0 
nd
 
0 
nd
 
15
.2
 
 
 
S
V
 
20
 
10
.0
 
0 
10
.0
 
nd
 
50
.0
 
nd
 
nd
 
nd
 
0 
0 
nd
 
0 
nd
 
30
.0
 
Is
ra
el
 
14
 
N
C
 
90
 
0 
2.
2 
6.
7 
0 
2.
2 
0 
80
.0
 
nd
 
4.
4 
nd
 
nd
 
0 
nd
 
4.
4 
Ita
ly
 
15
 
S
L 
90
 
23
.3
+1
2.
2 
2.
2 
26
.7
 
0 
0 
0 
1.
1 
0 
8.
9 
0 
nd
 
13
.3
 
nd
 
24
.4
 
 
 
S
V
 
30
 
3.
3+
3.
3 
0 
10
.0
 
0 
23
.3
 
0 
3.
3 
0 
6.
7 
0 
nd
 
16
.7
 
nd
 
33
.3
 
 
 
N
C
 
26
 
0+
0 
7.
7 
7.
7 
0 
7.
7 
0 
53
.8
 
0 
7.
7 
0 
nd
 
3.
8 
nd
 
11
.5
 
Ita
ly
 
16
 
S
L 
34
 
8.
8 
0 
64
.7
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1.8. Methods used to study CYP21 and the RCCX module 
The dual approach of RCCX variability analysis (see paragraph 1.6) is reflected in the 
methods used during the project described in this thesis.  This paragraph contains a brief 
outline of these methods and a discussion of some of their technical complications.  
Comprehensive descriptions and details such as hybridisation circumstances, primer 
composition and PCR conditions, can be found in Chapters 2 to 8 of this thesis. 
 
Restriction analysis of genomic DNA 
Basic molecular genetic techniques suffice for CYP21/C4 haplotyping [Ausubel et al. 1989; 
Sambrook et al. 1989].  Briefly, the following protocol was applied: 
- human genomic DNA was isolated from leukocytes [Wyman and White 1980]; 
- 10 µg of DNA was digested with an appropriate restriction enzyme; 
- the DNA was separated by electrophoresis on an agarose gel; 
- the DNA was transferred to a nitrocellulose membrane by capillary blotting [Southern 
1975]; 
- the DNA was fixed to the membrane by baking it at 80°C in a vacuum oven; 
- the membrane was hybridised to a mixture of 32P labelled cDNA probes; 
- after washing, the membrane was exposed to an X-ray film to detect the hybridisation 
signal by fluorography [Amersham International 1992]; 
- the intensity ratios of the bands were quantitated by laser densitometry; 
- haplotypes were deduced by segregation analysis in families of 21-hydroxylase deficiency 
patients; 
- some complicated cases required further analysis by long-range restriction mapping using 
pulsed-field gel electrophoresis [van Ommen and Verkerk 1986; Southern et al. 1987]. 
These techniques have been available for many years and have been applied by many 
investigators, but their technical intricacies should not be underestimated.  In many studies, 
banding patterns are used to establish segregation of haplotypes identifiable by unique bands.  
However, due to the high variability of the RCCX module (see paragraph 1.6 and Chapter 2), 
CYP21/C4 haplotyping depends on the ratio of specific bands: for example, it should be 
possible to distinguish a 2:1 ratio of the CYP21 3.2 and 3.7 kb bands from a 3:2 ratio.  There is 
no need to quote here several reports showing autoradiographs that are obviously unsuitable 
for this purpose, but considering that the average scientist probably does not select the worst 
available results for publication, it is clear that applying the techniques listed above requires 
some expertise.  Initially, our own results were by no means satisfactory either.  So, while the 
detailed protocols published elsewhere (see the references above) provide adequate general 
instructions, it seems suitable to address a few crucial technical issues here. 
Human genomic DNA (10 µg) was digested overnight with 40-60 units of the appropriate 
restriction enzyme, usually according to the manufacturer's instructions.  TaqI digest (at 65° 
C) typically produced good results without additional measures.  For most other enzymes, 
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addition of spermidine at a final concentration of 1-2 mM and addition of half the amount of 
enzyme initially followed by the other half after two hours of incubation, proved beneficial. 
Overnight electrophoresis was done on 0.7 - 1.5 % agarose gels, in 1xTBE with 0.5 µg/ml 
ethidium bromide, at 50-90 volts (depending on the expected fragment size), in a Pharmacia 
GNA-200 submarine electrophoresis unit, using its cooling facility when running at more than 
75 volts.  To obtain sharp bands, a 10 mm slot was used for 10 µg of DNA and ethidium 
bromide was added to the sample at a final concentration of 0.5 µg/µl. 
After electrophoresis, the DNA was partly hydrolysed by soaking the gel in 1 litre of 0.25 M 
HCl for exactly 15 minutes, followed by denaturation and neutralisation steps.  The hydrolysis 
step markedly improved the transfer of DNA.  Traditional overnight capillary Southern 
blotting yielded a more complete transfer of DNA than the use of a vacuum blotting apparatus.  
Accurate band ratios require complete transfer of DNA, which can be checked by re-staining 
the gel with ethidium bromide after blotting. 
Hybridisation was most often done in a plastic box, with 10 % dextran sulphate (later replaced 
with 8 % polyethylene glycol 6000 for economic reasons) in the buffer to improve the 
hybridisation rate.  The CYP21 probe used was pC21/3c [White et al. 1985]; since this cDNA 
probe only partly overlaps the adjacent TNX genes and primarily hybridises to the 3.2 and 3.7 
kb CYP21P and CYP21 bands, we sometimes used a mixture of 0.3 kb KpnI-BamHI fragments 
covering the 3' end of the insert in pC21/3c to obtain a better signal from the 2.4 and 2.5 kb 
bands.  The C4 DNA probe was pAT-A [Belt et al. 1984]; a 0.9 kb PstI fragment produced 
somewhat better results than the 0.6 kb BamHI-BglII fragment used initially [Koppens et al. 
1992a].  Quantitation by laser densitometry is discussed in detail in Chapter 2.1.  For 
interpretation, measured band ratios need to be rounded to integers. 
The procedure outlined here includes several overnight steps and may seem relatively slow, 
but the logistics of processing a few hundred samples (a number typical of this study) are very 
different from those of rapid tests aimed at DNA analysis of one or a few persons. 
Translating band ratios into two separate haplotypes per individual is not always easy and 
straigthforward, as illustrated by a controversy that arose between two prominent research 
groups during the early years of CYP21 haplotyping [Matteson et al. 1987; Miller 1987; White 
et al. 1987; White et al. 1988].  The key to understanding these haplotypes is the notion that 
deletions and insertions involve entire RCCX modules and not individual genes.  Anecdotal 
reports of deletions of CYP21 [Nakura et al. 1987; Rumsby et al. 1988] or CYP21P [Lim and 
Chan 1996] without concomitant deletion of an adjacent C4 gene, probably represent 
misinterpretations of non-standard bimodular RCCX configurations where only the C4 gene 
yields distinct banding patterns.  BglII patterns can be used to facilitate the interpretation of 
TaqI-based haplotypes, because pC21/3c hybridises to a 12 kb BglII fragment, the copy 
number of which is one fewer than the number of RCCX modules.  Several authors have 
therefore emphasised the importance of BglII digests [Donohoue et al. 1986; White et al. 
1988; Morel et al. 1989a].  Although we did use BglII patterns for the interpretation of all 
haplotypes reported in this thesis, simultaneous hybridisation of the CYP21 and C4 cDNA 
probes to Southern blots of TaqI digested DNA, combined with segregation studies, was 
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nearly always sufficient to deduce the haplotypes.  Since this co-hybridisation provides 
valuable additional information without requiring significant additional effort, it is difficult to 
understand why some investigators omit one of the probes, or perform the hybridisations 
separately. 
A final point in the interpretation of CYP21/C4 haplotypes, discussed in more detail in 
Chapter 2, is the fact that some combinations of haplotypes are indistinguishable and can be 
correctly assigned only by segregation study or by long-range restriction mapping.  In 
population studies, it is usually safe to exclude combinations of very rare haplotypes in cases 
where more common haplotypes provide an obvious explanation, if at least the Hardy-
Weinberg equilibrium is observed.  However, this strategy sometimes fails: for example, in an 
isolated individual with a total of three long and two short C4 genes, there is no compelling 
reason to prefer a distribution of long-short-short plus long-long to the alternative of long-
long-short plus long-short.  Surprisingly, this point has been missed even in a recent 
authoritative report from one of the leading groups in complement C4 genetics [Blanchong et 
al. 2000]. 
SacII restriction mapping was used to assess the total length of the RCCX module in 
complicated cases.  We devised a method to use DNA that had been isolated by a conventional 
protocol [Wyman and White 1980] in pulsed-field gel electrophoresis; the results suggest that 
prior to SacII digestion, most DNA was present as fragments of at least 200 Mb in size (see 
Chapter 7 for technical details). 
 
Specific amplification of CYP21, CYP21P and the TNX genes 
The analysis of the RCCX region by specific amplification of sequences of interest by means 
of the polymerase chain reaction [Saiki et al. 1985; Mullis and Faloona 1987] is hampered by 
the high similarity of the genes and pseudogenes in this region.  CYP21 and CYP21P are 98 % 
similar [Higashi et al. 1986], so the prospect of specific amplification depends on whether the 
small sequence differences allow the design of primer sets that are structurally sound, 
adequately specific and have the most important mutation sites between them.  Small-scale 
gene conversion creates the majority of the mutations that cause 21-hydroxylase deficiency, 
but it may likewise alter the site of the primer on which the detection of such mutations 
depends.  Also, amplification of sequences more than 1 kb in length was not feasible when 
CYP21 mutation analysis was first undertaken in the early 1990's [Owerbach et al. 1990; 
Mornet et al. 1991]. 
We therefore initially designed a comprehensive PCR strategy [Koppens et al. 2000] to make 
sure that the genes amplified with CYP21- and CYP21P-specific primer sets were indeed the 
same genes that were previously identified on the basis of TaqI restriction patterns.  First, 
genomic TaqI/EcoRI double digestion was used to confirm that an EcoRI site in the second 
intron of CYP21P was a reliable marker [Koppens et al. 1998].  Since this site was indeed 
present in all CYP21P genes and none of the CYP21 genes, EcoRI digestion could be used to 
confirm the specificity of a PCR that covered the second intron and third exon (section 1 in 
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fig. 1 in Chapter 3.1).  The section 1 PCR product includes the site of an 8 bp deletion in exon 
3 of CYP21P but not CYP21.  This difference was then used to specifically amplify section 2.  
Section 2 includes the site of 4 base pair changes in a small area of exon 6; this difference was 
in turn used to amplify section 3.  This cautious approach proved its value, because patients 
with mutations at the section 2 and section 3 primer sites were indeed found.  Because the 
sections 1 to 3 covered all conversion sites associated with classical steroid 21-hydroxylase 
deficiency, this strategy was used to detect those mutations in the patients' CYP21 genes and 
to chart the variability of the CYP21P pseudogene [Koppens et al. 2000]. 
The high performance of currently available thermostable polymerases allowed a more 
convenient strategy in later studies (see Chapter 3.2).  Since the 8 bp deletion in exon 3 was 
found in all CYP21P genes but in only one patient's CYP21 gene, specific primers based on 
that difference could be used, and the amplified section continued into the 5' and 3' flanking 
areas (see Chapter 3.2 for details). 
Amplification of a 2.7-2.8 kb section of TNXA or TNXB was based on one common primer 
and one specific primer positioned beyond the boundary of the RCCX module [Koppens et al. 
2002a; Koppens et al. 2002b]. 
Optimal primer design was not always possible due to the limited differences in sequence.  
Design of the first primer sets were based on algorithms available at the time [Thein and 
Wallace 1986]; later, freely accessible web sites (see paragraph 1.9) were used.  The addition 
of 1 % formamide to the reaction buffer [Sarkar et al. 1990] greatly improved the specificity 
of several PCR's.  DNA samples that were not  amplified efficiently were adjusted to 2.5 M 
ammonium acetate, precipitated with 2 volumes of ethanol and re-dissolved - this procedure 
very often solved the problem. 
Non-amplification of one allele has been reported in the analysis of CYP21 mutations [Day et 
al. 1996; Ozturk et al. 2000], but this was not observed in the PCR methods applied here (see 
Chapter 3). 
 
Mutation detection with allele-specific oligonucleotides 
The detection method used in this study to detect CYP21 mutations was hybridisation of 32P-
labelled DNA oligonucleotides to membrane-bound denatured PCR products (commonly 
known as allele-specific oligonucleotide hybridisation) [Thein and Wallace 1986; Owerbach 
et al. 1990; Mornet et al. 1990].  It is a convenient and reliable method for processing a large 
number of samples and it offers the important advantage that blots can be stripped and re-
probed many times to screen for different mutations that lie within the amplified region.  The 
main technical complication is oligonucleotide design [Thein and Wallace 1986; 
http://eatworms.swmed.edu/~tim/primerfinder/; http://www.idtdna.com/program/bioinformatics/ 
Sequence_Analysis_Tools.asp]: the environment of the mutation to be detected may be an 
obstacle (for example, no well-designed oligonucleotide exists for the rare CYP21 mutation 
Arg483→Pro).  Also, some oligonucleotides require careful post-hybridisation washing steps.  
Ideally, previously known positive and negative controls should be available, but for 
General Introduction   
   
 
65 
mutations that have not been checked before this is not feasible.  The purpose of the washing 
steps should not be to reduce the radioactivity of a negative control to background levels, but 
rather to obtain an optimal ratio between a positive and a negative control and to visualise the 
results by a carefully timed fluorographic exposure. 
 
1.9. Reference section 
Patients, family members, and controls 
The study group included 47 families of steroid 21-hydroxylase deficiency patients and 149 
controls.  Single patients were not included for genotyping because segregation studies were 
necessary.  The hospitals participating in this study were the Sophia Children's Hospital in 
Rotterdam (33 families), the Leiden University Medical Centre (10 families), the Catharina 
Hospital in Eindhoven (2 families), the Oosterschelde Hospital in Goes (1 family) and the 
Maria Hospital in Tilburg (1 family).  Families of Dutch ethnic origin were included into the 
haplotyping and mutation analysis studies (see Chapters 2 and 3), to assess allele frequencies 
in the Dutch population.  Three other families were also genotyped to check for unusual 
mutations, but their  numbers were to small for epidemiological purposes. 
The 44 Dutch families included 51 steroid 21-hydroxylase deficiency patients and 123 healthy 
family members. 
At the onset of the study, most patients were regularly seen at the outpatient department of 
these hospitals; most older patients responded positively to a recall request. All families 
involved gave their informed consent.  The diagnosis of SL 21-hydroxylase deficiency CAH 
was based on characteristic phenomena that occurred during the first weeks of life, such as 
hyponatraemia, hyperkalaemia, dehydration, vomiting, shock and highly elevated plasma 
levels of 17α-hydroxyprogesterone. Patients with  SV 21-hydroxylase deficiency had no 
history of salt-losing crises and presented during childhood, usually with ambiguity of the 
genitalia externa in females and precocious puberty in males, as well as accelerated growth in 
most patients. 
The clinical diagnosis was SL steroid 21-hydroxylase deficiency in 36 patients from 30 
families, SV in 12 patients from 11 families and NC in 3 patients from 3 families. 
 
Nomenclature 
In this thesis, the designation CYP21 (in italics) is used to indicate the steroid 21-hydroxylase 
gene; CYP21P is the pseudogene.  The non-italicised variant CYP21 is sometimes used for the 
enzyme, although the full 'steroid 21-hydroxylase' is preferred.  This is in agreement with most 
of the current literature; alternatively, some authors use CYP21A1P and CYP21A2 for the 
pseudogene and the gene, respectively.  The latter is in agreement with the recommended 
nomenclature [Nebert et al. 1991], but seems a bit cumbersome, and recently the 
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nomenclature committee has again moved away from these designations [Cytochrome P450 
Allele Nomenclature Committee 2002]. 
In the older literature, CYP21A is used for the pseudogene and CYP21B for the active steroid 
21-hydroxylase gene; this matches the designation of the adjacent C4 genes.  Note that this 
positional notation has no functional implications: in the mouse, the active gene lies between 
the C4A and C4B genes.  Mouse genes are distinguished from human genes by capitalising the 
first letter only; for example, Cyp21.  Several variants, such as '21OHB', have also been in 
used in the past. 
TNXB and TNXA are used for the TNX gene and the pseudogene, to underline their similarity; 
several authors prefer just XA for the TNX pseudogene.  Earlier literature used designations 
such as 'gene X' and 'OSG' (opposite strand gene) for TNXB. 
RP1 is used here for the most telomeric gene in the RCCX module (it was named after the late 
Nobel Prize winner Rodney Porter).  Alternative names are STK19 and G11. 
CYP21 amino acid and nucleotide numbering throughout this thesis is according to Higashi et 
al. [1986].  This implies that the last amino acid is Gln494 and that the neutral polymorphism 
in exon 1, a 3 bp insertion encoding an extra leucine residue, is not counted.  Some authors 
include this polymorphism, which may cause some confusion as common mutations get a 
different codon number (for example: Val282→Leu instead of Val281→Leu).  Although the 
single letter amino acid code has been recommended, the more descriptive (and, according to 
the current nomenclature [den Dunnen and Antonarakis 2000], 'acceptable') three letter code 
has been used in this thesis, considering that no long protein sequences are listed anywhere. 
 
 
Reviews 
To readers who require additional information, the author recommends the following reviews: 
 
On steroid 21-hydroxylase deficiency and CAH 
Ritzén EM, Lajic S, Wedell A (2000) 
 How can molecular biology contribute to the management of congenital adrenal 
hyperplasia? 
 Hormone Res 53 suppl. 1: 34-37 
Speiser PW, Guest Editor (2001) 
 Congenital Adrenal Hyperplasia 
 Endocr Metab Clin North Am 30 
White PC, Speiser PW (2000) 
 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency 
 Endocr Rev 21: 245-291 
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On adrenocortical steroidogenesis and its regulation 
Andrew R (2001) 
Clinical measurement of steroid metabolism 
 Best Practice Res Clin Endocrinol Metab 15: 1-16 
Pestell RG, Jameson JL (1995) 
 Transcriptional regulation of endocrine genes by second-messenger signaling pathways 
 In: Weintraub BD, ed.: Molecular endocrinology. Basic concepts and clinical correlations, 
pp. 59-76. New York, Raven Press 
White PC (1994) 
 Genetic disease of steroid metabolism 
 Vitam Horm 49: 131-195 
Waterman MR, Keeney DS (1996) 
 Signal transduction pathways combining peptide hormones and steroidogenesis 
 Vitam Horm 52: 129-148 
 
On cytochromes P450 and their genes 
Estabrook RW, Masters BSS, Prough RA, Waterman M, eds. (1996-1997) 
 Cytochromes P450 serial review (12 parts) 
 Faseb J 10: 202-227; 428-434; 552-558; 683-689; 809-818; 1112-1117; 1241-1248; 
1369-1377; 1456-1463; 1569-1577, and 11: 29-36; 419-427. 
Honkakoski P, Negishi M (2000) 
 Regulation of cytochrome P450 (CYP) genes by nuclear receptors 
 Biochem J 347: 321-337 
 
On the genetics of the MHC 
Dawkins R, Leelayuwat C, Gaudieri S, Hui J, Cattley S, Martinez P, Kulski J (1999) 
 Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses 
and disease 
 Immunol Rev 167: 275-304 
Milner CM, Campbell RD (2001) 
 Genetic organization of the human MHC class III region 
 Front Biosc 6: d914-d926 
 
On genetic mechanisms and evolution 
Carrington M (1999) 
 Recombination within the human MHC 
 Immunol Rev 167: 245-256 
Jeffreys AJ, Barber R, Bois P, Buard J, Dubrova YE, Grant G, Hollies CRH, May CA, 
Neumann R, Panayi M, Ritchie AE, Shone AC, Signer E, Stead JDH, Tamaki K (1999) 
 Human minisatellites, repeat DNA instability and meiotic recombination 
 Electrophoresis 20: 1665-1675 
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Klein J, Sato A (1998) 
 Birth of the major histocompatibility complex 
 Scand J Immunol 47: 199-209 
Martinsohn JT, Sousa AB, Guethlein LA, Howard JC (1999) 
 The gene conversion hypothesis of MHC evolution: a review 
 Immunogenet 50: 168-200 
Meyer D, Thomson G (2001) 
 How selection shapes variation of the human major histocompatibility complex: a review 
 Ann Hum Genet 65: 1-26 
 
On the RCCX module 
Blanchong CA, Chung EK, Rupert KL, Yang Y, Yang Z, Zhou B, Moulds JM, Yu CY (2001) 
 Genetic, structural and functional diversities of human complement components C4A and 
C4B and their mouse homologues, Slp and C4 
 Int Immunopharmacol 1: 365-392 
Yu CY (1998) 
 Molecular genetics of the human MHC complement gene cluster 
 Exp Clin Immunogenet 15: 213-220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Databases and web sites 
A growing number of databases and other resources relevant to the issues discussed in this 
thesis is available through the world wide web.  Below is a short list of freely accessible web 
sites per February 18th, 2002.  Doubtlessly, it is far from complete, outdated by the time this 
thesis is printed and inadequate in listing some of the reader's cherished favourites – but some 
of these sites proved useful to the author. 
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Table 6.  Web sites relevant to the subject of this thesis per February 18th, 2002. 
EMBL Search Page http://srs.ebi.ac.uk/srs6bin/cgi-bin/wgetz?-page+top+-id+10EIW1DOHxp 
Offers access to various databases 
MHC Sequence http://www.sanger.ac.uk/HGP/Chr6/MHC.shtml 
Sequence of the MHC, from the Sanger Institute 
Ensembl http://www.ensembl.org/Homo_sapiens/mapview?chr=6 
Chromosome 6 gene browser 
NCBI BLAST http://www.ncbi.nlm.nih.gov/BLAST/ 
Sequence database and sequence analysis tools 
NHGRI http://www.nhgri.nih.gov/ 
The human genome project 
HGMDB http://archive.uwcm.ac.uk/uwcm/mg/search/120605.html 
Human Gene Mutation Database, steroid 21-hydroxylase mutations 
SwissProt http://www.expasy.org/cgi-bin/niceprot.pl?P08686 
SwissProt entry for steroid 21-hydroxylase 
OMIM http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?201910 
Online Mendelian Inheritance in Man entry for steroid 21-hydroxylase deficiency 
Diseases Database http://www.diseasesdatabase.com/sieve/item1.asp?glngUserChoice=1854 
Diseases Database entry for steroid 21-hydroxylase deficiency 
FIDD http://archive.uwcm.ac.uk/uwcm/mg/fidd/ 
Frequency of Inherited Disorders Database 
IHGW http://www.ihwg.org/contents.htm 
International Histocompatibility Working Group 
IMGT http://www.ebi.ac.uk/imgt/hla/ 
HLA sequence database 
P450 Nomenclature http://www.imm.ki.se/cypalleles/ 
Cytochrome P450 nomenclature and mutations 
Cytochrome P450 http://www.icgeb.trieste.it/~p450srv/450.html 
Cytochrome P450 database 
WebCutter 2.0 http://www.firstmarket.com/cutter/cut2.html 
Restriction site analysis 
Primerfinder http://eatworms.swmed.edu/~tim/primerfinder/ 
The oligonucleotide analysis tool most frequently used for this study 
Oligo Analyzer http://207.32.43.248/ 
Another useful oligonucleotide analysis tool 
JaMBW 1.1 http://members.aol.com/_ht_a/lucatoldo/myhomepage/JaMBW/ 
Various sequence analysis tools 
IDT http://www.idtdna.com/program/bioinformatics/Sequence_Analysis_Tools.asp 
Various sequence analysis tools 
EBI Catalogue http://corba.ebi.ac.uk/Biocatalog/Sequence_analysis.html 
A catalogue of molecular biology software 
Molecular ToolBox http://www.pitt.edu/~rsup/molectoolbox.html 
A set of useful molecular biology bookmarks 
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Sequences 
A list of sequences that were used for this thesis appears in table 7.  These sequences were 
available from the EMBL web site http://srs.ebi.ac.uk/srs6bin/cgi-bin/wgetz?-page+top+-
id+10EIW1DOHxp on February 18th, 2002. 
 
Table 7.  Accession numbers of sequences used in this thesis. 
M12792 CYP21, 5.1 kb Higashi et al. [1986] 
M12793 CYP21P, 5.1 kb Higashi et al. [1986] 
M13936 CYP21, 3.4 kb White et al. [1986] 
M13935 CYP21P, 3.2 kb White et al. [1986] 
HSCP2113 CYP21, 4.0 kb Rodrigues et al. [1987] 
M26857 CYP21P, 4.0 kb Rodrigues et al. [1987] 
M28548 mutated CYP21, 4.0 kb Rodrigues et al. [1987] 
L26263 C4A, 5.0 kb Yu [1991; Shen et al. [1994] 
M94068 C4B-CYP21 intergenic region, 1.8 kb Donohoue and Collins 
[1992] 
M94069 C4B-CYP21 intergenic region with CYP21P deletion, 1.8 kb Donohoue and Collins 
[1992] 
M94070 C4A-CYP21P intergenic region with CYP21 deletion, 1.8 kb Donohoue and Collins 
[1992] 
S38953 TNXA, 6.9 kb Gitelman et al. [1992] 
X71937 TNXB, 12.7 kb Bristow et al. [1993b] 
AF077974 RP2-TNXA-CYP21P, 7.5 kb Rupert et al. [1999] 
AF086641 TNXB-TNXA recombinant, 2.5 kb Yang et al. [1999] 
AF019413 class III region, 109.6 kb Rowen et al. [1999a] 
U89337 class III region, 100.3 kb Rowen et al. [1999b] 
AL049547 class III region, 129.8 kb Barlow 2000] 
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Abstract 
Two steroid 21-hydroxylase genes are normally present within the human major 
histocompatibility complex near the genes encoding the fourth component of complement 
(C4A and C4B).  Steroid 21-hydroxylase is encoded by the CYP21 gene, while the highly 
homologous CYP21P gene is a pseudogene.  We studied steroid 21-hydroxylase and 
complement C4 haplotypes in 33 Dutch patients (29 families) suffering from classical 
congenital adrenal hyperplasia (CAH) and in their 80 family members, and also in 55 
unrelated healthy controls, using 21-hydroxylase and complement C4 cDNA probes.  Eleven 
different haplotypes, defined in terms of gene deletions, gene duplications, conversions of 
CYP21 to CYP21P, and 'long' and 'short' C4 genes, were found.  In 23 % of the patients' 
haplotypes, the CYP21 gene was deleted; in 12 %, it was converted into a CYP21P 
pseudogene.  In the remaining 65 %, the defect was apparently caused by a mutation not 
detectable by this method.  The most common haplotype (with one CYP21 and one CYP21P 
gene) was significantly more often observed in patients with simple virilising CAH than in 
those with salt-losing CAH.  Comparison of the 21-hydroxylase haplotypes found in CAH 
patients from several countries shows evidence for considerable genetic variation between the 
groups studied. 
 
Introduction 
Congenital adrenal hyperplasia (CAH; also known as the adrenogenital syndrome (AGS)) is 
caused by an inborn error of adrenocortical steroidogenesis.  In about 95 % of all cases, a 
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defect in steroid 21-hydroxylation is the cause of this disorder [Degenhart 1979; Miller and 
Levine 1987; White et al. 1987a; White et al. 1987b].  Steroid 21-hydroxylase deficiency is 
one of the most common inborn errors of metabolism, affecting about one in every 10,000-
15,000 newborns in Caucasian populations.  In the most severely afflicted patients, both 
cortisol and aldosterone synthesis are impaired, resulting in insufficient sodium retention as 
well as virilisation of the external genitalia.  These patients usually suffer from severe salt-
losing crises shortly after birth ('salt-losing' CAH).  If the cortisol synthesis is blocked but the 
aldosterone production is impaired to a lesser degree, virilisation will occur but the patients do 
not suffer from salt-losing crises ('simple virilising CAH').  Salt-losing and simple virilising 
CAH are manifestations of the so-called classical 21-hydroxylase deficiency.  Non-classical 
21-hydroxylase deficiency is a milder form of the same disorder; in this form, clinical 
symptoms do not become manifest until late childhood ('late onset' CAH) or remain absent 
('cryptic' CAH). 
The enzyme steroid 21-hydroxylase (cytochrome P-450C21) is encoded by the CYP21 gene in 
the class III region of the human major histocompatibility complex (MHC) on the short arm of 
chromosome 6.  It is the most centromeric of a cluster of two 21-hydroxylase genes (3.4 kb 
each), alternating with two genes encoding the fourth component of complement (16-22.5 kb).  
Usually, complement C4 locus I (the most telomeric) is occupied by a C4A gene and locus II 
by a C4B gene.  The other 21-hydroxylase locus contains the CYP21P pseudogene, which is 
highly homologous to CYP21, but inactive due to several deleterious mutations [Higashi et al. 
1986; White et al. 1986]. 
Deletions and duplications of a 30 kb area encompassing either CYP21 or CYP21P and one 
adjacent C4 gene and (partial) conversions of CYP21 into a CYP21P-like pseudogene have 
been reported to be very common in the 21-hydroxylase/complement C4 region [White et al. 
1985; Carroll et al. 1985; Harada et al. 1987; Matteson et al. 1987; Rumsby et al. 1988; White 
et al. 1988; Collier et al. 1989;  Miller and Morel 1989; Morel et al. 1989; Partanen et al. 
1989; White 1989].  In addition, a size difference of the C4 genes depending on the presence 
or absence of a 6.5 kb intron has been described [Schneider et al. 1986; Palsdottir et al. 1987; 
Yu and Campbell 1987].  C4A genes are (almost) always 'long' (22.5 kb), while C4B genes 
may be 'long' or 'short' (16 kb).  While most of these variations are inconsequential, there are 
several mutations that affect the CYP21 gene and cause steroid 21-hydroxylase deficiency.  
These mutations of CYP21 can be roughly categorised into three groups: CYP21 deletions, 
conversions into a CYP21P-like gene, and smaller mutations inside the CYP21 gene. 
In humans, use of 21-hydroxylase and complement C4 cDNA probes and several restriction 
enzymes (especially, TaqI and BglII) provides useful information about the configuration of 
the 21-hydroxylase / complement C4 section of the MHC class III region.  In this paper we 
describe the prevalence of gene deletions, duplications, conversions, and smaller mutations 
(by exclusion) in 29 Dutch CAH families.  The genetic variation between these families, 
healthy controls, and CAH populations from several other countries is discussed. 
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Patients and methods 
Patients, families and controls 
We studied 33 patients and 80 healthy family members from 29 families (all of Dutch ethnic 
origin).  The patients are regularly seen at the outpatient department of the Sophia Children's 
Hospital; most older patients responded positively to a recall request.  All families involved 
gave their informed consent.  At least three members of each family (including the patient) 
were available for haplotyping.  Four families each included two patients.  In 25 families, 
blood samples from both parents were obtained; in the other four families, blood samples from 
the fathers were not available.  Samples were also obtained from 26 clinically healthy brothers 
and sisters of the patients.  In all, 22 patients from 19 families were classified as having salt-
losing (SL) CAH.  These patients were usually admitted to the hospital in the first month of 
life with characteristic phenomena such as hyponatraemia, hyperkalaemia, dehydration, 
vomiting, shock, and highly elevated plasma levels of 17α-hydroxyprogesterone.  The other 
11 patients, from 10 families, had no history of salt-losing crises.  They presented during 
childhood, usually with ambiguity of the external genitalia in girls or precocious puberty in 
boys, and accelerated growth in most patients.  These patients were characterised as simple 
virilisers (SV). 
DNA samples from 55 healthy controls without a reported family history of CAH were 
obtained and investigated in a similar manner, though no corresponding family studies were 
performed. 
Biochemical data 
The clinical and biochemical data is summarised in table 1.  Serum electrolytes are the lowest 
(Na) and the highest (K) measured.  In SL patients, these values were generally found in the 
first weeks of life during hospitalisation; in some patients, the values presented in table 1 were 
obtained during a clinical re-evaluation when they were following a low-sodium diet and not 
receiving steroid therapy.  17α-hydroxyprogesterone levels are the highest measured using a 
standard radioimmunoassay.  If no such data was available, patients were categorised as SL or 
SV on the basis of their clinical history. 
Southern blotting and hybridisation 
Genomic DNA was prepared from peripheral leukocytes essentially as described elsewhere 
[Wyman and White 1980]; 10 µg was digested overnight with 40 units TaqI, BglII or KpnI as 
advised by the manufacturers' (Boehringer, Mannheim, FRG, or Pharmacia, Uppsala, Sweden) 
instructions.  After agarose gel electrophoresis and Southern blotting, hybridisation was 
performed with the 2.1 kb 21-hydroxylase cDNA probe pC21/3c [White et al. 1985], or the 
0.6 kb BamHI-BglII fragment of the complement C4 cDNA probe pAT-A [Belt et al. 1984].  
The probes were obtained from the American Type Culture Collection.  To estimate the 
amount of DNA in each lane and deduce the number of CYP21 and CYP21P genes in each 
individual, the TaqI blots were rehybridised with the 0.7 kb genomic probe pJ3.11 [Cooper et 
al. 1985], which was kindly provided by Dr. J. Schmidtke (University of Berlin, FRG).  As a 
reference, we used DNA from a healthy individual with two CYP21, CYP21P, and (long) C4A 
genes, and a long and a short C4B gene (haplotypes A1/A2 in fig. 1). 
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Laser densitometry 
The optical densities of the autoradiographic bands were determined by densitometry with an 
LKB 2222-020 Ultroscan XL laser densitometer.  The relative quantity of the fragments was 
calculated as the ratio of the area under the respective curves.  For a number (n) of different 
individuals with equal quantities of each band as determined by family studies, the mean ratios 
of the bands (all from different autoradiograms) were, respectively: CYP21 and CYP21P: TaqI 
3.2:3.7 kb = 0.99 ± 0.023 (SEM) (n=18); BglII 12:10 kb = 1.15 ± 0.028 (SEM) (n=16); 
complement C4: TaqI 7.2:6.6 kb = 1.01 ± 0.012 (SEM) (n=18); TaqI 7.2:5.6 kb = 0.98 ± 0.021 
(SEM) (n=15).  The coefficient of variation (CV) was ≤ 10 %.  Virtually identical results were 
obtained upon repeating the entire procedure 17 times for a single individual.  The 
contribution of the densitometry itself to the CV was less than 1 %; the blackening of the film 
used (Kodak X-Omat AR) was linear in proportion to the radioactivity present within an 
absorption range of 0.5-2.5 (results not shown).  The band ratios presented in table 1 have 
been rounded to whole numbers. 
Interpretation of the haplotypes 
Haplotyping of steroid 21-hydroxylase genes in CAH patients and healthy individuals using 
TaqI is based on the characterisation of the genes as CYP21-like or CYP21P-like because of 
the presence or absence of a TaqI site normally found in the 5' flanking sequence of the 
pseudogene only.  This extra site causes the CYP21 gene to be characterised by a 3.7 kb TaqI 
fragment, and the CYP21P gene by a 3.2 kb fragment [Higashi et al. 1986; White et al. 1986].  
Deletion of a 21-hydroxylase gene results in absence of the corresponding TaqI fragment.  
Normally, a 12 kb BglII fragment contains the CYP21P gene, and a 10 kb fragment the CYP21 
gene; the difference is caused by a BglII site present in the 3' flanking sequence of CYP21 
only.  The 12 kb BglII fragment is absent in case of a deletion of either CYP21P or CYP21, 
because the 30 kb deletion resulting in loss of CYP21 actually extends from the 3' region of 
CYP21P to the corresponding part of CYP21, so that the 3' flanking sequence of CYP21 is 
retained [White et al. 1988; Donohoue et al. 1989]. 
Duplication of a 21-hydroxylase gene can be deduced from an increased intensity of the 
respective TaqI band, and of the 12 kb BglII band.  In case of a conversion of CYP21 to 
CYP21P, the BglII pattern is normal, but the TaqI 3.7 kb fragment is absent. 
TaqI banding patterns also distinguish between long and short C4 genes and between their 
position at either locus I or locus II [Schneider et al. 1986; Yu and Campbell 1987; Partanen et 
al. 1989].  Four different fragments (usually described as 7, 6.4, 6, and 5.4 kb, but probably 
0.2 kb longer [Koppens et al. 1992]) are characteristic of, respectively: a long gene at locus I, 
a short gene at locus I, a long gene at locus II, and a short gene at locus II.  This approach 
allows the definition of several haplotypes, which are summarised in fig. 1 and table 2. 
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Table 1. Summary of clinical and biochemical patient data and CAH-bearing haplotypes 
 
patient 
  
sex 
  
CAH  
type 
  
electrolytes 
(mmol/l) 
relative band intensities CAH- 
bearing 
haplotypesc 
   Naa Ka 
17α-OH 
prog.b 
(nmol/l) 
21-hydroxylase  complement 
C4 
 
           TaqI  BglII   TaqI  
           3.2:3.7 12 : 10  7.2:6.6:6.2:5.6    
 1   F  SL 110 8.6  n.a.  2 : 1   1 : 2   2 : 0 : 1 : 0   A1 / E1d 
 2   F  SL 104 9.4  > 48  2 : 1   1 : 2   2 : 0 : 1 : 0   A1 / E1d 
 3   M  SL n.a. n.a.  > 48  3 : 1   2 : 2   2 : 0 : 1 : 1   A / D e 
 4a   M  SL 121 6.4  24  1 : 2   1 : 2   2 : 0 : 1 : 0   A1 / B1  
 4b   F  SL 125 11.2  > 48  1 : 2   1 : 2   2 : 0 : 1 : 0   A1 / B1  
 5a   F  SL 105 8.4  92  2 : 2   2 : 2   1 : 1 : 0 : 2   F2 / E1  
 5b   M  SL 126 8.2  >120  2 : 2   2 : 2   1 : 1 : 0 : 2   F2 / E1  
 6   F  SL 123 6.9  > 48  2 : 1   1 : 2   2 : 0 : 1 : 0   A1 / E1  
 7   F  SL 125 9.5  > 48  1 : 1   0 : 2   2 : 0 : 0 : 0   B1 / E1  
 8   F  SL 117 8.5  > 48  1 : 1   0 : 2   1 : 1 : 0 : 0   E1 / B2  
 9   M  SL 126 6.9  > 48  2 : 1   1 : 2   2 : 0 : 1 : 0   E1 / A1  
 10   F  SL low high  > 48  1 : 2   1 : 2   1 : 1 : 0 : 1   B2 / A2  
 11a   F  SL 122 5.3  n.a.  3 : 2   3 : 2   2 : 0 : 1 : 2   C2 / A1d 
 11b   M  SL n.a. n.a.  > 48  3 : 2   3 : 2   2 : 0 : 1 : 2   C2 / A1d 
 12   F  SL 111 11.6  > 48  1 : 2   1 : 2   2 : 0 : 1 : 0   B1 / A1d 
 13   F  SL 126 10.5  > 48  2 : 1   1 : 2   2 : 0 : 0 : 1   E1 / A2  
 14   F  SL 85 15.0  > 48  4 : 0   2 : 2   2 : 0 : 1 : 1   D1 / D2  
 15   M  SL 113 7.8  >150  3 : 1   2 : 2   2 : 0 : 2 : 0   D1 / A1  
 16   M  SL 110 8.7  1990  3 : 0   1 : 2   2 : 0 : 0 : 1   E1 / D2  
 17   M  SL 124 5.7  159  2 : 1   1 : 2   2 : 0 : 1 : 0   A1 / E1  
 18   M  SL 112 8.2  > 48  3 : 1   2 : 2   2 : 0 : 1 : 1   D2 / A1d 
 19   F  SL 103 11.6  > 48  3 : 1   2 : 2   2 : 0 : 1 : 1   .../...f 
 20   M  SV 134 5.1  99  2 : 1   1 : 2   2 : 0 : 0 : 1   .../...f 
 21   M  SV 138 4.2  240  3 : 1   2 : 2   2 : 0 : 1 : 1   .../...f 
 22   F  SV 138 5.6  > 48  2 : 2   2 : 2   2 : 0 : 1 : 1   A1 / A2  
 23a   F  SV normal normal  n.a.  2 : 1   1 : 2   2 : 0 : 1 : 0   E1 / A1d 
 23b   F  SV normal normal  n.a.  2 : 1   1 : 2   2 : 0 : 1 : 0   E1 / A1d 
 24   M  SV 127 4.6  > 48  2 : 2   2 : 2   2 : 0 : 2 : 0   A1 / A1d 
 25   F  SV 138 5.0  96  2 : 2   2 : 2   2 : 0 : 1 : 1   A2 / A1  
 26   M  SV normal normal  154  2 : 1   1 : 2   2 : 0 : 0 : 1   E1 / A2  
 27   M  SV n.a. n.a.  > 48  1 : 2   1 : 2   1 : 1 : 1 : 0   B2 / A1  
 28   F  SV 147 5.0  > 48  3 : 1   2 : 2   2 : 0 : 2 : 0   D1 / A1  
 29   F  SV 138 6.6  > 48  2 : 2   2 : 2   2 : 0 : 0 : 2   A2 / A2  
a: exact data not always available; norm.: normal 
b: upper limit of the reference range of 17α-hydroxyprogesterone is 6 nmol/l 
c: the paternal haplotype is shown first 
d: alternative scheme possible, but unlikely (see text) 
e: only the 21-hydroxylase haplotypes could be deduced 
f: no CAH-bearing haplotypes could be deduced 
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In a number of cases we also used KpnI, because an extra site in the 5' flanking sequence of 
CYP21 results in a characteristic 2.9 kb fragment as opposed to 4.0 kb for CYP21P [Higashi et 
al. 1986; White et al. 1986]. 
Following the recommendations of Sokal and Rohlf [1981], statistical analyses were 
performed using the G-test of independence for two-way tables with Williams' correction. 
Fig. 1. 21-hydroxylase / complement C4 haplotypes and associated restriction sites 
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Results and discussion 
Gene rearrangements and haplotypes 
We have studied 29 families from the Netherlands in order to obtain 21-hydroxylase / comple-
ment C4 haplotypes.  These haplotypes are defined in terms of the TaqI and BglII restriction 
fragments (see fig. 1 and table 2).  Eleven different haplotypes were found, most of which 
have also been described by other authors [Carroll et al. 1985; Donohoue et al. 1986; Garlepp 
et al. 1986; White et al. 1988; Collier et al. 1989; Morel et al. 1989; Partanen et al. 1989; 
White 1989; Schneider 1990]; we will refer to the combined 21-hydroxylase / complement C4 
haplotypes as A1, A2, etc., and to the 21-hydroxylase haplotypes independent of the C4 genes 
as A, B, C, etc (so that, in effect, A1+A2=A). 
 
Table 2. Ratios of restriction fragments characterizing 21-hydroxylase / complement C4 haplotypes 
haplotype  21-hydroxylase complement C4  
  TaqI BglII TaqI 
  3.2 : 3.7 12 : 10  7.2 : 6.6 : 6.2 : 5.6 
 A1a + +  + +  + - + - 
 A2a + +  + +  + - - + 
 B1a - +  - +  + - - - 
 B2a - +  - +  - + - - 
 C1a ++ +  ++ +  + - ++ - 
 C2a ++ +  ++ +  + - - ++ 
 C3ab ++ +  ++ +  + - + + 
 D1 ++ -  + +  + - + - 
 D2 ++ -  + +  + - - + 
 E1 + -  - +  + - - - 
 F1a + ++  ++ +  + - - ++ 
 F2a + ++  ++ +  - + - ++ 
 
The haplotypes reflect gene rearrangements within the 21-hydroxylase / complement C4 
region of the MHC.  They are thought to have originated from haplotype A through unequal 
crossovers, resulting in the simultaneous duplication and deletion of either CYP21 and C4B, or 
CYP21P and C4B, or CYP21P and C4A, or through gene conversion-like events.  These 
processes have been discussed in more detail elsewhere [Donohoue et al. 1986; Garlepp et al. 
1986; White et al. 1988; Collier et al. 1989; Donohoue et al. 1989; Miller et al. 1989; White 
1989].  Unequal crossover events are thought to have simultaneously generated gene deletions 
and duplications, resulting in haplotypes B and C, as well as in haplotypes E and F.  
Haplotype D is generated from A by conversion of (a part of) CYP21 into a CYP21P-like 
structure.  When we hybridised the 21-hydroxylase probe to KpnI blots, the ratio of the 4 kb 
and 2.9 kb fragment was found to be equal to the ratio of the TaqI 3.2 and 3.7 kb fragments in 
all cases.  These results indicate that all 21-hydroxylase genes studied have either a TaqI site 
(characteristic of CYP21P) or a KpnI site (characteristic of CYP21) in their 5' flanking 
sequence, but not both.  Though these sites lie outside the coding sequence, maintenance of a 
CYP21-like structure in the 5' flanking sequence may be necessary for gene expression.  In 
+ : normal quantity 
++: double quantity 
- : absent 
a : apparently bearing a 
defective CYP21 gene 
on CAH haplotypes 
b : the C3 haplotype has 
been included since it is 
mentioned in the text as 
an alternative possibility 
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mouse steroid 21-hydroxylase genes, several 5' regulatory elements have been described [Rice 
et al. 1990].  Of course, the current approach presumes a gene conversion on the basis of an 
extra TaqI site (reducing the original 3.7 kb fragment to 3.2 kb), and the absence of a KpnI site 
(resulting in a 4 kb fragment instead of 2.9 kb).  However, there are no reports of normal 
biological activity of a CYP21 gene characterised by a 3.2 kb TaqI fragment or a 4 kb KpnI 
fragment (it should be noted that patients 14 and 16 in this study, both of whom completely 
lack the 3.7 kb TaqI and 2.9 kb KpnI fragments, have SL CAH).  Nevertheless, the presence of 
the extra TaqI site and the absence of the KpnI site do not necessarily imply that the entire 
'converted' gene is CYP21P-like. 
Family studies 
A problem rarely mentioned in the literature is that combinations of some of the haplotypes 
described above yield the same patterns.  In single individuals, no distinction can be made 
between: A1/A1 and B1/C1; A1/A2 and B1/C3; A1/C2 and A2/C3 and D1/F1; A1/C3 and 
A2/C1; A1/D1 and C1/E1; A1/D2 and A2/D1 and C3/E1; A1/E1 and B1/D1; A2/A2 and 
B1/C2 and E1/F1; A2/C2 and D2/F1; A2/D2 and C2/E1; A2/E1 and B1/D2; B2/C3 and 
E1/F2; C1/C2 and C3/C3.  Though family studies greatly reduce this problem, such 
complications limit the number of families where the haplotypes can be fitted unambiguously 
into a Mendelian scheme.  To be certain, we took account of some unusual haplotypes 
comprising two CYP21 genes and no CYP21P genes; three CYP21P genes; one CYP21 gene 
and three CYP21P genes; and four CYP21P genes (the last possibility has been described by 
Collier et al. [1989]).  In addition, alternative sizes of the C4 genes were taken into 
consideration.  In 18 families, no other CAH-bearing haplotypes than those presented in table 
1 were possible.  In 7 families, other possibilities than those presented in table 1 existed but 
were highly unlikely (these alternatives implied replacement of at least two, and usually three, 
haplotypes A by other, far less frequent haplotypes).  In one family, only the 21-hydroxylase 
haplotypes (A-F) could be deduced for the CAH-bearing chromosomes; there was no certainty 
about the C4 genes.  In the remaining three families, no unambiguous Mendelian scheme 
could be drawn up.  Thus, a total of 52 haplotypes carrying 21-hydroxylase deficiency and 52 
normal haplotypes were finally established.  The relative intensities of the TaqI and BglII 
bands (rounded; patients only) and the 21-hydroxylase / complement C4 haplotypes deduced 
are presented in table 1.  The frequencies of the CAH and non-CAH haplotypes which were 
finally established are shown in table 3. 
Our approach was primarily aimed at the establishment of the haplotypes described.  
Nevertheless carrier status for steroid 21-hydroxylase deficiency could often be deduced: a 
distinction between carriers and non-carriers was possible in 16 families.  However, for the 
purpose of carrier detection and antenatal diagnosis, a combination of probes, including HLA 
probes, is better suited [Strachan et al. 1987; Speiser et al. 1990]. 
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Table 3. Frequencies of 21 hydroxylase / complement C4 haplotypes in classical congenital adrenal 
hyperplasia in the Netherlands             
haplotype SL SV total % fam. contr. total % 
A1a 10 7 17 32.7 31 52 83 51.6 
A2a 2 5 7 13.5 9 25 34 21.0 
Aab 1 0 1 1.9 1 7 8 4.9 
B1a 3 0 3 5.8 2 8 10 6.2 
B2a 2 1 3 5.8 7 10 17 10.5 
C1a 0 0 0 0.0 2 0 2 1.2 
C2a 1 0 1 1.9 0 0 0 0.0 
Cab 0 0 0 0.0 0 7 7 4.3 
D1 2 1 3 5.8 0 0 0 0.0 
D2 3 0 3 5.8 0 0 0 0.0 
Dab 1 0 1 1.9 0 0 0 0.0 
E1 10 2 12 23.1 0 0 0 0.0 
F1a 0 0 0 0.0 0 1 1 0.6 
F2a 1 0 1 1.9 0 0 0 0.0 
total 36 16 52 100 52 110 162 100 
SL: patients with salt-losing CAH 
SV: patients with simple virilising CAH 
fam.: non-CAH haplotypes in CAH families 
contr.: unaffected controls 
total: totals for classical CAH and unaffected haplotypes, respectively 
a : apparently bearing a defective CYP21 gene on CAH haplotypes 
b : only the 21-hydroxylase haplotype could be deduced (see text) 
 
Control haplotypes 
Almost all controls had two CYP21 genes; one had three.  We assumed presence of haplotype 
A on both chromosomes when the TaqI and BglII bands representing the 21-hydroxylase 
genes were of equal intensity.  However, considering the substantial number of haplotypes B 
and C, it seems likely that one or two controls considered to have A/A, in fact have B/C (E/F, 
combining CAH carrier status on one chromosome with a rare haplotype on the other, seems 
very improbable).  Seven controls had three CYP21P genes, two CYP21 genes, and two long 
C4 genes at locus I; six of them had two long and one short C4 gene on the loci II, one had 
one long and two short genes.  In such cases, no distinction can be made between the 
combinations A1/C3 and A2/C1, and A1/C2 and A2/C3, respectively.  Therefore, these 
haplotypes have simply been designated 'A' and 'C' in table 3. 
CAH and non-CAH haplotypes 
Haplotypes D and E lack a functional CYP21 gene and are always associated with 
21-hydroxylase deficiency.  Haplotypes A, B, C, and F are found in the general population and 
are only associated with 21-hydroxylase deficiency if the CYP21 genes present carry 
deleterious mutations.  A statistically significant difference between SL and SV patients was 
only found for haplotype A (13/36 vs 12/16; P<0.01), which is more prominent in the latter.  
The difference in the number of gene deletions and conversions is not statistically significant. 
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Taking into account a carrier frequency of CAH of 1:50 to 1:60, the contribution of carriers to 
the haplotypes of the control group can be assumed to be very limited.  The chance that more 
than three control subjects from a group of 55 are CAH heterozygotes is < 3 %; also, controls 
carrying CYP21 deletions or gene conversions are easily detectable from the TaqI and BglII 
banding patterns in most cases (ie, when combined with haplotypes A, B, or C). 
As expected, the frequencies of all haplotypes are similar in controls and in the non-CAH-
carrying haplotypes in the CAH families.  Haplotypes D and E, which carry CAH because of 
the absence of a normal CYP21 gene, are necessarily absent among the non-CAH haplotypes 
of the (unaffected) parents of CAH patients, and obviously rare in controls.  When D and E are 
excluded from the comparison, the frequencies of the other haplotypes are similar in CAH-
bearing and non-CAH-bearing chromosomes. 
Comparison of different populations 
In the last few years, a number of reports on 21-hydroxylase haplotypes and their occurrence 
in different populations have been published.  These include CAH patients from centres in the 
United States, Japan and some European countries.  Most of this data has been reviewed by 
Miller and Morel [1989].  Unfortunately, comparisons between a number of these studies are 
hampered by differences in approach, which sometimes make it actually impossible to arrive 
at definite conclusions.  For purposes of comparison, we used data from a limited number of 
recent studies from several countries, involving a sufficiently large number of patients and 
presenting established haplotypes defined in terms of gene rearrangements.  We compared 
only the 21-hydroxylase haplotypes (A-F), since most authors have not established combined 
21-hydroxylase / complement C4 haplotypes. 
 
Table 4. Comparison of 21-hydroxylase haplotypes on CAH-bearing chromosomes in several countries 
haplotype  
  
R
otterdam
, 
the 
N
etherlands a 
  France b 
  France c 
H
elsinki,  
Finland d 
  Japan e 
London,  
 U
K
f 
M
anchester,  
 U
K
g 
N
ew
 Y
ork,  
 U
S
A
h 
 A   25   68    18  14  32  24   45  
 B   6   4  81  0  0  2  5   4  
 C   1   5  
}
  1  0  0  3   0  
 D   7   13   11  3  4  3  5   2  
 E   12   13   24  12  0  11  19   13  
 F   1   0   0  0  0  0  1   0  
 total   52   103   116  34  18  48  57   64  
a: this study; see tables 1 and 3 
b: Morel et al. [1989]; not including two chromosomes with uninterpretable haplotypes 
c: Mornet et al. [1991]; the number of haplotypes A, B and C is not specified separately 
d: Partanen et al. [1989] 
e: Harada et al. [1987]; not including three patients heterozygous for either haplotype D or haplotype E 
f: Rumsby et al. [1988]; not including three patients with possible loss of a single restriction site 
g: Collier et al. [1989]; not including one chromosome bearing four CYP21P genes 
h: White et al. [1988] 
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Several authors give data on SL and SV patients; the number of SL patients always exceeds 
the number of SV patients, but its ratio relative to the total number of patients is variable (eg, 
22/33 in our study vs 24/27 in a report from the United Kingdom [Rumsby et al. 1988]; 
P<0.05).  While such variations may be real, they may also reflect differences in interpretation 
of clinical phenomena.  Also, some authors do not specify the haplotypes of each category of 
patients.  We therefore combined the data presented for SL and SV patients to obtain a total 
for classical 21-hydroxylase deficiency.  Patients with non-classical 21-hydroxylase 
deficiency were excluded; they are few in number in most haplotyping studies.  A compilation 
of data from several reports is presented in table 4.  Comparison of our results with those of 
other authors shows similarities and dissimilarities between different populations.  Haplotype 
A is less prominent in the Dutch patients than in the patients in the American study [White et 
al. 1988] (P<0.025) and one of the two French studies [Morel et al. 1989] (P<0.05). 
Several reports show significantly more CYP21 deletions (haplotype E) than conversions to 
the CYP21P pseudogene (haplotype D) [Rumsby et al. 1988; White et al. 1988; Collier et al. 
1989; Partanen et al. 1989; Mornet et al. 1991] (P<0.025 in all cases).  We also found more 
deletions, but the difference is not statistically significant; the (French) group of Morel et al. 
[1989] found the number of deletions and conversions to be equal, whereas in the Japanese 
study no deletions were reported [Harada et al. 1987].  Apart from difficulties in 
interpretation, it is clear that ethnical differences have contributed to the controversy about the 
number of CYP21 deletions in CAH families in recent years. 
Non-CAH haplotypes 
A remarkable feature in the non-CAH haplotypes studied is the high incidence of deletions of 
the CYP21P pseudogene in comparison with duplications of this gene (haplotype B vs C; 
P<0.005 (this study); P<0.001 ([Morel et al. 1989]; 12 vs 1 / 84 haplotypes); P<0.01 
([Partanen et al. 1989]; 5 vs 0 / 31 haplotypes)).  As haplotypes B (deletion) and C 
(duplication) are thought to have resulted simultaneously from an unequal crossover event, an 
equal frequency would be expected.  Attempts to explain the difference are necessarily 
speculative; possibly, the mechanisms of the (apparently frequent) unequal crossovers in this 
region play a role.  Sinnott et al. [1990] describe a crossover between a chromosome with both 
21-hydroxylase and complement C4 genes present and a chromosome with a CYP21P/C4A 
deletion; in such an event, about 30 kb of the longest chromosome is thought to loop out.  A 
similar phenomenon could be expected in an unequal pairing between a normal chromosome 
and one with a duplication.  Such an extended 'bulge' during meiosis may be a 
disadvantageous configuration compared with the 'straight' arrangement of the other 
chromosome.  As such loops are necessarily on the longest chromosome, there would be a 
tendency to favour the shorter ones. 
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2.2. CYP21/C4 haplotypes in the Netherlands: an update 
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Introduction 
The genetic map of the central (class III) region of the human MHC contains one to four 
tandem copies of a repeat known as the RCCX module after its main constituent genes: RP-
C4-CYP21-TNX.  These repeats vary in size (either 27 or 33 kb, depending on the C4 gene), 
position (centromeric: adjacent to the full-size TNXB gene; telomeric: adjacent to the full-size 
RP1 gene; intermediate: between two other RCCX modules), and composition (C4A or C4B, 
encoding variants of the fourth component of complement with different activities and 
specificities; CYP21 encoding steroid 21-hydroxylase or the pseudogene CYP21P; a truncated 
part of either TNXB or the TNXA pseudogene).  TaqI/BglII restriction analysis and 
hybridisation to C4 and CYP21 cDNA probes allows characterisation of the overall structure 
of the RCCX region in individuals and families [Carroll et al. 1985; Higashi et al. 1988; 
White et al. 1988; Morel et al. 1989].  We previously studied CYP21/C4 haplotypes in a group 
of steroid 21-hydroxylase deficiency patients and controls from the Netherlands [Koppens et 
al. 1992a].  This article is an update to our earlier study: the studied population was increased 
and novel haplotypes, some of which have been described in more detail elsewhere in this 
thesis [Koppens et al. 2002a; Koppens et al. 2002b; Koppens et al. 2002c], were found. 
 
Methods 
The original study group [Koppens et al. 1992a] was expanded to 44 families and 141 
controls.  Patients were from several hospitals in the Netherlands (see table 1).  A few families 
with late-onset 21-hydroxylase deficiency were added; otherwise, inclusion criteria and 
separation between clinical categories (salt-losing, simple virilising) were as before. 
Haplotyping was done as before; several unusual haplotypes were also characterised by SacII 
digest and pulsed field gel electrophoresis [Koppens et al. 2002c].  Two smaller TaqI 
fragments (2.4 and 2.5 kb) that were visible on many autoradiograms, were also considered.  
These fragments correspond to a TNXA-like (2.4 kb) or TNXB-like (2.5 kb) sequence 
downstream of CYP21 or CYP21P, and we developed a PCR-based method [Koppens et al. 
2002a; Koppens et al. 2002b] to further characterise this region.  The relative intensity of the 
2.4 and 2.5 kb fragments normally matches the 12 and 11 kb BglII fragments, respectively, but 
there are deviations in some haplotypes (see table 2). 
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Table 1.  CAH-bearing haplotypes (continued from p. 109) 
relative band intensities 
21-hydroxylase complement 
C4 
TaqI BglII TaqI 
patient hospitala sexb CAH typec 
3.2:3.7 12 : 10 7:6.4:6:5.4 
CAH-
bearing 
haplotypesd 
19 S F SL 3 : 1 2 : 2 2 : 0 : 1 : 1 A1 / D2 
20 S M SV 2 : 1 1 : 2 2 : 0 : 0 : 1 E1 / A2e 
30 L F SL 2 : 1 1 : 2 2 : 0 : 0 : 1 E1 / A2 
31 L M SL 2 : 1 1 : 2 2 : 0 : 0 : 1 E1 / A2 
32 M F + M SL 1 : 1 0 : 2 2 : 0 : 0 : 0 B1 / E1 
33 C M + M SL 2 : 2 2 : 2 2 : 0 : 2 : 0 A1 / A1 
34 L F SL 2 : 2 2 : 2 2 : 0 : 1 : 1 C3 / B1 
35 O M SV 2 : 2 2 : 2 2 : 0 : 2 : 0 A1 / A1 
36 L F SL 2 : 2 2 : 2 2 : 0 : 1 : 1 A1 / A2f 
37 L M SL 3 : 2 3 : 2 2 : 0 : 3 : 0 A1 / C1 
38 L M SL 3 : 1 2 : 2 2 : 0 : 2 : 0 D1 /A1 
39 L M + M SL 2 : 2 2 : 2 2 : 0 : 2 : 0 A1 / A1 
40 L M SL 1 : 2 1 : 2 2 : 0 : 0 : 1 B1 / A2 
41 S M SL 1 : 2 1 : 2 2 : 0 : 1 : 0 B1 / A1 
44 L F LO 3 : 2 3 : 2 2 : 0 : 1 : 2 C2 / A1 
45 S F LO 3 : 2 3 : 2 2 : 0 : 1 : 2 C2 / A1 
46 L M LO 3 : 2 3 : 2 2 : 0 : 0 : 3 C2 / A2 
a: S=Sophia Children's Hospital, Rotterdam; L=Leiden University Medical Centre; C=Catharina Hospital, 
Eindhoven; M=Maria Hospital, Tilburg; O=Oosterschelde Hospital, Goes 
b: two patients in some families 
c: SL=salt-losing 21-hydroxylase deficiency; SV=simple virilising; LO=late onset 
d: the paternal haplotype is shown first 
e: originated from a de novo unequal crossover [Koppens et al. 2002a] 
f: maternal haplotype not counted in table 3 due to known consanguinity 
 
 
In this update, we use 7-6.4-6-5.4 kb for the sizes of the C4 TaqI fragments to keep in line 
with the large body of literature that uses these designations, despite the fact that the sizes first 
mentioned by us [Koppens et al. 1992a, Koppens et al. 1992b] are more accurate, as 
confirmed by recent sequencing data [Rowen et al. 1999].  We here use 11 kb instead of 10 kb 
for the size of the smallest BglII fragment - the exact size is 10,758 bp [Rowen et al. 1999]. 
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Table 2.  Ratios of restriction fragments and SacII fragment sizes for each haplotype 
21-hydroxylase complement C4 bothf 
TaqI BglII TaqI SacII 
haplotype 
3.2  :  3.7 12  :  10 7  :  6.4  :  6  :  5.4 size (kb) 
A1a + + + + + - + - 76 
A2a + + + + + - - + 70 
A3b + + + + - + + - 64 
B1 - + - + + - - - 43 
B2 - + - + - + - - 37 
C1 ++ + ++ + + - ++ - 109 
C2 ++ + ++ + + - - ++ 96 
C3 ++ + ++ + + - + + 103 
D1 ++ - + + + - + - 76 
D2c ++ - + + + - - + 70 
E1d + - - + + - - - 43 
F1 + ++ ++ + + - - ++ 96 
F2 + ++ ++ + - + - ++ 90 
G1 - ++ + + + - + - 76 
H1 +++ + +++ + + - +++ - 142 
I1e ++++ - +++ + + - +++ - 142 
a: one control who carried A1 / A2 had a TaqI 2.4:2.5 kb band ratio of 1:3, indicating a TNXB-like 
structure in both RCCX modules in one of these haplotypes 
b: Hillarby et al. [1990]; Schneider [1990]; Weg-Remers et al. [1997] 
c: all of these haplotypes had a double quantity of the TaqI 2.4 kb band and no 2.5 kb, indicating a 
TNXA-like structure in both RCCX modules [Koppens et al. 2002b] 
d: these haplotypes had a 2.5 kb TaqI band as expected, except for the de novo deletion in family 20, 
where the 2.4 kb band was found ([Koppens et al. 2002a] 
e: Collier et al. [1989] 
f: covers both genes; most of these fragments are shown elsewhere in this thesis [Koppens et al. 2002b; 
Koppens et al. 2002c], some are deduced 
 
Results and discussion 
CYP21/C4 haplotypes 
Table 1 is an overview of the steroid 21-hydroxylase deficiency patients added since our 
original study [Koppens et al. 1992a] and contains a few updates of the earlier data.  The 
number of haplotypes found in this population has increased from 11 to 14; fig. 1 and table 2 
also include a few additional rare haplotypes described in the literature.  The rendering of 
haplotypes in fig. 1 is partly based on data from other chapters of this thesis or from the 
general literature: the designation of each haplotype follows the original definition, but details 
such as TNX variants and pseudogene-like regions have been added.  Long-range restriction 
mapping is more informative than BglII digests (see fig. 1) and the combination of SacII and 
TaqI provides all information necessary to accurately characterise the RCCX region.  
However, BglII mapping is technically easier and suffices in most cases, especially when 
family studies can be done. 
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We no longer endorse the concept of gene conversion as the most likely mechanism to create 
the 21-hydroxylase deficiency haplotypes D1 and D2.  Recombination by unequal crossover 
provides an adequate explanation for the origin of all chromosomes without a CYP21 gene 
[Koppens et al. 2002a; Koppens et al. 2002b].  Also, the assumption that these haplotypes 
have evolved from haplotype A during evolution needs to be amended since monomodular 
chromosomes (matching haplotype B) necessarily predate the primordial duplication of the 
RCCX module that generated haplotype A. 
 
Haplotype frequencies 
Band ratios do not provide direct information about single haplotypes, but rather about the 
combination of two haplotypes in an individual.  As mentioned before [Koppens et al. 1992a], 
some combinations cannot be distinguished from other combinations that yield the same 
banding pattern unless a family study or long-range restriction mapping is performed.  With 
one exception (family 3), complete CYP21/C4 haplotypes could be assigned to all 
chromosomes bearing 21-hydroxylase deficiency and all but two of the non-carrier 
chromosomes in all families; known consanguinity between two of the families reduced the 
total to 83 and 85 chromosomes, respectively.  Table 3 shows the band ratios found in the 
controls and the haplotypes that can be deduced from these ratios.  To count the haplotypes, 
we assumed that the banding patterns that matched the standard 'A' haplotype on both 
chromosomes indeed represented A1/A1, A1/A2 and A2/A2 rather than B1/C1, B1/C3 and 
B1/C2 (or even E1/F1), respectively; also, A2/B2 was preferred over A3/B1.  This assumption 
is based on the low frequency of the 'B' and 'C' haplotypes as compared to 'A', which makes a 
combination of them stochastically unlikely as compared to A/A.  As a single exception, one 
of the 40 banding patterns that could represent A1/A2 was counted as B1/C3.  This arbitrary 
correction matches the expected genotype frequency of B/C versus A/A as calculated from the 
family studies and results in a closer approximation of the Hardy-Weinberg equilibrium.  No 
similar assumption was made for undistinguishable combinations of 'A' and 'C' in order not to 
arrive at unreliable frequencies of each individual 'C' haplotype.  In each case it was assumed 
that in controls, combinations that did not involve carriership of steroid 21-hydroxylase 
deficiency were far more likely than those that did.  Table 3 also lists the combinations of the 
non-carrier haplotypes in the 21-hydroxylase deficiency families; here, the family study 
eliminated the interpretation problems just mentioned.  Some families actually have a son or 
daughter with this combination of haplotypes, most do not.  Table 4 shows the frequencies of 
all haplotypes thus obtained. 
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Table 3.  Band ratios and deduced genotypes in parents and controls 
21-hydroxylase complement 
C4 
number of genotypes 
TaqI BglII TaqI 
3.2:3.7 12 : 10 7 : 6.4 : 6 : 5.4 
assigned 
haplotypesa 
alternative 
haplotypesa 
parentsb controls 
2 : 2 2 : 2 2 : 0 : 2 : 0 A1 / A1c B1 / C1c 13 31 
2 : 2 2 : 2 2 : 0 : 1 : 1 A1 / A2d B1 / C3d 8 40 
1 : 2 1 : 2 2 : 0 : 1 : 0 A1 / B1  2 11 
1 : 2 1 : 2 1 : 1 : 1 : 0 A1 / B2  3 18 
3 : 2 3 : 2 2 : 0 : 3 : 0 A1 / C1  1 0 
3 : 2 3 : 2 2 : 0 : 1 : 2 A1 / C2e A2 / C3e 1 2 
3 : 2 3 : 2 2 : 0 : 2 : 1 A1 / C3e A2 / C1e 2 7 
1 : 3 2 : 2 2 : 0 : 2 : 0 A1 / G1f  0 1 
2 : 2 2 : 2 2 : 0 : 0 : 2 A2 / A2c B1 / C2c 4 6 
1 : 2 1 : 2 2 : 0 : 0 : 1 A2 / B1  1 2 
1 : 2 1 : 2 1 : 1 : 0 : 1 A2 / B2c A3 / B1c 2 8 
3 : 2 3 : 2 2 : 0 : 0 : 3 A2 / C2  1 0 
2 : 1 1 : 2 1 : 1 : 0 : 1 A2 / E1c,g B1 / D2c,g 0 1 
2 : 3 3 : 2 2 : 0 : 0 : 3 A2 / F1e  0 1 
1 : 3 2 : 2 2 : 0 : 1 : 1 A2 / G1h  0 1 
0 : 2 0 : 2 2 : 0 : 0 : 0 B1 / B1  0 1 
0 : 2 0 : 2 1 : 1 : 0 : 0 B1 / B2  0 2 
1 : 3 2 : 2 2 : 0 : 0 : 2 B1 / F1f  0 1 
0 : 2 0 : 2 0 : 2 : 0 : 0 B2 / B2  1 3 
2 : 2 2 : 2 1 : 1 : 2 : 0 B2 / C1  0 1 
1 : 3 2 : 2 0 : 2 : 0 : 2 B2 / F2f  0 1 
3 : 2 3 : 2 1 : 1 : 3 : 0 B2 / H2  1 0 
0 : 3 1 : 2 1 : 1 : 1 : 0 B2 / G1  0 1 
4 : 2 4 : 2 2 : 0 : 4 : 0 C1 / C1  0 1 
4 : 2 4 : 2 2 : 0 : 1 : 3 C2 / C3i  0 1 
a: the most likely alternative is mentioned first, excluding haplotypes D and E which are rare in controls; 
the rare haplotypes F1, F2, G1 and H1 were confirmed by SacII restriction mapping [Koppens et al. 
2002c] 
b: combinations of the father's and the mother's non-carrier haplotypes; totals do not completely add up 
to those in table 4 because three families where only one non-carrier haplotype could be deduced 
were not included here 
c: all counted as the most likely alternative in table 4 
d: 39 of these were counted as 'A1/A2', one as 'B1/C3' in table 4 (see text for rationale) 
e: counted as 'A1 or A2', 'C1 or C3' and 'C2 or C3' in table 4, but assuming 1 x A1/C2, 1 x A2/C3, 5 x 
A1/C3 and 2 x A2/C1 for the comparison in table 6 (see text for rationale) 
f: alternatives excluded by SacII long-range restriction mapping [Koppens et al. 2002c] 
g: a carrier of classical steroid 21-hydroxylase deficiency identified among the controls 
h: the alternative of A1 combined with a novel 'G' haplotype was ruled out by a family study 
i: no SacII results were available, but alternatives such as a combination of A1 and a novel 'H' haplotype 
are unlikely since mutation analysis showed that this control is a carrier of Val281→Leu, which we 
found on all chromosomes with haplotype C2 (see Chapter 3.2) 
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Table 4.  Frequencies of 21-hydroxylase/complement C4 haplotypes in the Netherlands 
haplotype SL SV LO SL + 
SV 
% fam. contr. fam. + 
contr. 
% 
A1 19 9 2 28 35.4 45 131a 176 48.2 
A2 5 6 1 11 13.9 20 64a 84 23.0 
A1 or A2b 1 0 0 1 1.3 0 9 9 2.5 
B1 7 0 0 7 8.9 4 19a 23 6.3 
B2 2 1 0 3 3.8 8 37 45 12.3 
C1 1 0 0 1 1.3 1 3 4 1.1 
C2 1 0 3 1 1.3 2 1 3 0.8 
C3 1 0 0 1 1.3 2 2a 4 1.1 
C1 or C3b 0 0 0 0 0.0 0 7 7 1.9 
C2 or C3b 0 0 0 0 0.0 0 2 2 0.5 
D1 3 1 0 4 5.1 0 0 0 0.0 
D2 4 0 0 4 5.1 0 0 0 0.0 
D1 or D2b 1 0 0 1 1.3 0 0 0 0.0 
E1 13 3 0 16 20.3 0 1 1 0.3 
F1 0 0 0 0 0.0 0 2 2 0.5 
F2 1 0 0 1 1.3 0 1 1 0.3 
G1 0 0 0 0 0.0 0 3 3 0.8 
H1 0 0 0 0 0.0 1 0 1 0.3 
total 59 20 6 79 100 83 282 365 100 
SL: patients with salt-losing CAH 
SV: patients with simple virilising CAH 
fam.: non-CAH haplotypes in CAH families 
contr.: unaffected controls 
a: assuming B1/C3 rather than A1/A2 in one of the controls with similar patterns (see text for 
rationale) 
b: for a few haplotypes, no distinction could be made between two possibilities (see text). 
 
 
Population differences 
A compilation of representative data from haplotyping studies done in different countries is 
presented in table 5 (more such studies are listed in our previous report [Koppens et al. 
1992a]).  Information on the configuration of the C4 genes is often not available from CYP21 
haplotyping reports, but has been provided by several groups focusing on diseases that may be 
complement-associated.  A comparison of C4 haplotypes in healthy controls from several 
countries is presented in table 6.  The haplotypes are grouped by the number and size of the 
C4 genes here, without taking the number of CYP21 and CYP21P genes into account.  In 
terms of the CYP21/C4 haplotypes used in fig. 1, this implies that the following haplotypes are 
merged: A1, D1 and G1; A2 and D2; B1 and E1; C2 and F1.  For clarity, a nomenclature that 
is entirely C4-based [Blanchong et al. 2000] is also listed in table 6. 
Interpretation of CYP21/C4 haplotypes is as difficult today as it was ten years ago: not all 
authors avoid the 'haplotypes combination' pitfall mentioned above and the necessity to do 
family studies is not always appreciated either.  For example, one recent report [Blanchong et 
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al. 2000] provides details on the frequencies of each individual 'C' haplotype and also on the 
frequency of haplotype combinations in a way somewhat similar to table 3 (figure 4C in that 
report).  However, they interpret some combinations as A1/C2 and A2/C1 rather than A2/C3 
and A1/C3, respectively and thus arrive at a very low frequency of haplotype C3 (LSS in their 
report).  Since no mention is made of either family studies or long-range restriction mapping, 
this interpretation seems arbitrary.  Such issues keep limiting the number of studies suitable 
for a comparison of haplotype frequencies; in addition, many recent reports focus on CYP21 
mutation analysis and no longer provide details on the layout of the RCCX module. 
Reliable and extensive information about C4/CYP21 haplotypes and their frequencies remains 
valuable today, because it can provide insight into questions regarding evolution, population 
genetics and mutational mechanisms.  For example, it has been suggested that monomodular 
haplotypes (notably, B2 associated with HLA-B8,DR1) can serve as a 'premutation', 
promoting unequal crossovers between RCCX modules and contributing to de novo loss of the 
CYP21 gene and to the relatively high frequency of the E1 haplotype in Western European 
populations [Sinnott et al. 1990].  Frequencies found in some, but not all, haplotyping studies 
support that notion. 
 
Table 5.  Comparison of CYP21 haplotypes on chromosomes bearing classical 21-hydroxylase deficiency 
in different populations 
haplotype the N
etherlands a 
E
ssen, G
erm
any b 
M
unich, G
erm
any c 
S
w
eden d 
Ireland e 
Italy f 
S
pain g 
C
olum
bus, O
hio, 
U
S
A
h 
C
am
pinas, B
razil i 
S
ao P
aulo, B
razil j 
A 40 18 24 46 16 47 56 18 27 94 
B 10 1 6 1 3 1 13 2 1 19 
C 3 1 0 2 0 7 14 4 3 9 
D 9 1 11 6 0 2 17 11 7 10 
E 16 15 11 12 10 7 20 9 3 9 
F 1 0 0 3 0 0 0 0 0 1 
other 0 0 0 4 1 2 0 0 0 0 
total 79 36 52 74 30 66 120 44 41 142 
a: this study, including the previous results [Koppens et al. 1992a] 
b: compiled from table 2 in the report of Keller et al. [1991] 
c: addition of the numbers for SL and SW from table 1 in the report of Strumberg et al. [1992] 
d: compiled from several tables in the report of Haglund-Stengler et al. [1990] 
e: compiled from table 1 and the text in the report of Sinnott et al. [1991] 
f: compiled from table 1 in the report of Sinnott et al. [1992] 
g: calculated from the percentages in fig. 2 in the report of Lobato et al. [1998]; contains 6 non-
independent alleles due to consanguinity 
h: compiled from table V in the report of Blanchong et al. [et al. 2000] 
i: addition of the numbers for SL and SW from table 2 in the report of de-Araujo et al. [1996] 
j: calculated from the percentages for SL and SW from table 1 in the report of Bachega et al. [1999] 
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Table 6.  Comparison of C4 haplotypes on chromosomes of healthy controls, or not carrying 
21-hydroxylase deficiency, in different populations 
haplotypes 
as in fig. 1 
C4 
haplotypea  
the N
etherlands b 
E
ssen, G
erm
any c 
N
orw
ay d 
Italy e 
Finland f 
N
orthern E
urope g 
C
olum
bus, O
hio, 
U
S
A
h 
B
razil (G
uarani) i 
B
razil (K
aingang) j 
A1, D1, G1 LL 185 18 45 39 35 50 138 18 92 
A2, D2 LS 87 11 12 15 21 19 69 30 57 
B1, E1 L 24 1 2 2 12 14 18 0 4 
B2 S 45 3 10 3 7 22 33 0 0 
C1 LLL 6 3 1 0 0 0 22 56 104 
C3 LLS 10 1 2 0 3 1 1 0 2 
C2, F1 LSS 6 1 3 1 0 0 19 0 0 
other  2 0 1 1 0 0 0 7 77 
total  365 38 76 60 78 106 300 111 336 
a: L=long C4 gene, S=short C4 gene [Blanchong et al. 2000] 
b: this study, including the previous results [Koppens et al. 1992a], and interpreting the control 
haplotypes as described under table 3 
c: compiled from table 2 in the report of Keller et al. [1991] 
d: from table 1 in the report of Teisberg et al. [1988], interpreting a-d as 'long' and e as 'short' 
e: from table 2 in the report of Sinnott et al. [1992] 
f: compiled from table 1 in the report of Partanen [1987] 
g: from table 1 in the report of Palsdottir et al. [1987]; probably mixed British, Icelandic and Norwegian 
h: calculated from the percentages in fig. 3 in the report of Blanchong et al. [2000] 
i: from tables 3 and 5 in the report of Weg-Remers et al. [1997] (the numbers are not quite consistent in 
these tables); Guarani Amerindian tribe 
j: as i; summation of two genetically very similar groups of the Kaingang Amerindian tribe 
 
 
An issue discussed in our earlier report [Koppens et al. 1992a] is the balance between 
monomodular and trimodular haplotypes, which are expected to be generated in equal 
amounts by crossing-over events between two bimodular chromosomes [Koppens et al. 
2002a].  One reason why trimodular chromosomes are not widespread may be the contribution 
of pre-existing monomodular chromosomes just mentioned: HLA-B8,DR1 may be an ancient 
conserved haplotype that escaped the RCCX module duplication.  There seems to be no 
disadvantage to having a trimodular RCCX area, as demonstrated by the high frequency in 
two South American Indian tribes [Weg-Remers et al. 1997]. 
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2.3. The PvuII restriction site in the second intron of the 
human steroid 21-hydroxylase gene CYP21 is 
polymorphic 
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Candidate gene 
CYP21 encoding steroid 21-hydroxylase, involved in adrenocortical steroidogenesis; 
deficiency leads to congenital adrenal hyperplasia.  The CYP21 cDNA probe used also 
hybridises to the 98 % homologous pseudogene CYP21P [White et al. 1985]. 
 
Source/description of probe 
We analysed TaqI/PvuII patterns using the 0.6 kb BamHI-EcoRI fragment of pC21/3c as a 
probe.  Probe availability: pC21/3c is available from the ATCC. 
 
Technical comments 
10 µg of human genomic DNA was first digested with TaqI and then with PvuII.  The 
fragments were separated on a 1.2 % agarose gel and transferred to nitrocellulose membranes 
by Southern blotting.  After hybridisation, the final washing step was performed at 60 °C, 
0.3 x SSC. 
 
Polymorphism 
TaqI/PvuII double digestion results in 3 fragments: a constant band at 1012 bp (representing 
CYP21P) and polymorphic bands at 1541 and 1360 bp (representing CYP21).  The fragment 
sizes have been deduced from published sequencing data [Higashi et al. 1986].   Lane 1: 
allele B / allele B; lane 2: allele A / allele B; lane 3: allele B / allele B, with a homozygous 
deletion of CYP21P; lane 4, homozygous deletion of CYP21. 
 
Frequencies 
The polymorphism was studied in 44 families with patients affected with steroid 
21-hydroxylase deficiency and 78 unrelated healthy controls.  Most of the patients and their 
family members have been described in a previous report [Koppens et al. 1992]; the others 
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1 2 3 4
1541
1360
1012
have been classified and studied in a similar way, allowing a distinction between 
chromosomes carrying and not carrying steroid 21-hydroxylase deficiency.  The controls were 
individuals randomly selected from the Dutch population and had no reported family history 
of steroid 21-hydroxylase deficiency.  The frequencies of allele A (the 1541 bp fragment) and 
allele B (the 1360 bp fragment) did not differ significantly between chromosomes carrying or 
not carrying steroid 21-hydroxylase deficiency (table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromosomal localisation 
CYP21 has been mapped to the human MHC on chromosome 6p21.3. 
 
Mendelian inheritance 
Codominant segregation was observed in two informative families. 
 
Other comments 
Haplotyping studies performed as described [Koppens et al. 1992] showed that the variation in 
fragment size described here could not be attributed to a TaqI polymorphism.  Absence of the 
PvuII site involved is normally a feature of the CYP21P pseudogene.  This was confirmed in 
this study, since no TaqI/PvuII fragments smaller than the 1012 bp fragment expected for 
CYP21P were found.  Gene conversion has been proposed as a mechanism causing deficiency 
of CYP21 genes by transfer of parts of CYP21P.  Presence of both deleterious and apparently 
harmless CYP21P-like sequences has been observed [Higashi et al. 1988].  It therefore seems 
possible that the polymorphism described here has also resulted for a gene conversion-like 
event. 
Care should be taken when interpreting PvuII restriction patterns in haplotyping studies.  
Presence of this polymorphism in CYP21 could lead to identification of CYP21 genes as 
CYP21P-like and hence to erroneous assignment of carrier status. 
 
Table 1. Frequencies of allele A (1541 bp) and allele B (1360 
bp) in steroid 21-hydroxylase deficient and normal 
chromosomes 
 allele A allele B total 
deficient (patients) 1 87 88 
normal (family members) 1 87 88 
normal (controls) 3 153 156 
total 5 327 332 
frequency 0.02 0.98  
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Abstract 
We studied the configuration of the complement C4/CYP21 (steroid 21-hydroxylase) region of 
the human major histocompatibility complex in patients suffering from congenital adrenal 
hyperplasia (CAH) and in the general population in the Netherlands, using C4 and CYP21 
probes and the restriction enzymes TaqI and BglII.  We found a rare TaqI 3.9 kb restriction 
fragment in the mother of a CAH patient and present evidence that this polymorphism is 
caused by an additional restriction site in the first intron of a complement C4 gene. 
 
Introduction 
The human major histocompatibility complex class III genes usually include two genes 
encoding the fourth component of complement, C4A and C4B, which are about 10 kb apart.  
About 3 kb centromeric of C4B lies a gene (CYP21) encoding the adrenocortical enzyme 
steroid 21-hydroxylase; in a similar arrangement, C4A is accompanied by the CYP21P 
pseudogene, which is inactive due to several deleterious mutations [Carroll et al. 1985; White 
et al. 1985; Higashi et al. 1986; White et al. 1986]. 
Deletions and duplications of the complement C4 and 21-hydroxylase genes are common; 
mutations affecting CYP21 lead to congenital adrenal hyperplasia (CAH), an inherited 
metabolic disease afflicting about 1:15,000 newborns. 
In recent years, the rearrangements in this region have been extensively studied using C4 and 
21-hydroxylase DNA probes.  The restriction enzyme TaqI is especially useful, providing 
information about both the C4 and 21-hydroxylase genes. 
In a study of C4 and 21-hydroxylase haplotypes in the Netherlands, we found a rare TaqI 
polymorphism in the mother of a CAH patient, on the chromosome not carrying CAH.  We 
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here present evidence that this polymorphism is caused by an additional restriction site in the 
first intron of a C4 gene. 
 
 
lane 1 lane 2 lane 3
7.2
6.2
3.9
3.7
3.2
complement C4 bands
steroid 21-hydroxylase bands
1 2 3
a
b
c
Fig. 1. a. Pedigree of family W.  b. TaqI restriction patterns in family W.  Hybridisation was performed with 
the 0.6 kb BamHI-KpnI fragment of pAT-A and with pC21/3c in a single experiment.  Lane 1, father W; lane 
2, mother W; lane 3, son W (CAH patient).  c. Densitometric scans corresponding to fig. 1b, lanes 1-3. 
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Materials and methods 
CAH patients and controls 
We characterised the configuration of the complement C4/CYP21 region in 44 unrelated 
families with CAH patients and 147 unrelated healthy controls, all of Dutch ethnic origin 
(results to be published elsewhere).  TaqI and BglII restriction patterns were established using 
complement C4 and steroid 21-hydroxylase probes.  In one CAH family (family W), an 
unusual TaqI restriction pattern was found (see fig. 1).  The son is a CAH patient, who 
presented with the salt-losing form of the disease in the first month of life. 
Southern blotting, hybridisation and laser densitometry 
Genomic DNA was prepared from peripheral leukocytes essentially as described [Wyman and 
White 1980]; 10 µg was digested overnight with 40 units BamHI, BglII, HindIII, KpnI, PstI, 
PvuII or TaqI, according to the manufacturers' (New England Biolabs, Beverly MA, USA, or 
Pharmacia, Uppsala, Sweden) instructions.  After agarose gel electrophoresis and Southern 
blotting, hybridisation was performed with the 1 kb PstI fragment of the complement C4 
cDNA probe pAT-A [Belt et al. 1984] or the 2.1 kb 21-hydroxylase cDNA probe pC21/3c 
[White et al. 1985]; the probes were obtained from the American Type Culture Collection.  
The optical densities of the autoradiographic bands were determined by densitometry with an 
LKB 2222-020 Ultroscan XL laser densitometer.  The relative quantities of the fragments 
were calculated as the ratio of the areas under the respective curves. 
 
Results and discussion 
In the most common arrangement, two complement C4 loci are present in the human MHC 
class III region, with C4A positioned at locus I and C4B at locus II.  TaqI polymorphisms are 
used to distinguish between these loci, as well as between 'long' and 'short' complement C4 
genes (22 vs 16 kb, depending on the presence or absence of a 6-7 kb intronic sequence) 
[Schneider et al. 1986; Palsdottir et al. 1987; Yu and Campbell 1987]. 
Fig. 1 shows the TaqI restriction patterns obtained with the complement C4 and 
21-hydroxylase cDNA probes in family W.  The 7.2 kb and 6.2 kb bands shown represent long 
C4 genes at locus I and II, respectively; the 3.7 and 3.2 kb bands represent the steroid 
21-hydroxylase genes CYP21 and CYP21P [Carroll et al. 1985; White et al. 1985; Higashi et 
al. 1986; White et al. 1986; Schneider et al. 1986; Palsdottir et al. 1987; Yu and Campbell 
1987].  In mother W (lane 2 in fig. 1), a band was observed at 3.9 kb; when the probes were 
used separately, the 3.9 kb band hybridised to the C4 probe only.  For father W, the intensity 
of the TaqI 3.2 and 3.7 kb fragments is equal; the 3.7 kb fragment of mother and son is only 
half as intense as the 3.2 fragment (fig. 1c), which means the number of CYP21 and CYP21P 
genes is equal in father W, while in mother and son there are twice as many CYP21P genes as 
CYP21 genes.  Using BglII with the 21-hydroxylase probe, we found an equal intensity of the 
12 and 10 kb bands in father, and a diminished 12 kb fragment in mother and son (results not 
shown).  The 10 kb BglII band is constant; the relative intensity of the 12 kb band varies with 
the number of C4/CYP21(P) repeats present, the bands being equal for individuals with four 
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such units.  These results indicate that father W has two 22 kb C4 genes, a CYP21 gene and a 
CYP21P pseudogene on each chromosome.  Mother W has a single 22 kb C4 gene and a 
CYP21P pseudogene on one chromosome.  On the other chromosome she has a 22 kb C4 gene 
and a C4 gene characterised by the 3.9 kb fragment, and a CYP21 gene and a CYP21P 
pseudogene.  Deletions in this region usually encompass a C4 gene as well as one of the 
adjacent 21-hydroxylase genes [Carroll et al. 1985; White et al. 1985; Schneider et al. 1986; 
Palsdottir et al. 1987; Uring-Lambert et al. 1987; Yu and Campbell 1987].  The son, a CAH 
patient, apparently inherited the chromosome carrying a deletion of CYP21 and one C4 gene 
from his mother.  The rare 3.9 kb TaqI fragment is therefore not associated with CAH in this 
family.  This data strongly suggests that this fragment represents a C4 gene at locus II on the 
mother's chromosome not carrying a deletion. 
 
 
We attempted to further characterise this polymorphism using several other restriction 
enzymes.  First, mother W's DNA was digested with KpnI, HindIII and BamHI.  The 
complement C4 probe hybridised to the following restriction fragments: KpnI: 12 kb, 7.5 kb 
and 3.7 kb; HindIII: 32 kb and 15 kb; BamHI: 4.5 kb.  These fragments have been described in 
3.5
1.255
1.044
0.976
0.9
2.4
3.0
3.2
4.2
1 2 3 4
Fig. 2. Restriction patterns of mother W 
and a control.  Hybridisation was 
performed with the 1 kb PstI fragment 
of pAT-A.  Lane 1, TaqI/KpnI pattern of 
a control with long C4 genes at locus I 
and short C4 genes at locus II, 
showing bands characteristic of locus I 
(4.2 kb), locus II (3.2 kb), long C4 
genes (3.0 kb) and short C4 genes (2.4 
kb).  Lane 2-4, mother W: TaqI/KpnI, 
PstI/KpnI and BamHI/KpnI patterns, 
respectively.  Double digests of DNA 
from controls with long C4 genes 
showed the same PstI/KpnI and 
BamHI/KpnI patterns as in lanes 3 and 
4.  Mother W's bands correspond to 
restriction fragments shown in fig. 3.  
The numbers indicate the sizes of the 
TaqI/KpnI fragments (left) and of the 
PstI/KpnI and BamHI/KpnI fragments 
(right). 
 
CYP21/C4 haplotyping   
 
141 
the literature [Carroll et al. 1985; Palsdottir et al. 1987; Uring-Lambert et al. 1987; Yu and 
Campbell 1987].  From these data, it can be concluded that all complement C4 genes in 
mother W are 'long' (characterised by the 7.5 kb KpnI and 4.5 kb BamHI fragments), and that 
both locus I and II are present (characterised by the 12 and 3.7 kb KpnI fragments, 
respectively).  This was confirmed by the HindIII pattern (the 15 and 32 kb bands are 
characteristic of long genes at locus I and II, respectively).  Also, the relative intensity of the 
7.5 and 3.7 kb KpnI bands and the 32 kb HindIII band was diminished relative to the same 
bands in individuals with two long C4 genes on each chromosome, confirming a deletion of 
one C4 (and one 21-hydroxylase) gene on one of mother W's chromosomes. 
These findings suggest that the 3.9 kb TaqI fragment is the result of an additional restriction 
site rather than a major rearrangement or a deletion.  Normally, a 'long' C4 gene at locus II 
would be characterised by a 6.2 kb TaqI fragment; an extra TaqI site within this fragment 
could reduce its size to 3.9 kb.  We determined the location of this putative additional TaqI 
site using double digests with several restriction enzymes. 
Fig. 2 shows that in a TaqI/KpnI double digest, mother W (lane 2) lacks the 3.2 kb band 
typically seen in controls having C4 genes at locus II (lane 1), but has an additional band at 
0.9 kb.  Recently, the nucleotide sequence of a C4 gene was published [Yu 1991]; within 
about 1 kb of the 5' terminus are a BamHI site and a PstI site (both in the first exon) and a 
PvuII and a KpnI site (see fig. 3).  Lane 2-4 of fig. 2 show mother W's additional 0.9 kb 
TaqI/KpnI band in comparison with the 1044 bp BamHI-KpnI fragment and the 976 bp PstI-
KpnI fragment predicted by the sequence.  The TaqI/KpnI fragment is about 70 bp smaller 
than the PstI/KpnI fragment, and thus approximately 900 bp in size.  These findings were in 
agreement with the size differences of the fragments observed after TaqI/PvuII, BamHI/PvuII 
and PstI/PvuII double digests (results not shown). 
 
 
Fig. 3. Restriction map of the 5' end and flanking sequence of mother W's C4 gene at locus II; the 3' end of 
the adjacent CYP21P gene is shown.  B-BamHI; K-KpnI; Ps-PstI; Pv-PvuII; T-TaqI; T*: additional restriction 
site described here.  The beginning of the C4 gene (0 on the kb scale) and the relative position of several 
restriction sites are according to the sequence published by Yu [1991].  The black bars indicate the 
sections covered by the C4 cDNA probe (right) and the 21-hydroxylase cDNA probe (left), respectively. 
CYP21
Locus I
C4A C4B
Locus II
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These results can only be explained by an additional TaqI site in the first intron of the C4 
gene, located about 70 bp downstream of the PstI site in the first exon (see fig. 3).  In a TaqI 
digest (fig. 1), no 2.7 kb fragment (the other part of the original 6.6 kb) is seen, because this 
would hybridise to only about 30 bp of the cDNA probe.  It is highly unlikely that the 
sequence alteration described here could in any way adversely affect the functioning of the C4 
gene.  The data presented here shows that it is located well outside the coding sequences.  
Also, assuming a point mutation has occurred, generation of a consensus splice junction 
sequence seems improbable, because this would require a sequence TCGNG to be changed 
into TCGAG, and no such sequence is present in the first intron of the published C4 sequence 
[Yu 1991] (apart from the fact that GAG is rarely seen at splice junctions). 
Recently, Goldstein et al. [1991] reported a polymorphism in a human complement C4 gene 
characterised by a 3.5 kb TaqI fragment in two patients with systemic lupus erythematosus.  In 
their study as well as in ours, a 21-hydroxylase probe was used, which hybridises to a 3.73 kb 
TaqI band fragment (the size of which has been determined by sequence analysis [Higashi et 
al. 1986; White et al. 1986]).  A clear distinction between 3.5 and 3.9 kb should therefore be 
possible; when the C4 and 21-hydroxylase probes are used in a single hybridisation 
experiment, the 3.9 kb C4 band is located above the 3.73 kb CYP21 band (see fig. 1).  
Therefore, the 3.5 and 3.9 kb bands appear to represent different polymorphisms as well as 
two new classes when the combined C4 / CYP21 haplotypes defined in terms of TaqI 
restriction patterns are considered. 
Clearly, these polymorphisms are rare: Goldstein et al. found the 3.5 kb band twice in 79 SLE 
patients and 60 controls (278 chromosomes), and we found the 3.9 kb band once in 44 CAH 
families and 147 controls (470 chromosomes); neither has been previously reported in the 
literature. 
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Abstract 
Steroid 21-hydroxylase deficiency is caused by defectiveness of the CYP21 gene.  Such 
defects have presumably originated from interactions with the nearby CYP21P pseudogene 
during evolution.  We studied these mechanisms by comparing the genetic variability of 
CYP21, CYP21P and CYP21P/CYP21 hybrids (resulting from large-scale rearrangements) at 
eight mutation sites in a group of Dutch steroid 21-hydroxylase deficiency patients, their 
family members, and controls.  The most common CYP21 defect in patients with salt-losing 
steroid 21-hydroxylase deficiency was a splice junction mutation in intron 2.  The most 
common defect in the simple virilising form of the disease was Ile172→Asn.  CYP21P 
showed considerable sequence variation in its central and 3' sections; the 5' section was 
constant.  A single nucleotide (T) insert in exon 7 was found in all CYP21P genes.  During the 
course of evolution, this was probably the third defect introduced into CYP21P after the splice 
junction mutation in intron 2 and the 8 bp deletion in exon 3.  Gene conversions introducing 
CYP21-like sequences contribute to CYP21P variability.  Such an event has occurred de novo 
in one family.  A comparison of CYP21 and CYP21P mutations on the same chromosome 
shows that at least some of the small-scale gene conversions that supposedly transfer defects 
to CYP21 involve interaction between homologous chromosomes.  The majority of the 
putative CYP21P-CYP21 transitions in hybrid genes appears to occur in a distinct zone that 
lies 5' of nucleotide 2108, which is further downstream than previously hypothesised.  The 
other transitions lie upstream of nucleotide 999.  Apparent 'large-scale' CYP21-CYP21P gene 
conversions lead to hybrid genes that are very similar to those found in CYP21 deletions, so 
these haplotypes have probably resulted from a meiotic double unequal crossover. 
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Introduction 
The human CYP21 gene, located on chromosome 6 (6p21.3), encodes the adrenocortical 
enzyme steroid 21-hydroxylase [White et al. 1985].  CYP21P is a pseudogene sharing 98 % 
sequence homology with CYP21 but containing several alterations rendering it inactive 
[Higashi et al. 1986; White et al. 1986].  CYP21 and CYP21P are about 30 kb apart and are 
part of a cluster of duplicated genes that includes genes encoding the fourth component of 
complement (C4) and tenascin-X [White et al. 1985; Gitelman et al. 1992; Miller et al. 1992]. 
Defectiveness of CYP21 leads to steroid 21-hydroxylase deficiency, which is the cause of over 
90 % of all cases of congenital adrenal hyperplasia.  Complete deficiency results in severe 
salt-loss crises in untreated paediatric patients due to lack of aldosterone ('salt-losing' 
21-hydroxylase deficiency), while increased androgen levels cause virilisation even in patients 
with less severe defects ('simple virilising' 21-hydroxylase deficiency) [White 1994; Pang 
1997; Wedell 1998]. 
Genetic analysis of steroid 21-hydroxylase deficiency is complicated by the existence of many 
different arrangements of CYP21 and CYP21P, including gene deletions, duplications and 
large-scale gene conversions.  Analysis of TaqI and BglII restriction patterns is commonly 
used to determine the gross arrangement of the CYP21/C4 region in steroid 21-hydroxylase 
deficiency patients and their family members [Carroll et al. 1985; White et al. 1985; 
Donohoue et al. 1986; Schneider et al. 1986; Matteson et al. 1987; Higashi et al. 1988; White 
et al. 1988; Morel et al. 1989].  This approach allows the definition of CYP21/C4 haplotypes, 
some of which are associated with steroid 21-hydroxylase deficiency [White et al. 1988; 
Collier et al. 1989; Morel et al. 1989; Mornet et al. 1991; Helmberg et al. 1992; Koppens et 
al. 1992; Strumberg et al. 1992; Lobato et al. 1998; Paulino et al. 1999].  Three categories of 
defects can be distinguished: 
(a) Haplotypes with a single gene that features a CYP21P-like TaqI restriction pattern 
('CYP21 deletions').  These have resulted from a meiotic unequal crossover between 
CYP21 and CYP21P, creating a gene consisting of the 5' section of CYP21P and the 3' 
section of CYP21 [Carroll et al. 1985; White et al. 1985; Donohoue et al. 1989; Collier et 
al. 1993; Tusié-Luna and White 1995].  
(b) Haplotypes with two genes, both with a CYP21P-like restriction pattern ('large-scale gene 
conversions').  Here, a section of CYP21 that includes at least the TaqI site in the 5' flank 
has been replaced by a CYP21P-like sequence [Donohoue et al. 1986; Matteson et al. 
1987; Higashi et al. 1988]. 
(c) Haplotypes where a gene with a CYP21-like restriction pattern is present (by exclusion).  
On chromosomes bearing steroid 21-hydroxylase deficiency, the CYP21 gene carries one or 
more deleterious mutations [Higashi et al. 1991; Mornet et al. 1991; Owerbach et al. 1992; 
Speiser et al. 1992; Wedell 1998].  With a few exceptions, these mutations are found in the 
consensus sequence of CYP21P [Higashi et al. 1986; White et al. 1986] and have supposedly 
been transferred to CYP21 during evolution ('small-scale gene conversions'). 
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The nature and the frequencies of the mutations in CYP21 have been well studied.  They vary 
among different populations [Higashi et al. 1991; Mornet et al. 1991; Helmberg et al. 1992; 
Owerbach et al. 1992; Speiser et al. 1992; Barbat et al. 1995; Evgrafov et al. 1995; Ezquieta 
et al. 1995; Wilson et al, 1995; Wedell 1998; Paulino et al. 1999].  However, information on 
the variability of the CYP21P pseudogene, especially in association with the TaqI/BglII 
haplotypes that define the overall structure of the region, is rather limited [Helmberg et al. 
1992; Wedell and Luthman 1993].  Such information is highly relevant to the hypotheses 
describing the origin of the different categories of disease-causing mutations in CYP21: the 
location of crossover sites and the extent of conversion zones depend on the composition of 
the CYP21P gene involved.  We compared CYP21 and CYP21P in a single population, to 
assess the consequences of CYP21P variability to the hypothetical concepts of 'hybrid genes' 
and 'gene conversions'.  The distribution of the ten most common CYP21 defects (gene 
deletion, large-scale conversion, and eight mutations) was determined in 38 steroid 
21-hydroxylase deficiency patients from the Netherlands, a population which has not been 
studied before.  The sites corresponding to these mutations were also studied in CYP21P in 
these families, and in 46 controls having only one CYP21P gene. 
 
Methods 
Patients, family members, and controls 
Steroid 21-hydroxylase deficiency patients, their parents and any available sibs from 38 
families were included; in six families, only one of the parents was available.  The number of 
independent chromosomes was 150 (due to consanguinity between two of the families), 75 of 
which carried a steroid 21-hydroxylase deficiency allele.  Single patients and two families 
with apparent de novo gene rearrangements were not included.  There were 29 families with 
salt-losing (SL) patients and 9 families with simple virilising (SV) patients.  From our group 
of 143 healthy controls from the general Dutch population, 46 had a heterozygous deletion of 
CYP21P and were selected to study CYP21P separately.  All subjects were informed about the 
purpose of the study and gave their consent. 
Haplotyping and mutation analysis 
TaqI and BglII restriction analysis  [Carroll et al. 1985; White et al. 1985; Donohoue et al. 
1986; Schneider et al. 1986; Matteson et al. 1987; Higashi et al. 1988; White et al. 1988; 
Morel et al. 1989] was used as described earlier [Koppens et al. 1992] to establish CYP21/C4 
haplotypes in all families and controls. 
Polymerase chain reaction (PCR) amplification of CYP21 and CYP21P followed by 
oligonucleotide hybridisation [Mornet et al. 1991; Helmberg et al. 1992; Owerbach et al. 
1992; Speiser et al. 1992; Barbat et al. 1995] was used to determine sequence variability. 
 
Table 1. Oligonucleotides used as primers and for mutation detection 
sequence description final washa 
CAGACCTGAGCCACTTACCT nt 367: forward primer CYP21 and CYP21P, section 1  
ATCCCCAATCCAGGTCCCT nt 530: forward primer CYP21, section 1  
TTTGTTAGAGATGGGGTCTTG nt 430: forward primer CYP21P, section 1b  
CAGGAGGAGTTGGGGGCTG A at nt 655: splice junction intron 2 (normal) 52ºC, 0.5xSSC 
CAGGAGGAGGTGGGGGCTG C at nt 655: splice junction intron 2 (normal)  52ºC, 0.5xSSC 
CAGGAGGAGCTGGGGGCTG G at nt 655: splice junction intron 2 (mutant)  52ºC, 0.5xSSC 
TCCTTGGGAGACTACTCCCT nt 700: absence of 8 bp deletion in exon 3 (normal); also forward primer CYP21, section 2 48ºC, 0.4xSSC 
TGTCGTTGGTCTCTGCTCTG nt 698: presence of 8 bp deletion in exon 3 (mutant); also forward primer CYP21P, section 2 52ºC, 0.4xSSC 
TTCTTGTGGGCTTTCCAGAG nt 721: reverse primer CYP21 and CYP21P,  section 1  
GCGGCATCATCTGTTACCT T at nt 999: Ile172 (normal)  48ºC, 0.5xSSC 
GCGGCATCAACTGTTACCT A at nt 999: Asn172 (mutant)  48ºC, 0.5xSSC 
CACATCGTGGAGATGCAGCTG TCGTGGAGAT at nt 1380-1389: IleValGluMet236 (normal), also forward primer CYP21, section 3 52ºC, 0.3xSSC 
CACAACGAGGAGAAGCAGCTG ACGAGGAGAA at nt 1380-1389: AsnGluGluLys236 (mutant), also forward primer CYP21P, section 3c 52ºC, 0.3xSSC 
CACAAGGAGGAGAAGCAGCTG AGGAGGAGAA at nt 1380-1389: LysGluGluLys236 (mutant)  52ºC, 0.1xSSC 
AGTCCCCACCTTGTGCTGCCT nt 1397: reverse primer CYP21 and CYP21P, section 2  
CCATGTGCACGTGCCCTTC G at nt 1683: Val281 (normal)  48ºC, 0.5xSSC 
CCATGTGCAAGTGCCCTTC T at nt 1683: Leu281 (mutant)  48ºC, 0.5xSSC 
GTGAAGCAAAAAAACCACGG nt 1760: absence of T insertion in exon 7 (normal)  48ºC, 0.4xSSC 
GTGAAGCAAAAAAAACCACG nt 1760: presence of T insertion in exon 7 (mutant)  48ºC, 0.4xSSC 
GCTCCTCCTGCAGTCGCTG C at nt 1994: Gln318 (normal)  48ºC, 0.7xSSC 
GCTCCTCCTACAGTCGCTG T at nt 1994: stop318 (mutant)  48ºC, 0.7xSSC 
CTGCGCCTGCGGCCCGTTG C at nt 2108: Arg356 (normal)  52ºC, 0.2xSSC 
CTGCGCCTGTGGCCCGTTG T at nt 2108: Trp356 (mutant)  52ºC, 0.2xSSC 
AACCCTCGGGAGTCACCTGCT nt 2153: reverse primer CYP21 and CYP21P, section 3  
nt = nucleotide number according to Higashi et al. [1986] 
a: the final wash in the oligonucleotide hybridisation was done for 20 minutes at these conditions 
b: primer site chosen about 100 bp upstream of the CYP21 primer, to include the EcoRI site in exon 2 
c: section 3 of genes carrying LysGluGluLys236 was amplified normally using this primer, but it was easily washed off in the hybridisation experiments of the section 2 
PCR product 
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Fig. 1.  Map of the consensus CYP21 and CYP21P genes; open boxes are exons.  Restriction sites used 
for identification (see text) are shown: E=EcoRI site, N=NdeII site, Ps=PstI site, Pv=PvuII site, T=TaqI site.  
The bold black lines below represent the three amplified sections. The amplification of CYP21 and CYP21P 
in a single reaction (see text) matched section 1, extended further to the 5' side as indicated by the thinner 
black line to the left. 
 
 
Three overlapping parts of either CYP21 or CYP21P (see following sections 1, 2 and 3; fig. 1) 
were specifically amplified using the primers listed in table 1.  PCR conditions (annealing 
temperature, number of cycles, MgCl2 concentration) were: CYP21, section 1: 54 °C, 30 
cycles, 2.5 mM; CYP21P, section 1: 55 °C, 32 cycles, 2.5 mM; CYP21, section 2: 55 °C, 33 
cycles, 2.5 mM; CYP21P, section 2: 57 °C, 32 cycles, 2.5 mM; CYP21, section 3: 56 °C, 32 
cycles, 2.4 mM; CYP21P, section 3: 56 °C,  32 cycles, 2.4 mM.  All reactions were done with 
1 unit of GoldStar DNA polymerase (Eurogentec, Seraing, Belgium) in a final volume of 50 µl 
in the presence of 2 % formamide.  In each case, the reverse primer was non-specific (not 
distinguishing between CYP21 and CYP21P) and downstream of the forward primer of the 
next section.  The specificity of each reaction was checked by digesting 20 % of the amplified 
product with PvuII (section 1), NdeII (section 2), or PstI (section 3), followed by 
electrophoresis in 2-2.5 % agarose gels.  These restriction sites are normally present in CYP21 
and absent from CYP21P.  Section 1 was also digested with EcoRI; the EcoRI site is specific 
for CYP21P (see fig. 1).  The PvuII and EcoRI restriction patterns of the section 1 PCR were 
matched to the bands shown by TaqI/PvuII and TaqI/EcoRI double digests of genomic DNA 
[Koppens et al. 1995; Koppens et al. 1998].  Control samples containing or not containing 
these sites were included in each reaction.  The results for section 1 were confirmed by 
amplification of CYP21 and CYP21P in a single reaction using the same (non-specific) reverse 
primer and a non-specific forward primer (see fig. 1; 53 °C, 32 cycles, 3 mM MgCl2) followed 
by EcoRI digestion to distinguish between CYP21 and CYP21P, Southern blotting and 
hybridisation as described elsewhere [Koppens et al. 1998].  The remainder of the product was 
slot-blotted onto Hybond-N+ (Amersham Pharmacia, Little Chalfont, UK), and mutations 
were detected by hybridisation to allele-specific oligonucleotides, some of which were also 
used for amplification (see table 1 and fig. 2). 
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Results 
Arrangement of CYP21/CYP21P and complement C4 genes 
An overview of the CYP21/CYP21P arrangements in the 38 families and 143 controls 
investigated is presented in table 2.  Several CYP21/C4 haplotypes not described in our earlier 
report [Koppens et al. 1992] were detected in the larger population now studied.  Three 
controls had two CYP21 genes and no CYP21P genes on one chromosome, suggesting a 
'large-scale' conversion of CYP21P to CYP21.  Both C4 genes were 'long' (22 kb) in this 
haplotype.  One control carried one CYP21 gene, three CYP21P genes, one long C4 gene and 
three short (16 kb) C4 genes on one chromosome.  The mother of one patient had one CYP21 
gene, three CYP21P genes and four 'long' C4 genes on one chromosome.  These unusual 
haplotypes were confirmed by SacII digestion and pulsed field gel electrophoresis 
(unpublished observations). 
 
Table 2. CYP21/CYP21P haplotypes in the Dutch population 
 families, 
normal 
haplotypesa 
families, 
defective 
haplotypesb 
controls 
all 
haplotypes 
haplotype    
 CYP21-CYP21P  (normal) 58 38 212 
 CYP21 (CYP21P  deletion) 11 9 55c 
 CYP21-CYP21P-CYP21P (CYP21P duplication) 2 3 11 
 CYP21-CYP21-CYP21P (CYP21 duplication) 0 1 3 
 CYP21-CYP21P-CYP21P-CYP21P (CYP21P  triplication) 1 0 1 
 CYP21-CYP21 (CYP21P  to CYP21 conversion) 0 0 3 
 CYP21Pd (CYP21 deletion) 0 15 1 
 CYP21P-CYP21Pd (CYP21 to CYP21P conversion) 0 9 0 
total 72 75 286 
a: haplotypes not carrying steroid 21-hydroxylase deficiency; in three families, these could not be 
deduced because one of the parents was missing 
b: haplotypes carrying steroid 21-hydroxylase deficiency 
c: the genotypes were: four persons with CYP21/CYP21, one person with CYP21-CYP21/CYP21 and 46 
persons with CYP21-CYP21P/CYP21; these 46 were used as controls in the CYP21P mutation 
analysis 
d: these haplotypes carry steroid 21-hydroxylase deficiency due to absence of the CYP21 gene 
 
 
Polymerase chain reaction and oligonucleotide hybridisation 
The PvuII and EcoRI restriction patterns for section 1 matched the genomic TaqI/PvuII and 
TaqI/EcoRI results in each case.  The specificity of the amplification of section 2 could then 
be deduced from the mutation analysis of section 1, which contains its forward primer sites.  
Similarly, section 2 contains the forward primer site of section 3.  This strategy allowed 
assignment of each sequence variant to either CYP21 or CYP21P in all cases. 
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Fig. 2.  CYP21 intron-exon structure (open boxes are exons) and the mutations studied: a = intron 2 splice 
junction mutation (A/C/G) (nt 655); b = 8 bp deletion (present or absent) (nt 700); c = Ile172/Asn172 (nt 
999); d = IleValGluMet236/AsnGluGluLys236/LysGluGluLys236 (nt 1380); e = Val281/Leu281 (nt 1683); f = 
1 bp insertion between codons 306 and 307 (present or absent) (nt 1760); g = Gln318/stop318 (nt 1994); h 
= Arg356/Trp356 (nt 2108). The characteristics of the consensus CYP21 gene at each mutation site are, 
respectively: A or C at the splice junction mutation; no 8 bp deletion; Ile172; IleValGluMet236; Val281; no 1 
bp insertion; Gln318; Arg356. The characteristics of the consensus CYP21P gene are: G; 8 bp deletion; 
Asn172; AsnGluGluLys236; Leu281; 1 bp insertion; stop318; Trp356.  The limits of the putative CYP21P-
CYP21 transition zones have been drawn at arbitrary places relative to Ile172/Asn172 (zone a, 5' limit) and 
Arg356/Trp356 (zone b, 3' limit), respectively, since no further distinction is possible because the 
sequences of CYP21 and CYP21P are equal there.  The arrows indicate that the actual transition site 
within these zones may vary for each hybrid.  Bottom: hybrid genes with transition zone a and b, 
respectively; the hatched section is CYP21P-like. 
 
 
Mutation detection by oligonucleotide hybridisation to slot blots or Southern blots usually 
produced straightforward results, with the exception of the (non-defective) 'C' variant at 
nucleotide 655 (the site of the splice junction mutation in intron 2; see fig. 2), which 
hybridised poorly and required careful washing steps.  Similar weak signals with the 'C' 
variant were found by Rumsby et al. [1993].  The 'C' variant was readily detected in 
individuals homozygous for it, but the hybridisation signal was much weaker when the other 
chromosome carried either 'A' or 'G'.  The (normal) 'A' and (defective) 'G' variants performed 
equally well in this analysis.  In each parent carrying the 'G' allele on one chromosome, a non-
defective ('A' or 'C') allele could also be detected, indicating that dropout of one allele in the 
PCR [Day et al. 1996] did not occur here.  On the other hand, the amplification of both genes 
in a single reaction often produced a higher amount of CYP21P (containing 'G') than CYP21, 
especially when one or both of the CYP21 genes carried a 'C' at nucleotide 655. 
CYP21 mutations 
In 89 % of the patients' CYP21 genes, the defect could be attributed to one of the deleterious 
mutations investigated here (see table 3).  In general, there was a good match between 
phenotype and genotype: a severe defect (deletion, large conversion, intron 2 splice mutation, 
8 base pair deletion, AsnGluGluLys236, 1 base pair (T) insertion, stop318, Trp356 - mutation 
group A in the classification of Speiser et al. [1992]) was found on both chromosomes in 25 
out of 29 families with the salt-losing variety of the disease.  None of the SV patients had one 
of the more severe defects on both chromosomes.  The EcoRI site in intron 2 was not found in 
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any CYP21 gene.  The PvuII site in intron 2 was missing from one CYP21 gene that also 
carried the splice junction mutation, suggestive of a small-scale conversion transferring both 
alterations. 
 
Table 3. CYP21 defects in Dutch patients with classical steroid 21-hydroxylase deficiency 
defect SL SV 
CYP21 deletion (5' CYP21P / 3' CYP21 hybrid) 13 2 
CYP21 large conversion (5' CYP21P / 3' CYP21 hybrid and CYP21P gene ) 8 1 
splice junction mutation in intron 2a 21 1 
8 bp deletion in exon 3 1 - 
Ile172 → Asn 1 7 
IleValGluMet236 → AsnGluGluLys 4 - 
IleValGluMet236 → LysGluGluLys - - 
Val281 → Leu - - 
1 bp insertion in exon 7 (between codon 306 and 307) - - 
Gln318 → stop 1 - 
Arg356 → Trp 2 1 
1 bp insertion in exon 7 and Gln318→stop 1 - 
Val281 → Leu and Gln318 → stop and Arg356 → Trp 1 1 
splice junction mutation and Gln318 → stop (2 CYP21 genes on one allele) 1 - 
no defect found 3b 5 
total 57c 18 
The numbers refer to the independent chromosomes carrying the steroid 21-hydroxylase deficiency allele 
(see text) 
a: a G at position 655; of the remaining genes, 83 had an A and 18 a C (equally distributed between SL 
and SV patients) 
b: in one of these genes, the milder defect Pro30 → Leu was detected in a separate experiment (results 
not shown) 
c: one fewer than expected for 29 families due to known consanguinity (see text) 
 
 
One patient had both the 1 bp insertion in exon 7 and stop318 in exon 8, which have probably 
been transferred from CYP21P in a single event during evolution.  Two patients had 
Val281→Leu, the 1 bp insertion (codon 306-307), Gln318→stop and Arg356→Trp in the 
CYP21 gene, suggesting that a single conversion event has occurred in the past to introduce 
these defects into CYP21. 
One patient had a defective allele with two CYP21 genes.  This haplotype carried the intron 2 
splice junction mutation and Gln318→stop, and is probably the same as a haplotype described 
in the Swedish population [Wedell et al. 1994]. 
CYP21P mutations 
CYP21P mutation analysis was complicated by the lack of clinical association and by the 
relatively frequent occurrence of chromosomes with more than one CYP21P gene.  Only 
mutations that could be assigned to a specific haplotype with certainty were included.  The 
distribution of CYP21P mutations in the most common haplotypes is shown in table 4. 
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Table 4. Distribution of CYP21P variability per haplotype 
mutation CYP21-
CYP21P 
(normal) 
familiesa 
 
CYP21-
CYP21P 
(normal) 
controlsb 
 
CYP21P 
alone 
(CYP21 
del.) 
patientsc 
 
CYP21P-
CYP21P 
(large 
conv.) 
patientsd 
 
CYP21-
CYP21P-
CYP21P 
(CYP21P 
dupl.) 
familiese 
 (n=96) (n=46) (n=15) (n=18) (n=10) 
presence of EcoRI site in intron 2 100 100 100 100 100 
absence of EcoRI site in intron 2 0 0 0 0 0 
absence of PvuII site in intron 2 100 100 100 100 100 
presence of PvuII site in intron 2 0 0 0 0 0 
splice junction in intron 2, 'G' 100 100 100 100 100 
splice junction in intron 2, 'A' 0 0 0 0 0 
splice junction in intron 2, 'C' 0 0 0 0 0 
presence of 8 bp deletion in exon 3 100 100 100 100 100 
absence of 8 bp deletion in exon 3 0 0 0 0 0 
Asn172 98 100 67 82 100 
Ile172 2 0 33 18 0 
AsnGluGluLys236 86 81 33 82 100 
LysGluGluLys236 13 19 33 18 0 
IleValGluMet236 1 0 33 0 0 
Leu281 72 79 25 64 87 
Val281 28 21 75 36 13 
presence of 1 bp insertion in exon 7 100 100 73 82 100 
absence of 1 bp insertion in exon 7 0 0 27 18 0 
stop318 89 88 27 31 70 
Gln318 11 12 73 69 30 
Trp356 60 52 21 67 50 
Arg356 40 48 79 33 50 
The mutations are grouped per site; the variant matching the consensus sequence is mentioned first. The 
frequency of each mutation per haplotype is shown in percentages. The numbers in each column heading 
refer to the CYP21P genes, not to the chromosomes: for the haplotypes CYP21-CYP21P-CYP21P and 
CYP21P-CYP21P, the number of chromosomes is half the number of CYP21P genes. Mutations were only 
counted when they could be assigned to a haplotype with certainty. 
a: steroid 21-hydroxylase deficiency families; numbers for chromosomes carrying and not carrying 
steroid 21-hydroxylase deficiency were added; 'standard' CYP21-CYP21P haplotypes; n=90 for 
Val/Leu281; n=93 for Gln/stop318 and for Arg/Trp356 
b: controls with CYP21-CYP21P on one chromosome and a CYP21P deletion on the other; n=46 for 
mutations upstream of and including the 8 bp deletion, n=42 for the remaining mutations 
c: steroid 21-hydroxylase deficiency patients; hybrid genes due to a 30 kb deletion; n=12 for Val/Leu281, 
n=14 for Arg/Trp356 
d: patients; hybrid genes due to a large-scale gene conversion (two CYP21P genes were counted per 
chromosome); n=14 for Val/Leu281, n=16 for Gln/stop318, n=12 for Arg/Trp356 
e: families; numbers for chromosomes carrying and not carrying steroid 21-hydroxylase deficiency were 
added; CYP21P duplication (two CYP21P genes were counted per chromosome); n=8 for Val/Leu281 
and for Arg/Trp356 
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On 36 chromosomes where the CYP21 defect was found, at least one CYP21P gene was 
present.  On 32 of these chromosomes, there was a match between the CYP21 defect and the 
CYP21P sequence at the corresponding site - in these cases, CYP21P matched the consensus 
sequence [Higashi et al. 1986].  Four CYP21 genes had a defect not found in the 
accompanying CYP21P gene.  These were: Leu281 and stop318 and Trp356 on CYP21 vs 
Val281 on CYP21P; Leu281 and stop318 and Trp356 on CYP21 vs Arg356 on CYP21P; 
Trp356 on CYP21 vs LysGluGluLys236 and Val281 and Arg356 on CYP21P; and Trp356 on 
CYP21 vs Val281 and Arg356 on CYP21P.  Seven chromosomes carried a defective CYP21 
gene but no CYP21P gene.  The CYP21 defects were: all four AsnGluGluLys236 mutations; 
two of the intron 2 splice junction mutations; and one stop318 mutation. 
The variation in the central and 3' sections of 'normal' CYP21P genes (ie, CYP21P genes on 
the CYP21-CYP21P haplotype) was considerable.  The most frequent deviations from the 
consensus CYP21P sequences were LysGluGluLys236, Val281, Gln318 and Arg356.  On the 
other hand, the T insert between codons 306 and 307 in exon 7 was present in all pseudogenes 
on the CYP21-CYP21P haplotype. 
Many CYP21P genes carry more than one mutation as compared with the consensus 
sequences [Higashi et al. 1986; White et al. 1986].  The following combinations were found in 
the control group of individuals with a single CYP21P gene, where they could be 
unambiguously linked: AsnGluGluLys236-Leu281-stop318-Trp356 (20x); AsnGluGluLys236-
Leu281-stop318-Arg356 (8x); LysGluGluLys236-Val281-stop318-Arg356 (8x); 
AsnGluGluLys236-Leu281-Gln318-Arg356 (4x); AsnGluGluLys236-Leu281-Gln318-Trp356 
(1x); AsnGluGluLys236-Val281-stop318-Arg356 (1x). 
Additional combinations were found in the family studies: of the 16 possible combinations of 
AsnGluGluLys/LysGluGluLys236, Leu/Val281, stop/Gln318 and Trp/Arg356, only 
LysGluGluLys-Leu-Gln-Trp, LysGluGluLys-Val-Gln-Trp, LysGluGluLys-Leu-Gln-Arg and 
LysGluGluLys-Leu-stop-Arg were not found.  One CYP21P gene carried both Ile172 and 
Arg356; another carried both Ile172 and IleValGluMet236.  There were no statistically 
significant differences in the frequencies of the CYP21P mutations between 'standard' 
(CYP21-CYP21P) chromosomes with functional or non-functional CYP21 genes, or between 
21-hydroxylase deficiency families and controls. 
Table 5 shows all combined mutations on haplotypes carrying a single CYP21P-like gene 
(CYP21 'deletions') or two CYP21P-like genes ('large-scale' CYP21 conversions).  All these 
genes are CYP21P-like from their 5' flank to, at least, the 8 bp deletion in exon 3, and 
therefore defective. 
De novo CYP21P mutation in one family 
In a family with two patients each having two CYP21P genes, one patient carried 
IleValGluMet236 on one chromosome and AsnGluGluLys236 on the other, whereas all other 
family members only had AsnGluGluLys236 on their CYP21P genes.  Paternity was 
confirmed by testing independent genetic markers (results not shown).  All other investigated 
mutations  and the CYP21/C4 haplotypes were inherited in a normal Mendelian fashion in this 
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family.  A de novo conversion event locally changing CYP21P to a CYP21-like sequence is 
the most obvious explanation.  All CYP21 genes in this family carried IleValGluMet236. 
 
Discussion 
Mutations in the CYP21 gene 
The CYP21 mutations causing salt-losing 21-hydroxylase deficiency occurred at frequencies 
similar to those observed in other populations, the intron 2 splice mutation (a 'G' at nucleotide 
655) being the most common.  The frequency distribution is different for simple virilising 
21-hydroxylase deficiency, where Ile172→Asn is clearly more abundant.  This finding is in 
agreement with some studies [Helmberg et al. 1992; Speiser et al. 1992; Carrera et al. 1996; 
Dardis et al. 1997]; others found the intron 2 splice mutation more often in simple virilising 
patients as well [Higashi et al. 1991; Mornet et al. 1991; Ordoñez-Sánchez et al. 1998; 
Paulino et al. 1999].  The chance that a randomly selected Dutch individual who is a carrier of 
salt-losing steroid 21-hydroxylase deficiency can be detected by analysis of the mutations 
described here, is about 95 % (table 3).  This degree of certainty is unlikely to become much 
higher by checking additional mutations because de novo events are relatively frequent (in our 
population, twice in 40 families).  In all patients described here, a genetic defect was found on 
at least one of both CYP21 alleles.  Non-detection of both mutations in a single patient is 
unlikely, so it may indicate clinical misdiagnosis of steroid 21-hydroxylase deficiency. 
Variability and evolution of CYP21P 
CYP21P is constant in its 5' section up to and including the 8 bp deletion in exon 3, but shows 
considerable variation in its central and 3' parts even on 'standard' chromosomes carrying one 
copy of CYP21 and CYP21P each.  The evolutionary origin of CYP21P variability is 
uncertain.  The concept of 'back conversions' has been proposed to introduce CYP21-like 
sequences into CYP21P [Day et al. 1995].  A de novo mutation introducing IleValGluMet236 
into CYP21P (not previously described in the literature) was observed in one 21-hydroxylase 
deficient patient, so 'back conversions' evidently play a role in maintaining CYP21P 
variability. 
It is assumed that the duplicated arrangement of the CYP21-C4-TNX gene cluster has resulted 
from unequal crossover events that occurred independently in primates and other mammals 
during evolution [Gitelman et al. 1992; Kawaguchi et al. 1992; Miller et al. 1992; Horiuchi et 
al. 1993].  Therefore, CYP21-like sequences in the pseudogene may also be a leftover 
predating such a duplication.  Comparison of primate CYP21P genes [Kawaguchi et al. 1992] 
suggests that after the duplication, deleterious mutations gradually accumulated in the gene 
now known as CYP21P.  The splice junction mutation in intron 2 (found in the gorilla) was 
first introduced into the pseudogene, the 8 bp deletion in exon 3 (found in the chimpanzee) 
came next, and other mutations (only found in humans) followed later.  The T insertion in 
exon 7 seems to be the next in line, because it is found in all CYP21P genes on normal 
(CYP21-CYP21P) chromosomes.  Two previous studies [Helmberg et al. 1992; Wedell and 
Luthman 1993] found no variation at this site either on the CYP21-CYP21P haplotype.  The 
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evolution of CYP21P may be further clarified by determining whether the T insert is 
ubiquitous in other human (especially, non-Western) populations as well. 
CYP21P variability may influence the outcome of small-scale gene conversions, because the 
physical conversion zone may extend beyond the region of similarity between a mutated gene 
and the CYP21P consensus sequence.  In addition, CYP21P variability may contribute to the 
creation of 'mosaic' genes with multiple apparent CYP21/CYP21P transitions. 
Mechanisms of small-scale gene conversions 
By analogy to fungal genetics, the term gene conversion is used in higher eukaryotes to 
describe a non-reciprocal transfer of genetic information.  The presence of CYP21P-like 
defects in CYP21 is usually attributed to a gene-conversion-like mechanism, although donor 
and recipient can only be studied directly in case of a de novo event.  Collier et al. [1993] 
described a de novo Ile172→Asn conversion from CYP21P to CYP21; all CYP21P genes 
involved carried Asn172.  The opposite, a de novo conversion from CYP21 to CYP21P 
described in this report, was also non-reciprocal: AsnGluGluLys236 was changed to 
IleValGluMet, while all CYP21 genes retained IleValGluMet.  The necessary interaction 
between CYP21P and CYP21 may occur either between sister chromatids or between 
homologous chromosomes, but the distinction could not be made in the two de novo 
conversions mentioned above, because all potential donor sequences were identical.  Since 
small-scale gene conversions are primarily mitotic processes [Tusié-Luna and White 1995], 
sister chromatid interaction might be expected to provide the donor sequence.  Four of the 
chromosomes studied here carried a CYP21 defect not found in the CYP21P gene on the same 
chromosome.  In these cases, CYP21P matched the consensus non-mutated CYP21 sequence 
at the sites involved, and cannot have provided the donor sequence for the CYP21 conversion.  
This implies that at least some of the small-scale gene conversions involve interactions 
between homologous chromosomes rather than between identical sister chromatids. 
CYP21P-CYP21 transition zones in hybrid genes 
Absence of the CYP21 gene (as judged by TaqI/BglII restriction analysis) is one of the major 
causes of steroid 21-hydroxylase deficiency.  Allowing for rare exceptions [Collier et al. 
1989], there are two main categories of chromosomes without a CYP21 gene: those with one 
and those with two CYP21P genes.  Chromosomes with one CYP21P gene (CYP21 deletion; 
table 5, middle) carry a single hybrid gene that has a CYP21P-like 5' section and a CYP21-like 
3' section.  Differences between the CYP21 and CYP21P consensus sequences (table 5, top) 
have frequently been used to define a putative CYP21P-CYP21 transition zone, and thus to 
determine the breakpoint of the unequal crossover that created these hybrids during the course 
of evolution.  However, several of such landmarks (Val281, Gln318, Arg356, and to some 
degree even Ile172 and IleValGluMet236) are not necessarily specific for CYP21 on normal 
chromosomes, but appear in CYP21P as well (table 4).  This causes ambiguity in locating the 
5' limit of CYP21P-CYP21 transition areas (unless a de novo mutation is available for 
analysis). 
Two crossover regions have been proposed for hybrid genes: (a) between the 8 bp deletion in 
exon 3 and the Ile172→Asn site in exon 4, and (b) between the end of exon 7 and the 
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Gln318→stop site in exon 8 [Donohoue et al. 1989; Chu et al. 1992; Levo and Partanen 
1997].  In our patient group, the breakpoint lies in zone (a) in the families 8, 9 and 17 (see 
table 5).  Zone (a) extends further upstream, because it has been shown that de novo 
recombinations can also occur upstream of the 8 bp deletion in exon 3 [Tusié-Luna and White 
1995].  In the other twelve families with the 'deletion' haplotype, the breakpoint cannot lie 
immediately downstream of exon 7, because several of the hybrid genes carry either stop-318 
or Trp-356 instead of the expected CYP21-like sequence.  We therefore hypothesise that the 
second putative conversion zone (b) lies downstream of the Arg356→Trp site (see fig. 2), and 
that the differences between these haplotypes can be explained by variation between the 
CYP21P genes involved in the crossover.  This model also explains the variability at the other 
sites listed in table 5, and the differences at the Val281→Leu and Gln318→stop sites 
previously found in the analysis of several HLA-B47 haplotypes [Chu et al. 1992; Levo and 
Partanen 1997].  However, the alternative of later introduction of these mutations in a pre-
existing HLA-B47 associated hybrid gene cannot be excluded.  A reliable marker for 
distinguishing between conversion zone (a) and conversion zone (b) in hybrid genes, is the 
absence (zone a) or presence (zone b) of the T insert in exon 7. 
Chromosomes with two CYP21P genes ('large-scale conversions'; table 5, bottom) carry one 
regular CYP21P gene and one CYP21P-CYP21 hybrid.  The transition zones in the hybrid 
gene are the same as for the 'single' hybrid genes described above: zone (a) in the families 3, 
14 (one of the two chromosomes) and 28, and zone (b) in the other cases. 
Tusié-Luna and White [1995] have found that de novo unequal crossovers leading to CYP21 
deletions occur during meiosis only.  However, this also applies to apparent 'large-scale 
conversions', because the hybrid genes found in CYP21 deletions and in large-scale 
conversions are so similar (see table 5) that the PCR amplification used in that study doesn't 
distinguish between them. 
Since CYP21 'deletions' and 'large-scale' conversions are both meiotic and result in a very 
similar layout of the CYP21P-CYP21 hybrid gene, they are probably created by similar 
processes.  We therefore hypothesise that large-scale gene conversions of CYP21 to a CYP21-
CYP21P hybrid are actually meiotic double unequal crossovers.  One putative crossover site 
lies within region (a) or (b) as shown in fig. 2, the other one lies upstream of the TaqI 
restriction site at nucleotide -211 in the 5' flank.  Interestingly, the other product expected 
from such an event, a chromosome with two CYP21-like genes and no CYP21P-like genes, 
was found in three healthy controls.  Contrary to the single unequal crossovers that lead to 
deletions and duplications of CYP21 or CYP21P [Carroll et al. 1985; White et al. 1985; 
Donohoue et al. 1989; Miller et al. 1992; White 1994], the proposed double unequal crossover 
does not alter the number of C4-CYP21-TNX units or the overall size of the region. 
Conclusions 
Our mutation analysis detects 95 % of all defects causing salt-losing steroid 21-hydroxylase 
deficiency in the Netherlands and hence provides a guideline for the diagnosis of the most 
severe form of this disease in the Dutch population. 
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CYP21P shows a high variability, and non-consensus CYP21P genes are widespread in the 
general population.  This necessitates a revised definition of CYP21P-CYP21 transition zones 
in gene conversions and unequal crossovers generating CYP21 defects. 
At least some of the small-scale gene conversions between CYP21 and CYP21P involve 
interaction between homologous chromosomes.  Large-scale gene conversions appear to be 
the result of a completely different genetic mechanism: these rearrangements are probably 
generated by a meiotic double unequal crossover. 
Future research on the genetic mechanisms underlying the variability in the CYP21 / 
complement C4 region should take account of the high variability of the CYP21P pseudogene.  
This notably applies to the study of de novo mutations, where information on donor and 
recipient DNA can be obtained more easily than in population studies. 
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3.2. Distribution of CYP21 mutations in a Dutch population 
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Introduction 
Steroid 21-hydroxylase deficiency is an inherited metabolic disease characterised by partial or 
complete impairment of the adrenocortical conversion of progesterone to 11-
deoxycorticosterone and 17α-hydroxyprogesterone to 11-deoxycortisol.  These reactions are 
necessary intermediate steps in the biosynthesis of aldosterone and cortisol, respectively.  
Steroid 21-hydroxylase deficiency is the cause of more than 90 % of all cases of congenital 
adrenal hyperplasia and has an incidence of approximately 1 in 10,000 to 1 in 15,000 in most 
populations [New et al. 1989].  The severity of the disease varies and the spectrum of its 
clinical manifestations is manifold [New et al. 1989; Pang 1997; White and Speiser 2000].  In 
classical 21-hydroxylase deficiency, androgen excess causes pre- and postnatal virilisation in 
untreated patients and about three-quarters of all patients are to some degree unable to 
synthesise aldosterone, a defect that may result in a life-threatening salt-losing crisis in the 
first weeks of life.  Nonclassical (NC) steroid 21-hydroxylase deficiency is an attenuated form, 
often diagnosed at a later age ('late onset').  Patients typically present with manifestations of 
mild androgen excess, such as accelerated growth or precocious puberty in children and 
hirsutism, acne, or infertility in adults [New et al. 1989; Pang 1997; Morán et al. 1998; White 
and Speiser 2000].  A high frequency of NC 21-hydroxylase deficiency alleles has been 
observed in some populations: for example, 0.223 in Ashkenazi Jews [Sherman et al. 1988] 
and 0.092 in Croatians [Dumic et al. 1990]. 
Steroid 21-hydroxylase is encoded by the CYP21 gene in the central region of the human 
Major Histocompatibility Complex on the short arm of chromosome 6 (6p21.3).  Over the past 
decade, many CYP21 defects have been characterised at a molecular level (recently reviewed 
by [White and Speiser 2000; Lee 2001]).  We previously investigated the most common 
CYP21 defects in a group of Dutch patients with classical steroid 21-hydroxylase deficiency 
[Koppens et al. 2000].  Here, we report on an exhaustive search of NC mutations in the same 
group, which was expanded with three families with NC 21-hydroxylase deficiency.  To 
assess the frequency of 21-hydroxylase deficiency alleles in the general population in the 
Netherlands, we also scanned for these mutations and those previously reported [Koppens et 
al. 2000], in a group of healthy controls. 
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Non-amplification of specific alleles in PCR-based mutation analysis of CYP21 ('allele 
dropout') has been reported by several authors [Day et al. 1996; Ozturk et al. 2000].  This 
notably affects the analysis of the 'intron 2 splice mutation', the most common genetic defect 
in classical steroid 21-hydroxylase deficiency.  Instead of the normal 'A' or 'C' at nucleotide 
655, this defective allele has a 'G', creating a spurious splice acceptor site [Higashi et al. 
1988].  To check for non-amplification, we determined the number of heterozygotes and 
homozygotes for this mutation and for a neutral polymorphism in the same PCR fragment. 
 
Methods 
Nearly all steroid 21-hydroxylase deficiency patients, their family members, and the controls, 
had participated in our earlier haplotyping [Koppens et al. 1992] and mutation analysis 
[Koppens et al. 2000] studies (new data on three patients with NC steroid 21-hydroxylase 
deficiency has not been published before).  A small number of persons with more than two 
CYP21 genes as found by Southern blotting analysis [Koppens et al. 1992] were not included.  
We adapted our earlier PCR strategy [Koppens et al. 2000] to include the sites of several 
additional mutations.  The entire CYP21 gene was specifically amplified in two separate 
reactions: a section from the 5' flank to exon 3 using the forward primer 
CCAGGCAAACCAGGCTTAAAC and the reverse primer AGGGAGTAGTCTCCCAAGGA 
(basepair -496 to 719  [Higashi et al. 1986]) and a section from exon 3 to the 3' flank using the 
 
 
 
Notes to table 1. 
a: 141 persons were included, but the totals for each mutation add up to 281 chromosomes, because 
one control carried a heterozygous CYP21 deletion 
b: referred to as 'non-carrier' because these were the chromosomes not inherited by the index case in 
each family, although some of these chromosomes were now found to carry a CYP21 gene with a NC 
mutation (see text) 
c: chromosomes of all patients with classical steroid 21-hydroxylase deficiency with a CYP21 gene 
present 
d: chromosomes of three patients with NC steroid 21-hydroxylase deficiency, each having Val281→Leu 
on one chromosome and a more severe defect on the other 
e: these conditions produce a good signal-to-background ratio, but the exposure times needed vary from 
one hour to overnight 
f: not including CYP21 genes that also carry other, more severe defects 
g: represents one CYP21 deletion and one CYP21 gene carrying the contiguous mutations Ile172→Asn, 
IleValGluMet236→AsnGluGluLys and Val281→Leu 
h: represents all previously reported defects (including deletions) and a few new cases, but excludes 
CYP21 genes where no defect has been found yet 
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forward primer ACCTGTCCTTGGGAGACTACTC and the reverse primer 
AAGAGCCAGGGTCCTTCACCA (basepair 695 to 2857).  A touchdown PCR protocol was 
used: for the 5' section: first, 8 cycles of 30 s at 94°C, 60 s at 60 °C decreasing 0.5 °C per 
cycle and 3 min at 72 °C; next, 28 cycles of 30 s at 94°C, 60 s at 56 °C and 3 min at 72 °C 
extending 20 s per cycle; and for the 3 min section: first, 10 cycles of 30 s at 94°C, 60 s at 63 
°C decreasing 0.5 °C per cycle and 5 min at 72 °C; next, 30 cycles of 30 s at 94°C, 60 s at 58 
°C and 5 min at 72 °C.  Amplification was done with 0.5 units of Thermoperfect DNA 
polymerase (Integro, Leuvenheim, The Netherlands) in the presence of 1.5 mM MgCl2 and, 
for the 3 min section, 1 % formamide.  The reaction was checked by electrophoresis of 20 % 
of the product on agarose gels; the remainder of the product was slot-blotted onto Hybond-N+ 
(Amersham Pharmacia, Little Chalfont, UK) and mutations were detected by hybridisation to 
32P-labelled allele-specific oligonucleotide probes, in the presence of a 50-fold excess of the 
unlabeled complementary probe.  Oligonucleotides for NC mutations are listed in table 1, the 
others are the same as in our earlier study [Koppens et al. 2000].  The DYEnamic ET 
terminator cycle sequencing kit (Amersham Pharmacia, Little Chalfont, UK) was used in the 
detection of a novel polymorphism at Pro105. 
Codon and nucleotide numbering is according to Higashi et al. [1986]. 
 
Results and discussion 
The results of the mutation analysis are presented in table 1.  Mutation detection with the 
allele-specific oligonucleotides usually produced straightforward results; notably, the 
distinction between the normal 'A' and 'C' variants at nucleotide 655 was much clearer than in 
our earlier study [Koppens et al. 2000].  All classical mutations detected earlier, including the 
splice junction mutations ('G' at nucleotide 655), were confirmed using the current protocol.  
In a few cases, hybridisation with the oligonucleotides detecting Pro105 and Leu105 both 
failed; sequencing analysis (details not shown) revealed a novel neutral polymorphism, with 
Pro105 encoded by CCC instead of the usual CCG. 
To check for allele dropout in the PCR, the distribution of two neutral polymorphisms in the 5' 
section was established in persons with two CYP21 genes (see table 2).  The genotype 
frequencies found in the control group are in agreement with the Hardy-Weinberg equilibrium.  
The same applies to the distribution in a group of parents of the patients, taking into account a 
selection bias against homozygous defects.  We conclude that non-amplification of specific 
alleles is not a problem in our studies. 
The neutral polymorphisms (insertion/deletion of Leu10 and A or C at nucleotide 655) 
occurred at frequencies similar to those reported elsewhere [Lobato et al. 1999; Ozturk et al. 
2000].  The high variability at these sites makes them attractive markers for tracking the 
segregation of individual alleles in 21-hydroxylase deficiency families. 
The three patients with NC steroid 21-hydroxylase each carried Val281→Leu on one 
chromosome and a classical mutation (the intron 2 splice mutation, once; and Ile172→Asn, 
twice) on the other.  All Val281→Leu mutations identified in the families studied were 
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associated with a duplication of the CYP21P pseudogene and one 'long' (32 kb) plus two 
'short' (26 kb) C4 genes on the same chromosome.  Both controls with the Leu281 mutation 
also carried this duplication and so did two parents of 21-hydroxylase patients where Leu281 
was detected on the chromosome not transmitted to the patient.  Other characteristics of this 
haplotype were the presence of Leu10, 'A' at nucleotide 655 and the absence of any of the 
other defects investigated here or in our earlier study [Koppens et al. 2000]. 
The two parents with Ser453 on their 'non-carrier' chromosome (see table 1) had this mutation 
on a chromosome with one CYP21 gene, one CYP21P pseudogene and one long plus one short 
C4 gene.  Without the instrument of family studies, the same cannot be said with certainty for 
the controls carrying Ser453, but the band intensities found there [Koppens et al. 1992] were in 
agreement with the configuration mentioned.  Other characteristics of this haplotype were the 
presence of Leu10, 'C' at nucleotide 655 and the absence of any other defect.  Curiously, these 
characteristics differ from those found on a Ser453-carrying chromosome found in Sweden 
[Wedell et al. 1992], which had a CYP21 deletion and carried the additional mutation 
Pro105→Leu.  Another CYP21 gene with Ser453 carried the additional mutation Arg339→His 
[Helmberg et al. 1992].  These differences suggest that Pro453→Ser is evolutionary older than 
Pro105→Leu and Arg339→His, and may provide an explanation for its higher frequency.  The 
other mutations we checked were not found in the control group.  With the exception of 
Pro30→Leu and, to some extent, Arg339→His, these defects appear to be quite rare. 
In conclusion, we found four NC 21-hydroxylase deficiency alleles in 370 chromosomes 
tested (141 controls and the non-carrier chromosomes in 44 families).  Thus, the total 
frequency of NC steroid 21-hydroxylase deficiency alleles in the general population in the 
Netherlands is 0.011 (95 % confidence limits: 0.004 to 0.024)  [Linder 1960]. 
 
Table 2. Genotype distribution of two neutral polymorphisms (insertion of Leu 10 and A or C at nucleotide 
655) in the 5' part of the CYP21 genes 
genotype general 
population 
parents of 
patients 
  
 (141 persons) (88 persons)   
Leu10 / Leu10 60 17  
Leu10 / no Leu10 62 32  
Leu10 / deletion 1 17  
no Leu10 / no Leu10 18 7  
no Leu10 / deletion 0 15  
nucleotide 655 A / A 46 16  
nucleotide 655 A / C 73 10  
nucleotide 655 A / G 0 13  
nucleotide 655 A / deletion 1 20  
nucleotide 655 C / C 21 7  
nucleotide 655 C / G 0 10  
nucleotide 655 C / deletion 0 12  
nucleotide 655 G / G 0 0  
nucleotide 655 G / deletion 0 0  
deletion / deletion 0 0  
The allele frequencies in the 
general population are: Leu10, 
0.649; no Leu10, 0.348; deletion, 
0.004; and 655A, 0.589; 655C, 
0.408; deletion, 0.004.  In the 
parents of steroid 21-hydroxylase 
deficiency patients, the frequencies 
are: Leu10, 0.472; no Leu10, 
0.347; deletion, 0.182; and 655A, 
0.426; 655C, 0.261; 655G, 0.131; 
deletion, 0.182.  The term 'deletion' 
also includes haplotypes 
previously termed 'large-scale 
gene conversion'. 
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Abstract 
The RCCX module is a tandemly repeated set of (parts of) four genes (RP, C4, CYP21, TNX) 
in the human Major Histocompatibility Complex on chromosome 6p21.3.  Most chromosomes 
are bimodular (carrying two RCCX modules).  Meiotic unequal crossover within the RCCX 
module potentially causes deletion of the CYP21 gene, contributing to congenital adrenal 
hyperplasia (CAH) caused by steroid 21-hydroxylase deficiency.  Misalignment of parental 
chromosomes that differ in RCCX modularity probably increases the likeliness of such 
unequal crossovers.  We here describe a CAH patient with a CYP21 gene deletion that was not 
present in his parents.  Using a combination of long-range and short-range restriction analysis, 
we found that a de novo unequal crossover had occurred in the patient's father.  The crossover 
site was mapped to a 640 bp region of the TNX gene, adjacent to CYP21.  This type of 
crossover does not create the CYP21P/CYP21 hybrid gene found in most CAH 'deletion' 
haplotypes.  Instead, it eliminates CYP21 in its entirety and also confers a defect to TNX, 
which has been implicated in the pathology of the Ehlers-Danlos syndrome.  In contrast with 
earlier observations, this disease-causing unequal crossover occurred between chromosomes 
with equal numbers of RCCX modules. 
 
Introduction 
In the human genome, the Major Histocompatibility Complex class III region on chromosome 
6p21.3 stands out as an area of remarkably high gene density [MHC Sequencing Consortium 
1999; International Human Genome Sequencing Consortium 2001]. Within this region, a 
section of particular complexity centres around the C4 genes, which encode the fourth 
component of complement [Belt et al. 1984; Carroll et al. 1985; Schneider et al. 1986; Yu 
1991; Blanchong et al. 2001].  Centromeric to C4 lies the CYP21 gene, which encodes steroid 
21-hydroxylase, a key enzyme in the biosynthesis of cortisol and aldosterone [White et al. 
1985; Carroll et al. 1985; Higashi et al. 1986].  The TNX gene, which encodes the 
extracellular matrix protein tenascin-X, lies centromeric to CYP21 and is transcribed from the 
opposite strand [Gitelman et al. 1992; Matsumoto et al. 1992; Bristow et al. 1993].  Telomeric 
to C4 lies the RP gene, encoding a putative serine/threonine kinase [Sargent et al. 1994; Shen 
et al. 1994; Gomez-Escobar et al. 1998].  Some 70 % of all chromosomes 6 carry a 
duplication of an area comprising the entire C4 and CYP21 genes and small truncated sections 
of RP and TNX.  This stretch of DNA is known as the RCCX module [Shen et al. 1994; 
Rupert et al. 1999; Yang et al. 1999; Blanchong et al. 2001], and most haplotypes have a 
characteristic bimodular arrangement similar to the one shown in fig. 1.  The complex genetics 
of this region and the activities and clinical significance of the proteins encoded here have 
been the subject of several recent reviews [Wedell 1998; White and Speiser 2000; Blanchong 
et al. 2001]. 
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Fig. 1. Overview of a typical C4/CYP21 area within the MHC class III region, showing two RCCX modules 
as found on most chromosomes.  TNXB is the full-size 68 kb gene for tenascin-X, TNXA (also known as 
XA) is a truncated pseudogene of 5.7 kb that not only lacks most of the coding sequence of TNXB but also 
has a 120 bp deletion (indicated by the small triangle) spanning an exon-intron boundary [Gitelman et al. 
1992; Bristow et al. 1993].  CYP21 (also known as CYP21B) is the active steroid 21-hydroxylase gene; 
CYP21P (also known as CYP21A) is a full-size pseudogene containing several deleterious mutations 
throughout its sequence, including three in-phase stop codons [Higashi et al. 1986].  The C4 genes 
express variants of the fourth component of complement with different affinities, known as C4A and C4B.  
About three quarters of the C4 genes, including nearly all C4A genes, are 'long' (20.6 kb in size); the others 
are 'short' (14.2 kb).  This difference is reflected in the size of the entire RCCX module, since the other 
components total approximately 12 kb.  Assignment of C4A and C4B is tentative: the arrangement shown 
is the most common, but the specificity of the C4 genes cannot be determined by means of the restriction 
sites shown.  The arrows show the orientation of transcription; there is an overlap between the 3' sections 
of the oppositely transcribed genes TNXB and CYP21, and of TNXA and CYP21P, respectively.  Several 
short transcripts encoded in the same region are not shown.  Bottom: characteristic TaqI, BglII and SacII 
restriction fragments.  Only fragments mentioned in the text are shown; a SacII site internal to the RCCX 
module is not cut in genomic DNA, possibly due to methylation.  Top: scale in kb. 
 
 
Each chromosome 6 has at least one RCCX module, most have two as described above, some 
have three, and in rare cases, as many as four contiguous RCCX modules have been found on 
a single chromosome.  Since bimodularity is the standard, the literature often refers to 
haplotypes with one module as 'deletions' and to haplotypes with three modules as 
'duplications', especially when focusing on the C4 or CYP21 genes.  The overall layout of the 
RCCX region can be determined by short-range and long-range restriction mapping.  
TaqI/BglII restriction analysis of genomic DNA and comparison of the relative intensities of 
the bands obtained by hybridisation to C4, CYP21 and TNX probes [White et al. 1985; Carroll 
et al. 1985; Harada et al. 1987; Higashi et al. 1988; Morel et al. 1989], has been used in many 
studies to establish haplotypes in families of CAH patients and controls.  This approach is 
usually sufficient, but in complicated cases, large fragments from rare-cutters such as SacII or 
BssHII can be used to determine the size of the entire region and hence, the number of RCCX 
modules [Collier et al. 1989; Dunham et al. 1989]. 
0 10 20 30 40 50 60 70
HLA-DR TNXB CYP21 C4B CYP21P C4A RP1 HLA-BTNF
RCCX module (short) RCCX module (long)
     @@@@@ÀÀÀÀÀ
2.5 3.7 5.4 2.4 3.2 7.0
11 12
Taq I
Bgl II
Sac II 70
TNXARP2
Crossover site in a de novo CYP21A2/TNXB deletion   177 
The tandem-repeat structure of several lined-up RCCX modules promotes the chances of 
misalignment during meiosis.  If a crossover then occurs, it effectively removes one of the 
RCCX modules.  On a 'standard' bimodular chromosome, this process joins a part of the 
telomeric module to its homologous counterpart in the centromeric module (see fig. 6 in the 
Discussion for a typical example).  The site of such a crossover determines whether or not the 
remaining monomodular chromosome carries a genetic disorder.  An unequal crossover 
between C4A and C4B is relatively harmless, because both genes express a functional C4 
protein and so does their fusion gene.  Such monomodular haplotypes lacking one of the C4 
genes and the CYP21P gene occur at a frequency of 5 to 20 % in the general population 
[White et al. 1988; Collier et al. 1989; Koppens et al. 1992; Ezquieta et al. 1995]. 
An unequal crossover between CYP21P and CYP21 on the other hand, usually generates a 
fusion gene that is CYP21P-like in its 5' section and contains several mutations rendering it 
inactive (a haplotype often referred to as a 'CYP21 deletion').  Absence of a functional CYP21 
gene is one of the defects that contributes to steroid 21-hydroxylase deficiency, the cause of 
over 90 % of all cases of congenital adrenal hyperplasia (CAH).  CAH is a disorder of 
adrenocortical steroid biosynthesis which in severe cases causes life-threatening salt-losing 
crises in untreated paediatric patients [Wedell 1998; White and Speiser 2000]. 
An unequal crossover between TNXA and TNXB not only eliminates the CYP21 gene, but may 
also result in a defective TNXB/TNXA pseudogene containing the 120 bp deletion normally 
found in TNXA only and unable to express the tenascin protein.  This defect contributes to the 
Ehlers-Danlos syndrome, a disease of the connective tissue [Burch et al. 1997; Yang et al. 
1999; Schalkwijk et al. 2001]. 
The mechanisms of these crossovers are difficult to understand, because usually only the 
recombinational end product is available for analysis.  The concept of a deletion of the 
CYP21P pseudogene as a 'premutation' has been advanced in a report on a de novo deletion of 
CYP21 by recombination between a 'standard' bimodular chromosome and a monomodular 
chromosome [Sinnott et al. 1990].  More recently published studies also provide evidence that 
TNXB/TNXA hybrids are the result of a crossover between a bimodular and a monomodular 
chromosome [Rupert et al. 1999; Yang et al. 1999]. 
We here present a de novo unequal crossover that occurred between two bimodular 
chromosomes in the father of a patient suffering from CAH caused by steroid 21-hydroxylase 
deficiency.  The crossover site was mapped to a 640 bp region of the TNX gene that starts at 
approximately 1.6 kb from the centromeric boundary of the RCCX module.  This de novo 
mutation eliminates the CYP21 gene and also disrupts TNXB by replacing its 3' end by a 
homologous section from TNXA, conveying the 120 bp deletion. 
 
Methods 
Patient and family members 
The patient, a boy, presented to the Sophia Children's Hospital at age 7 years 8 months with 
signs of precocious puberty.  The patient was tall for his age (above the 90th percentile) and 
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bone age was strongly advanced (13½ years).  Basal plasma 17α-hydroxyprogesterone was 99 
nmol/l, testosterone was 4.3 nmol/l.  Sodium and potassium levels were normal.  The patient 
was diagnosed with simple virilising congenital adrenal hyperplasia caused by steroid 21-
hydroxylase deficiency, and hydrocortisone replacement therapy, initially supplemented with 
cyproterone acetate, was installed.  The family consists of both parents, the patient, two 
healthy brothers who are monozygotic twins and a healthy sister.  They were informed about 
the purpose of the study and gave their consent. 
CYP21/C4 haplotyping 
The family participated in our haplotyping study [Koppens et al. 1992] as family 20, and 
CYP21/C4 haplotypes were established as described there.  Briefly, genomic DNA was 
digested with TaqI or with BglII, separated by electrophoresis on agarose gels, Southern-
blotted onto nitrocellulose and hybridised to the CYP21 cDNA probe pC21/3c [White et al. 
1985] and the 5' section of the C4 cDNA probe pAT-A [Belt et al. 1984]; the resulting 
autoradiographic bands were quantitated by laser densitometry. 
Long-range restriction mapping 
Genomic DNA had been prepared earlier for CYP21/C4 haplotyping [Koppens et al. 1992], 
using a conventional method [Wyman and White 1980] not aimed at conserving large DNA 
fragments.  Nevertheless, careful handling of the available DNA (stored at -20 °C in 10 µg 
aliquots of varying volume) by using wide-bore tips and avoiding repeated freeze-thaw cycles, 
permitted its use in long-range restriction mapping.  10 µg of DNA was digested overnight 
with 50 units of SacII (Eurogentec, Seraing, Belgium) in a total volume of 250 µl at 37 °C.  
The next day, the volume was reduced to approximately 90 µl by evaporation at 65 °C, after 
which 30 µl of molten 2 % low-melting agarose (FMC Bioproducts, Rockland ME, USA) was 
added.  This mixture was allowed to solidify in the slots of a 10-slot 1 % agarose gel in a 
CHEF-DR III electrophoresis system (Bio-Rad, Hercules CA, USA).  The gel was equilibrated 
in the electrophoresis buffer (0.5 x TBE with 0.2 µg/ml ethidium bromide) for one hour, after 
which pulsed-field gel electrophoresis was performed for 18 hours at 6 V/cm with an included 
angle of 120 ° and a switch time linearly increasing from 2 to 17 seconds, at 14 °C.  Southern 
blotting and hybridisation were the same as for short-range mapping (see above). 
Analysis of flanking MHC markers 
Genomic DNA was digested with EcoRI, HindIII, PvuII and TaqI, separated by 
electrophoresis and Southern-blotted and hybridised to the HLA-B probe pHLA2 [Sood et al. 
1981] and the HLA-DQA probe pDCH-1 [Auffray et al. 1982], resulting in distinctive banding 
patterns [Mornet et al. 1986].  Length polymorphism of a microsatellite marker near the 
tumour necrosis factor (TNF) locus was used as an additional marker [Nedospasov et al. 
1991]. 
CYP21 and CYP21P mutation analysis 
Mutation analysis of all CYP21 and CYP21P genes in this family was done as described 
before [Koppens et al. 2000].  Briefly, three sections of either CYP21 or CYP21P were 
specifically amplified and hybridised to oligonucleotides detecting the most common 
mutations: intron2splice; exon3del8bp; Ile172→Asn; IleValGluMet236→ AsnGluGluLys/ 
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LysGluGluLys; Val281→Leu; exon7ins1bp; Gln318→stop and Arg356→Trp.  We since 
altered our PCR strategy to include the mutations Pro30→Leu and Pro453→Ser (details to be 
published elsewhere). 
 
 
Fig. 2.  Amplified region of TNXA and TNXB showing the site of the 120 bp deletion in TNXA, the 
crossover, and the ApaI and BstUI restriction sites used to map it to a 640 bp region.  The amplified 
stretches are : a: the father's first allele in the TNXA PCR (open box); b: the father's second allele in the 
TNXB PCR (densely hatched box); b/a: the hybrid found in the patient (densely hatched: from b; open: from 
a; lightly hatched: recombinant zone).  Note that the specific TNXA and TNXB forward primer sites differ by 
34 bp, causing an additional size difference between the PCR products.  crossover region lies between the 
BstUI and ApaI restriction sites shown.  Top: scale in bp, with underneath it the beginning of the 2.4 or 2.5 
kb TaqI fragment that partly overlaps the CYP21 or CYP21P gene (see fig. 1). 
 
 
Amplification and restriction analysis of TNXA and TNXB 
Parts of TNXA and TNXB that encompass the site of the 120 bp deletion normally found in 
TNXA only, were specifically amplified.  The forward primer for TNXB 
(TCTCTGCCCTGGGAATGACAG) lies beyond the duplication boundary of the RCCX 
module, in the large non-duplicated part of the TNXB gene.  The forward primer for TNXA 
(CTTGAGCTGCAGATGGGATAC) lies within the RP2 pseudogene.  The reverse primer 
(CAATCCCCACCCTGAACAAGT) was the same for both genes and lies between the site of 
the 120 bp deletion and the 3' end of the CYP21/CYP21P gene (see fig. 2).  A touchdown PCR 
protocol was used to amplify these stretches of approximately 2.7 kb: first, 8 cycles of 30 s at 
94°C, 60 s at 66 °C decreasing 0.5 °C per cycle and 3 min at 72 °C; next, 26 cycles of 30 s at 
94°C, 60 s at 62 °C and 3 min at 72 °C extending 30 s per cycle.  Amplification was done with 
0.5 units of Thermoperfect DNA polymerase (Integro, Leuvenheim, The Netherlands) in the 
presence of 1.5 mM MgCl2 and 1 % formamide.  The size of the PCR product directly shows 
presence or absence of the 120 bp deletion/insertion.  In addition, comparison of published 
TNX sequences (EMBL/GenBank/DDBJ accession numbers S38953 [Gitelman et al. 1992], 
X71937 [Bristow et al. 1993], AL049547 [Barlow 2000], AF019413 [Rowen et al. 1999a], 
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U89337 [Rowen et al. 1999b], AF077974 [Rupert et al. 1999], AF086641 [Yang et al. 1999] 
and L26263 [Yu 1991; Shen et al. 1994]) revealed several polymorphic sites throughout the 
amplified region, most of which can be detected by restriction analysis.  Digestion of the PCR 
product with BstUI (New England Biolabs, Beverly MA, USA) and ApaI (Eurogentec, 
Seraing, Belgium) proved particularly useful in locating the crossover site.  BstUI detects a 
polymorphism at 1626 bp downstream of the border of the RCCX module, ApaI detects a 
polymorphism at 2266 bp (in this context, 'downstream' is relative to the transcription of the 
TNX gene and sequence AL049547 [Barlow 2000] has been used to compute fragment sizes 
and nucleotide positions). 
 
Results 
CYP21/C4 haplotypes and flanking MHC markers 
The relative intensities of the TaqI and BglII restriction bands in this family are listed in table 
1.  The results, notably the diminished intensity of the TaqI 3.7 kb and the BglII 12 kb 
fragments in the patient, could not be explained by normal segregation of regular CYP21/C4 
haplotypes [Koppens et al. 1992].  Long-range restriction mapping by SacII digestion and 
pulsed field gel electrophoresis provides a size estimate of the entire contiguous array of 
RCCX modules, because the SacII sites lie just outside the module (see fig. 1).  In this family, 
both parents had 70 and 76 kb bands, typical of a bimodular arrangement with two long C4 
genes on one chromosome and one long and one short gene on the other chromosome.  The 
patient, on the other hand, had one bimodular chromosome, but also showed a 43 kb band 
indicating the presence of a single RCCX module with a long C4 gene on the other 
chromosome (see fig. 3).  These results match the TaqI/BglII band intensities (see table 1). 
Since testing of several independent genetic markers on chromosomes 1, 7, 16 and 21 
confirmed paternity (results not shown), a de novo mutation seemed the most obvious 
explanation for these observations. 
This notion was confirmed by analysis of markers centromeric (HLA-DQA) and telomeric 
(TNF and HLA-B) to the RCCX module (details not shown).  Normal Mendelian segregation 
of all alleles was demonstrated in all healthy family members.  The patient however, carried 
the father's HLA-DQA markers from one chromosome, together with the TNF and HLA-B 
markers from the other chromosome, in addition to a normal maternal chromosome. 
Combining these findings, it was concluded that an unequal crossover had occurred de novo 
between the father's chromosomes, eliminating the CYP21 gene and the adjacent C4 gene.  
The segregation of chromosome 6 in this family is shown in fig. 4. 
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Table 1.  Relative intensities of TaqI and BglII bands and size of the SacII bands, after hybridisation to 
CYP21 and C4 cDNA probes. 
CYP21 probe 
pC21/3c 
C4 probe pAT-A CYP21 and C4 
probes 
TaqI BglII TaqI 
 
3.7 : 3.2 12 : 11 7.0 : 6.4 : 6.0 : 5.4 
 
SacII band sizes 
father 2 : 2 2 : 2 2 : 0 : 1 : 1 76 and 70 kb 
mother 2 : 2 2 : 2 2 : 0 : 1 : 1 76 and 70 kb 
patient 1 : 2 1 : 2 2 : 0 : 0 : 1 43 and 70 kb 
twin brothers 2 : 2 2 : 2 2 : 0 : 2 : 0 not determined 
sister 2 : 2 2 : 2 2 : 0 : 1 : 1 not determined 
C4 band sizes are those traditionally given in the literature [Schneider et al. 1986], although the actual 
fragments are approximately 0.15 kb larger. 
 
F M P C
76
70
43
37 a b c d
a ac c a d db/a
Fig. 4.  Pedigree of the family.  Characteristics of 
the haplotypes: a: CYP21(normal)-C4(long)-
CYP21P-C4(long); b: CYP21(normal)-C4(short)-
CYP21P-C4(long); c: CYP21(normal)-C4(long)-
CYP21P-C4(long); d: CYP21(Ile172→Asn)-
C4(short)-CYP21P-C4(long); b/a: recombinant: 
CYP21P-C4(long). 
Fig. 3. SacII digested genomic DNA 
separated by pulsed field gel electrophoresis 
and hybridised to a mix of a CYP21 and a C4 
cDNA probe.  F: father; M: mother; P: patient 
with a de novo deletion; C: control with two 
monomodular chromosomes (one with a long 
and one with a short C4 gene).  Right:  
fragment sizes in kb. 
Chapter 4 
 
182
CYP21 and CYP21P mutation analysis 
The Ile172→Asn mutation was found in the mother, the patient and the healthy daughter.  
This mutation is typical of the simple virilising form of CAH [Amor et al. 1988], matching the 
patient's phenotype.  Consistent with the segregation of the haplotypes, no deleterious 
mutations were found in the CYP21 genes of the patient's father or the twin brothers. 
All CYP21P genes in this family matched the consensus sequence [Higashi et al. 1986] for all 
markers tested up to and including the fourth exon.  Further downstream, distinctive markers 
(named after the matching codons in the CYP21 gene) were found on each allele (see fig. 4).  
Presence of the Leu281 marker in the recombinant positioned the putative crossover site 
downstream of that marker, but the markers Gln318, Arg356 and Pro453 were not 
informative. 
 
 
Fig. 5.  Full-size and digested PCR products (see fig. 2); F: father; M: mother; P: patient(s); B: twin 
brother(s); S: sister; fragment sizes in bp.  5a: TNXB PCR product showing the 120 bp size difference 
caused by the de novo unequal crossover; left: 5 µl SmartLadder (Eurogentec, Seraing, Belgium); 
electrophoresis was for 20 h at 40 V on 1 % agarose.  5b: TNXA and TNXB BstUI digest; left: 5µl 
SmartLadder; electrophoresis was for 22 h at 140 V on 3.2 % polyacrylamide.  5c: ApaI digest; 
electrophoresis was for 10 h at 50 V on 1.2 % agarose.  The twin brothers and the sister showed the same 
pattern as the mother in the BstUI and ApaI digests (results not shown). 
 
 
PCR and restriction analysis of the TNX genes. 
PCR products of TNXA and TNXB and restriction patterns after digestion with BstUI and ApaI, 
are shown in fig. 5.  The 2688 bp band represents the recombinant TNXB gene of the patient, 
with the 120 bp deletion that has been transferred from TNXA (fig. 5a).  The segregation of the 
fragments within the family allows assignment of the 120 bp deletion and the BstUI and ApaI 
polymorphisms to each allele as listed in table 2.  The recombinant matches the TNXB gene of 
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chromosome b up to and including the BstUI polymorphism 1626 bp downstream of the 
RCCX boundary and the TNXA gene of chromosome a from the ApaI polymorphism at bp 
2266.    This implies that the crossover occurred in the 640 bp stretch that separates these sites, 
as shown in fig. 2.  A BseRI polymorphism at 1951 bp and a PvuII polymorphism at 2191 bp 
were not informative in this family (results not shown). 
 
Table 2.  Presence (+) or absence (-) of the polymorphic BstUI site at 1626 bp from the RCCX boundary, of 
the ApaI site at 2266 bp and of the 120 bp (+: present; -: deleted) in the TNXA and TNXB genes on each 
chromosome (the letters match the alleles shown in fig. 4; x: no PCR product: the recombinant cannot be 
amplified in the TNXA PCR). 
  TNXA    TNXB  
chromosome BstUI ApaI 120 bp  BstUI ApaI 120 bp 
a + + -  + - + 
b - + -  - - + 
c + + -  + - + 
d + + -  + - + 
b/a recombinant x x x  - + - 
 
Discussion 
Deletions of approximately 30 kb of DNA containing the CYP21 gene are a major factor in the 
genetics of steroid 21-hydroxylkase deficiency.  Such deletions have been attributed to 
unequal crossover due to misalignment of homologous chromosomes during meiosis [White et 
al. 1988; Sinnott et al. 1990; Tusié-Luna and White 1995; Rupert et al. 1999; Yang et al. 
1999].  In this report, we present such an unequal crossover as a de novo mutation in the father 
of a steroid 21-hydroxylase deficiency patient.  The crossover breakpoint was mapped to a 640 
bp region between two polymorphic restriction sites in the TNX gene, which lies immediately 
centromeric to the CYP21 gene (see figs. 2 and 6).  A de novo deletion of the CYP21 gene 
reported earlier [Sinnott et al. 1990] was caused by an unequal crossover between a 
chromosome with one RCCX module (monomodular: a single C4 gene and a CYP21 gene) 
and a chromosome with two RCCX modules (bimodular: two C4 genes, a CYP21 gene and a 
CYP21P pseudogene).  The authors point out that since the bimodular chromosome has no 
equally sized homologue to align to during meiosis, misalignment of its CYP21P and TNXA 
genes to the CYP21 and TNXB genes of the monomodular chromosome would have a 
probability close to 50 %.  This notion of the common monomodular CYP21P deletion 
chromosome serving as a premutation was further strengthened by two more recent reports 
describing reciprocal TNXB/TNXA and TNXA/TNXB hybrids in unrelated individuals [Rupert 
et al. 1999; Yang et al. 1999].  A de novo deletion that eliminated the CYP21P pseudogene 
[Fasano et al. 1992] also involved one bimodular and one monomodular chromosome. 
The current report provides a clear illustration of the fact that de novo unequal crossovers 
between bimodular chromosomes also contribute to the pathogenesis of steroid 21-
hydroxylase deficiency.  Fig. 6 shows a misalignment that may explain such a rearrangement.  
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It is reasonable to assume that the flanking sequences of the RCCX module (ie, the TNXB and 
RP1 genes) will align correctly.  The crossover could then be explained by two looping-out 
stretches of DNA, each comprising a single RCCX module.  The size differences between the 
C4 genes on the chromosomes involved may contribute to inducing such an arrangement.  It 
has been hypothesised that retroviral inserts such as HERV-K(C4), which makes up this size 
difference, have contributed to genetic rearrangement in the MHC during evolution [Dawkins 
et al. 1999]. 
 
 
Fig. 6.  Hypothetical misalignment and loop-out of two bimodular chromosomes contributing to an unequal 
crossover causing deletion of a 30 kb region including the CYP21 gene and the 5' portion of the TNXB 
gene.  The figure shows separate loops of two sections of DNA, but other configurations involved in this 
crossover events can also be envisioned.  The open and hatched boxes match the father's chromosomes a 
and b and the sections of the patient's recombinant chromosome derived from them.  See fig. 1 for details 
on the graphics. 
 
 
The presence of sequences promoting recombination, such as the E. coli crossover hotspot 
instigator (chi) and the human minisatellite consensus sequence, has been implicated in 
genetic rearrangement of the RCCX module [Amor et al. 1988; Chu et al. 1992; Martínez-
Quiles et al. 1998; Yang et al. 1999].  It is possible that such sequences play a role in the 
generation of small-scale gene conversions between the CYP21 and CYP21P genes, but we do 
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not believe that at present, there is any reason to assume that the RCCX module is a region of 
increased levels of crossover.  Instead, the high degree of sequence homology between genes 
in this area combined with the frequent size differences and variability in the number of 
modules, seems to promote misalignment, so that when a crossover does occur, it has an 
increased chance of producing a genetic rearrangement and potentially an inherited disease.  
Consistent with this notion, the present case is only the second clearly documented instance of 
a de novo unequal crossover in this region, despite the fact that over the years, haplotyping 
studies that could have detected such events have been done in several thousands of families 
by many different research groups around the world.  The earlier report [Sinnott et al. 1990] 
was published before the structure of the RCCX module became known in detail [Bristow et 
al. 1993; Shen et al. 1994; Sargent et al. 1994; Rupert et al. 1999; Yang et al. 1999; 
Blanchong et al. 2001], but the crossover apparently also occurred within the TNX gene, 
because the 2.4 kb TaqI fragment was retained.  Another case involved a very large area 
including HLA-D in the MHC class II region [Hejtmancik et al. 1992] and probably arose by a 
mechanism very different from the one discussed here.  Despite the small number of de novo 
deletions in this region described so far, it is remarkable that none of them appears to have its 
recombination breakpoint within the CYP21 gene.  It has been well documented that many 
apparent CYP21 deletions represent a hybrid gene with a CYP21P-like 5' section and a 
CYP21-like 3' section and that transition zones between these sections are positioned at 
different locations within the hybrid gene [White et al. 1988; Chu et al. 1992; Donohoue et al. 
1995; Levo and Partanen 1997; Koppens et al. 2000; l'Allemand et al. 2000; Baumgartner-
Parzer et al. 2001].  In line with those findings, we did not find the 120 bp deletion in 15 other 
deletion haplotypes after testing them with the TNXB-specific PCR described here 
(unpublished observations).  CYP21 gene deletions with the crossover site in the TNX gene 
have so far been described in a few isolated cases [Sinnott et al. 1990; Burch et al. 1997; Yang 
et al. 1999; Schalkwijk et al. 2001; this report].  Whether the additional TNX defect adds 
significantly to selection against this allele as compared to a defect in CYP21 alone is unclear, 
since the frequency of tenascin-X deficiency has not been established.  However, steroid 21-
hydroxylase deficiency alleles occur at different frequencies in different populations [Mornet 
et al. 1991; Owerbach et al. 1992; Wedell et al. 1994; Ezquieta et al. 1995; Wilson et al. 
1995; Levo and Partanen 1997; Ordoñez-Sánchez et al. 1998; Lako et al. 1999; Balsamo et al. 
2000; Koppens et al. 2000; Krone et al. 2000; Baumgartner-Parzer et al. 2001], and most 
reports do not describe putative crossover sites.  This dual-deficiency allele may therefore play 
a role in the pathogenesis of congenital adrenal hyperplasia, the Ehlers-Danlos syndrome, or 
both, in some populations.  Future studies could address this question by means of PCR 
methods such as the one described here or elsewhere [Burch et al. 1997; Yang et al. 1999], or 
by checking the intensity ratio of the 2.4 and 2.5 kb TaqI bands on autoradiograms of genomic 
DNA.  Analysis of de novo mutations in the male germline, which has previously been done 
for a small area within the CYP21 gene [Tusié-Luna and White 1995] can determine whether 
there are differences in the frequency of (unequal) crossover between different sections of the 
RCCX module. 
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Finally, the current report clearly illustrates that a de novo recombination may be a pitfall in 
understanding RCCX haplotypes, emphasising the importance of studying entire families 
rather than isolated patients and of using flanking MHC markers on either side of the CYP21 
locus to avoid erroneous assignment of carrier status. 
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Abstract 
Steroid 21-hydroxylase deficiency is caused by a defect of the CYP21 gene.  CYP21, the 
adjacent complement C4 gene and parts of the flanking genes RP1 and TNX make up the 
RCCX module, a tandemly duplicated arrangement in the central Major Histocompatibility 
Complex (MHC).  The standard layout is bimodular, with one RCCX module carrying CYP21 
and the other one carrying the highly homologous pseudogene CYP21P.  By comparison to 
this standard, CYP21 defects have traditionally been categorised into deletions of the RCCX 
module that contains CYP21, large-scale gene conversions of CYP21 into a structure similar to 
CYP21P and smaller mutations in CYP21 (also derived from CYP21P by means of small-scale 
gene conversions).  The genetic mechanisms suggested by these designations have originally 
been inferred from the layout of the haplotypes involved and were later confirmed by 
observation of deletions and small mutations, but not large-scale conversions, as de novo 
events.  Apparent large-scale conversions account for the defect in 9 out of 75 chromosomes 
in our patient group.  We here demonstrate that 4 out of these 9 'conversions' extend into the 
flanking TNXB gene, which encodes tenascin-X.  This implies that approximately 1 in every 
10 steroid 21-hydroxylase deficiency patients is a carrier of tenascin-X deficiency, which is 
associated with a recessive form of the Ehlers-Danlos syndrome.  Currently available data on 
the structure of 'deletion' and 'large conversion' chromosomes strongly suggests that both are 
the result of the same mechanism, namely unequal meiotic crossover.  Since it is unlikely that 
the term 'large-scale gene conversion' describes a mechanism that actually occurs between the 
CYP21 and CYP21P genes, we propose the discontinuation of that terminology. 
 
Introduction 
Steroid 21-hydroxylase deficiency is the foremost cause of congenital adrenal hyperplasia 
(CAH), an inborn error of metabolism with an incidence ranging between 1:10,000 and 
1:15,000 in most populations [Strachan 1990; New 1998; Wedell 1998; White and Speiser 
2000].  CAH due to 21-hydroxylase deficiency is characterised by an impaired adrenocortical 
synthesis of cortisol and aldosterone.  Lack of aldosterone often results in severe salt loss in 
untreated paediatric patients, a potentially life-threatening condition.  Also, the adrenal which 
has increased in size due to continuous ACTH stimulation induced by lack of cortisol, shunts 
excess precursor steroids into the androgen synthesis pathway.  The elevated androgen levels 
then cause pre- and postnatal virilisation. 
Steroid 21-hydroxylase deficiency has a wide range of clinical manifestations which are 
associated with more or less severe defects of the CYP21 gene.  Over 15 years ago, it was 
found that CYP21 and the highly homologous but deficient pseudogene CYP21P lie in the 
central region of the human Major Histocompatibility Complex (MHC) near the two genes 
encoding the fourth component of complement (C4A and C4B) in a tandemly duplicated 
arrangement [White et al. 1985; Carroll et al. 1985]. 
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Later studies have shown that the CYP21 and C4 genes are part of a repeated stretch of 
approximately 30 kb of DNA that also includes parts of the RP1 gene (also named G11 or 
STK19 and encoding a serine-threonine kinase [Sargent et al. 1994; Shen et al. 1994; Gomez-
Escobar et al. 1998]) and of the TNXB gene (encoding the extracellular matrix protein 
tenascin-X [Gitelman et al. 1992; Matsumoto et al. 1992; Bristow et al. 1993]).  This unit, 
which comes in two sizes variants ('long' or 'short') depending on the presence or absence of 
an endogenous retroviral sequence in the C4 gene, has been named the RCCX module after 
the principal genes it encompasses [Shen et al. 1994; Yang et al. 1999; Blanchong et al. 
2000].  TaqI/BglII restriction analysis of genomic DNA has become a tried-and-proven 
method to establish the overall genetic arrangement of the CYP21/C4 region [Carroll et al. 
1985; Donohoue et al. 1986; Schneider et al. 1986; Higashi et al. 1988; White et al. 1988; 
Morel et al. 1989].  A 'standard' chromosome bears two modules, containing a CYP21 gene 
characterised by a 3.7 kb TaqI fragment and a CYP21P gene characterised by a 3.2 kb TaqI 
fragment  (see fig. 1). 
 
 
 
Fig. 1. a. Overview of the C4/CYP21 area, showing two RCCX modules as found on most chromosomes.  
TNXB is the full-size 68 kb gene for tenascin-X, TNXA (also known as XA) is a truncated pseudogene of 
5.7 kb that lacks most of the coding sequence of TNXB and has a deletion of 120bp (indicated by the small 
triangle) spanning an exon-intron boundary [Gitelman et al. 1992; Bristow et al. 1993].  CYP21 (also known 
as CYP21B) is the active steroid 21-hydroxylase gene; CYP21P (shown in black; also known as CYP21A) 
is a full-size pseudogene containing several deleterious mutations throughout its sequence, including three 
in-phase stop codons [Higashi et al. 1986].  The C4 genes express variants of the fourth component of 
complement with different affinities, known as C4A and C4B.  Assignment of C4A and C4B is tentative: the 
arrangement shown is the most common, but the specificity of the C4 genes cannot be determined by 
means of the restriction sites shown.  About three quarters of all RCCX modules are 'long' (33 kb in size); 
the others are 'short' (27 kb).  The difference depends on the presence or absence of an endogenous 
retroviral sequence in one of the introns of the C4 gene.  The arrows show the orientation of transcription; 
there is an overlap between the 3' sections of the oppositely transcribed genes TNXB and CYP21, and of 
TNXA and CYP21P, respectively.  Bottom: characteristic TaqI and BglII restriction fragments; top: scale in 
kb, with the centromeric RCCX duplication boundary at 0. 
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Studies of fragment ratios of 21-hydroxylase deficiency alleles early on led to their 
classification into three main categories of defects: 
(a) chromosomes with a single RCCX module having a CYP21P-like gene and no CYP21 
gene ('CYP21 deletions'); 
(b) chromosomes with two RCCX modules where the CYP21 gene has apparently been 
replaced by an additional CYP21P-like gene ('large-scale gene conversions'); 
(c) chromosomes with varying numbers of RCCX modules (mostly, one to three), at least one 
of which contains a CYP21 gene. 
Further analysis of the latter category demonstrated that most (but not all) defective CYP21 
genes carried one or more of a limited set of mutations typically found in CYP21P.  These 
defects were therefore designated 'small-scale gene conversions'. 
Unequal meiotic crossover is believed to be the mechanism causing CYP21 deletions, a notion 
firmly supported by studies of deletion haplotypes [Carrroll et al. 1985; Rumsby et al. 1986; 
White et al. 1988; Chu et al. 1992; Donohoue et al. 1995; Lee et al. 2000] and de novo events 
[Sinnott et al. 1990; Koppens et al. 2002].  These chromosomes usually carry a hybrid gene, 
where the crossover joined the 5' portion of CYP21P onto the 3' portion of CYP21.  Since the 
5' portion contains the extra TaqI site [White et al. 1985; Higashi et al. 1986], the hybrid is 
recognised as a CYP21P-like gene in restriction analysis of genomic DNA.  The location of 
the recombination breakpoint determines the size of the pseudogene-like portion and hence the 
genetic defects carried by these deletion chromosomes.  While in rare cases, enough of CYP21 
has been retained to produce a partly active 21-hydroxylase enzyme [l'Allemand et al. 2000], 
nearly all of the hybrid genes studied so far include at least an 8 bp deletion in the third exon 
leading to premature termination of translation [Chu et al. 1992; Helmberg et al. 1992; Levo 
and Partanen 1997; Koppens et al. 2000; Lee et al. 2000].  Recently, breakpoint locations 
beyond the 3' end of CYP21 have been found [Burch et al. 1997; Yang et al. 1999; Schalkwijk 
et al. 2001; Koppens et al. 2002].  Such alleles carry an additional genetic defect, because a 
part of the tenascin-X-producing TNXB gene has been replaced by its TNXA counterpart, a 
truncated pseudogene carrying a 120 bp deletion on an exon-intron boundary.  A homozygous 
defect of TNXB causes type II Ehlers-Danlos syndrome, a connective-tissue disease [Burch et 
al. 1997; Schalkwijk et al. 2001]. 
Insight into the mechanisms of gene conversions has not progressed at the same pace, 
however.  The 'large-scale gene conversion' chromosomes with two CYP21P-like genes (that 
is, two genes characterised by a 3.2 kb TaqI fragment) indeed carry a stretch of CYP21P-like 
DNA encompassing several exons [Levo and Partanen 1997; Koppens et al. 2000] although 
here too, an exception where the 'converted' region was limited in size and the gene retained 
some activity, has been demonstrated [Killeen et al. 1991].  Most 'small-scale gene 
conversions', on the other hand, involve a stretch of CYP21P-like DNA that is at most a few 
hundred base pairs in size and contains only one recognisable mutation as a marker of 
'CYP21P-ness'. 
We here report on the extension of the pseudogene-like region in bimodular chromosomes 
with two CYP21P-like genes.  Out of nine such haplotypes in a population of steroid 21-
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hydroxylase deficiency from 38 families studied by us [Koppens et al. 2000], five have a 
CYP21P-CYP21 transition zone in the CYP21 gene, but the other four are pseudogene-like 
well into the TNXB-gene.  This implies that approximately 10 % of the patients with classical 
21-hydroxylase deficiency are also carriers of tenascin-X deficiency.  Thus, defectiveness of 
the TNXB gene due to the 120 bp deletion normally found in the TNXA pseudogene appears to 
be much more common than previously reported, and also much more common in bimodular 
'conversion' haplotypes than in monomodular 'deletion' haplotypes. 
 
Methods 
Subjects and haplotyping 
The study population of 21-hydroxylase deficiency patients, family members, and controls 
was the same as before [Koppens et al. 2000], and CYP21/C4 haplotyping was done as 
described earlier [Koppens et al. 1992].  Briefly, TaqI and BglII restriction patterns were 
obtained with the CYP21 cDNA probe pC21/3c [White et al. 1985] and the 5' section of the 
C4 cDNA probe pAT-A [Belt et al. 1984].  The principal markers for CYP21 and CYP21P are 
the 3.7 and 3.2 kb TaqI fragments, respectively (see figs. 1 and 3).  The 3' flanking region of 
these genes is usually investigated by BglII digestion, because the CYP21 cDNA probe 
overlaps the 2.4 and 2.5 kb TaqI fragments in this region by only a few hundred bp, often 
resulting in poor visualisation of the bands.  Normally, the estimated ratio of the TaqI 2.4 and 
2.5 kb bands is equal to the ratio of the BglII 12 and 11 kb bands.  However, we could 
distinguish the 2.4 and 2.5 kb bands on many autoradiograms, and in some patients with an 
apparent 'large-scale conversion' of CYP21 into CYP21P, a discrepancy between the TaqI and 
BglII patterns clearly existed (see fig. 3). 
Amplification and restriction analysis of TNXA and TNXB 
Parts of TNXA and TNXB that encompass the site of the 120 bp deletion normally found in 
TNXA only, were specifically amplified.  The forward primer for TNXB 
(TCTCTGCCCTGGGAATGACAG) lies beyond the duplication boundary of the RCCX 
module, in the large non-duplicated part of the TNXB gene.  The forward primer for TNXA 
(CTTGAGCTGCAGATGGGATAC) lies within the RP2 pseudogene.  The reverse primer 
(CAATCCCCACCCTGAACAAGT) was the same for both genes and lies between the site of 
the 120 bp deletion and the 3' end of the CYP21/CYP21P gene (see fig. 2).  A touchdown PCR 
protocol was used to amplify these stretches of approximately 2.7 kb: first, 8 cycles of 30 s at 
94°C, 60 s at 66 °C decreasing 0.5 °C per cycle and 3 min at 72 °C; next, 26 cycles of 30 s at 
94°C, 60 s at 62 °C and 3 min at 72 °C extending 30 s per cycle.  Amplification was done with 
0.5 units of Thermoperfect DNA polymerase (Integro, Leuvenheim, The Netherlands) in the 
presence of 1.5 mM MgCl2 and 1 % formamide.  The size of the PCR product directly shows 
presence or absence of the 120 bp deletion/insertion.  In addition, comparison of published 
TNX sequences (EMBL/GenBank/DDBJ accession numbers S38953 [Gitelman et al. 1992], 
X71937 [Bristow et al. 1993], AL049547 [Barlow 2000], AF019413 [Rowen et al. 1999a], 
U89337 [Rowen et al. 1999b], AF077974 [Rupert et al. 1999], AF086641 [Yang et al. 1999] 
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and L26263 [Yu 1991; Shen et al. 1994]) revealed several polymorphisms throughout the 
amplified region, most of which can be detected by restriction analysis: PflMI at 276 bp 
downstream of the border of the RCCX module, StyI at 719 bp, BstUI at 1626 bp and PvuII at 
2190 bp (in this context, 'downstream' is relative to the transcription of the TNXB gene and 
sequence AL049547 [Barlow 2000] has been used to compute fragment sizes and nucleotide 
positions).  To determine whether these polymorphisms could be used as reliable markers of a 
typical TNXA or TNXB gene, we amplified a large number of 'standard' TNXA and TNXB 
genes from individuals with one to three copies of TNXA and two copies of TNXB, digested 
the products with these enzymes and analysed them on agarose or polyacrylamide gels. 
 
 
 
Fig. 2.  Amplified region of TNXA and TNXB (bottom) showing the site of the 120 bp deletion (shown as a 
triangle) in TNXA and the beginning of the TaqI fragment that partly overlaps the CYP21 or CYP21P gene 
(see fig. 1).  The location of the TaqI site in the TNX genes is the same relative to the nearby RCCX 
boundary, but the 120 bp size difference determines whether the fragment is 2.4 or 2.5 kb. The 
polymorphic sites used as a marker for TNXA or TNXB are shown.  The four amplified stretches of DNA 
are, from top to bottom: a. regular TNXA PCR; b. regular TNXB PCR, which produces similar stretches for 
a haplotype with a normal CYP21 gene and one with a CYP21/CYP21P hybrid; c and d. TNXB PCR of a 
TNXB/TNXA hybrid with two different conversion zones, typical of the novel haplotype described here.  
TNXA-like sequences are shown in black, TNXB-like sequences in white, and putative transition zones 
between them are hatched. Top: scale in bp.   
 
Results 
TaqI/BglII restriction analysis 
Typical TaqI and BglII restriction patterns are shown in fig. 3.  Some steroid 21-hydroxylase 
deficiency patients have two bimodular chromosomes and a total of three CYP21P-like genes 
as indicated by the 3.2 and 3.7 kb TaqI bands.  These persons all have equal density ratios of 
the BglII 11 and 12 kb bands (fig. 3b, lane 5), but while some of them also have equal TaqI 
2.4 and 2.5 kb fragments (fig. 3a, lane 3), others have a diminished intensity of the 2.5 kb 
fragment and an increased 2.4 kb fragment (fig. 3a, lane 4).  The difference depends on the 
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presence or absence of a 120 bp stretch of DNA on the boundary of exon 36 and intron 36 of 
the TNXB gene [Gitelman et al. 1992; Bristow et al. 1993].  In the population studied, there 
were nine bimodular chromosomes with two CYP21P genes.  Four of these had two 2.4 kb 
TaqI fragments and hence, the 120 bp deletion in TNXB; these chromosomes all had one short 
and one long C4 gene.  The other five did not have the 120 bp deletion in TNXB, and all of 
these had two long C4 genes.  Such apparent discrepancies between the BglII and TaqI 
restriction fragments were found on two other chromosomes in our study population: once as a 
result of a de novo unequal crossover on a monomodular chromosome [Koppens et al. 2002] 
and once on a bimodular chromosome where the TNXA gene had partly assumed a TNXB-like 
structure that is probably the same as reported earlier [Rupert et al. 1999].  All other 
chromosomes tested, including 15 monomodular 'CYP21 deletion' alleles, had the 120 bp 
present in TNXB and absent in TNXA. 
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Fig. 3. a. TaqI restriction patterns of genomic 
DNA hybridised to a mixture of the CYP21 and 
C4 cDNA probes.  Genotypes: lane 1: normal 
pattern, two bimodular RCCX modules, one with 
a 'short' and one with a 'long' C4B gene; lane 2: 
heterozygous deletion of CYP21 on one 
chromosome and CYP21P on the other, two 
monomodular chromosomes, both with 'long' C4
genes; lane 3: heterozygous 'large conversion', 
two bimodular RCCX modules, one with CYP21-
CYP21P and one with CYP21P-CYP21P; 'long' 
C4 genes only and equal intensity of the 2.4 and 
2.5 kb bands, so no 120 bp deletion in TNXB; 
lane 4: as lane 3, but one short and one long C4
gene and increased intensity of the 2.4 kb band 
due to a 120 bp deletion in TNXB.  Fragment 
sizes in kb; the C4 fragment sizes listed (7.0, 
6.4, 6.6) are those traditionally used in the 
literature [Schneider et al. 1986] although the 
actual fragments are approximately 0.15 kb 
larger. 
b. BglII restriction patterns obtained with the 
CYP21 probe only.  Genotypes: lane 5: pattern 
of two bimodular chromosomes, matching the 
TaqI patterns in lanes 1, 3 and 4; lane 6: two 
monomodular chromosomes, matching the TaqI 
pattern in lane 2. 
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Informative markers in the TNX genes 
The most informative restriction sites to distinguish TNXA from TNXB were the PflMI site 
(present in 193 out of 241 TNXA genes and 0 out of 294 TNXB genes) and the PvuII site 
(present in 5 out of 131 TNXA genes and 85 out of 129 TNXB genes).  The StyI and BstUI sites 
provided no distinction between TNXA and TNXB.  All 298 TNXB genes tested contained the 
120 bp, as opposed to only 1 out of 270 TNXA genes. 
 
 
 
 
Restriction analysis of the TNX genes 
Typical PflMI restriction patterns of the TNXA and TNXB PCR products are shown in fig. 4.  
Out of the four bimodular CYP21P-CYP21P chromosomes with the 120 bp deletion in TNXB, 
one carried the PflMI site at bp 276 (fig. 4, lane 4); the other three, and the other five 
CYP21P-CYP21P chromosomes, did not have this site (fig. 4, lane 5).  This shows that in one 
case, the transition between a TNXA-like sequence and a TNXB-like sequence lies within 276 
bp of the RCCX boundary.  In the other three cases, the transition probably lies further 
downstream because absence of the PflMI site is a TNXB-like feature (although it also occurs 
in about 20 % of the TNXA genes).  All four genes are, of course, TNXA-like at the site of the 
120 bp insertion (bp 2290) and possibly already at bp 2190 since they did not carry a PvuII 
site found in most TNXB genes (results not shown). 
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Fig. 4. PflMI restriction analysis.  Lane 1: 
TNXA without the PflMI site; lane 2: TNXA, 
heterozygous for the PflMI site; lane 3: TNXA, 
homozygous for the PflMI site;  lane 4: TNXB, 
no PflMI site; lane 5: TNXB, heterozygous for 
the 120 bp deletion without the PflMI site; 
lane 6: TNXB, heterozygous for the 120 bp 
deletion with the PflMI site.  Left: 5 µl 
SmartLadder (Eurogentec, Seraing, 
Belgium); electrophoresis was for 28 h at 40 
V on 1 % agarose. 
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Discussion 
Combined defectiveness of the CYP21 and TNX genes has so far been described in a few 
isolated cases in CYP21 deletions caused by meiotic unequal crossover.  We here report that 
such 'double deficiency' alleles are indeed rare on monomodular chromosomes, but relatively 
common (four out of nine cases) on bimodular chromosomes with two CYP21P-like genes 
(usually termed 'large-scale conversions' in the literature).  This haplotype is characterised by 
two 2.4 kb TaqI fragments matching the 120 bp deletion in both TNX genes and distinguishing 
it from previously described 'large-scale conversions' which have one 2.4 and one 2.5 kb 
fragment.  Given the large number of CYP21/C4 haplotyping reports available to date (most of 
which were recently reviewed by White and Speiser [2000]), it is surprising that this haplotype 
has not been documented before: an apparently similar case was reported only once [Dawkins 
et al. 1987], before the discovery of the TNX genes.  Poor resolution or poor visualisation of 
the 2.4 and 2.5 kb bands sometimes (but not always) hampers the analysis when a CYP21 
cDNA probe is used.  However, studies with probes that overlap a large part of these 
fragments [Morel et al. 1989; Bachega et al. 1999; Blanchong et al. 2000] did not detect this 
haplotype either.  To find the TNXB-TNXA transition zone in this type of hybrid, we checked 
which of the polymorphisms in published TNX sequences (for references, see the Methods 
section) are reliable markers of 'TNXA-ness' or 'TNXB-ness'.  A characteristic PflMI site at 276 
bp downstream of the RCCX boundary was present in one of the four TNXB-TNXA hybrids, 
but absent in the others, indicating that at least two distinct transition zones exist.  In the other 
three cases, the transition apparently occurred further downstream.  The TNXB-TNXA 
transition zone in a de novo unequal crossover was also found in this downstream area, 
beyond the BstUI site at bp 1626 [Koppens et al. 2002]. 
In our patient group [Koppens et al. 2000], this TNXB/TNXA hybrid was found on four out of 
75 chromosomes, a frequency of 0.053 (95 % confidence limits 0.018 to 0.12) [Linder 1960].  
Considering a carrier rate for classical steroid 21-hydroxylase deficiency of approximately 
1:50, we estimate the frequency of this dual deficiency allele in the general population in the 
Netherlands at 1:1,000.  If the high frequency of this allele in 21-hydroxylase deficiency 
patients is unique to the Dutch population, a founder effect would be a logical explanation, but 
one would then have to postulate an additional mutation to explain the PflMI difference.  This 
issue could be resolved by systematic re-evaluation of apparent large-scale conversions in 
other populations by a suitable PCR method [Burch et al. 1997; this report].  Interestingly, 
TNXB-TNXA hybrid genes were recently reported in two Dutch patients suffering from the 
Ehlers-Danlos syndrome [Schalkwijk et al. 2001].  The number of RCCX modules was not 
determined in that study, so it seems possible that these patients have the bimodular structure 
described here. 
Chromosomes carrying two RCCX modules, each with a CYP21P-like gene, have been called 
'large-scale gene conversions' because as compared to the 'standard' layout, the CYP21 gene 
appears to have been converted into a CYP21P gene.  It has, however, become clear that the 
'converted' CYP21P gene on such chromosomes is either a CYP21P/CYP21 hybrid [Levo and 
Partanen 1997; Koppens et al. 2000] or a regular CYP21P gene adjacent to a TNXA/TNXB 
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hybrid (this report), and thus structurally indistinguishable from the CYP21P genes on 'CYP21 
deletion' chromosomes.  Although definite proof awaits the description of a de novo event, the 
structural similarity makes it highly likely that bimodular CYP21P-CYP21P haplotypes arise 
by the same mechanism as monomodular CYP21P-only haplotypes, namely meiotic unequal 
crossover: in this case, involving a trimodular CYP21P-CYP21P-CYP21 chromosome 
[Strachan 1990, Blanchong et al. 2000].  We therefore propose that in this context, the term 
'gene conversion' be reserved for small-scale events only, ideally with demonstrable non-
converted regions on either side of the converted region.  Gene conversion is indeed a 
reasonable explanation for small-scale CYP21-CYP21P sequence transfer, as supported by 
studies of de novo mutations [Collier et al. 1993; Tajima et al. 1993; Ordoñez-Sánchez et al. 
1998] and sperm cells [Tusié-Luna and White 1995].  Although historically understandable, 
the term 'large-scale gene conversion' in its present sense suggests a mechanism that probably 
never occurs between RCCX modules.  Instead, the term 'CYP21 deletion by unequal 
crossover' adequately describes all chromosomes with a hybrid RCCX module and without a 
CYP21 gene, irrespective of the number of CYP21P genes. 
 
Acknowledgements 
The authors wish to thank Prof. Dr. S.L.S. Drop and Dr. S.M.P.F. de Muinck Keizer-Schrama 
(Sophia Children's Hospital, Rotterdam), Dr. W. Deetman-Oostdijk and Dr. J. Derksen 
(Leiden University Medical Centre) and Dr. J.J.J. Waelkens (Catharina Hospital, Eindhoven) 
for providing the families' blood samples, and Dr. D.J.J. Halley for her valuable comments 
about the manuscript 
 
References 
Bachega TASS, Billerbeck AEC, Madureira G, Arnhold IJP, Medeiros MA, Marcondes JAM, Longui 
CA, Nicolau W, Bloise W, Mendonça BB (1999). Low frequency of CYP21B deletions in Brazilian 
patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Hered 49: 9-
14. 
Barlow K (2000). EMBL/GenBank/DDBJ accession number AL049547. 
Belt KT, Carroll MC, Porter RR (1984). The structural basis of the multiple forms of human complement 
component C4. Cell 36: 907-914. 
Blanchong CA, Zhou B, Rupert KL, Chung EK, Jones KN, Sotos JF, Zipf WB, Rennebohm RM, Yu CY 
(2000). Deficiencies of human complement component C4A and C4B and heterozygosity in length 
variants of RP-C4-CYP21-TNX (RCCX) modules in Caucasians: the load of RCCX genetic 
diversity on Major Histocompatibility Complex-associated disease. J Exp Med 191: 2183-2196. 
Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL (1993). Tenascin-X: a novel extracellular 
matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 122: 265-278. 
Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, Miller WL, Bristow J (1997). Tenascin-X 
deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 17: 104-108. 
Carroll MC, Palsdottir A, Belt KT, Porter RR (1985). Deletion of complement C4 and steroid 21-
hydroxylase genes in the HLA class III region. EMBO J 4: 2547-2552. 
Chapter 5 
 
202
Chu X, Braun-Heimer L, Rittner C, Schneider PM (1992). Identification of the recombination site within 
the steroid 21-hydroxylase gene (CYP21) of the HLA-B47,DR7 haplotype. Exp Clin Immunogenet 
9: 80-85. 
Collier S, Tassabehji M, Sinnott PJ, Strachan T (1993). A de novo pathological point mutation at the 21-
hydroxylase locus: implications for gene conversion in the human genome. Nat Genet 3: 260-265; 
4: 101. 
Dawkins RL, Martin E, Kay PH, Garlepp MJ, Wilton AN, Stuckey MS (1987). Heterogeneity of steroid 
21-hydroxylase genes in classical congenital adrenal hyperplasia. J Immunogenet 14: 89-98. 
Donohoue PA, Van Dop C, Jospe N, Migeon CJ (1986). Congenital adrenal hyperplasia: molecular 
mechanisms resulting in 21-hydroxylase deficiency. Acta Endocrinol 113 suppl. 279: 315-320. 
Donohoue PA, Guethlein L, Collins MM, Van Dop C, Migeon CJ, Bias WB, Schmeckpeper BJ (1995). 
The HLA-A3,Cw6,B47,DR7 extended haplotypes in salt losing 21-hydroxylase deficiency and in 
the Old Order Amish: identical class I antigens and class II alleles with at least two crossover sites 
in the class III region. Tissue Antigens 46: 163-172. 
Gitelman SE, Bristow J, Miller WL (1992). Mechanism and consequences of the duplication of the 
human C4/P450c21/gene X locus. Mol Cell Biol 12: 2124-2134; 3313-3314. 
Gomez-Escobar N, Chou CF, Lin WW, Hsieh SL, Campbell RD (1998). The G11 gene located in the 
major histocompatibility complex encodes a novel nuclear serine/threonine protein kinase. J Biol 
Chem 47: 30954-30960. 
Helmberg A, Tabarelli M, Fuchs MA, Keller E, Dobler G, Schnegg I, Knorr D, Albert E, Kofler R 
(1992). Identification of molecular defects causing congenital adrenal hyperplasia by cloning and 
differential hybridization of polymerase chain reaction-amplified 21-hydroxylase (CYP21) genes. 
DNA Cell Biol 11: 359-368. 
Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y (1986). Complete nucleotide sequence 
of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a 
genuine gene. Proc Natl Acad Sci USA 83: 2841-2845. 
Higashi Y, Tanae A, Inoue H, Fujii-Kuriyama Y (1988). Evidence for frequent gene conversion in the 
steroid 21-hydroxylase P-450(C21) gene: implications for steroid 21-hydroxylase deficiency. Am J 
Hum Genet 42: 17-25. 
Killeen AA, Sane KS, Orr HT (1991). Molecular and endocrine characterization of a mutation involving 
a recombination between the steroid 21-hydroxylase functional gene and pseudogene. J Steroid 
Biochem Mol Biol 38: 677-686. 
Koppens PFJ, Hoogenboezem T, Halley DJJ, Barendse CAM, Oostenbrink AJ, Degenhart HJ (1992). 
Family studies of the steroid 21-hydroxylase and complement C4 genes define 11 haplotypes in 
classical congenital adrenal hyperplasia in the Netherlands. Eur J Pediatr 151: 885-892. 
Koppens PFJ, Hoogenboezem T, Degenhart HJ (2000). CYP21 and CYP21P variability in steroid 21-
hydroxylase deficiency patients and in the general population in the Netherlands. Eur J Hum Genet 
8: 827-836. 
Koppens PFJ, Smeets HJM, de Wijs IJ, Degenhart HJ (2002). A de novo unequal crossover generates a 
dual deficiency allele carrying no steroid 21-hydroxylase (CYP21) gene and a non-functional hybrid 
tenascin-X (TNX) gene: mapping of the recombination site between chromosomes each carrying 
two RCCX modules. Chapter 4 of this thesis. 
l'Allemand D, Tardy V, Grüters A, Schnabel D, Krude H, Morel Y (2000). How a patient homozygous 
for a 30-kb deletion of the C4-CYP21 genomic region can have a nonclassic form of 21-
hydroxylase deficiency. J Clin Endocrinol Metab 85: 4562-4567. 
Lee HH, Chang JG, Tsai CH, Tsai FJ, Chao HT, Chung BC (2000). Analysis of the chimeric 
CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency. Clin Chem 46: 606-611. 
Carriership of a defective TNXB gene   203 
Levo A, Partanen J (1997). Mutation-haplotype analysis of steroid 21-hydroxylase (CYP21) deficiency 
in Finland. Implications for the population history of defective alleles. Hum Genet 99: 488-497. 
Linder A (1960). Statistische Methoden, 3. Auflage, pp. 286-287. Basel-Stuttgart, Birkhäuser Verlag. 
Matsumoto K, Ishihara N, Ando A, Inoko H, Ikemura T (1992). Extracellular matrix protein tenascin-
like gene found in human MHC class III region. Immunogenetics 36: 400-403. 
Morel Y, André J, Uring-Lambert B, Hauptmann G, Bétuel H, Tossi M, Forest MG, David M, Bertrand 
J, Miller WL (1989). Rearrangements and point mutations of P450c21 genes are distinguished by 
five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with 
congenital adrenal hyperplasia. J Clin Invest 83: 527-536. 
New MI (1998). Diagnosis and management of congenital adrenal hyperplasia. Annu Rev Med 49: 311-
328. 
Ordoñez-Sánchez M, Ramírez-Jiménez S, López-Gutierrez AU, Riba L, Gamboa-Cardiel S, Cerillo-
Hinojosa M, Altamirano-Bustamante N, Calzada-León R, Robles-Valdés C, Mendoza-Morfín F, 
Tusié-Luna MT (1998). Molecular genetic analysis of patients carrying steroid 21-hydroxylase 
deficiency in the Mexican population: identification of possible new mutations and high prevalence 
of apparent germ-line mutations. Hum Genet 102: 170-177. 
Rowen L, Dankers C, Baskin D, Faust J, Loretz C, Ahearn ME, Banta A, Schwartzell S, Smith TM, 
Spies T, Hood L (1999a). Sequence determination of 300 kilobases of the human class III MHC 
locus. EMBL/GenBank/DDBJ accession number AF019413. 
Rowen L, Dankers C, Baskin D, Faust J, Loretz C, Ahearn ME, Banta A, Schwartzell S, Smith TM, 
Spies T, Hood L (1999b). Sequence determination of 300 kilobases of the human class III MHC 
locus. EMBL/GenBank/DDBJ accession number U89337. 
Rumsby G, Carroll MC, Porter RR, Grant DB, Hjelm M (1986). Deletion of the steroid 21-hydroxylase 
and complement C4 genes in congenital adrenal hyperplasia. J Med Genet 23: 204-209. 
Rupert KL, Rennebohm RM, Yu CY (1999). An unequal crossover between the RCCX modules of the 
human MHC leading to the presence of a CYP21B gene and a tenascin TNXB/TNXA-RP2 
recombinant between C4A and C4B genes in a patient with juvenile rheumatoid arthritis. Exp Clin 
Immunogenet 16: 81-97. 
Sargent CA, Anderson MJ, Hsieh SL, Kendall E, Gomez-Escobar N, Campbell RD (1994). 
Characterisation of the novel gene G11 lying adjacent to the complement C4A gene in the human 
major histocompatibility complex. Hum Mol Genet 3: 481-488. 
Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, 
Bristow J (2001). A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X 
deficiency. New Engl J Med 345: 1167-1175. 
Schneider PM, Carroll MC, Alper CA, Rittner C, Whitehead AS, Yunis EJ, Colten HR (1986). 
Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction 
fragment length polymorphisms revealing structural deletions, homoduplications, and size variants. 
J Clin Invest 78: 650-657. 
Shen L, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel AW, Carroll MC, Zipf WB, Yu CY (1994). 
Structure and genetics of the partially duplicated gene RP located immediately upstream of the 
complement C4A and the C4B genes in the HLA class III region. J Biol Chem 269: 8466-8476. 
Sinnott PJ, Collier S, Costigan C, Dyer PA, Harris R, Strachan T (1990). Genesis by meiotic unequal 
crossover of a de novo deletion that contributes to steroid 21-hydroxylase deficiency. Proc Natl 
Acad Sci USA 87: 2107-2111. 
Strachan T (1990). Molecular pathology of congenital adrenal hyperplasia. Clin Endocrinol 32: 373-393. 
Tajima T, Fujieda K, Fujii-Kuriyama Y (1993). De novo mutation causes steroid 21-hydroxylase 
deficiency in one family of HLA-identical affected and unaffected siblings. J Clin Endocrinol 
Metab 77: 86-89. 
Chapter 5 
 
204
Tusié-Luna MT, White PC (1995). Gene conversions and unequal crossovers between CYP21 (steroid 
21-hydroxylase gene) and CYP21P involve different mechanisms. Proc Natl Acad Sci USA 92: 
10796-10800. 
Wedell A (1998). Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): 
implications for diagnosis, prognosis and treatment. Acta Paediatr 87: 159-164. 
White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL (1985). Two 
genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of 
complement in man. Proc Natl Acad Sci USA 82: 1089-1093. 
White PC, Vitek A, Dupont B, New MI (1988). Characterization of frequent deletions causing steroid 
21-hydroxylase deficiency. Proc Natl Acad Sci USA 85: 4436-4440. 
White PC, Speiser PW (2000). Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr 
Rev 21: 245-291. 
Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY (1999). Modular variations of the human major 
histocompatibility complex class III genes for serine/threonine kinase RP, complement component 
C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). J Biol Chem 274: 
12147-12156. 
Yu CY (1991). The complete exon-intron structure of a human complement component C4A gene. DNA 
sequences, polymorphism, and linkage to the 21-hydroxylase locus. J Immunol 146: 1057-1066. 
 
   
Chapter 6 
 
Aldosterone production despite absence or 
defectiveness of the CYP21 genes in two patients 
with salt-losing congenital adrenal hyperplasia 
caused by steroid 21-hydroxylase deficiency 
 
 
Paul F.J. Koppens, Theo Hoogenboezem, Stenvert L.S. Drop, 
Sabine M.P.F. de Muinck Keizer-Schrama and Herman J. Degenhart 
Department of Paediatrics, Erasmus University Rotterdam / 
Sophia Children's Hospital, Rotterdam, The Netherlands 
 
 
 
Clin Endocrinol 1998; 49: 815-822 
 
 
 
 
 
Chapter 6 206
leeg 
Aldosterone in 21-hydroxylase deficient patients   207 
Abstract 
Aldosterone and cortisol were found in plasma samples from two patients with salt-losing 
congenital adrenal hyperplasia caused by steroid 21-hydroxylase deficiency.  One patient had 
a CYP21 gene deletion on one chromosome and a mutation causing erroneous mRNA splicing 
on the other.  The other patient had a CYP21 gene deletion on one chromosome and a large-
scale conversion of CYP21 to CYP21P on the other.  All CYP21P-like genes in these patients 
were defective, as they carried a deleterious 8 bp deletion in the third exon.  After HPLC 
purification of the patients' plasma samples, cortisol was no longer detectable in the 
radioimmunoassay, but aldosterone levels were still within or slightly above the normal 
reference range.  Aldosterone dropped to very low levels after steroid replacement therapy had 
taken effect.  In at least one of these patients, the genetic defect rules out normal functioning 
of the adrenocortical steroid 21-hydroxylase, which implies involvement of an alternative 
enzyme system. 
 
Introduction 
In the adrenal cortex, multiple enzymatic steps are required for the synthesis of steroid 
hormones.  The main mineralocorticoid, aldosterone, is produced in the zona glomerulosa 
under control of the renin-angiotensin system.  The larger zona fasciculata, which is under 
control of ACTH, produces the main glucocorticoid, cortisol, as well as the androgen 
precursor androstenedione.  Steroid 21-hydroxylase (E.C. 1.14.99.10) is involved in two of 
these pathways: it converts both progesterone to 11-deoxycorticosterone and 
17α-hydroxyprogesterone to 11-deoxycortisol.  A deficiency of this enzyme occurs in about 
one in every 15,000 newborns, causing over 90 % of all cases of congenital adrenal 
hyperplasia (CAH).  The most severely afflicted patients suffer from urinary salt loss due to 
lack of aldosterone, frequently resulting in a life-threatening condition within several weeks 
after birth ('salt-losing' CAH).  In others, the enzyme defect is milder, and aldosterone 
production is sufficient to preclude salt loss ('simple virilising' CAH).  Abnormally high levels 
of precursor steroids (notably, 17α-hydroxyprogesterone) and androgens (which do not 
require 21-hydroxylation) are characteristic of steroid 21-hydroxylase deficiency. 
Steroid 21-hydroxylase is encoded by the CYP21 gene in the class III region of the major 
histocompatibility complex on the short arm of chromosome 6.  On most chromosomes, a 
single CYP21 gene and the highly homologous pseudogene CYP21P lie interspersed between 
the genes encoding the fourth component of complement (C4A and C4B).  However, many 
alternative configurations exist, including some which lead to steroid 21-hydroxylase 
deficiency: CYP21 gene deletions and conversions of (parts of) CYP21 into a CYP21P-like 
pseudogene [White 1994]. 
Although molecular genetic analysis is often in good agreement with clinical phenomena, 
phenotypical variation exists between genotypically identical sibs [Stoner et al. 1986; Sinnott 
et al. 1989; Bormann et al. 1992], between patients carrying the same mutation [Higashi et al. 
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1991; Mornet et al. 1991; Speiser et al. 1992; Kohn et al. 1995; Schulze et al. 1995; Wilson et 
al. 1995], and in the same patient over time [Stoner et al. 1986; Speiser et al. 1991; Hoffman 
et al. 1996].  This variation remains unexplained.  Biochemically, the presence of 
21-hydroxylated steroids such as (plasma) aldosterone [Horner et al. 1979; Stoner et al. 1986], 
(urinary) aldosterone metabolites [Stoner et al. 1986; Speiser et al. 1991; Speiser et al. 1992], 
deoxycorticosterone [Antonipillai et al. 1983] and 21-hydroxypregnenolone [Shackleton et al. 
1987], even in patients with severe salt loss and apparently complete enzyme deficiency, is 
remarkable.  Most case reports deal with aldosterone production by adult or adolescent 
patients.  We here present data on two paediatric patients with salt-losing steroid 
21-hydroxylase deficiency.  One of these patients lacked the CYP21 gene altogether.  The 
other patient had one single CYP21 gene, which carried a splice junction mutation in intron 2, 
seriously impairing gene expression.  Nevertheless, their plasma aldosterone levels were 
equivalent to those of healthy controls.  We also present accurate measurement of plasma 
steroid levels in these patients using HPLC. 
 
Patients and methods 
Patients 
The patients (A and B), both boys born at term, were admitted to the Sophia Children's 
Hospital within the first 10 days of life because of dehydration, vomiting and weight loss.  
Low sodium levels and extremely high levels of 17α-hydroxyprogesterone led to the diagnosis 
of salt-losing steroid 21-hydroxylase deficiency.  Electrolytes were measured upon admission 
to the hospital, as were plasma steroid levels and plasma renin activity (PRA) in patient A; in 
patient B, steroids and PRA were measured during clinical observation at age 7 months, when 
no replacement steroids were given.  Patient A was number 16 and patient B was number 18 
in a previously published haplotyping study [Koppens et al. 1992].  Treatment with cortisol 
and 9α-fluorocortisone was started, and both patients are regularly seen at the outpatient 
department. 
Biochemical assays and HPLC 
Aldosterone, cortisol, 17α-hydroxyprogesterone and androstenedione were purified from 
plasma samples by extraction with dichloromethane using Extrelut columns (Merck no. 
15371).  Cortisol was measured with a Baxter-Travenol GammaCoat RIA kit.  
17α-hydroxyprogesterone was measured with a Medgenix RIA kit.  Aldosterone was 
measured according to Van Vliet et al. [1992].  The sensitivity of the aldosterone assay was 
0.07 nmol/l; the intra- and inter-assay coefficient of variation were 5 % and 9 %, respectively 
(data collected over a number of years; W. Hackeng, personal communication).  
Androstenedione was measured using an antibody obtained from Dr. J.J. Pratt [De Lange et al. 
1980].  Initial measurements had shown extremely high levels of 17α-hydroxyprogesterone, 
but normal to elevated cortisol and aldosterone concentrations (see table 1).  Because these 
findings appeared to contradict the diagnosis of 21-hydroxylase deficiency, the aldosterone 
and cortisol extracts were purified by HPLC.  A Waters HPLC instrument with a 15 cm 5 µm 
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silica column (Merck no. 15655) was used.  The peaks were detected by a Waters 441 
absorbance detector equipped with a 214 nm optical filter.  Cortisol was eluted with 25 % 
isooctane, 71 % chloroform, 3.75 % methanol and 0.25 % water; aldosterone was eluted with 
56.5 % isooctane, 40.5 % chloroform, 2.9 % methanol and 0.12 % water.  The flow rate was 1 
ml/min at 1250 psi.  A standard addition method [Willard et al. 1965] was used to establish 
the base level and the recovery of these steroids.  Briefly, commercially available standards 
were added to the plasma samples, and the recovery after HPLC was determined. 
At the time of these measurements, no urine was available for steroid assays (the limited 
amounts that had been collected were used for electrolyte production measurements). 
 
 
Table 1.  Biochemical parameters and therapeutical effects in patients A and B. 
without steroid replacement therapya patient A patient B 
Na (mmol/l) 110  112  
K (mmol/l) 8.7  8.2  
PRA (ng/ml/hr) 130  150  
17α-hydroxyprogesterone (nmol/l) 1990  1200  
androstenedione (nmol/l) 24  14.5  
aldosterone before HPLC (nmol/l) 0.63  1.4  
aldosterone after HPLC (nmol/l) 0.46  0.47  
cortisol before HPLC (µmol/l) 0.37  0.36  
cortisol after HPLC (µmol/l) < 0.03  < 0.03  
after therapy had taken effectb     
daily intake of cortisol (mg) 1+1+2  3+3+3 3+3+6 
daily intake of 9α-fluorocortisone (µg) 50+50  30+30 30+30 
age 5 months  1 year 3 y 8 m 
Na (mmol/l) 141  134 141 
K (mmol/l) 5.1  5.5 4.4 
PRA (ng/ml/hr) 0.6  10 3.9 
17α-hydroxyprogesterone (nmol/l) 4.3  > 48 43 
androstenedione (nmol/l) < 0.03  2.1 2 
aldosterone (no HPLC) (nmol/l) < 0.05  0.86 < 0.05 
Reference ranges: 17α-hydroxyprogesterone 0.5-6 nmol/l; androstenedione 0.35-1.2 nmol/l; aldosterone 
0.03-0.35 nmol/l (recumbent); cortisol 0.15-0.7 µmol/l (in the morning); PRA 8-17 ng/ml/hr (0 - 3 months of 
age); 3-10 ng/ml/hr (3 - 12 months); 3-8 ng/ml/hr (12 months - 4 years). 
a: upon admission or during later clinical observation (see text) 
b: measurements at age 5 months (patient A) and at ages 1 year and 3 years 8 months (patient B) 
 
 
HLA typing and CYP21/C4 haplotyping 
In both families, blood samples from the father, the mother and the patient were available for 
HLA typing and DNA studies.  HLA-A, -B, -DR, and -DQ typing was performed at the 
Department of Immunohaematology of the Leiden University Hospital using a standard 
microlymphocytotoxicity assay.  The haplotypes found previously indicated complete absence 
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of the CYP21 gene in patient A.  Patient B had a single CYP21 gene on one chromosome and a 
conversion of CYP21 into CYP21P on the other [Koppens et al. 1992]. 
Mutation analysis of the CYP21 gene of patient B 
A part of the second intron and third exon of the single CYP21 gene of patient B was 
amplified using the oligonucleotide primers NORMin2F and BOTHex3R.  PCR was 
performed at 3 mM MgCl2 and 2 % formamide, for 32 cycles consisting of 30 s at 95 °C, 45 s 
at 53 °C and 2 min at 72 °C.  The identity of the amplified product was confirmed by PvuII 
digestion (see fig. 1).  The PvuII site distinguishes CYP21 from CYP21P in these patients, and 
matches the TaqI restriction patterns [Koppens et al. 1995].  The remainder of the PCR 
product was slot blotted onto Hybond-N+ (Amersham) and hybridised to the oligonucleotides 
in2GsplR, in2CsplR and in2AsplR.  The final washing steps were at 52 °C in 0.5 x SSC. 
 
 
Fig. 1. Top: restriction sites (E=EcoRI, P=PvuII, T=TaqI) and TaqI/EcoRI fragments in the 5' section and 
flanking area of CYP21 and CYP21P.  Bottom: PCR fragments and primers; open box: amplified with 
BOTHex2F (forward; CAGACCTGAGCCACTTACCT ) and BOTHex3R (reverse; 
TTCTTGTGGGCTTTCCAGAG); hatched box: amplified with NORMin2F (forward; 
ATCCCCAATCCAGGTCCCT) and BOTHex3R.  Hybridisation site spl: splice junction mutation in intron 2; 
oligonucleotides in2GsplR (defective; CAGGAGGAGCTGGGGGCTG), in2CsplR (normal; 
CAGGAGGAGGTGGGGGCTG) and in2AsplR (normal: CAGGAGGAGTTGGGGGCTG).  Hybridisation site 
∆8: 8 base pair deletion in exon 3; oligonucleotides ex3del8F (defective; TGTCGTTGGTCTCTGCTCTG) 
and ex3normF (normal; TCCTTGGGAGACTACTCCCT).  Scale below in bp; nucleotide numbering 
matches Higashi et al. (1986). 
 
 
Mutation analysis of the CYP21P pseudogenes 
In haplotyping studies, it is usually assumed that steroid 21-hydroxylase genes corresponding 
to a 3.7 kb TaqI restriction fragment are genuine CYP21 genes, while genes corresponding to a 
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3.2 kb fragment are non-functional CYP21P pseudogenes.  Because in the normal arrangement 
one CYP21 gene and one CYP21P pseudogene are present, haplotypes with two 3.2 kb 
fragments and no 3.7 kb fragments are supposed to represent 'large-scale' gene conversions of 
CYP21 to CYP21P.  However, the size of these TaqI fragments merely reflects the presence or 
absence of a restriction site in the 5' flanking sequence of the gene.  Killeen et al. [1991] 
described a haplotype with two steroid 21-hydroxylase genes both characterised by a 3.2 kb 
fragment, one of which encoded a partially active enzyme.  The unexpected presence of 
aldosterone in our patients and the fact that both carry a 'converted' gene on one chromosome 
called for an investigation of their CYP21P genes.  We checked the presence of an 8 bp 
deletion usually present in CYP21P, rendering this gene inactive.  CYP21 and CYP21P were 
amplified in a single PCR, which was performed at 2.5 mM MgCl2 and 2 % formamide, for 32 
cycles consisting of 30 s at 95 °C, 45 s at 58 °C and 3 min at 72 °C.  The product was digested 
with EcoRI, resulting in a distinct banding pattern for each gene.  The Southern blots thus 
obtained were hybridised to the oligonucleotides ex3del8F and ex3normF, detecting the 
presence or absence of an 8 bp deletion found in virtually all CYP21P genes.  The final 
washing steps were at 52 °C in 0.4 x SSC (ex3del8F) and 48 °C in 0.4 x SSC (ex3normF).  
Concordance between TaqI and EcoRI patterns was established by TaqI/EcoRI double 
digestion of genomic DNA and hybridisation to the 0.6 kb BamHI-EcoRI fragment of pC21/3c 
[White et al. 1985].  DNA samples from healthy individuals and, when appropriate, other 
CAH patients from the previous study, were used as controls. 
 
Results 
Steroid measurements and HPLC 
Electrolytes, plasma steroid levels and PRA with and without treatment are presented in table 
1.  Since steroid replacement therapy initially did not result in normalisation of all biochemical 
parameters in patient B, measurements from a later date are also given.  The HPLC protocol 
used to purify the aldosterone and cortisol fractions before RIA was tested by addition of 
known amounts of each compound.  Aldosterone was virtually 100 % recovered; the recovery 
of cortisol was about 70 %.  After HPLC purification of the patient samples, cortisol was 
below the detection limit (< 0.03 µmol/l), but aldosterone remained slightly above the 
reference range.  Apparently, the steroid measured before HPLC was not cortisol but an 
interfering compound, while the aldosterone measured was authentic.  If the compound 
measured was not aldosterone, the assumption would have to be made that it cross-reacted in 
the RIA as well as co-eluted in the HPLC.  None of over 150 other steroids tested was even 
close to fulfilling both conditions (results not shown).  A similar procedure (HPLC followed 
by RIA) was not deemed necessary for 17α-hydroxyprogesterone, since this steroid was 
present in amounts directly measurable by HPLC.  The location of the 
17α-hydroxyprogesterone HPLC peak matched the standard, and the amount was in 
agreement with the RIA results. 
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HLA types and CYP21/C4 haplotypes 
In family A, the father's haplotypes were: (a): HLA-A1,B71,DR13,DQ1; CYP21/C4: A1; (b): 
HLA-A3,B47,DR7,DQ2; CYP21/C4: E1.  The mother's haplotypes were: (c): HLA-
A28,B27,DR4,DQ3; CYP21/C4: A1; (d): HLA-A30,B49,DR13,DQ1; CYP21/C4: D2.  In 
family B, the father's haplotypes were: (a): HLA-A2,B51,DR11,DQ3; CYP21/C4: A1; (b): 
HLA-A30,B49,DR13,DQ1; CYP21/C4: D2.  The mother's haplotypes were: (c): HLA-
A2,B62,DR1,DQ1; CYP21/C4: A1; (d): HLA-A3,B44,DR13,DQ1; CYP21/C4: A1.  The 
patients inherited the (CAH-bearing) haplotypes (b) and (d).  The CYP21/C4 haplotypes are as 
defined previously [Koppens et al. 1992]; A1: the CYP21 and CYP21P genes are both present; 
D2: large-scale conversion of the CYP21 gene to a CYP21P-like pseudogene; E1: deletion of 
the CYP21 gene. 
Defects in the CYP21 gene of patient B 
Hybridisation of the CYP21 specific PCR fragment (the first PCR described in the Methods 
section) of patient B to oligonucleotide in2GsplR showed that a mutation leading to alternative 
mRNA splicing was present in the second intron of the patient's single CYP21 gene.  This 
CYP21 gene was also checked for the presence of several other severe defects: the 8 bp 
deletion in exon 3 (see fig. 2), a change of 3 codons in exon 6, a frameshift mutation in exon 
7, a termination codon in exon 8 and the Arg→Trp mutation in exon 8 (results not shown), but 
none of these were detected.  As expected, the same results were found in the mother of 
patient B. 
 
384 bp
b
280 bp
280 bp
384 bp
c
a
1 2 3 4 5 6 7
A B
Fig. 2.  PCR and hybridisation of 
(parts of) CYP21 and CYP21P.  
Lanes 1-3: family A (father, 
patient, mother); lanes 4-6: 
family B (father, patient, 
mother); lane 7: control having 
only CYP21 genes.  Fig. 2a: 
EcoRI digested PCR products; 
fig. 2b: hybridisation to ex3del8F 
(detecting the 8 bp deletion in 
exon 3); fig. 2c: hybridisation to 
ex3normF (detecting the normal 
sequence).  The 384 bp 
fragment represents CYP21; the 
280 bp fragment represents 
CYP21P. 
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Defects in the CYP21P genes of both patients 
Fig. 2 shows restriction (2a) and hybridisation (2b and 2c) patterns of PCR products obtained 
after amplification of both CYP21 and CYP21P in a single reaction.  The results show that all 
CYP21P genes in both families are indeed defective.  Fig. 3 shows typical patterns of 
TaqI/EcoRI digested genomic DNA hybridised to the 0.6 kb BamHI-EcoRI fragment of 
pC21/3c.  The 0.5 kb and 0.7 kb fragments characteristic of CYP21P and the 1.7 kb fragment 
characteristic of CYP21, respectively, corresponded to the TaqI patterns in all members of 
both families, indicating that presence of the EcoRI site in intron 2 accurately identified 
CYP21P.  In contrast with the nearby PvuII site [Koppens et al. 1995], this apparently is a 
general feature, since similar results with TaqI/EcoRI were obtained in 162 unrelated controls, 
including CAH patients and healthy individuals. 
 
Discussion 
Steroid measurements 
We studied two patients suffering from salt-losing steroid 21-hydroxylase deficiency with 
severe defects in their CYP21 genes, who nevertheless were able to produce significant 
amounts of aldosterone.  In steroid 21-hydroxylase deficient children aldosterone does not 
preclude salt loss, because high 17α-hydroxyprogesterone levels counteract aldosterone action 
[Jacobs et al. 1961].  In addition, increased amounts of 11-deoxycorticosterone function as a 
competitor at receptor level [Land and Ulick 1987]. 
Cortisol was also found initially, but the levels fell below the detection limit after HPLC 
purification.  Several compounds may interfere with cortisol RIAs, most notably 21-
deoxycortisol [Brotherton and Rothbart 1990].  Aldosterone measurements were also lower 
after HPLC, but amounts typical of normal individuals were still found. 
0.5 kb
0.7 kb
1.7 kb
1 2 3 4 5 6 7
A B
Fig. 3.  Hybridisation patterns 
of the 0.6 kb BamHI - EcoRI 
fragment of pC21/3c to 
genomic DNA double 
digested with TaqI and EcoRI.  
Lanes 1-3: family A (father, 
patient, mother); lanes 4-6: 
family B (father, patient, 
mother); lane 7: control 
having only CYP21 genes.  
The 1.7 kb bp fragment 
represents CYP21; the 0.7 kb 
and the (weaker) 0.5 kb 
fragment represent CYP21P 
(see fig. 1). 
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Because aldosterone is one of the (quantitatively) minor plasma steroids, antisera used in its 
assay must be highly specific a priori.  The only interfering compounds described in the 
literature after 1980 are aldosterone metabolites, glucuronic acid conjugates and a few drugs.  
All such compounds are easily removed by HPLC.  Schöneshofer and Weber [1983] used 
HPLC purification to ascertain the analytical aspects of 15 steroids, including aldosterone.  
Egfjord and Olgaard [1992] showed convincing HPLC separation of labelled aldosterone and 
aldosterone metabolites, some of which showed cross-reactivity in the RIA they used. 
CYP21/CYP21P haplotypes and mutations 
Patient A and patient B each had one chromosome with two CYP21P genes and no CYP21 
genes.  Patient A had a CYP21 deletion on the other.  Thus, the genetic defect precluded all 
activity of the normal adrenocortical steroid 21-hydroxylase enzyme in this patient.  All 
CYP21P-like genes in both patients were genuine pseudogenes carrying an 8 bp deletion 
causing a frameshift (see fig. 2). 
The single CYP21 gene in patient B had a mutation in intron 2 creating an alternative splice 
site.  Patients homozygous or 'hemizygous' (having a CYP21 deletion on the other 
chromosome) for this common mutation usually have salt-losing steroid 21-hydroxylase 
deficiency.  However, in some cases the symptoms were milder [Mornet et al. 1991; Speiser et 
al. 1992, Wilson et al. 1995] or delayed [Kohn et al. 1995], and homozygosity for this 
mutation has even been reported in asymptomatic relatives of patients [Schulze et al. 1995].  
The presence of a small amount of correctly spliced mRNA cannot be excluded, as in vitro 
studies have demonstrated some remaining enzyme activity [Higashi et al. 1991].  Remaining 
adrenocortical steroid 21-hydroxylase activity may be the source of aldosterone in this patient. 
Aldosterone in CAH patients 
Factors influencing measured aldosterone levels in CAH patients are the genetic defect, the 
age of the patient, the renin-angiotensin system, and the use of different aldosterone assays.  
Patient A has no CYP21 genes at all and was nevertheless able to produce aldosterone in early 
childhood.  The only similar case described in the literature concerns a patient of 
approximately the same age when urinary aldosterone 18-glucuronide was detected [Speiser et 
al. 1992].  Although this patient (no. 21) had two CYP21 genes, each carried a change of 3 
codons in exon 6, a mutation expected to completely abolish gene function.  An earlier study 
[Speiser et al. 1991] described aldosterone synthesis in a 19-year-old patient who carried a 
homozygous deletion of the CYP21 genes and had no detectable aldosterone production in 
early childhood. 
The influence of the renin-angiotensin system on aldosterone synthesis in 21-hydroxylase 
deficient patients is difficult to assess.  The ratio of PRA to urinary aldosterone 18-
glucuronide ranges widely and shows a relatively poor correlation with the CYP21 genotype 
[Speiser et al. 1992].  Plasma aldosterone levels are more directly influenced by PRA, as a 
close synchronisation between the two exists [James et al. 1978].  Horner et al. [1979] 
described seven older patients (10-19 years of age) with salt-losing CAH having elevated 
plasma aldosterone levels when they were off treatment.  Aldosterone reached normal levels 
when reinstitution of mineralocorticoid therapy resulted in suppression of PRA, which 
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suggested a functional renin-angiotensin-aldosterone system.  In our (much younger) patients, 
plasma aldosterone was not found at all when therapy had taken effect (table 1).  Stoner et al. 
[1986] measured significant plasma aldosterone levels in patients 7-33 years of age, in some 
of whom an aldosterone synthesis defect existed in childhood.  Although methodological 
aspects in aldosterone measurements play a role, ageing is evidently instrumental in 
aldosterone synthesis in many 21-hydroxylase deficient patients. 
Alternative enzymatic pathways 
Alternative steroid 21-hydroxylases either inside or outside the adrenal and alternative 
synthetic pathways towards aldosterone may account for the presence of aldosterone in the 
blood of patients not having a functional CYP21 gene, such as patient A.  The existence of an 
alternative adrenal 21-hydroxylase system has been postulated [Franklin et al. 1987].  
Although no mRNA for such an enzyme has so far been found, conditions of adrenal 
hyperplasia and high levels of precursor steroids might induce the expression of hitherto 
unknown enzymes in vivo. 
Extra-adrenal steroid 21-hydroxylation, notably conversion of progesterone to 
deoxycorticosterone, has been demonstrated in human adults [Winkel et al. 1980] and in foetal 
tissue [Casey et al. 1983].  High amounts of 21-hydroxypregnenolone have been found in 
newborns with a deficiency of the adrenal steroid 21-hydroxylase [Shackleton et al. 1987].  
Although steroid 21-hydroxylase activity in the rat and mouse kidney has recently been 
associated with the presence of genuine CYP21 mRNA [Lajic et al. 1995], several human 
tissues capable of steroid 21-hydroxylation do not contain CYP21 mRNA [Voutilainen and 
Miller 1986; Mellon and Miller 1989].  Peripheral conversion of progesterone to 
deoxycorticosterone is only between 0.2 % and 3 % [Winkel et al. 1980; Antonipillai et al. 
1983; Speiser et al. 1991], which makes entry of circulating deoxycorticosterone into the 
(relatively small) adrenal cortex followed by resumption of the normal biosynthetic pathway 
most unlikely. 
The involvement of other organs than the adrenal in aldosterone formation provides a more 
plausible hypothesis.  Lewicka et al. [1987] have demonstrated enhanced production of 21-
deoxyaldosterone by patients with steroid 21-hydroxylase deficiency.  Aldosterone can be 
synthesised from this steroid by a single enzymatic step, which may be mediated by a non-
adrenal enzyme.  Low sodium concentrations, comparable to those initially present in our 
patients, enhance 21-deoxyaldosterone synthesis in rat adrenal tissue [Lewicka et al. 1990].  
Angiotensin II also stimulates 21-deoxyaldosterone synthesis [Abdelhamid et al. 1994].  This 
is in agreement with our finding that when therapy had resulted in normalisation of sodium 
levels and reduction of PRA, aldosterone could no longer be detected (table 1). 
In this model, the renin-angiotensin system influences peripheral aldosterone secretion in an 
indirect way, by controlling adrenal precursor synthesis.  This might contribute to the poor 
correlation of PRA to urinary aldosterone metabolites [Speiser et al. 1992]. 
Synthesis of significant amounts of cortisol, normally required in amounts 100 - 1,000 times 
larger than aldosterone, from circulating 21-deoxycortisol is improbable.  The normal pathway 
involves adrenal 17α-hydroxylase and 21-hydroxylase, both located in the microsomes of the 
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zona fasciculata.  It is unlikely that a peripheral mechanism could be equally efficient.  
Nevertheless, amounts equal to the aldosterone measured may be present but will go 
undetected by assays aimed at the much higher 'normal' levels. 
In conclusion, aldosterone but not cortisol is found in blood samples of some untreated 
paediatric salt-losing steroid 21-hydroxylase deficiency patients.  HPLC is valuable in 
analysing apparently controversial steroid profiles in such patients.  Although in some cases 
(patient B) there may be remaining activity of the defective CYP21 gene, in others (patient A) 
alternative mechanisms or enzymes must be considered. 
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Abstract 
Steroid 21-hydroxylase deficiency, the primary cause of congenital adrenal hyperplasia, is 
caused by defects of the CYP21 gene.  Mutation analysis of CYP21 plays a key role in the 
diagnosis of steroid 21-hydroxylase deficiency and in fundamental research of phenotype-
genotype relationship in this common inherited metabolic disease.  Contemporary PCR-based 
mutation detection protocols often depend on the assumption that no more than one CYP21 
gene is present on each chromosome 6.  We here describe three haplotypes with two CYP21 
genes on the same chromosome, with defects typical of salt-losing steroid 21-hydroxylase 
deficiency in one of those genes, but not necessarily in the other.  The frequency of these 
haplotypes in the general population is 6/365 (1.6 %), so they are not less frequent than other 
haplotypes that indeed carry steroid 21-hydroxylase deficiency.  Chromosomes that carry two 
CYP21 genes therefore represent a significant pitfall in the molecular diagnosis of steroid 
21-hydroxylase deficiency.  We recommend that whenever CYP21 mutation analysis of an 
individual who is not a known carrier of steroid 21-hydroxylase deficiency is performed, the 
overall structure of the CYP21/C4 region (RCCX area) is determined to avoid erroneous 
assignment of carrier status. 
 
Introduction 
The CYP21 gene, which encodes the adrenocortical enzyme steroid 21-hydroxylase, lies in the 
central (class III) region of the human Major Histocompatibility Complex (MHC) on the short 
arm of chromosome 6 (6p21.3).  Together with the adjacent complement C4 gene and 
truncated parts of the RP1 and TNXB genes, CYP21 constitutes a highly variable stretch of 
DNA known as the RCCX module [Blanchong et al. 2000].  All chromosomes 6 so far studied 
carry one to four RCCX modules, each of which may be either 27 or 33 kb in size depending 
on the presence or absence of an intronic sequence in the C4 gene [Dangel et al. 1994].  The 
active CYP21 gene lies on the centromeric module next to the full-size TNXB (tenascin-X) 
gene, while any other RCCX modules on the same chromosome usually carry the pseudogene 
CYP21P which shares 98 % sequence homology with CYP21 [Higashi et al. 1986] but 
contains several deleterious mutations. 
Defectiveness of CYP21 results in steroid 21-hydroxylase deficiency, the foremost cause of 
congenital adrenal hyperplasia (CAH), an inborn error of metabolism affecting 1:10,000 to 
1:15,000 newborns in most populations.  In steroid 21-hydroxylase deficiency patients, 
impaired cortisol synthesis leads to ACTH-induced hyperplasia of the adrenal cortex, while 
accumulating cortisol precursors are converted to androgens.  If the enzyme block is complete, 
synthesis of aldosterone (which is required in far lower quantities than cortisol) also fails.  
Untreated patients with a severe defect may therefore succumb to a neonatal salt-losing crisis, 
and all patients with this 'classical' form of steroid 21-hydroxylase deficiency have signs of 
virilisation and abnormal growth patterns due to the androgen excess [Morel and Miller 1991; 
Wedell 1998; White and Speiser 2000]. 
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Molecular analysis of CYP21 defects is the key to understanding the aetiology of steroid 
21-hydroxylase deficiency, both in basic science and in clinical diagnosis.  In most Caucasian 
populations, about one-third of the chromosomes carrying 21-hydroxylase deficiency have a 
CYP21P-like pseudogene in place of the regular CYP21 gene in the centromeric RCCX 
module.  Such configurations are often referred to as 'CYP21 deletions' on monomodular 
chromosomes and 'large-scale gene conversions of CYP21 to CYP21P' on bimodular 
chromosomes, although the molecular mechanisms causing these defects appear to be similar.  
The remaining two-thirds of all CYP21 defects is caused by one or more small changes in 
CYP21 that are associated with varying degrees of enzyme deficiency and clinical defects 
[Speiser et al. 1992; Wedell 1998; White and Speiser 2000]. 
The overall layout of the RCCX area can be established by restriction enzyme mapping, a 
method which has often been used to distinguish the above-mentioned categories of CYP21 
defects in steroid 21-hydroxylase deficiency patients [White et al. 1988; Collier et al. 1989; 
Dunham et al. 1989; Morel et al. 1989].  If a CYP21 gene is present, further mutation analysis 
is usually done by any one of a steadily growing number of PCR-based approaches that rely 
on sequence differences between CYP21 and CYP21P [White and Speiser 2000].  Since the 
restriction mapping method, which requires Southern blotting and hybridisation, is rather 
laborious, it has gradually gone out of fashion for the detection of presence or absence of the 
CYP21 gene, and recent studies rely on PCR for this purpose as well.  Thus, mutation analysis 
is often based on the assumption that each chromosome 6 carries at most one CYP21 gene.  
While that assumption holds true for the large majority of all 21-hydroxylase deficiency 
patients and controls investigated to date, exceptions have been reported [Schneider 1990; 
Haglund-Stengler et al. 1991; Koppens et al. 1992; Wedell et al. 1994; Bachega et al. 1999]. 
We here describe four unusual CYP21/C4 haplotypes, three of which carry two CYP21-like 
genes.  Because the second CYP21-like gene on these chromosomes carries one or more 
defects, non-carrier individuals from the general population who have such a haplotype would 
have been mistyped as steroid 21-hydroxylase deficiency heterozygotes had an entirely PCR-
base approach been used.  This CYP21 duplication was found in six out of 365 independent 
haplotypes.  This phenomenon may complicate mutation analysis in family members of CAH 
patients and it is a definite pitfall in the detection of unrelated heterozygotes because in the 
general population, the haplotypes described here are not less common than the mutations 
associated with classical congenital adrenal hyperplasia. 
 
Methods 
Haplotyping 
Common CYP21/CYP21P haplotypes in the general population are: CYP21-CYP21P 
('standard'), CYP21 ('CYP21P deletion') and CYP21-CYP21P-CYP21P ('CYP21P 
duplication'), with CYP21P ('CYP21 deletion') and CYP21P-CYP21P ('CYP21 large-scale 
gene conversion') as additional possibilities in carriers of steroid 21-hydroxylase deficiency 
[Morel et al. 1989].  In a previous study, we used TaqI and BglII restriction analysis [White et 
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al. 1988] and CYP21 [White et al. 1985] and C4 [Belt et al. 1984] cDNA probes to analyse the 
haplotypes in a group of families with 21-hydroxylase deficiency patients and healthy controls 
in the Netherlands [Koppens et al. 1992].  We since expanded this group to 43 families and 
141 controls, found several banding patterns that could not be explained in terms of the five 
haplotypes mentioned above and selected these for further analysis. 
Long-range restriction mapping 
Genomic DNA had been prepared earlier for CYP21/C4 haplotyping [Koppens et al. 1992], 
using a conventional method [Wyman and White 1980] not aimed at conserving large DNA 
fragments.  Nevertheless, careful handling of the available DNA (stored at -20 °C in 10 µg 
aliquots of varying volume) by using wide-bore tips and avoiding repeated freeze-thaw cycles, 
permitted its use in long-range restriction mapping.  10 µg of DNA was digested overnight 
with 50 units of SacII (Eurogentec, Seraing, Belgium) in a total volume of 250 µl at 37 °C.  
The next day, the volume was reduced to approximately 90 µl by evaporation at 65 °C, after 
which 30 µl of molten 2 % low-melting agarose (FMC Bioproducts, Rockland ME, USA) was 
added.  This mixture was allowed to solidify in the slots of a 10-slot 1 % agarose gel in a 
CHEF-DR III electrophoresis system (Bio-Rad, Hercules CA, USA).  The gel was equilibrated 
in the electrophoresis buffer (0.5 x TBE with 0.2 µg/ml ethidium bromide) for one hour, after 
which pulsed-field gel electrophoresis was performed for 18 hours at 6 V/cm with an included 
angle of 120 ° and a switch time linearly increasing from 2 to 17 seconds, at 14 °C.  Southern 
blotting and hybridisation were the same as described before [Koppens et al. 1992]. 
CYP21 mutation analysis 
CYP21/CYP21P mutation analysis by specific amplification of three sections of each gene was 
performed as described earlier [Koppens et al. 2000].  In addition, a smaller part of CYP21 
(from the third to the sixth exon) was amplified to check whether the mutations Ile172→Asn 
and IleValGluMet-236→AsnGluGluLys, which were found on the same chromosome by 
segregation analysis, were in the same CYP21 gene.  This was done with the forward primer 
TCCTTGGGAGACTACTCCCT (CYP21, exon 3) and the reverse primers 
TGCCTCAGCTGCATCTCCAC (IleValGluMet-236) and TGCCTCAGCTGCTTCTCCTC 
(AsnGluGluLys-236); 30 cycles of PCR at an annealing temperature of 57 °C using 1 unit of 
GoldStar DNA polymerase (Eurogentec, Seraing, Belgium) in a final volume of 40 µl in the 
presence of 1 % formamide and 1.25 mM MgCl2.  Nucleotide and amino acid numbering is 
according to Higashi et al. [1986]. 
TNXB and XA analysis 
The tenascin-X (TNXB) gene differs from the truncated XA pseudogene by a 120 bp deletion 
[Gitelman et al. 1992].  To determine the extent of any unequal crossover or gene conversion 
that may have created the unusual haplotypes described here, we amplified an approximately 
2.7 kb section of either gene using specific primers that lie beyond the RCCX module's 
duplication boundary combined with a non-specific primer between the 3' part of CYP21 or 
CYP21P and the location of the 120 bp deletion (details to be published elsewhere). 
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Results 
Restriction mapping 
Characteristic TaqI restriction patterns are shown in fig. 1.  Since the band intensities obtained 
after hybridisation to the CYP21 and C4 probes did not match the common haplotypes, we 
used SacII digestion and pulsed field gel electrophoresis [Carroll et al. 1989; Dunham et al. 
1989] to determine the size of the entire RCCX area on each chromosome (see fig. 2).  
Combining these banding patterns and sizes with family study data where available (details 
not shown), the results were interpreted as follows: 
- lane 1: four RCCX modules on one chromosome, with one CYP21 gene and three 
CYP21P pseudogenes and four long C4 genes (haplotype H1 in fig. 3); on the other 
chromosome, a standard bimodular arrangement (haplotype A2 [Koppens et al. 1992]); 
- lane 2: three RCCX modules on one chromosome, with two CYP21 genes and one 
CYP21P pseudogene and three short C4 genes (haplotype F2); on the other chromosome, 
a monomodular arrangement with a CYP21 gene and a short C4 gene (haplotype B2); 
- lane 3 and 4: as lane 2, but one long and two short C4 genes on the trimodular 
chromosome (haplotype F1); on the other chromosome, a bimodular (haplotype A1) and a 
monomodular (haplotype B1) arrangement, respectively; 
- lane 5: a bimodular chromosome with two CYP21 genes and no CYP21P gene (haplotype 
G1); on the other chromosome, a bimodular (haplotype A1) arrangement. 
 
 
 
 
 
P1 1 2 3 4 5
7+6+5.4
7+6+5.4
6.4+5.4
7+5.4
7+5.4
7+6
3.7
3.2
2.5
2.4
7
6.4
6
5.4
Fig. 1. TaqI digested genomic DNA 
separated by agarose gel 
electrophoresis and hybridised to a 
mix of a CYP21 and C4 cDNA 
probe.  P1: person with two 
bimodular chromosomes, one with 
two long C4 genes and one with a 
short and a long C4 gene;  1-5: 
persons with an unusual RCCX 
arrangement on one chromosome 
(see text for interpretation).  Right: 
CYP21 (3.7/3.2) and TNX (2.5/2.4) 
fragments; the C4 fragment sizes 
are at the bottom of each lane. 
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CYP21 mutation analysis 
The haplotypes with two CYP21 genes and one CYP21P gene were found in three controls 
(haplotype F1, twice; F2, once) and in one 21-hydroxylase deficiency patient.  They all carried 
the Gln318→stop mutation in one of the two CYP21 genes.  No other mutations were found in 
the controls (all of them also had Gln318).  The 21-hydroxylase deficiency haplotype 
(haplotype F2) had the intron 2 splice mutation in addition. 
The haplotypes with two CYP21 genes and no CYP21P genes (haplotype G1) were found in 
three controls.  All these chromosomes carried Ile172→Asn and IleValGluMet→ 
AsnGluGluLys.  A separate PCR from exon 3 to exon 6 confirmed that the two mutations 
were in the same CYP21 gene: the allele-specific oligonucleotide detecting Asn172 hybridised 
only to the product of the PCR that used the AsnGluGluLys oligonucleotide as a reverse 
primer.  Still, these haplotypes were not completely identical in all three persons: one person 
had only the 'A' variant at nucleotide 655, one had 'C' only, and one had both 'A' and 'C'. 
The number of independent haplotypes not carrying steroid 21-hydroxylase deficiency in our 
study was 365; the total for haplotypes with two CYP21 genes (F1, F2 and G1) among these 
was 6, or 1.6 %; 95 % confidence interval 0.7-3.3 % [Linder 1960]. 
The chromosome with four RCCX modules was found in the mother of a CAH patient and 
does not carry 21-hydroxylase deficiency.  As expected, none of the common mutations were 
found in the CYP21 gene on this chromosome. 
TNXB / XA characteristics 
The 120 bp deletion was found in all RCCX modules except in the most centromeric one in 
each haplotype, so only the genuine full-size TNXB gene contained the extra 120 bp.
P1
37+43
C2 1 2 3 4 5
103+109
70+142
37+90
76+96
43+96
76+76
Fig. 2.  SacII digested genomic DNA 
separated by pulsed field gel 
electrophoresis and hybridised to a mix 
of a CYP21 and C4 cDNA probe.  P2: 
person with two monomodular 
chromosomes; P3: person with two 
trimodular chromosomes; 1-5: persons 
with an unusual RCCX arrangement on 
one chromosome (see text for 
interpretation).  The fragment sizes in kb 
are at the bottom of each lane. 
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Discussion 
We used a combination of restriction mapping and PCR-based mutation analysis to 
characterise four uncommon variants of the RCCX region found in a population of steroid 
21-hydroxylase deficiency patients and controls from the Netherlands (see fig. 3). 
Two haplotypes (F1 and F2 in our earlier report [Koppens et al. 1992]) each carry three 
RCCX modules and two CYP21 genes.  Haplotype F1 is the same as haplotype H in the report 
of Schneider [1990] and haplotype 9 in the report of Haglund-Stengler et al. [1991].  Each of 
the haplotypes F1 and F2 has the Gln318→stop mutation in one of the CYP21 genes, but not 
all of them carry a defect in the other CYP21 gene.  Haplotype F1 has been found in three 
Swedish patients who also carried the codon 318 nonsense mutation, plus the intron 2 splice 
mutation in the other CYP21 gene [Wedell et al. 1994].  We also found the intron 2 splice 
mutation as an additional defect in one patient, but in haplotype F2 rather than F1.  Haplotype 
F2, which has not been described before in the literature, has the rare feature of lacking a long 
C4 gene despite being multimodular.  Bimodular [Hillarby et al. 1990; Schneider 1990] and 
trimodular [Weg-Remers et al. 1997] haplotypes without a long C4 gene have been found 
before, but their frequency is very low in Caucasians. 
Haplotype G1 has two CYP21 genes and no CYP21P genes and is the same as haplotype 10 in 
the report of Haglund-Stengler et al. [1991]; it has also been mentioned by Sinnott et al. 
[1991].  We here demonstrate that one of the CYP21 genes on such chromosomes has two 
contiguous mutations (Ile172→Asn and IleValGluMet236→AsnGluGluLys) and that not all 
haplotypes G1 are the same. 
Chromosomes with more than three RCCX module are quite rare.  Haplotype H1 is 
characterised by three CYP21P pseudogenes and one functional CYP21 gene.  The only 
previously described chromosome with four RCCX modules carried only CYP21P genes and 
was found in a steroid 21-hydroxylase patient who was homozygous for it due to 
consanguinity [Collier et al. 1989]. 
In total, we found six chromosomes carrying two CYP21 genes each in our control group of 
(currently) 145 persons and three more such chromosomes in a group of 45 families with 
steroid 21-hydroxylase deficiency patients.  All these chromosomes carry one CYP21 gene 
with a genetic defect that would have caused classical steroid 21-hydroxylase deficiency in the 
absence of a second, functional, CYP21 gene.  This has significant implications for PCR-based 
carrier detection in the general population: without knowledge of the overall structure of their 
RCCX regions, these individuals could easily have been mistaken for carriers of salt-losing 
steroid 21-hydroxylase deficiency.  This diagnostic pitfall is likely to play a role in other 
populations too, since CYP21 duplications have been found in several countries, sometimes 
with a frequency equal to or above the normal carrier rate of 21-hydroxylase deficiency  
[Haglund-Stengler et al. 1991; Koppens et al. 1992; Wedell et al. 1994; Bachega et al. 1999].  
Mutation analysis of spouses of known carriers for purposes of genetic counselling should 
take special account of this possibility. 
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In conclusion, we have characterised four unusual variants of the RCCX module.  Three of 
these variants carry two CYP21 genes, and they are not less frequent than steroid 
21-hydroxylase deficiency alleles.  We therefore recommend that whenever a CYP21 defect is 
found in an individual not otherwise known as a carrier of steroid 21-hydroxylase deficiency, 
the overall structure of the RCCX module is ascertained to avoid erroneous assignment of 
carrier status that could otherwise result from PCR-based mutation analysis. 
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8.1. Mutational mechanisms causing CYP21 defects 
What has mutated? 
Mutation means change, so the study of disease-causing mutations finds its basis in the 
assumption that certain states are 'normal', and that mutations may change those states to 
'defective'.  Understanding the mutational mechanisms that ultimately lead to steroid 
21-hydroxylase deficiency therefore starts with charting the differences between normal and 
defective CYP21 genes and haplotypes.  For clarity, mutations will be described here relative 
to a 'standard' haplotype with a repetitive layout consisting of two tandemly arranged RCCX 
modules (schematically shown below in a 5' to 3' orientation relative to the transcription of 
CYP21; C4, TNX and RP1 have been omitted): 
 
 
CYP21P differs from CYP21 by a number of deleterious mutations rendering it a pseudogene 
and by several neutral polymorphisms, the most characteristic of which associates CYP21P 
with a 3.7 kb TaqI fragment as opposed to 3.2 kb for CYP21 [Higashi et al. 1986; White et al. 
1986; Rodrigues et al. 1987].  With a frequency of 40-70 %, this haplotype is the most 
common in all populations studied (see table 4 in Chapter 2.1 and table 5 in Chapter 2.2). 
 
Categories of defects 
Early haplotyping studies that predate CYP21 mutation analysis [White et al. 1985; Carroll et 
al. 1985; Donohoue et al. 1986a; Donohoue et al. 1986b; Werkmeister et al. 1986] found three 
categories of defects on the chromosomes of steroid 21-hydroxylase deficiency patients, 
which by comparison to the standard haplotype were named: 
- CYP21 gene deletion: 
 
 
- CYP21 gene conversion: 
 
 
CYP21P CYP21
telomere centromere
5' 5'3' 3'
CYP21P
CYP21P CYP21P
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- and, by exclusion, CYP21 'small' mutation: 
 
 
Various other configurations were also found (CYP21P deletion, CYP21P duplication), but 
these entailed only differences in the copy number of the CYP21P pseudogene and the size of 
the C4 genes (not shown) and were categorised 'CYP21 small mutation' if they carried steroid 
21-hydroxylase deficiency. 
This approach was based on the presence or absence of a TaqI restriction site normally found 
in the 5' flanking sequence of CYP21P only.  This marker has since proved its value as a very 
reliable identifier of pseudogene-like structures and hence, defectiveness.  The above-
mentioned categorisation still persists and is used even by modern mutation analysis studies, 
although the distinction between the categories is often made by a PCR-based method.  While 
there is nothing wrong with this categorisation from the viewpoint of establishment of 
mutation frequencies in different populations (see table 5 in Chapter 1), later studies have 
shown that the names originally assigned to the three categories do not completely match the 
genetic mechanisms that created them [White et al. 1988; Higashi et al. 1988; Donohoue et al. 
1989; Sinnott et al. 1990; Donohoue et al. 1995; Yang et al. 1999; Chapters 3-5].  This has 
resulted in a somewhat confusing terminology to describe different configurations and defects.  
As discussed in the following three paragraphs, there are indeed three categories, but they do 
not necessarily match the three possibilities mentioned above on a 1-to-1 basis. 
 
Sequence transfer by unequal crossover 
Meiotic unequal crossover between homologous chromosomes occurs when similar sequences 
that are part of different genes align and a crossover transfers the stretch of DNA separating 
the misaligned gene from one chromosome to the other.  Differences in RCCX modularity 
apparently enhance the propensity to misalign [Sinnott et al. 1990, Yang et al. 1999], but 
unequal crossover can also occur between two 'standard' chromosomes [Chapter 4].  
Depending on the original RCCX arrangement on each chromosome, the crossover may give 
rise to new configurations with the same or a different number of modules than the original 
chromosomes.  As shown in fig. 1, this process of combined expansion and contraction can 
hypothetically generate all known CYP21 haplotypes.  Of course, many other crossover events 
than the examples shown are conceivable: fig. 1 is a simplification, providing a hypothetical 
origin for CYP21 haplotypes that have been defined on the basis of TaqI restriction analysis.  
In reality, the site of the crossover may vary and the high degree of similarity between RCCX 
modules makes it uncertain whether crossovers are limited to specific regions [Donohoue et 
al. 1989; Chu et al. 1992; Donohoue et al. 1995; Burch et al. 1997; Levo and Partanen 1997; 
Rupert et al. 1999; Yang et al. 1999; l'Allemand et al. 2000; Chapters 3-5] or whether they 
can occur anywhere within the approximately 30 kb region involved. 
CYP21P CYP21
   Fi
g.
 1
.  
P
ut
at
iv
e 
cr
os
so
ve
r 
ev
en
ts
 g
en
er
at
in
g 
va
ria
bl
e 
m
od
ul
ar
ity
 o
f t
he
 R
C
C
X
 m
od
ul
e 
an
d 
he
nc
e,
 d
iff
er
en
t C
Y
P
21
 h
ap
lo
ty
pe
s.
  
S
om
e 
of
 th
es
e 
po
ss
ib
ili
tie
s 
ha
ve
 
ac
tu
al
ly
 b
ee
n 
ob
se
rv
ed
 a
s 
de
 n
ov
o 
m
ut
at
io
ns
 i
n 
st
er
oi
d 
21
-h
yd
ro
xy
la
se
 d
ef
ic
ie
nc
y 
pa
tie
nt
s 
[S
in
no
tt 
et
 a
l. 
19
90
; 
C
ha
pt
er
 4
], 
th
e 
ot
he
rs
 a
re
 h
yp
ot
he
tic
al
. 
 T
he
 
ha
pl
ot
yp
e 
de
si
gn
at
io
ns
 (A
-H
) a
re
 d
ef
in
ed
 in
 C
ha
pt
er
 2
.  
Th
e 
da
sh
ed
 li
ne
s 
co
nn
ec
tin
g 
ea
ch
 s
et
 o
f c
hr
om
os
om
es
 s
ho
w
n 
on
 th
e 
le
ft 
ha
nd
 s
id
e 
of
 th
e 
fig
ur
e 
in
di
ca
te
 th
e 
cr
os
so
ve
r s
ite
.  
A B
CY
P2
1P
CY
P2
1
A A A C A C
H
A A
BG DEC E FFB
Chapter 8 
 
236
Examples of hybrid RCCX modules generated by crossovers occurring at different sites are 
given in fig. 7 in Chapter 1.  Focusing on CYP21 and CYP21P, some typical outcomes are: 
 
  
or: 
 
 
or: 
 
 
or: 
 
 
or: 
 
 
Clearly, not each unequal crossover necessarily contributes to steroid 21-hydroxylase 
deficiency.  This concept provides an adequate explanation for the 'CYP21 gene deletions' and 
'CYP21 gene conversions' mentioned above.  The notion that these configurations represent 
different outcomes of essentially the same process, effectively unites the first two of the 
original categories.  Unequal crossover was early recognised as the mechanism for 30 kb 
deletion in the C4/CYP21 region [Carroll et al. 1985], and detailed comparison of the 
centromeric RCCX modules of haplotypes previously designated 'deletion' and 'conversion' 
later showed a high degree of similarity [Chapters 3 and 5].  Since there is no reason to 
propose different mechanisms for equal outcomes, the term 'conversion' should be avoided in 
this context [Chapter 5], especially since it may cause confusion with the mechanism that 
causes 'smaller' mutations of CYP21. 
Defects attributed to past meiotic unequal crossover account for 20-40 % of the steroid 
21-hydroxylase deficiency alleles in most populations studied. 
 
CYP21P hybrid
hybrid
hybrid
hybrid
CYP21
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Sequence copying by gene conversion 
Gene conversion is a non-reciprocal transfer of sequences of near-identity and is believed to 
be responsible for the large majority of CYP21 defects other than those caused by unequal 
crossover.  Introduction of CYP21P-like defects into CYP21 by putative gene conversion 
occurs primarily during mitosis [Tusié-Luna and White 1995].  This would seem to imply 
copying of a section of the CYP21P gene that lies on the same chromosome by means of sister 
chromatid interaction, but a comparison of homologous sequences in CYP21 and CYP21P 
suggests that the other (homologous) chromosome is involved in at least some of these 
conversions [Chapter 3.1].  Consistent with this finding, the preference for sister chromatid 
interaction in mitotic repair processes has been attributed to its proximity rather than to any 
mechanism excluding the other chromosome from conversion-like events [Johnson and Jasin 
2000]. 
Gene conversions in the MHC typically involve an area not larger than a few hundred bp 
[Kuhner et al. 1991; Bergström et al. 1998; Högstrand and Böhme 1999; Martinsohn et al. 
1999], a much smaller area than the entire 30 kb RCCX module exchanged by the large-scale 
unequal crossovers described above.  These small-scale gene conversions may therefore 
transfer individual defects of varying severity (as well as neutral polymorphisms) between 
CYP21P and CYP21: 
 
 
or: 
 
 
or: 
 
 
or: 
 
 
A gene conversion is assumed whenever comparison to the consensus sequences [Higashi et 
al. 1986; White et al. 1986; Rodrigues et al. 1987] shows that a CYP21P-like change is 
present in an otherwise (especially, TaqI restriction pattern-wise) CYP21-like gene, or vice 
CYP21P CYP21
CYP21P CYP21
CYP21P CYP21
CYP21P CYP21
Chapter 8 
 
238
versa.  Small-scale gene conversions transferring a mutation from CYP21P to CYP21 have 
attracted attention as the most common cause of CYP21 defects, but they may also involve 
neutral polymorphisms [Chapter 2.3], provide transfers in the opposite direction [Chapter 3.1], 
or change the flanking C4 or TNX genes. 
 
Old and new mutations 
Recombination has been extensively studied in yeast, where the possibilities to examine all 
products of crossing over or gene conversion and to artificially induce mutagenic DNA repair 
mechanisms provide excellent research opportunities.  Advances in PCR-based analysis 
methods have greatly contributed to our understanding of analogous processes in the 
mammalian MHC [Carrington 1999; Martinsohn et al. 1999; Jeffreys et al. 2001], but so far 
only one study directly comparing meiotic crossovers and mitotic conversions between CYP21 
and CYP21P has been done [Tusié-Luna and White 1995].  Therefore, assumptions about the 
causes of CYP21 defects are typically based on comparison of the mutated sequence to the 
CYP21 and CYP21P consensus sequence [Higashi et al. 1986; White et al. 1986; Rodrigues et 
al. 1987] or on relatively rare de novo events that have occurred in patients suffering from 
21-hydroxylase or complement C4 deficiency [Fasano et al. 1992; Chapter 4].  While firm 
evidence now supports de novo unequal crossover, gene conversion is still a more difficult 
process to understand.  It has been demonstrated that gene conversion can introduce CYP21P-
like sequences into CYP21 [Tusié-Luna and White 1995], but authors reporting on de novo 
small-scale mutations in 21-hydroxylase deficiency patients have been quick to attribute 
similar events to gene conversion without analysing the CYP21P genes that supposedly 
provided these altered sequences (see table 4 in Chapter 1).  Since CYP21P genes present in 
the general population are highly variable, especially in the 3' region [Helmberg et al. 1992a; 
Wedell and Luthman 1993a; Chapter 3.1], a complete analysis is necessary to distinguish gene 
conversion from unequal crossover.  Vice versa, a conversion involving the TaqI site in the 5' 
flank of CYP21P may resemble an unequal crossover with the crossover site in or near the 
first exon of CYP21; the difference can often be inferred from the composition of the adjacent 
C4 gene. 
Deducing mutational mechanisms from the analysis of existing defects is equally difficult: for 
example, 'mosaic genes' with multiple CYP21-CYP21P transitions can be explained by 
multiple independent conversion events, by a single complex 'patchwork' conversion [Jeffreys 
et al. 1999], or by a crossover with a non-standard CYP21P gene.  While the RCCX module 
provides an interesting model to study recombinational events in humans, a full understanding 
the intricacies of misalignment and sequence transfer in this region is still beyond the scope of 
present-day knowledge. 
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Mutations not related to CYP21P 
A small number (under 5 % in most populations) of all steroid 21-hydroxylase deficiency 
alleles are attributed to 'other' mutations: CYP21 defects that are not found in the consensus 
CYP21P sequence: 
 
 
The only mutation of this category found at a somewhat higher frequency is Pro453→Ser, 
typical of late-onset 21-hydroxylase deficiency [Helmberg et al. 1992b; Owerbach et al. 1992; 
Wedell et al. 1992; Chapter 3.2].  An overview of all CYP21 defects known to date is 
presented in table 3 in Chapter 1. 
 
8.2. Steroid 21-hydroxylase deficiency alleles in the population 
Classical congenital adrenal hyperplasia conveys a severe selective disadvantage 
Today's high standard of medical care allows patients with severe steroid 21-hydroxylase 
deficiency to live and thrive.  However, only a few decades ago the picture was quite different: 
salt-losing congenital adrenal hyperplasia was nearly always fatal [Iversen 1955].  In addition, 
reduced fertility is an issue even today in classical [Meyer-Bahlburg 1999; Jääskelainen et al. 
2000; Cabrera et al. 2001; Krone et al. 2001] and, to a lesser degree, in nonclassical patients 
[Morán et al. 2000].  This raises the question how steroid 21-hydroxylase deficiency alleles 
have persisted at the relatively high frequency of (approximately) 1 %. 
 
Ancestral haplotypes and heterozygosity 
Specific combinations of MHC alleles appear to be evolutionary conserved in certain 
populations [Degli-Esposti et al. 1992; Dawkins et al. 1999].  Although it is not known 
whether the HLA specificities carried by these 'ancestral' haplotypes confer an immunological 
advantage, association of steroid 21-hydroxylase deficiency alleles with such haplotypes may 
contribute to maintaining these alleles in the population.  It has been suggested that HLA 
specificities associated with the 21-hydroxylase deficiency allele found at high frequency in 
Yupik-speaking Inuit population of Alaska offer protection against Haemophilus influenzae 
type b infections [Petersen et al. 1984].  If the total number of MHC alleles in a population is 
limited, the benefit of HLA heterozygosity in pathogen resistance [Meyer and Thomson 2001] 
may counteract the disappearance of specific MHC alleles and at the same time maintain 
recessive defects associated with them.  In addition, a more vigorous cortisol response to 
ACTH in carriers of 21-hydroxylase deficiency than in controls has been observed [Witchel et 
al. 1997a].  The authors suggest that this constitutes a state of heightened resistance to 
CYP21P CYP21
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environmental stress and thus offers a selectional advantage to heterozygotes, but this 
interpretation is open to debate [Wilckens 1997; Witchel et al. 1997b]. 
 
Founder effects and de novo mutations 
The frequency of steroid 21-hydroxylase deficiency alleles varies between populations (see 
table 5 in Chapter 1).  Two well-known examples are the high frequency of classical 
21-hydroxylase deficiency in Yupik-speaking Inuits [Speiser et al. 1992] and of nonclassical 
21-hydroxylase deficiency in Ashkenazi Jews [Speiser et al. 1985, Zerah et al. 1990], each 
caused by a specific mutation and associated with specific HLA serotypes.  These phenomena 
are attributed to founder effects. 
The contribution of de novo mutations to the genetic defects in classical steroid 
21-hydroxylase deficiency has been estimated at 1-2 % [Speiser et al. 1992; Levo and 
Partanen 2001].  Assuming a carrier rate of 1:55 for classical 21-hydroxylase deficiency, this 
corresponds to a mutation frequency of 1:5500 to 1:2750.   De novo unequal crossovers and 
gene conversions have been tested in a 100 bp area of CYP21 and were found in frequencies 
of 1 in 105 to 106 and 1 in 103 to 105, respectively [Tusié-Luna and White 1995].  For the 
crossovers, this corresponds to a mutation frequency of 1:2,000 to 1:20,000 in the 
approximately 5 kb area where they can occur.  The only gene conversion tested was the 
common intron 2 splice mutation; a similar contribution may be expected from other 
mutations. 
Thus, de novo mutations appear to play a significant role in maintaining the relatively high 
frequency of steroid 21-hydroxylase deficiency alleles.  Improved medical care may tilt the 
balance between de novo mutations and alleles lost to selection that apparently existed 
throughout history, but the above numbers clearly indicate that no significant addition to the 
current carrier rate is to be expected from de novo mutations within the foreseeable future. 
 
Allele frequencies and genetic mechanisms 
It is an appealing thought that population genetics, mutational mechanisms and disease 
severity may each have contributed to the frequencies of different steroid 21-hydroxylase 
deficiency alleles in different ways.  Apart from founder effects and selectional advantages 
conferred by linked genes see above), de novo mutations may contribute to the relatively high 
allele frequencies of some severe defects that constitute a large selectional disadvantage as 
compared to milder defects. 
Chromosomes without a CYP21 gene have been observed at high frequencies (30-45 %) in 
steroid 21-hydroxylase patients from Northern Europe (for references, see table 5 in Chapter 
1, table 4 in Chapter 2.1 and table 5 in Chapter 2.2).  De novo unequal crossovers involving 
chromosomes with a single RCCX module [Sinnott et al. 1990; Yang et al. 1999] may have 
contributed to this high frequency because they necessarily misalign to bimodular 
chromosomes during meiosis (see fig. 7 in Chapter 1).  The ancestral haplotype HLA-
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A1,B8,DR3 [Tokunaga et al. 1988; Zhang et al. 1990; Price et al. 1999] accounts for many of 
these monomodular chromosomes, since its frequency in the general population is as high as 
13 % in Great Britain [Davidson et al. 1988] and 24 % in Ireland [T. Barnes, quoted by 
Sinnott et al. 1990].  For the Netherlands, the phenotype frequency of HLA-B8 is 0.228 
[Lagaay et al. 1991], matching an allele frequency of 0.12; the data from Great Britain show 
that the large majority of HLA-B8 haplotypes also carries DR3 [Davidson et al. 1988].  In 
contrast, the lower frequency of chromosomes lacking CYP21 in 21-hydroxylase deficiency 
patients from Japan is paralleled by a low frequency of HLA-A1,B8,DR3 in that country 
[Tokunaga et al. 1997]. 
Another example is the 'intron 2 splice' mutation, the most common defect in many 
populations (see table 5 in Chapter 1).  Intron 2 is a region of high sequence variability in both 
CYP21 and CYP21P [Killeen et al. 1998; Jiddou et al. 1999] and a neutral intron 2 
polymorphism typical of CYP21P was found at a low frequency in CYP21 genes [Chapter 
2.3].  This suggests a relatively high frequency of small-scale gene conversion in or around 
intron 2, and since the splice junction defect is found in all CYP21P genes [Chapter 3.1], a 
small-scale CYP21P to CYP21 gene conversion involving this site will always transfer this 
defect. 
Other severe defects (IleValGluMet-236→AsnGluGluLys, Gln318→stop and Arg356→Trp), 
are not as common as the two mentioned above (see table 5 in Chapter 1).  De novo mutations 
more often involve the region from intron 2 to intron 3 than the region from exon 6 to exon 8, 
which is the location of these mutations (see table 4 in Chapter 1).  This region may be less 
prone to gene conversion; also, many conversions at these sites would remain without effect 
since CYP21P does not always carry these defects [Helmberg et al. 1992a; Wedell and 
Luthman 1993a; Chapter 3.1]. 
The less severe defect Val281→Leu lies in the same area as the three severe mutations just 
mentioned.  Here, the contribution of de novo mutations to the allele frequency is probably 
less than in the case of the intron 2 splice mutation, but the selectional disadvantage of this 
nonclassical mutation is also smaller.  It has even been suggested that virilisation and early 
puberty caused by nonclassical steroid 21-hydroxylase deficiency may be a selectional 
advantage in dire circumstances [Hochberg 1995]. 
Defects that are not normally found in CYP21P typically have very low frequencies in CYP21, 
because their numbers are not augmented by gene conversion.  The only exception is 
Pro453→Ser, again a very mild mutation. 
Summarising, a picture emerges of severe CYP21 defects that confer a definite selectional 
disadvantage, but are more likely to arise as de novo mutations, versus mild CYP21 defects 
that spread more freely through the population.  This is in line with the rather similar 
worldwide mutational spectrum and incidence of classical steroid 21-hydroxylase deficiency 
(ranging between 1 in 10,000 to 1 in 20,000 in most populations) versus the much larger 
differences for nonclassical 21-hydroxylase deficiency [Speiser et al. 1985; Zerah et al. 1990; 
Chapter 3.2]. 
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8.3. Implications and perspectives of CYP21 mutation analysis 
Phenotype-genotype relationship 
Whereas 'genotype' of course refers to DNA sequence variability, 'phenotype' may be treated 
as a biochemical or a clinical entity, or both.  The possibility of different genetic defects in 
salt-losing and simple virilising steroid 21-hydroxylase deficiency was recognised early 
[Degenhart et al. 1965] and combinations of 'severe defect', 'mild defect' and 'normal' were 
used to categorise patients and heterozygotes [New et al. 1988] even before these defects 
could be identified at a molecular level.  Mutation analysis has since allowed definition of 26 
'mutation groups': combinations of two specific mutations in a patient.  Many of these groups 
show some degree of discordance between the observed phenotype and the phenotype 
predicted from the mildest of the two defects [Wilson et al. 1995]; a recent review [New 2001] 
mentions 85 mutation groups.  The authors of these reports emphasise the importance of this 
'mutation group' concept especially for directing prenatal treatment. 
In most patients, there is a good correlation between genotype and clinical phenotype [Speiser 
et al. 1992; Wilson et al. 1995; Krone et al. 2000].  Nevertheless, the severity of steroid 
21-hydroxylase deficiency shows a remarkable variation between individuals within the same 
mutation group [Wilson et al. 1995; Witchel et al. 1996b; Chapter 3.1], even between sibs 
[Bormann et al. 1992; Speiser et al. 1992; Wilson et al. 1995; Chin et al. 1998] and in the 
same patient over an extended period of time [Speiser et al. 1991; Kohn et al. 1995; Hoffman 
et al. 1996; Morán et al. 2000].  The most remarkable cases are those where mutation analysis 
indicates complete steroid 21-hydroxylase deficiency, but steroids normally requiring 
21-hydroxylation were still found [Speiser et al. 1991; Chapter 6].  Identification of alternative 
enzymes that may explain such findings has already been described as 'the next major advance 
in our understanding of the clinical biology of congenital adrenal hyperplasia due to 
21-hydroxylase deficiency' [Miller 1997].  The versatility of cytochrome P-450 enzymes 
[Negishi et al. 1996] makes them prime candidates to be involved in alternative pathways, 
notably in the unusual physiological circumstances provided by accumulating adrenocortical 
precursor steroids.  A further indication of the involvement of alternative synthetic routes are 
the genotype-phenotype discrepancies found in other defects of adrenocortical steroid 
biosynthesis [Zachmann 1995]. 
 
Mutation analysis in patients and their family members 
The complications in genotype-phenotype relationship notwithstanding, mutation analysis 
holds definite benefits to steroid 21-hydroxylase deficiency patients and their family members 
[Nordenström et al. 1999, Ritzén et al. 2000].  Checking for the most common mutations can 
conveniently be done by rapid detection methods such as allele-specific PCR [Wedell and 
Luthman 1993b], and these mutations account for approximately 90 % of all defects.  
Mutation analysis can take away any doubts by confirming a diagnosis based on 
17α-hydroxyprogesterone measurements, notably in cases where higher levels may be 
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attributable to other factors (such as stress, or an adenoma), or in premature infants where they 
are intrinsically high.  In patients where steroid replacement therapy has already been 
installed, a discrepancy between the established diagnosis and the CYP21 defects found would 
justify a re-evaluation of clinical chemical data that may result in alteration of the diagnosis 
and the treatment protocol. 
A lot of experience has been gained with prenatal treatment of 21-hydroxylase deficient 
patients [Forest et al. 1998; New 2001], although this remains a controversial issue [Miller 
1998].  Prenatal treatment is installed before the diagnosis can be made, and mutation analysis 
provides the earliest possibility to determine whether the foetus is affected and thus, whether 
treatment should be continued.  It has been advised that only centres able to perform rapid 
genotyping should be involved in prenatal treatment [Ritzén 1998]. 
In members of a patient's family, direct analysis of CYP21 defects provides the most reliable 
identification of heterozygote carriers for purposes of genetic counselling, since it avoids 
interpretation problems due to recombination that may occur when flanking markers are used.  
Knowledge of the carried mutation is especially relevant to family members of patients with 
milder forms of steroid 21-hydroxylase deficiency.  These patients are often compound 
heterozygotes with mutations of different severity, so sibs may be carriers of either a mild or a 
severe defect. 
Finally, since the clinical phenotype may vary considerably, mutation analysis may identify 
sibs (notably, older brothers) who carry the same defects as the index case, or even an 
unsuspected different defect [Witchel et al. 1996a; Oriola and Pavia 1997], but have so far not 
presented with clinical signs of congenital adrenal hyperplasia.  This may justify a clinical 
(re-)examination of such sibs. 
 
Mutation analysis in the general population 
Mutation detection in unrelated individuals is more difficult due to the variable nature of the 
RCCX module.  Routine PCR-based analysis typically produces false-negatives in carriers 
with a heterozygous CYP21 deletion [Ritzén et al. 2000] and false-positives in case of a 
heterozygous CYP21 duplication [Chapter 7].  To avoid such pitfalls, the overall genetic 
structure of the RCCX module should be charted by means of, for example, restriction 
analysis of genomic DNA. 
When common CYP21 defects have been reliably ruled out in a person without a family 
history of steroid 21-hydroxylase deficiency, the availability of allele frequencies in a typical 
patient group and in the general population [Chapter 3] allows an estimate of the remaining 
chance that the person in question is still a carrier.  This falls short of 'absolute' certainty, but 
in view of the frequent occurrence of de novo mutations (see above), the possibility of 
transmitting steroid 21-hydroxylase deficiency to one's children cannot be ruled out even by 
exhaustive mutation searching. 
Molecular genetic research may yet provide an answer to the question whether some persons 
are especially susceptible to de novo mutations in this region.  As argued before, misalignment 
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between CYP21 and CYP21P is more likely to occur when the modularity of the RCCX area 
differs on each chromosome.  In addition, subtle sequence variations that influence the RCCX 
mutation rate may be identified, by analogy to the small changes that have been found to exert 
a profound influence on minisatellite instability [Jeffreys et al. 1999]. 
Mass screening of CYP21 mutations in the general population is not feasible at present.  
Therefore, case survey and neonatal screening programmes will remain the key to early 
detection of at-risk children.  Nevertheless, ongoing advances in DNA technology may make 
mutation analysis replace 17α-hydroxyprogesterone measurement as the method of choice for 
this purpose within the foreseeable future.  The authors of a recent large genotyping study 
[Fitness et al. 1999] discussed several methods to make routine DNA analysis in population 
screening programmes more rapid and cost-effective.  CYP21 genotyping has already been 
used to confirm screening results in preterm infants [Nordenström et al. 2001].  Mutation 
analysis will also improve the detection of  patients with nonclassical steroid 21-hydroxylase 
deficiency, who may escape detection by current screening programmes [Tajima et al. 1997].  
Inevitably, implementing mutation analysis will lead to the identification of not only steroid 
21-hydroxylase deficiency patients, but also many heterozygous carriers of the disease, so the 
ethical implications of such a change need to be carefully considered. 
 
Future developments: a speculation 
For all the benefits that DNA analysis already offers to basic science and clinical diagnosis, 
we only begin to understand the impact of mutations on the functioning of enzymes such as 
steroid 21-hydroxylase in vivo.  Nobody knows the treatment protocols of the future, but since 
the CYP21 defects hitherto discovered affect such various aspects of enzymatic function as 
membrane attachment, haem group integration, cytochrome P-450 reductase interaction and 
enzyme stability, it may one day seem less than obvious to continue the current practice of 
treating these different defects in the same way. 
Gene therapy of steroid 21-hydroxylase deficiency has met with success in mouse models 
[Gotoh et al. 1994; Tajima et al. 1999], but considering the difficulties of mimicking the 
subtle regulatory mechanism of the hypothalamic-pituitary-adrenal axis, its application in 
humans does not seem imminent [White 2001]. 
Finally, basic genomic research in this field is also far from completed: the intricacies of the 
genetic mechanisms causing CYP21 and RCCX variability are still far from clear.  The 
complexity of this highly variable section of the central MHC makes it as challenging a 
subject as ever to investigators of human evolution. 
A quote from a 1987 Lancet editorial reads: 'Nothing in genetics is as straightforward as it 
seems at first sight, and this is certainly true of 21-hydroxylase deficiency' [Lancet 1987; ii: 
663].  This seems every bit as true today as it was 15 years ago. 
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9.1. Summary 
 
The human adrenal cortex synthesises three main classes of steroids from cholesterol: 
mineralocorticoids, glucocorticoids, and (pre-)androgens.  Aldosterone, the main 
mineralocorticoid, contributes to the regulation of plasma sodium levels, primarily by 
stimulating renal salt resorption.  Cortisol, the main glucocorticoid, plays a key role in the 
body's response to stress: it influences the metabolism of both lipids and carbohydrates, has an 
anti-inflammatory effect and functions in many other physiological processes.  Pre-androgens 
secreted by the adrenal have a limited biological activity, but they are converted peripherally 
to the powerful androgen testosterone. 
Three biosynthetic pathways are active in distinct parts of the adrenal cortex to produce these 
steroids.  Two of these pathways, those producing aldosterone and cortisol, require an 
enzymatic conversion step catalysed by steroid 21-hydroxylase.  Deficiency of steroid 21-
hydroxylase occurs in approximately 1 in 10,000 to 1 in 15,000 newborn children around the 
world.  In its severe (classical) form, lack of cortisol continually stimulates the hypothalamic-
pituitary-adrenal axis, and the resulting high levels of plasma ACTH cause the symptom that 
gives this disease its name: congenital adrenal hyperplasia due to steroid 21-hydroxylase 
deficiency (other adrenocortical enzyme deficiencies cause under 10 % of all cases of 
congenital adrenal hyperplasia).  The hyperplastic adrenal produces excess amounts of pre-
androgens, which cause pre- and postnatal virilisation and initially, rapid growth with 
advanced bone age, but results in below-average final height.  If the defect is complete, lack of 
aldosterone causes urinary salt loss.  Untreated patients may succumb to dehydration 
combined with loss of sodium and electrolyte imbalance within the first weeks of life. 
Steroid 21-hydroxylase is encoded by the CYP21 gene, which lies near the gene encoding the 
fourth component of complement (C4) in the central (class III) region of the human major 
histocompatibility complex (MHC) on chromosome 6p21.31.  CYP21 is part of a 30 kb stretch 
of DNA known as the RCCX module after its constituent genes: (part of) RP-C4-CYP21-(part 
of) TNX.  Most chromosomes have two RCCX modules arranged in tandem, and the 
counterpart of CYP21 in the other module is CYP21P, a pseudogene which is 98 % 
homologous to CYP21 but inactive due to several deleterious mutations.  Steroid 21-
hydroxylase deficiency is caused by a defect in CYP21, and nearly all such defects are the 
result of some form of interaction that occurred between CYP21 and CYP21P during the 
course of evolution. 
Many alternatives to the 'standard' arrangement with two RCCX modules exist, and the first 
step towards understanding the origin of disease-causing mutations in this region is mapping 
these so-called 'haplotypes'.  Haplotyping, which is described in Chapter 2, is based on the 
analysis of characteristic restriction patterns that match various arrays of CYP21, CYP21P, C4, 
and TNX.  A combination of short-range and long-range mapping and segregation analysis in 
families of 21-hydroxylase deficiency patients, allowed the definition of about 15 distinct 
haplotypes, the frequencies of which vary between populations. 
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Haplotyping also provides a categorisation of CYP21 defects: as judged by haplotype analysis, 
about one-third of all steroid 21-hydroxylase deficiency alleles results from absence of the 
CYP21 gene.  Such chromosomes carry one or two RCCX modules with only CYP21P-like 
genes.  Unequal crossover during meiosis is the genetic mechanism that causes deletions of 
CYP21.  The high degree of similarity between RCCX modules promotes misalignment, as 
illustrated in Chapter 4: a de novo deletion had occurred in a patient's father, who thus 
transmitted this genetic defect without being a carrier himself.  The crossover site was mapped 
to the TNX gene, centromeric to CYP21. 
By comparison to the standard layout (one CYP21 gene and one CYP21P pseudogene), 
bimodular haplotypes with two CYP21P genes (carrying 21-hydroxylase deficiency) have 
been labelled 'large-scale gene conversion of CYP21 to CYP21P' (as opposed to monomodular 
'CYP21 deletion' chromosomes with one CYP21P gene).  However, the identification of each 
gene as either CYP21 or CYP21P by means of haplotyping is based on a very reliable but 
functionally indifferent marker: a single TaqI restriction site in the 5' flanking sequence of 
CYP21P only. A detailed comparison of haplotypes without CYP21 genes (Chapters 3 and 5) 
showed that two categories exist: CYP21P/CYP21 hybrids, with the putative crossover site in 
CYP21, and TNX hybrids, where CYP21 is completely missing and the crossover site lies 
within the TNX gene.  The hybrid TNX gene in the latter category carries an additional genetic 
defect:  tenascin-X deficiency, which in its homozygous state causes a variant of the Ehlers-
Danlos syndrome, a group of connective-tissue diseases.  The two categories are identical in 
monomodular and in bimodular chromosomes without a CYP21 gene, so we hypothesised that 
these hybrids were generated by similar genetic mechanism (unequal crossover) regardless the 
presence or absence of an additional RCCX module, and argued against the usage of the term 
'large-scale gene conversion' in this context (Chapter 5). 
Gene conversion does play a role in the origin of CYP21 defects, however.  In two-thirds of all 
steroid 21-hydroxylase deficiency alleles, CYP21 is present.  Chapter 3 contains a comparison 
of the disease-causing mutations in defective CYP21 genes to the variability of CYP21P 
pseudogenes.  CYP21 defects can be transferred from CYP21P by small-scale gene 
conversions covering at most a few hundred base pairs.  However, CYP21P is so variable 
(especially in its 3' section) that often, conclusions about the extension of small-scale gene 
conversions cannot be inferred from the mutations found in CYP21.  This notably applies to 
the 'mosaic' conversions with multiple apparent CYP21-CYP21P transitions that have been 
reported in the literature. 
As shown in Chapters 2 and 3, about 90 % of all deficiency alleles in salt-losing 21-
hydroxylase deficiency are the result of either a CYP21 deletion or a small-scale conversion 
that causes a CYP21P-like mutation in CYP21. 
Some steroid 21-hydroxylase defects are relatively mild and do not become manifest until 
puberty or adolescence.  The allele frequency of this 'nonclassical' form of 21-hydroxylase 
deficiency is very high (up to 20 %) in some populations.  However, a mutation analysis in a 
group of healthy controls (Chapter 3) demonstrated that the frequency of nonclassical 21-
hydroxylase deficiency alleles in the Netherlands is approximately 1 %. 
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In steroid 21-hydroxylase deficiency, the correlation between genotype and phenotype is good 
in most patients: a severe defect on both chromosomes nearly always causes salt loss.  The 
most severe defects are those that preclude any transcription of CYP21, or cause a structural 
distortion of steroid 21-hydroxylase that abolishes its enzymatic activity.  Surprisingly, two 
patients with such severe defects (described in Chapter 6) were able to synthesise significant 
amounts of aldosterone.  Presence of aldosterone in these patients' serum was confirmed by 
combining two analytical methods (HPLC and radioimmunoassay).  Peripheral aldosterone 
synthesis by other enzymes may be the cause of this peculiar phenomenon. 
For genetic analysis of CYP21 defects, it is often assumed that a chromosome either carries a 
CYP21 gene, or has a CYP21 deletion.  Chapter 7 demonstrates that this assumption is not 
without risk: chromosomes with two CYP21 genes in tandem are found in the general 
population at a frequency equal to or higher than steroid 21-hydroxylase deficiency alleles.  
Since one of the two CYP21 genes is defective on such chromosomes, PCR-based mutation 
analysis without haplotyping can lead to erroneous assignment of carrier status. 
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9.2. Samenvatting 
 
De bijnierschors van de mens zet cholesterol om in drie hoofdgroepen van steroïden: 
mineralocorticoïden, glucocorticoïden en (pre-)androgenen.  Aldosteron is het belangrijkste 
mineralocorticoïde: het draagt bij tot de regulatie van de natriumspiegels in het bloed, o.a. 
door de zoutresorptie door de nieren te stimuleren. Cortisol is het belangrijkste glucocorticoïde 
en speelt een belangrijke rol bij de reactie van het lichaam op stress: het beïnvloedt het 
koolhydraat- en het vetmetabolisme, onderdrukt ontstekingsreacties en heeft functies in vele 
andere fysiologische processen.  De pre-androgenen die door de bijnier geproduceerd worden 
hebben zelf een beperkte biologische activiteit, maar ze worden perifeer omgezet in het 
krachtige androgeen testosteron. 
Deze steroïden worden in drie verschillende compartimenten van de bijnier gesynthetiseerd 
via afzonderlijke routes.  Een enzymatische omzetting die door steroïd 21-hydroxylase 
gekatalyseerd wordt, maakt deel uit van twee van deze routes: de produktie van aldosterone en 
van cortisol.  Wereldwijd worden ongeveer 1:10000 à 1:12000 kinderen geboren met steroïd 
21-hydroxylase deficiëntie.  In de ernstige (klassieke) vorm van deze ziekte induceert de lage 
cortisolspiegel via de hypothalamus-hypofyse-as afscheiding van extra ACTH.  De permanent 
verhoogde ACTH-spiegel leidt weer tot het verschijnsel waar de ziekte haar naam aan 
ontleent: congenitale bijnierschorshyperplasie.  Steroïd 21-hydroxylase deficiëntie komt 
verreweg het meeste voor: deficiënties van andere bijnierschors-enzymen veroorzaken minder 
dan 10 % van de gevallen van congenitale bijnierschorshyperplasie.  De sterk in omvang 
toegenomen bijnier produceert dan grote hoeveelheden pre-androgenen, wat tot prenatale en 
postnatale virilisatie leidt, en aanvankelijk snelle groei met sterk voorlopende botleeftijd 
veroorzaakt, maar in relatief geringe eindlengte resulteert.  Bij volledige deficiëntie is ook 
geen aldosteron aanwezig, waardoor zoutverlies via de urine optreedt.  Onbehandelde 
patiënten kunnen hierdoor binnen enkele weken na de geboorte overlijden door ernstig 
natrium- en vochtverlies, gepaard gaande met andere electrolyt-afwijkingen. 
Het steroïd 21-hydroxylase-gen heet CYP21.  Dit gen ligt naast het gen voor de vierde 
component van het complement-systeem (C4) in het ‘major histocompatibility 
complex’(MHC) op chromosoom 6p21.31.  CYP21 maakt deel uit van een stuk DNA van 30 
kb dat bekend staat als de RCCX-module.  Vier genen geven de RCCX-module haar naam: 
(een deel van) RP1-C4-CYP21-(een deel van) TNX.  Op de meeste chromosomen liggen twee 
RCCX-modules naast elkaar.  Het equivalent van CYP21 in de ander module heet CYP21P, 
een pseudogen dat voor 98 % overeenkomt met CYP21 maar niet functioneert omdat het 
verschillende mutaties bevat.  Steroïd 21-hydroxylase deficiëntie wordt veroorzaakt door een 
defect in CYP21.  Zulke defecten zijn bijna altijd het gevolg van tijdens de evolutie 
opgetreden interactie tussen CYP21 en CYP21P. 
Er bestaan veel andere mogelijkheden dan de standaardconfiguratie met twee RCCX-modules.  
Om te begrijpen hoe de mutaties die tot 21-hydroxylase deficiëntie leiden ontstaan zijn, 
moeten eerst deze zogenaamde 'haplotypen' in kaart gebracht worden.  Haplotypering (zie 
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hoofdstuk 2) is gebaseerd op analyse van restrictiepatronen die karakteristiek zijn voor diverse 
configuraties van CYP21, CYP21P, C4 en TNX.  Ongeveer 15 verschillende haplotypen 
konden gedefinieerd worden door in families van patiënten met 21-hydroxylase deficiëntie een 
segregatieanalyse van restrictiepatronen uit te voeren. 
Haplotypering levert ook een indeling van defecten in CYP21 op: deze methode laat zien dat 
ongeveer een derde van alle deficiëntie-allelen veroorzaakt wordt door afwezigheid van het 
CYP21-gen.  Op zulke chromosomen zijn één of twee RCCX-modules aanwezig, steeds met 
alleen CYP21P-achtige genen.  Dergelijke deleties van CYP21 worden veroorzaakt door 
ongelijke crossing-over tijdens de meiose: omdat de RCCX-modules sterk op elkaar lijken 
kunnen ze 'verkeerd' naast elkaar gaan liggen.  Hoofdstuk 4 geeft een voorbeeld hiervan: een 
deletie van CYP21 was de novo opgetreden in de vader van een patiënt, die zodoende een 
defect erfde terwijl de vader zelf geen drager was.  Deze crossing-over was opgetreden in het 
TNX-gen, dat aan de centromere kant van CYP21 ligt. 
In vergelijking met de standaardconfiguratie (één CYP21-gen en één CYP21P-pseudogen) 
worden haplotypen met twee RCCX modules die allebei een CYP21P-gen bevatten (en dus 
21-hydroxylase deficiëntie dragen) vaak 'grootschalige genconversies van CYP21 naar 
CYP21P' genoemd (tegenover 'deleties van CYP21' voor haplotypen met één RCCX-module 
met een CYP21P-gen).  Maar de genen worden alleen als CYP21 of als CYP21P 
geïdentificeerd op grond van één betrouwbare, maar functioneel neutrale, marker: een TaqI 
restrictiesite die alleen voorkomt in de flankerende sequentie aan de 5' kant van CYP21P.  Een 
gedetailleerde vergelijking van haplotypen zonder CYP21-genen (hoofdstukken 3 en 5) toonde 
aan dat er twee categorieën zijn: CYP21/CYP21P-hybriden, waarbij de plaats van de 
veronderstelde crossing-over in CYP21 ligt, en TNX-hybriden, waarbij CYP21 volledig 
ontbreekt en de plaats van de crossing-over in TNX ligt.  In deze laatste categorie is er een 
extra defect door het hybride TNX-gen: tenascine-X deficiëntie.  Als dit defect homozygoot 
aanwezig is, leidt het tot een vorm van het syndroom van Ehlers-Danlos, een groep van 
bindweefselziekten.  De beide categorieën zijn identiek op monomodulaire en bimodulaire 
chromosomen zonder CYP21-gen.  We gaan er daarom van uit dat, ongeacht de aan- of 
afwezigheid van nog een extra RCCX-module,  hetzelfde genetische mechanisme (ongelijke 
crossing-over) ten grondslag ligt aan deze hybriden.  Dit vormt een argument tegen het 
gebruik van de term 'grootschalige genconversie' in dit verband (zie hoofdstuk 5). 
Toch speelt genconversie een rol bij het ontstaan van defecten in CYP21.  Bij tweederde van 
de steroïd 21-hydroxylase deficiëntie-allelen is CYP21 aanwezig.  In hoofdstuk 3 worden de 
CYP21-mutaties die steroïd 21-hydroxylase deficiëntie veroorzaken, vergeleken met de 
variabiliteit van het CYP21P pseudogen.  Kleinschalige genconversie die hoogstens een paar 
honderd baseparen omvatten kunnen defecten overbrengen van CYP21P naar CYP21.  Omdat 
CYP21P echter zo variabel is, vooral aan de 3'-kant, kunnen conclusies over de grootte van 
deze conversies niet afgeleid worden uit de mutaties in CYP21.  Dit speelt in het bijzonder bij 
de in de literatuur beschreven 'mozaiek-conversies' die meerdere CYP21-CYP21P-overgangen 
lijken te hebben. 
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Uit de hoofdstukken 2 en 3 blijkt dat ongeveer 90 % van de deficiëntie-allelen in steroïd 21-
hydroxylase met zoutverlies, het resultaat is van hetzij een deletie van CYP21, hetzij een 
kleinschalige conversie die een CYP21P-achtig defect in CYP21 veroorzaakt heeft. 
Bepaalde steroïd 21-hydroxylase-defecten zijn relatief mild en komen pas tegen de puberteit 
of later naar voren.  De allelfrequentie van deze 'niet-klassieke' vorm van 21-hydroxylase 
deficiëntie is zeer hoog (tot 20 %) in sommige bevolkingsgroepen.  Een mutatie-analyse in een 
groep controlepersonen (hoofdstuk 3) toonde echter aan dat de allelen voor niet-klassieke 21-
hydroxylase deficiëntie in Nederland een frequentie hebben van ongeveer 1 %. 
Er bestaat bij steroïd 21-hydroxylase deficiëntie een goed verband tussen fenotype en 
genotype bij de meeste patiënten: een ernstige mutatie op beide chromosomen leidt bijna altijd 
tot zoutverlies.  De ernstigste defecten verstoren de transcriptie van CYP21 of veroorzaken een 
structurele verandering van steroïd 21-hydroxylase die enzymatische activiteit onmogelijk 
maakt.  Het is dan ook verrassend dat twee patiënten met dergelijke ernstige defecten toch in 
staat waren, aldosteron te synthetiseren (zie hoofdstuk 6).  Een combinatie van twee 
analytische methoden (HPLC en radioimmunoassay) werd gebruikt om de aanwezigheid van 
aldosteron in het serum van deze patiënten te bevestigen.  Dit eigenaardige verschijnsel wordt 
wellicht veroorzaakt door perifere vorming van aldosteron door andere enzymen. 
Bij de genetische analyse van CYP21-defecten wordt vaak aangenomen dat een chromosoom 
een CYP21-gen heeft, of dat er een CYP21-deletie is.  In hoofdstuk 7 wordt aangetoond dat 
deze aanname niet zonder risico is: chromosomen met twee CYP21 genen komen in de 
bevolking minstens zo vaak voor als steroïd 21-hydroxylase deficiëntie-allelen.  Omdat één 
van deze twee CYP21-genen op dergelijke chromosomen defect is, zou mutatieanalyse 
uitsluitend op basis van de polymerase-kettingreactie en zonder haplotypering tot verkeerde 
conclusies over dragerschap leiden. 
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Nawoord 
 
Nou, het was nog een hele klus, dat proefschrift.  Gelukkig heb ik het niet helemaal alleen 
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altijd diepe indruk op me gemaakt.  Een betere paranymf kan ik me niet wensen.  Bedankt 
voor al je inzet en vriendschap, voor de gezellige avonden bij jou en Hanna thuis, en vooral 
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als de mensen je soms lijken te begrijpen: ze kijken stiekem in een woordenboek. 
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punt....op welke bladzijde zitten we hier eigenlijk? 
Prof. Dr. Hans Büller, mijn tweede promotor.  Beste Hans, hartelijk dank dat je zo vlot bereid 
was om deze taak op je te nemen - ik ben uiteindelijk bepaald niet de enige die op zo'n manier 
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niet wensen!  Bedankt dat je deze taak op een zo prettige en adequate wijze hebt volbracht.  
Beste Bernard, bedankt dat je dit uitstapje terug naar je 'oude' onderwerp voor mij hebt willen 
maken, en bedankt voor de prettige samenwerking tijdens je Nijmeegse periode.  Beste Rob, 
bedankt dat je zonder aarzelen 'ja' zei op het verzoek om in de commissie te zitten, en bedankt 
voor de ruimte die je mij de afgelopen tijd hebt geboden om dit proefschrift af te ronden. 
Prof. Dr. Sten Drop, Dr. Sabine de Muinck Keizer-Schrama, Dr. Wilma Oostdijk, Dr. Jan 
Derksen, bedankt voor jullie betrokkenheid bij dit project gedurende vele jaren en jullie 
inspanningen om in de begintijd het patiëntenmateriaal bijeen te krijgen.  Beste Sten, ik vind 
het leuk dat je er vandaag bij bent als lid van de promotiecommissie.  Ook Dr. Anita Hokken, 
Dr. Johan Waelkens en Dr. Piet de Haas zeg ik dank voor het leveren van een aantal monsters.  
Ik bedank eenieder (patiënten, familieleden, controles) die bereid was een buisje bloed voor 
dit onderzoek af te staan. 
Anita Oostenbrink en Corine Barendse, bedankt voor jullie hulp bij het praktisch werk.  
Vooral jullie nauwkeurige overzicht van de Rotterdamse patiëntengegevens is mij nog jaren 
later van pas gekomen. 
Dr. Bert Smeets en Ilse de Wijs, ook jullie wil ik bedanken voor de hulp bij de analyse van 
enkele ingewikkelde gevallen - er is nog een aardig verhaal uit voortgekomen. 
Wout Deelen, Jorine Witte en Mieke van der Est, bedankt voor jullie hulp bij het onder de 
knie krijgen van een aantal tijdens dit project veel gebruikte technieken. 
Suzan Zwakhals, Christel Jansen en Hans van der Maarel.  Tja, we hadden ons het verloop van 
het project iets anders voorgesteld.....maar met wat ik nu weet kan ik toch zeggen dat we het 
toen, gegeven de mogelijkheden, nog niet zo slecht gedaan hebben.  Ik wil jullie hartelijk 
bedanken voor de plezierige samenwerking in wat nu zo ongeveer 'de oertijd' lijkt. 
Vele anderen hebben in de loop der jaren hun steentje bijgedragen, en in enkele gevallen zijn 
al die steentjes toch wel een berg gaan vormen.  Karin Wielsma en Ada Blanken, bedankt voor 
jullie vriendelijkheid en flexibiliteit als ik in drukke tijden een beroep op jullie deed.  Marcel 
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Sluijter, jarenlang een bron van kennis als labgenoot en ook onze grote hoofd-ACPer, bedankt 
voor je vele adviezen en praktische hulp.  Wim Rietveld, bron van levenswijsheid en inventief 
bedenker en bouwer van onontbeerlijke apparatuur, bedankt voor de gezellige gesprekken en 
de prima werkende instrumenten.  Ingrid Luijendijk, 'moeder van het lab', bedankt dat je altijd 
klaarstond om praktische problemen snel, adequaat en goedgehumeurd op te lossen.  Anita, 
Dicky en Rolien: een vriendelijk woord en een gezellig praatje waren er van velen in de 
afgelopen jaren, maar slechts voor een select gezelschap gold dat van begin tot eind. 
Amy, Barbara, Debby, Henne, Inez, Jeroen, John, Marcel, Marieke, Marjolein, Marli, Marrit, 
Melissa, Mireille, Natasja, Peter, Ronald, Wim: laten we de 'vergaderingen' in ere houden, en 
de agenda leeg. 
Aart, Ab, Ad, Agnes, Anita, Anja, Anneke, Annemieke, Arantza, Ariette, Arlène, Bas, Björn, 
Cora, Cynthia, Daniëlle, Daniëlle, Daphne, Darcos, David, Ellen, Francisca, Frank, Freek, 
Guido, Han, Hannie, Hans, Ingrid, Irma, Jacqueline, Jan, Jan, Jane, Jeanine, Jessica , Joris, 
Jos, Jozien, Jules, Karen, Karin, Karin, Kim, Kim, Leon, Louis, Maaike, Maartje, Manou, 
Maria, Marieke, Marjolein, Martina, Michiel, Monique, Najat, Natasja, Nathalie, Nathalie, 
Nicole, Nicole, Niels, Paul, Paula, Pershing, Peter, Pim, Rachid, Rahéna, Rolien, Sandra, 
Shirley, Silvia, Thea, Thomas, Thomas, Trudy, Vanessa, Vera, Vesna, Wendy, Wendy, 
Willem, Wim, Wim: bedankt voor de collegialiteit en de bijzondere sfeer die het lab 
Kindergeneeskunde zo kenmerkt. 
Annemarie, Annemarie, Barbara, Carola, Daphne, Debby, Clementien, Edwin, Ester, Geert, 
Hestien, Hettie, Inge, Jeroen, José, Karen, Laurens, Leon, Marcel, Marieke, Natasja, Pieter, 
Rianne, Robbert, Sacha, Saskia, Sophie, Venje, Ward, Wendy, Yvonne: bedankt voor de 
gezellige aio-weekenden en borrels. 
André, Anne-Paulet, Annette, Bas, Bas, Bert, Bob, Bob, Bram, Chen, David, David, Debra, 
Diny, Dirk, Dorine, Edzard, Ella, Elly, Eric, Floris, Fred, Geoffrey, Gerard, Guus, Hans, 
Henk, Henk, Henk, Henk, Henk-Jan, Herman, Ineke, Inge, Jaap, Jack, Jacques, Jan, Jan, Jan, 
Jan, Jan-Erik, Jan-Willem, Jelco, Jochen, Joost, Jos, Josée, Kareem, Liesbeth, Luc, Marcel, 
Marcel, Marcel, Marian, Marion, Marion, Marja, Marja, Maryam, Michael, Mu, Murat, 
Nathalie, Onno, Patricia, Paul, Peter, Peter, Pieter-Dirk, Rembert, Rene, René, Rob, Roel, 
Ronald, Ruud, Sagita, Sam, Sam, Suzanne, Tineke, Tom, Vincent, Wilbert, Willem, Wim, 
Wim, Wistaria, Wouter: bedankt voor een onvergetelijke tijd. 
Mijn lieve zus Hanneke, je hebt er 'even' op moeten wachten, maar ik vind het fantastisch dat 
je nu toch mijn paranymf wilt zijn.  Frans en Mieke, ik weet hoe jullie over 'dankbare 
kinderen' denken, maar mag ik na een paar honderd bladzijden taaie tekst een halve regel 
gebruiken om te zeggen dat ik van jullie hou? 
Tenslotte een woord van dank aan de Sophia Stichting Wetenschappelijk Onderzoek, die dit 
project gedurende een aantal jaren heeft gefinancierd, en aan de Stichting 'Irene 
Kinderziekenhuis', die ons een financiële bijdrage verschafte op een moment dat die hard 
nodig was. 
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Een nawoord schrijven is leuk, maar ook lastig.  Het is het laatst geschreven en eerst gelezen 
deel van een proefschrift, dus het vergt enige oplettendheid.  Het duiden van de formuleringen 
in de dankjewel-paragraaf en het afleiden van verborgen betekenissen daaruit zou een nieuwe 
categorie schriftgeleerden in het leven kunnen roepen.  De verleiding is groot om er een soort 
'disclaimer' in te zetten, zoiets als: "wie niet expliciet als 'gezellig' omschreven wordt, moet 
daaruit niet opmaken dat...." - maar ja, dat snappen jullie wel. 
Beste Herman, één kleine revanche moet je me maar gunnen: ik laat het uitgaan 'als een 
nachtkaars'. 
 
26 juni 2002 Paul Koppens 
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'There was a point to this story, but it has temporarily escaped the chronicler's mind.' 
 
Douglas Adams 
 
 leeg 
 leeg 
